



Universiteit
Leiden
The Netherlands

Immunotherapy for atherosclerosis

Monaco, C.; McNamara, C.A.; Slütter, B.A.; Foks, A.C.; Bekiranov, S.; Mulder, W.J.M.; ... ; Lutgens, E.

Citation

Monaco, C., McNamara, C. A., Slütter, B. A., Foks, A. C., Bekiranov, S., Mulder, W. J. M., ... Lutgens, E. (2025). Immunotherapy for atherosclerosis. *Physiological Reviews*.
doi:10.1152/physrev.00016.2024

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4250623>

Note: To cite this publication please use the final published version (if applicable).

Physiological Reviews

Immunotherapy for Atherosclerosis

Claudia Monaco¹, Coleen A. McNamara², Bram Slütter³, Amanda C. Foks³, Stefan Bekiranov⁴, Willem J.M. Mulder^{5,6}, Isabel Goncalves⁷, Esther Lutgens⁸.

¹*Kennedy Institute of Rheumatology, Old Road Campus, Roosevelt Drive, OX3 7FY University of Oxford, Oxford, UK.*

²*Carter Immunology Research Center and Division of Cardiology, University of Virginia, 415 Lane Road Room G231, Charlottesville, VA 22908, USA*

³ *Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55 2333CC, Leiden, NL.*

⁴*University of Virginia, dept of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, 22908, USA*

⁵*Laboratory of Chemical Biology, dept of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.*

⁶ *Dept of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.*

⁷*Cardiovascular Translational Studies, Clinical Sciences Malmö and Cardiology Department, Clinical Research Center, house 91, floor 12, Jan Waldenströmsg 35, Lund University, 20502 Malmö, Sweden.*

⁸*Experimental Cardiovascular Immunology Laboratory, Dept of Cardiovascular Medicine and Immunology, Mayo Clinic, 200 First St SW, Rochester MN 55905, USA*

On behalf of the LeDucq International Network of Excellence on Immune Checkpoints in Atherosclerosis: "CHECKPOINT ATHERO".

Correspondence:

Esther Lutgens, MD, PhD, FAHA
Dept of Cardiovascular Medicine & Immunology
Experimental CardioVascular Immunology Laboratory
Mayo Clinic
200 First St, Rochester, MN, 55905, USA
Lutgens.Esther@Mayo.edu

Abstract

Cardiovascular disease is the global #1 cause of mortality and morbidity. The majority of cardiovascular diseases is caused by atherosclerosis, a lipid-driven, inflammatory disease of the middle- and large-sized arteries. The disease is characterized by the formation of atherosclerotic plaques throughout the arterial tree. Over the years, insights into the pathogenesis of atherosclerosis have shifted from a 'lipid-driven' model to a 'response-to-injury' perspective, and more recently to a 'lipid-driven inflammatory disease' viewpoint.




We are now aware that a network of multiple immune cell-types and -subsets of the innate and adaptive immune system inhabit our arteries. Intricate interactions between these immune cell-subsets, non-immune cells, and local environmental substances such as lipids, cell debris and calcium cause a fluidic balance of pro-inflammatory and regulatory responses. A dysregulation of this balance towards a pro-inflammatory milieu drives atherosclerotic disease progression.

Although we have acknowledged that atherosclerosis is an inflammatory disease, state-of-the-art treatments are still based on lipid lowering, anti-hypertensive and lifestyle-changing strategies. In the past decade, clinical phase I, II and III trials targeting the immune system revealed that patients tolerate immunotherapy, show decreased inflammation and/or had a reduction in cardiovascular endpoints. However, the search for novel immunotherapeutic targets and treatment regimens as well as stratification of patients who would benefit from such treatments to combat atherosclerotic cardiovascular disease is only just beginning. In this review article, we will highlight the newest insights on the different cell subsets and components of the immune system in atherosclerosis and elaborate on current and future immunotherapeutics to treat atherosclerotic cardiovascular disease.

Call out box for clinicians

Although we have acknowledged for decades that atherosclerosis is an inflammatory disease, state-of-the-art treatments are still based on lipid-lowering, anti-hypertensive and lifestyle-changing strategies, and not on modulating inflammation. Recent clinical trials targeting the immune system revealed that CVD patients tolerate immune therapy, show decreased levels of inflammation and/or had a reduction in cardiovascular endpoints. We here describe the intricate network of immune cell interactions relevant for atherosclerosis and discuss potential immunotherapeutic approaches to treat cardiovascular disease.

Atherosclerosis is an inflammatory disease



Summary Figure. The current concept of atherosclerosis is that it is a lipid-driven immune disease, in which both the innate and adaptive immune system play a major role. In atherosclerotic plaques, a plethora of innate and adaptive immune cell subsets inhabit the atherosclerotic plaque, as well as the underlying adventitia and perivascular adipose tissue (left). *Pre-clinical* studies in cell culture models and atherosclerotic mouse models have provided major insights into immune cell subsets as well as inflammatory pathways that drive atherosclerosis. Using single cell technologies on human atherosclerotic plaque specimens, novel (non-)immune cell subsets and their interactions have been identified and detailed. Clinical trials using immunotherapies for autoimmune diseases such as rheumatoid arthritis (RA), revealed that RA patients treated with immunotherapy had decreased CVD. Patients receiving immunotherapy in oncology, that boost T cell activation to facilitate tumor killing, has aggravated cardiovascular disease (CVD). The first clinical trials targeting inflammation in atherosclerotic CVD in humans showed a reduction in (vascular) inflammation and/or CVD events (right). Current immunotherapies in CVD are promising, but need optimization as some induce side effects, and do not decrease overall mortality. Future immunotherapeutics aim to target atherosclerosis-associated immunological and inflammatory pathways in a cell-type specific manner to reduce CVD and overall mortality without causing side-effects.

1. ATHEROSCLEROSIS: EPIDEMIOLOGY, RISK FACTORS AND CLINICAL MANIFESTATIONS

1.1 Epidemiology

Atherosclerosis, a lipid-driven inflammatory disease characterized by a buildup of atherosclerotic plaques of middle- and large-sized arteries, is a major underlying cause of cardiovascular disease (CVD). Clinically, atherosclerosis frequently presents as ischemic heart disease, ischemic stroke, and peripheral arterial disease. CVD are the #1 global cause of mortality and a significant contributor to disability. In 2019 alone, CVD claimed 17.9 million lives worldwide, comprising 32% of all recorded deaths ([https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))). The prevalence of CVD persists in an upward trajectory across most nations, with age-standardized CVD rates witnessing a concerning resurgence (1). Eastern Europe bears the highest total CVD mortality rate, standing at 553 deaths per 100,000 individuals, whereas Australasian countries exhibit the lowest rate at 123 deaths per 100,000 (Figure 1). The escalation in global CVD deaths from 12.4 million in 1990 to 19.8 million in 2022 not only reflects population growth and aging, but also worsening of preventable metabolic, environmental, and behavioral risk factors (2).




Figure 1. Epidemiology, risk factors and clinical manifestations of atherosclerosis

CVD associated mortality is on the rise, especially in eastern Europe, the Middle East, North Africa and Central Asia, where mortality rates are above 400 per 100,000 (source: <https://www.jacc.org/global-burden-cvd/interactive/21-region>). Major risk factors for atherosclerotic CVD can be divided in non-modifiable risk factors (i.e., age and sex); metabolic risk factors (i.e., hyperlipidemia); inflammation (chronic inflammatory disease (CID), acute inflammatory disease (AID), Clonal hematopoiesis of Indeterminate Potential (CHIP), and infections); environmental risk factors (i.e., air pollution) and behavioral risk factors (i.e., lack of physical exercise). Atherosclerosis can result in a wide range of clinical symptoms, including coronary artery disease, cerebral artery disease and peripheral artery disease, depending on the arterial bed affected.

1.2 Risk factors for atherosclerotic cardiovascular disease

The latest update of the 'Global Burden of Diseases, Injuries, and Risk Factors' Study (GBD), involving over 10,000 collaborators worldwide, underscored the main risk factors for CVD. These include *environmental factors* such as (household) air pollution, lead exposure, and extreme temperatures; *metabolic factors* including systolic blood pressure, LDL cholesterol levels, body mass index, fasting plasma glucose, and kidney dysfunction; and *behavioral factors* encompassing dietary habits, smoking, exposure to secondhand smoke, alcohol consumption, and physical activity levels. Additionally, non-modifiable risk factors like sex, age, and family history of cardiovascular events have been extensively documented (2). In a 2023 meta-analysis on the prevalence of cardiovascular risk factors, the global prevalence of 8 of the most important cardiovascular risk factors was high, with insufficient sleep quality (38.5%), no adherence to a healthy diet (34.1%), dyslipidemia (34.1%), hypertension (29.4%) and insufficient physical activity (26.4%) scoring the highest, followed by obesity (17.3%), nicotine exposure (15.4%) and diabetes (12.1%), stressing the need to implement prevention strategies involving lifestyle-changes and adequate treatment strategies to keep hypertension, dyslipidemia and diabetes under control (3). An additional important risk factor that increases the prevalence of (atherosclerotic) CVD is inflammation. Patients suffering from chronic inflammatory diseases (including COPD or asthma) (4), auto-immune diseases (including systemic lupus erythematosus and rheumatoid arthritis) (5, 6), acute inflammation following injury (7), as well as infections, such as influenza, HIV or SARS-CoV-2 (8-10), are all at an increased risk at developing cardiovascular disease. Another disorder that stresses the importance of inflammation as a risk factor, and driver for CVD is Clonal hematopoiesis of Indeterminate Potential (CHIP). CHIP is characterized by the presence of somatic mutations in blood leukocytes with a clonal size of at least 2% allele frequency. These somatic mutations occur during ageing (11), and most frequently affected genes are the epigenetic regulators Tet methylcytosine dioxygenase 2 (*tet2*) and DNA (cytosine-5) methyltransferase 3 alpha (*DNMT3A*). Genes that are less frequently affected are sex combs like 1 (*ASXL1*), serine/arginine-rich splicing factor 2 (*SRSF2*), or signaling proteins such as Janus kinase 2 (*JAK2*). Mouse models in which *tet2* and *JAK2* were modified exhibited an increase in atherosclerosis, by aggravating macrophage inflammation (12-15). In humans, CHIP was shown to nearly double the cardiovascular risk compared to healthy individuals establishing CHIP as a new cardiovascular risk factor (12, 16) (Figure 1).

1.3 Clinical manifestations of atherosclerosis

The clinical repercussions of atherosclerosis hinge on two key factors: the arterial territory primarily affected at a given time, and the speed of arterial occlusion. Given its systemic nature, atherosclerosis can concurrently affect multiple territories, thus patients experiencing a myocardial infarction face heightened stroke risks and vice versa. Notably, within one month of a myocardial infarction, 0.9% of patients may suffer an ischemic stroke, escalating to 3.7% within a year, with a doubled one-year mortality compared to those unafflicted by stroke (17, 18). Conversely, a meta-analysis from 2018 indicated a myocardial infarction risk of up to 3.6% annually following a stroke (19). Atherosclerosis impacts diverse arterial systems: it can affect coronary arteries, precipitating coronary artery disease (CAD), arteries irrigating the brain culminating in cerebrovascular disease, and peripheral arteries, compromising circulation to extremities and visceral organs (Figure 1).

Coronary artery disease syndromes are classified as acute or chronic, depending on the speed of arterial occlusion. Typical clinical presentations include chest discomfort, often described as pain, pressure, or tightness (*angina pectoris*), as well as chest pain-equivalents such as dyspnea, epigastric pain, and pain in the left or right arm or neck and/or jaw. While some patients may exhibit few symptoms, others may experience fainting due to circulatory collapse, cardiogenic shock, acute heart failure, arrhythmias, or cardiac arrest.

Acute coronary syndromes (ACS) encompass patients with recent changes in clinical symptoms or signs, with or without alterations on the 12-lead electrocardiogram (ECG), and with or without acute elevations in cardiac troponin concentrations. This spectrum includes myocardial infarction, marked by troponin C (TnC) release due to acute cardiomyocyte injury/necrosis, in contrast with unstable angina, defined as myocardial ischemia at rest or with minimal exertion without acute cardiomyocyte injury/necrosis. Unstable angina is characterized by prolonged (>20 min) angina at rest, new-onset severe angina (angina increasing in frequency, duration, or threshold) or angina following a recent myocardial infarction episode. Currently, in acute scenarios, ECG and TnC, in addition to clinical manifestations, guide the initial therapeutic management. The presence of ST-segment elevation defines ST-elevation myocardial infarction (STEMI), indicating total luminal occlusion, whereas ST-elevation absence with cardiomyocyte necrosis is a non-ST-elevation myocardial infarction (NSTEMI) (20).

In chronic coronary syndromes, various clinical presentations may occur, ranging from asymptomatic to *angina pectoris* (with or without obstructive disease in the epicardial coronary arteries), often associated with physical or psychological exertion, or chest pain-equivalent symptoms such as dyspnea and new onset of heart failure or left ventricular dysfunction (21).

Stroke is the second most common cause of death following coronary artery disease (CAD). Projections from Eurostat, the statistical office of the European Union, predict a 34% increase in the total number of strokes in Europe between 2015 and 2035 ([https://strokeeurope.eu/executive-summary/Stroke Alliance for Europe: The burden of stroke in Europe](https://strokeeurope.eu/executive-summary/Stroke%20Alliance%20for%20Europe%3A%20The%20burden%20of%20stroke%20in%20Europe)). Of all strokes, 80% are ischemic, with one-third of them related to extracranial carotid disease. Atherosclerosis in the carotid artery affects approximately 21% of people aged 30–79 years, resulting in carotid plaque rupture in around 816 million individuals and carotid stenosis in about 58 million individuals (22). Among the ischemic strokes, only 20% are vertebrobasilar, and these are also primarily caused by atherosclerosis. A recent symptomatic >50% vertebral artery stenosis may be associated with a 30% risk of stroke over a 5-year period (23).

A stroke is a sudden-onset focal neurological dysfunction, with symptoms lasting more than 24 hours (or resulting in death in less than 24 hours), typically from non-traumatic, vascular origins (24). Stroke in evolution is either a fluctuating neurological deficit without full recovery or a progressively worsening neurological deficit over a 24-hour period (24). In contrast, a transient ischemic attack (TIA) is an episode of focal brain, retinal, or spinal cord dysfunction lasting less than 24 hours, also of non-traumatic, vascular origin (25). Crescendo TIAs refer to multiple TIAs in a short time frame, usually more than two TIAs in 24 hours, or at least three events in one week, with full recovery between each episode (26). The clinical manifestations of stroke vary widely and may include contralateral motor or sensory deficits, slurred speech, cranial nerve deficits, limb weakness, or visual disturbances such as amaurosis fugax. Hemodynamic symptoms may be less predictable and atypical, including limb tremor, retinal claudication, headache, syncope, and generalized fatigue. Symptoms may arise from artery occlusion or embolization to

the cerebral circulation and depend on hemodynamic conditions and the presence and/or patency of collaterals.

Patients with lower extremity artery atherosclerotic disease (LEAD) can be asymptomatic, and clinical signs can vary widely. Assessing walking capacity is crucial for detecting clinically silent LEAD. Walking difficulties may stem from an inability to walk enough to reveal symptoms (e.g., due to heart failure) and/or reduced pain sensitivity (e.g., diabetic neuropathy), both common co-morbidities. The ankle-brachial index serves as a first-line test for screening and diagnosis, alongside duplex ultrasound, a non-radiation imaging method. Intermittent claudication, ranging from mild to severe or disabling, is a classical symptom akin to angina but affecting the lower extremities. Critical limb ischemia is characterized by ischemic rest pain, with or without tissue loss (ulceration or gangrene) or infection. It often represents generalized, severe atherosclerosis, carrying a three-fold increased risk of myocardial infarction, stroke, and vascular death compared to patients with intermittent claudication (27, 28).

Upper extremity artery disease due to atherosclerosis is rare and poorly studied, typically involving the brachiocephalic trunk, subclavian, and axillary arteries (29). Possible clinical manifestations include arm claudication, Raynaud's syndrome, rest pain, ischemic ulcerations, or gangrene. Another organ affected by atherosclerosis is the kidney, contributing to 1-2% of all cases of hypertension in the general population (30). Atherosclerotic plaques typically form at the origin of the renal artery, often associated with areas of flow turbulence (31, 32). Many lesions have minimal hemodynamic effects and remain clinically silent until they progress to a "critical" level, which triggers pressor mechanisms or inflammatory and ischemic injury (33). Atherosclerotic renovascular disease can manifest as renal artery stenosis and renal ischemia. It may be a discreet process, as blood pressure does not rise until the stenosis reaches 60% or greater, and the kidney can tolerate moderate flow reduction. It may be incidentally discovered by abdominal murmurs or during vascular imaging for other reasons. In addition to hypertension, sodium and water retention may contribute to circulatory congestion and pulmonary edema in patients with left ventricular deterioration, leading to ischemic nephropathy, which involves both large and small blood vessels and results in a decline in glomerular filtration rate.

Like CAD in the heart, intestinal ischemia, caused by atherosclerosis in the superior and/or inferior mesenteric artery/ies can be categorized based on the timing of onset into acute and chronic forms. Collateral circulation in the gastrointestinal tract can compensate for a 75% acute reduction in mesenteric perfusion for up to 12 hours without causing significant injury (34). In chronic mesenteric ischemia, atherosclerosis is the underlying cause in 95% of cases. The etiologies of acute intestinal ischemia are largely associated with atherosclerosis, such as mesenteric arterial embolism (50%), intestinal hypoperfusion or nonocclusive mesenteric ischemia (20%-30%), and mesenteric arterial thrombosis (15%-25%) (35). Symptoms and signs may vary, often including recurrent abdominal pain after eating, which can lead to weight loss in chronic cases. In acute cases, abdominal pain and tenderness may be accompanied by rectal bleeding or bloody diarrhea. Mesenteric ischemia accounts for only 0.1% of all hospital admissions, making it a rare medical condition, despite its high mortality rates ranging from 24% to 94% (36) (Figure 1).

Atherosclerosis is thus the underlying cause of a wide range of cardiovascular diseases. Although a significant reduction in cardiovascular mortality and morbidity has been achieved using LDL-

cholesterol lowering therapies, antihypertensives and lifestyle-changing strategies, atherosclerotic CVD still poses a major global health burden (21, 37, 38) (Figure 1).

2. THE ATHEROSCLEROTIC PLAQUE

The name *atherosclerosis* refers to thickening of the arterial wall (*sclerosis* means ‘hardening’) and accumulation of lipids, cells, extracellular matrix, and calcium (*athere* means ‘gruel’) that characterize the atherosclerotic plaque (39). Atherosclerotic plaques selectively form in middle- and large-sized arteries and can be found in every human being to a greater or lesser extent. The formation of atherosclerotic plaques starts in early childhood, where it remains clinically silent (40), and progresses with age, when atherosclerotic CVD becomes evident (41-43).

Although considered a major health problem of modern age, atherosclerotic CVD has been bothering mankind for millennia. Atherosclerotic plaques have been found in aorta, coronary arteries, and peripheral arteries of mummies from all over the world dated as early as 3000 BC (44-47). Remarkably, mummies carrying SNPs in their ancient DNA that are currently associated with a predisposition to atherosclerotic CVD, were found to have higher atherosclerotic plaque burden than those who with a low polygenic risk score for ASCVD (48).

The macroscopical and microscopical characterization of the atherosclerotic plaque forms the basis of many of our current theories and insights into the pathogenesis of atherosclerosis. A detailed understanding of the histological and morphological features of the progressing atherosclerotic plaque is key to understanding pathophysiological mechanisms underlying the disease.

2.1 The non-diseased artery

The non-diseased human artery contains four layers: the intima, the media, the adventitia and the peri-vascular adipose tissue (PVAT) (Figure 2). The intima is the innermost part of the artery and enclosed by the lumen-facing endothelium and the internal elastic lamina, that demarks the arterial media. The intima contains delicate connective tissue with a few vascular smooth muscle cells (VSMCs) (49). Throughout the arterial tree, the intima varies in thickness and often undergoes eccentric or diffuse adaptive intimal thickening. These intimal thickenings are not due to atherosclerosis but are physiological adaptations of the intima caused mechanical stresses, such as changes in pulse rate, blood pressure, arterial geometry, flow rate, and flow resistance (41).

The media is the muscular arterial wall and is confined by the internal and external elastic laminae. The media is composed of fenestrated elastic laminae of VSMCs, interspersed with collagen fibrils and proteoglycans. Its main function is to support the arterial structure and change vessel diameter to regulate blood flow and blood pressure (50).

The adventitia is the outermost layer of the artery and comprised of a dense collagen-rich matrix containing fibroblast, VSMCs, vasa vasorum, nerve fibers and, in a non-diseased artery, immune regulatory immune cells (mostly resident macrophages). The role of the adventitia is not completely understood but is considered an essential regulator of vascular wall structure and function (reviewed in (51)). The adventitia is surrounded by perivascular adipose tissue, a layer

of adipocytes that contains vasa vasorum, nerve fibers, and (resident) immune cells (52, 53) (Figure 2).




Figure 2. Structure of a non-diseased artery. The non-diseased arterial wall consists of 4 layers: the intima, media and adventitia and the perivascular adipose tissue (PVAT). The intima consists of an endothelial cell layer, a subendothelial layer with some connective tissue and is separated from the media by the internal elastic lamina. The media predominantly contains multiple layers of vascular smooth muscle cells, with dispersed elastic laminae, and other extracellular matrix components. The media is separated from the adventitia by the external elastic lamina. The adventitia is composed of a collagen rich matrix, with dispersed VSMCs, nerve fibers, resident and a few recruited immune cells are found, and vasa vasorum, that can extend into the media and intima. The PVAT contains adipocytes and similar components as the adventitia.

2.2 Histology of the atherosclerotic plaque

2.2.1 The first descriptions of atherosclerotic plaques

The first reports on the characteristics of the atherosclerotic plaque date from the 19th century. In 1855, Carl von Rokitansky (1804-1878) described atherosclerosis as an excessive formation of plaques on the interior of arteries. According to von Rokitansky, these plaques start as thickening of the vascular inner layer, which becomes covered by a pseudo membrane: fibrin. This pseudo membrane develops either in an atheromatous process with debris and cholestearine, or into vascular ossifications (54). In 1858, Virchow (1821-1902), the founder of cellular pathology, presented a lecture on the 'atheromatous affection of arteries. He described atherosclerosis as a process of *simply fatty metamorphosis*, which is characterized by the transformation of the existing histological elements into a state of degeneration. Second, he claimed that atherosclerotic plaques transfer to a *stage of irritation*, comparable to the stage of swelling an enlargement seen in inflammatory processes. Lastly, he described a stage of '*atheromatous degeneration*' where plaques consist of cholestearine plates, granule cells and fat granules, and hard lumps of softened substance resulting in the *pultaceous* character of the atheromatous matter (55).

Although we now have a more pronounced knowledge of processes and features of the different stages of atherosclerosis, many aspects of current histological classifications are based on the observations of our predecessors in the 1850s-1950s (56).

2.2.2 Classifications of atherosclerosis

After Virchow and von Rokitansky described the morphological features of atherosclerotic plaques, several histological classifications of atherosclerosis have been developed. The classifications that are currently in use are the AHA classification of atherosclerosis, developed on behalf of the 'Committee on Vascular Lesions' of the Atherosclerosis of the American Heart Association in 1992-1995 (41-43) and an updated more refined classification of human atherosclerosis as proposed by Dr Virmani in 2000 (49).

The AHA classification of atherosclerosis recognizes 6 different stages of atherosclerotic plaque development (41-43), but starts out with a detailed description of a normal intima. Type I lesions, the first atherosclerotic lesions, are characterized by an increased number of intimal macrophages of which some have a foamy appearance. Type II lesions, or fatty streak lesions are the first macroscopically visible lesions and look like small lipid dots. They consist of layers of macrophage foam cells, lipid-droplet containing VSMCs, and occasional extracellular lipid droplets. Type III lesions are characterized by extracellular lipid pools and represent the transition from early to and advanced lesion type: the pre-atheroma (42). The first type of advanced atherosclerotic plaque is the type IV lesion, which contains a necrotic core with extracellular lipids and cholesterol crystals, the atheroma, but no increase in extracellular matrix. The type V lesion is characterized by prominent new extracellular matrix formation, that form a fibrous cap: the fibro-atheroma. Both type IV and type V lesions can develop fissures, hematoma or thrombi, and are then considered a type VI lesion, i.e., plaque rupture or intraplaque hemorrhage (43). Type VI lesions have the highest association to clinical symptoms resulting from atherosclerosis, as the forming thrombus can rapidly occlude the lumen and cause ischemia or infarction, such as myocardial infarction or stroke, depending on the arterial bed affected (43, 57).

The classification as proposed by Dr Virmani is more refined, and better reflects the complexity of the atherosclerotic plaque (49), as has been detailed in Figure 3. The first stages of atherosclerosis are defined as *intimal thickenings* and *intimal xanthomas*. Intimal thickenings consist of VSMCs embedded in a proteoglycan rich matrix, whereas *intimal xanthomas* reflect the accumulations of lipid laden macrophages into the intima. *Pathological intimal thickenings* are poorly qualified intermediate lesions, with no apparent necrosis, no cellular debris, and dispersed lipids in the deeper layers that are overgrown by a SMC-rich fibrous caps and scattered sparse lymphocytes and macrophages. The *fibrous cap atheroma* contains a true necrotic core containing cholesterol esters, phospholipids, free cholesterol and triglycerides, The fibrous cap consists of smooth muscle cells in a proteoglycan-collagen matrix, with a variable number of macrophages and lymphocytes. Fibrous cap atheromata can progress toward vulnerable atherosclerotic lesions and then become thin fibrous cap atheromata that show signs of loss of SMCs, overlay a large necrotic core, and exhibit features of inflammation (49) (Figure 3).

Lesions with thrombi are considered responsible for clinical symptoms of CVD, as thrombi can occlude arterial beds (57). However, the presence of plaque rupture is not always associated with clinical events, as non-fatal lesions were shown to exhibit features of plaque rupture (57). Vice versa, many plaques show luminal thrombi, without evidence for plaque rupture (58). Therefore, the designation of a single category to atherothrombotic lesions is too simplistic. Dr Virmani's classification distinguishes two types of atherothrombotic lesions: *plaque rupture* and *plaque erosion*. Plaque rupture is characterized by the presence of a fissure, where the thrombus is in direct contact with the necrotic core. Plaque erosion is characterized by absence of a fissure, and

the endothelium is often absent at the site of thrombus. Additional subtypes of lesions containing thrombi are plaques with intraplaque hemorrhage and, plaques with healed ruptures or erosions (49) (Figure 3).




Figure 3: Histological features of the pathogenesis of atherosclerosis 1.*Intimal thickening*: the process of atherosclerosis starts when VSMCs and lipids accumulate in the proteoglycan-rich intima. 2. *Intimal xanthoma*: excess uptake of lipids attracts the first immune cells into the intima, i.e., (lipid laden) macrophages and T cells. 3. *Pathological intimal thickening*: Immune cells keep accumulating, more and more macrophages obtain a foam cell rich appearance, and the first extracellular lipid pools become visible. A fibrous cap, composed of VSMCs, fibroblasts and extracellular matrix components is forming. 4. *Fibrous cap atheroma*: immune cells keep accumulating and a fibrous cap has fully developed. The core of the plaque shows necrosis and extracellular lipids, often in the forms of cholesterol crystals. Calcium deposits form. This area is called the necrotic core. The fibrous cap starts thinning in some areas. 5. *Plaque rupture*: a fissure in the fibrous cap exposes the thrombogenic contents of the plaque to the blood. A thrombus forms on top of the plaque and may narrow or occlude the arterial lumen. 6. *Plaque erosion*: Thrombus on top of an intact atherosclerotic plaque. The endothelium can be intact, damaged or absent.

Plaque formation can take several years, depending on various risk factors. The biological age of different components of advanced human plaques has been analyzed using the ^{14}C bomb-peak dating method, employing accelerator mass spectrometry (59)—a technique used in archaeology and forensic medicine. Human plaque tissue turnover time in living patients has been demonstrated to vary and can be very long, with calcified areas found to be up to 20 years old. Significant differences in the age of various plaque regions have been observed, with the cap being the youngest part (59). These differing biological ages seem to be independent of symptoms, but using the same technique, apoptosis (mainly in the cap and core of plaques) was identified as the most significant mechanism associated with a younger plaque age, reflecting rapid plaque progression in living patients (60). Atherosclerosis can thus remain asymptomatic for extended periods before becoming suddenly unstable, typically due to an acute atherothrombotic event caused by plaque rupture (~65% in coronaries from patients suffering sudden coronary death), plaque erosion (~30%) or calcified nodule (~5%) (49, 61).

2.3 Animal models of atherosclerosis

Animal models of atherosclerosis have been invaluable to the understanding of the pathogenesis of atherosclerosis. The first animals to be used were non-human primates and rabbits, who develop atherosclerosis after being fed a high cholesterol containing diet (62-65). In non-human primates, the first fatty streak lesions can be observed within one month, and fibrous cap atheromas occur within 1 year (62-64). Rabbits also develop atherosclerosis upon a being fed a high cholesterol diet. Several models are in use, ranging from New Zealand white rabbits, Watanabe rabbits, and rabbits that have been genetically modified (65, 66). Rabbits develop large, foam cell rich lesions within weeks, and fibrous cap atheromas within months (66).

Nowadays, the mouse is the most common experimental animal model used for atherosclerosis research, due to the ability to easily introduce and mutate genes. However, mice do not develop atherosclerosis spontaneously. The strain that is most susceptible to develop atherosclerosis is the C57Bl6 mouse strain. When fed a high cholesterol diet, these mice develop fatty streak lesions, but not fibrous cap atheromas (67). This strain has been used as background for the gene-deficient models that are more prone to atherosclerosis. The most used mouse models for atherosclerosis today are the *Apoe*^{-/-} and the *Ldlr*^{-/-} mouse models. The *Apoe*^{-/-} mouse model, that lacks apolipoprotein E, is hyperlipidemic, and develops atherosclerosis when fed either a normal chow or a high cholesterol diet (68). *Apoe*^{-/-} mice develop all stages of atherosclerosis, from fatty streak lesions to advanced fibrous cap atheromata (69), to intraplaque hemorrhage and rupture (70-72), although the latter is still under debate (73). *Ldlr*^{-/-} mice lack the low-density lipoprotein receptor and display low levels of hyperlipidemia when fed a normal chow diet, and severe hyperlipidemia when fed a diet high in cholesterol, and develop atherosclerosis comparable to the *Apoe*^{-/-} mouse model (74). Inducible models of atherosclerosis include the injection of an adeno-associated virus vector containing the D374Y gain-of-function mutant form of PCSK9 (75), and administration of an siRNA directed against the LDL receptor (76).

Pig models of atherosclerosis have become popular for late pre-clinical studies, as the pig's cardiovascular system more closely resembles human cardiovascular physiology than the mouse. Pig models used for atherosclerosis research are pigs susceptible to hyperlipidemia (77), such as the Yucatan minipig (78), FBM (Familial Hypercholesterolemia Bretoncelles Meishan) pigs (79) or

Göttingen pig (80), as well as genetically modified pig models such as the Yucatan minipig containing the human gain of function D374Y-PCSK9 mutant (81).

3. EMERGING THEORIES ON THE PATHOGENESIS OF ATHEROSCLEROSIS (1850-NOW): A TALE OF THROMBOSIS, LIPIDS, INJURY AND INFLAMMATION

In the past two centuries, our insights into the pathogenesis of atherosclerosis have gone through many theories and concepts which are still evolving. The evolution of the pathobiological insights on how plaques form and progress closely mirror the advancements of cellular and molecular biology. Our scientific insights into cell-types and molecules involved in the initiation, progression and regression of atherosclerotic plaques go hand in hand with major technical discoveries in histology, flow cytometry, development of mutant mouse models and genomics, all the way to the single cell (spatial) technologies that we use nowadays. The following section will give a short overview on the emergence and development of the 5 fundamental theories on the pathogenesis of atherosclerosis: **1.** the thrombosis model; **2.** the infiltration model; **3.** the lipid model; **4.** the response to injury model and **5.** the inflammation model (Figure 4). All 5 models are derived from observations and experimental data and have contributed insights into the pathogenesis of atherosclerosis as we know it today.

3.1 Atherosclerosis: the thrombosis model

In the 1850s, von Rokitansky was one of the first trying to explain the pathogenesis of atherosclerosis. Based on his observations that atherosclerotic plaques often contained mural thrombi or fibrin depositions inside the plaque, he theorized that atherosclerotic plaques were formed by organized thrombi (the so called "*encrustation*" hypothesis) (54). In 1949, Duguid postulated that an encrustation of small mural thrombi existed at the sites of arterial injury. These thrombi would subsequently undergo organization by the growth of SMC and fibrous tissue into them, and they would become incorporated into vascular lesions, causing luminal narrowing (82) (Figure 4). Over the years, this theory has been significantly refined but is still considered to be one of the contributing mechanisms to growth of atherosclerotic plaques (83).

3.2 Atherosclerosis: the infiltration model

Around the same time (1856), Virchow observed lipid deposits in the atherosclerotic plaque(55). Based on these findings, Virchow proposed the '*infiltration*' theory. He suggested that a low-grade injury to the arterial wall resulted in inflammatory infiltration, causing an increased passage and accumulation of plasma constituents in the intima (Figure 4). He dismissed von Rokitansky's '*encrustation*' hypothesis because the localized intimal thickenings (atherosclerotic plaques) were subendothelial and '*hence could not be derived from surface deposits*' (56).

3.3 Atherosclerosis: the lipid model

Based on the observations of Virchow and others, the Russian scientist Ignatowski tried to develop an animal model of atherosclerosis by inducing hyperlipidemia. He fed rabbits a diet of milk and egg yolk and was able to induce atherosclerosis (84). In 1913, Anitschkow reproduced this model, by adding cholesterol to the normal rabbit diet (85). This gave rise to the lipid theory




Figure 4: Emerging theories on the pathogenesis of atherosclerosis. In the 1850s, von Rokitansky proposed the 'encrustation' model. He theorized that thrombi would adhere to the arterial wall and undergo reorganization, thereby forming a plaque (1). Around the same time, Virchow viewed atherosclerotic plaques to be composed as an inflammatory cell infiltrate embedded in plasma constituents, including cholesterol (2). Between 1900 and the 1980s, atherosclerosis was merely seen as a lipid driven disease. Lipids infiltrate into the arterial wall where they accumulate and are being engulfed by macrophages. The continuous lipid loading causes these macrophages to die. Extracellular lipid accumulation and cell death results in the formation of a necrotic core full of cholesterol crystals (3). In the 1970s, Ross and Glomset developed new theory. Atherosclerosis is caused by a 'response to injury', induced by shear stress and reactive oxygen species. As a response, VSMCs migrate into the intima, proliferate and produce extracellular matrix. Modified lipids can induce injury and are being taken up by macrophages (4). Nowadays, atherosclerosis is considered a lipid driven immune disease. It was discovered that (modified) lipid infiltration cause innate and adaptive immune cells to infiltrate into the arterial wall, including the adventitia and PVAT where they are activated, and cause a chronic inflammatory response, thereby progressing the disease (5).

of atherosclerosis that remained the dominant theory on the origin of atherosclerosis until the 1990s and forms a major part of our understanding of atherogenesis today.

In this classical model, which is still accepted today, an excess of lipids caused lipid accumulation in the intima of the arterial wall. The excess of intimal lipids results in an infiltration of macrophages that were believed to play a crucial role in phagocytosing lipids. Macrophages were primarily viewed as scavenger cells, working to remove infiltrated fat particles within the intima. It was acknowledged that these macrophages would "overeat," leading to cell death and the spillover of lipids, ultimately resulting in the formation of atheromas (Figure 4). Consequently, the pathogenesis of atherosclerosis was predominantly considered a lipid disorder, characterized by an excessive influx of lipids into the arterial wall (86). The success of the theory was reinforced by the discovery of the LDL Receptor by Goldstein and Brown. They found that the LDL receptor was able to regulate the systemic levels in the blood of the LDL via its rate of uptake through the hepatic LDL receptor pathway. This was evidenced by the fact that lack of functional LDL receptors is responsible for the massive accumulation of LDL in patients with homozygous familial hypercholesterolemia (87, 88).

3.4 Atherosclerosis: the response to injury model

As insights into the pathogenesis of atherosclerosis progressed, and as it was observed that besides lipids, plaques were composed of different cell types that were affected by hyperlipidemia, novel insights emerged. In 1976, Ross and Glomset postulated that endothelial cell injury, particularly by oxidative LDL and shear stress was the initiating event in atherosclerosis (89, 90). The "*response to injury*" hypothesis of atherosclerosis proposed that endothelial denudation was the first step in atherosclerosis and evolved over the years. In 1986, novel insights lead to an update of this hypothesis and highlighted the possible interaction between endothelial cells, macrophages and VSMCs (91). This version emphasized that endothelial dysfunction and/or endothelial activation rather than denudation caused atherosclerosis. The injury can be mechanical, chemical, or immunological. The response of the local arterial wall is characterized by migration of VSMCs from the media into the intima, rapid proliferation of these VSMCs within the intima, massive production of extracellular matrix and accumulation of lipids (91) (Figure 4).

3.5 Atherosclerosis: the inflammation hypothesis

In the 1990s, it became clear that other factors besides lipids and endothelial dysfunction were driving atherosclerosis. Despite changes in lifestyle and lipid lowering pharmacological approaches, atherosclerotic cardiovascular disease still ranked #1 as cause of death (92). Furthermore, it was observed that atherosclerosis was not a slow-developing process per se, and that plaque rupture and thrombosis were responsible for acute cardiovascular events such as myocardial infarction or stroke (93). None of these phenomena could be explained by current theories, and the search for new mechanisms was initiated.

The observation that inflammation plays a role in atherosclerosis was already proposed in the 19th century (55), but firm evidence was provided in the 1980s, when immunohistochemistry enabled precise identification of cell types that were present in atherosclerotic plaques. Not only macrophages (94), but also T cells were observed to be present in atherosclerotic plaques (95), and over the years, almost every immune cell was found to be represented within an

atherosclerotic plaque (96, 97). Moreover, a wide range of pro-inflammatory cytokines, such as tumor necrosis factor α , IL1 β and IL6, and chemokines such as MCP-1, were observed in atherosclerotic plaques (98, 99) (Figure 4). In clinical studies, elevated levels of CRP and its main inducer IL6 were associated with adverse prognosis in unstable angina patients (100, 101). Elevated levels of CRP, IL6 and TNF α were associated with an adverse cardiovascular prognosis in larger population studies (102, 103).

Not only the atherosclerotic lesion itself, but also the adventitia and peripheral adipose tissue were found to contribute to vascular inflammation. When atherosclerosis progresses, both the adventitia and PVAT not only house resident immune cells, but become infiltrated with both innate and adaptive immune cells, which, in addition to the adipocytes, secrete inflammatory mediators contributing to the progression of atherosclerosis (53, 96, 104).

These, and many more experimental findings set the stage for the hypothesis of inflammation as the pathogenic mechanism for atherosclerosis. In a 1999 review by Ross, atherosclerosis was defined as “an inflammatory disease” (105). *“It is well established that lesions of atherosclerosis represent a series of highly specific cellular and molecular responses that can be best described, in aggregate, as an inflammatory disease. In fact, key cell types and mediators of the inflammatory and immune response are main regulators of the evolution of an atherosclerotic plaque. The response is mediated by monocyte-derived macrophages and specific subsets of T lymphocytes, which both migrates from the blood and multiply within the lesion. Activation of these cells leads to the release of hydrolytic enzymes, cytokines, chemokines, and growth factors, which can induce further damage and eventually leading to focal necrosis. Thus, cycles of accumulation of mononuclear cells, migration and proliferation of smooth muscle cells, and formation of fibrous tissue leads to further enlargement and remodeling of the lesion, so that it become covered by a fibrous cap that overlies a core of lipid and necrotic tissue. Furthermore, a consensus is emerging that inflammation plays a role in the pathophysiology of acute complications of atherosclerotic process, such as thrombosis”* (Figure 4).

4. THE CURRENT PARADIGM: ATHEROSCLEROSIS: A LIPID-DRIVEN, CHRONIC INFLAMMATORY DISEASE

In the past 35 years, our insights into how immune cells and their inflammatory mediators drive and modulate atherosclerosis have increased exponentially (96, 106). Novel single cell technological developments have provided the field with novel tools to map the many cell subsets that are present in the atherosclerotic plaque, the adventitia, and perivascular adipose tissue (107). We have only just begun to determine their characteristics, functions, interactions, and roles in atherosclerosis. The capability to quickly generate conditional knockout mice, lineage tracing mice and the advancement of analysis methods has provided novel insights on the effects of the immune system and inflammation in an in vivo setting. Lastly, the concept that inflammation, besides lipids, is an important driver of atherosclerotic cardiovascular disease has also entered the clinical arena. Plasma biomarkers, including hsCRP and IL6 are now commonly used to determine individuals at risk for atherosclerotic cardiovascular disease (108). Advances in PET technology and tracer synthesis technologies made it possible to detect atherosclerotic plaques that show high levels of inflammation, with ^{18}F -FDG PET being used in a clinical (trial) setting (109). Using the Fat

Attenuation Index during CT imaging can detect changes in PVAT induced by inflammation, that correlate with atherosclerotic plaque inflammation in patients (110). Lastly, clinical trials using anti-inflammatory drugs such as anti-IL1 β and colchicine, were successful and showed that immunotherapeutics can be effective in combatting ASCVD (96).

4.1 A short pathogenesis of atherosclerosis: the current view

The current view of atherosclerosis is that of a lipid-driven chronic inflammatory disease of the medium-sized and large arteries, that involves an intricate interaction between immune cells of the innate and adaptive immune system and non-immune cells within the atherosclerotic plaque and the arterial wall (summarized in Figure 5), but also in blood and secondary lymphoid organs.

Atherosclerotic plaques are located in non-laminar flow regions, often at the opposite flow-divider walls. These areas are prone to shear stress induced endothelial cell activation and exhibit increased permeability, and leukocyte recruitment (111). Circulating lipids, especially LDL cholesterol starts entering the subendothelial space, where LDL, containing apolipoprotein B, becomes modified, thereby eliciting danger signals that are recognized by the innate immune system present in the arterial intima. These ‘Danger Associated Molecular Patterns’ (DAMPs) activate Toll Like Receptor signaling as well as the inflammasome in innate immune cells, thereby initiating the inflammatory cascade. Monocytes, macrophages, and neutrophils start releasing chemokines and cytokines, neutrophils release their neutrophil extracellular traps (NETs), resulting in a perpetuating cascade of leukocyte recruitment and activation. In parallel, VSMCs and fibroblasts become activated, and migrate from the media to form the fibrous cap. Activated VSMCs and fibroblasts produce extracellular matrix, further contributing to fibrous cap formation. Macrophages, but also VSMCs phagocytose excessive lipids, and become foam cells. Excess lipid uptake, as well as inadequate efferocytosis results in cell death and extracellular lipid accumulation in the plaque as well as the formation of cholesterol crystals: the beginning of the necrotic core.

At the same time, antigens, including peptides from apolipoprotein B, are being presented in the immunological synapse by antigen presenting cells, including macrophages, dendritic cells and B cells, and drain to secondary lymphoid organs. In the plaque, but especially in secondary lymphoid organs, antigens are recognized by iNKT- cells (particularly lipid antigens) and/or T cells. If antigens are presented to T cells with support of co-stimulation, this will provoke an adaptive immune response, resulting in antigen specific T cell proliferation and antibody production. Innate type B cells, producing only anti-OSE IgM antibodies are also found in the plaque. The continued inflammatory response results in worsened endothelial dysfunction, increased lipid uptake, recruitment and influx of more immune cells (reviewed in (96)).

During atherogenesis, the adventitia and PVAT that mostly house resident immune cells, becomes inhabited with activated innate and adaptive immune cells, that form clusters and lymphoid aggregates, that facilitate immune cell interactions, as well as APC-T cell interactions. The perivascular adipocytes underlying the atherosclerotic plaque are avid producers of chemokines and cytokines (52, 53, 96, 104). Ultimately, the chronic inflammatory response induces breakdown of the fibrous cap as well as thrombogenicity of the endothelium, resulting in plaque rupture or erosion, i.e., atherothrombosis (reviewed in (96)) (Figure 5).




Figure 5: The Pathogenesis of Atherosclerosis Atherosclerotic plaques mostly form at sites where laminar flow is disturbed. This, combined with oxidative stressors, results in the activation of the endothelium, increased permeability, upregulation of leukocyte adhesion molecules and leukocyte recruitment (1). Circulating lipids, especially LDL cholesterol starts entering the subendothelial space, where LDL, containing apolipoprotein B, becomes modified (2), thereby eliciting danger signals that are recognized by the innate immune system present in the arterial intima. Monocytes, macrophages, and neutrophils start releasing chemokines and cytokines (3), and neutrophils form neutrophil extracellular traps (NETs) (4), resulting in a perpetuating cascade of leukocyte recruitment and activation. This includes the recruitment of adaptive immune cells, including T and B cells, into the plaque (5). VSMCs and fibroblasts migrate from the media to form the fibrous cap (6). Activated VSMCs and fibroblasts produce collagen and other extracellular matrix molecules, further contributing to fibrous cap formation (7). Macrophages, but also VSMCs phagocytose excessive lipids, and become foam cells (8). Excess lipid uptake, as well as inadequate efferocytosis results in cell death and extracellular lipid accumulation in the plaque as well as the formation of cholesterol crystals: the beginning of the necrotic core (9). In parallel, antigens, including peptides from apolipoprotein B, are being presented in the immunological synapse (TCR-MHC complex and co-stimulatory/co-inhibitory complex) by antigen presenting cells, resulting in antigen specific T cell proliferation and cytokine production (10), and antibody production (IgG) by B cells (11). Innate type B cells, producing only anti-OSE IgM antibodies are also found in the plaque (12). Ultimately, the chronic inflammatory response induces breakdown of the fibrous cap (13), development of a necrotic core (14), resulting in plaque rupture and atherothrombosis (15). During atherosclerosis, the adventitia and perivascular adipose tissue, originally house resident immune cells become inhabited by a plethora of immune cells, similar to those in the atherosclerotic plaque, thereby actively contributing to vascular inflammation and progression of atherosclerosis (16).

4.2 Immune cells populating our non-diseased and atherosclerotic arteries

Immune cells are common inhabitants of both the non-diseased arterial wall as well as the atherosclerotic plaque, and a large variability of immune cell types and subsets populate our non-diseased and atherosclerotic arteries. The immune cells enter and sometimes exit the atherosclerotic plaque and are capable of aggravating and regulating local inflammation, and therefore are crucial in the progression, stability, and regression of atherosclerotic plaques. Numerous experimental and preclinical studies have proven a key role for both the innate and the adaptive immune system in atherosclerosis (52, 96, 104). In the next section, we will summarize the contribution of the most important immune cell types and their subsets in atherosclerosis.

5. CELLS OF THE INNATE IMMUNE SYSTEM IN ATHEROSCLEROSIS

The innate immune system serves as the body's first line of defence against pathogens, providing a rapid, nonspecific response to potential threats. Unlike the adaptive immune system, which develops specific responses tailored to specific antigens, the innate immune system relies on evolutionarily conserved mechanisms to recognize and combat a wide array of invaders. Key components of the innate immune system include skin and mucosal barriers, soluble components, and cellular responses. The innate immune system relies on soluble components, such as the complement system, antimicrobial peptides, and acute-phase proteins. The complement system, for example, facilitates pathogen clearance by promoting opsonization (a process that helps identify and destroy old cells or pathogens, by coating them with opsonins, such as antibodies and complement proteins), membrane attack complex (MAC) formation, and recruitment of phagocytic cells. The cellular components are mediated by innate immune cells, including macrophages, monocytes, neutrophils, dendritic cells, and natural killer (NK) cells.

5.1 Macrophages

Macrophages are mononuclear phagocytes that are integral to every organ, where they support tissue homeostasis through functional specialization (112). Tissue resident macrophages are identifiable by their characteristic expression of a handful of pan-macrophage markers (e.g. CD11b, F4/80, MertK and CD64). They are endowed with core macrophage functions and related gene signatures that underpin their survival (Csf1 and Maf), non-opsonic phagocytosis (CD14, CD36, Clec7a and Mrc1), opsonic receptor-dependent phagocytosis (fcgr1, 3, 4 and Itgam), complement pathway (C1qb, c and C3ar1) and efferocytosis (Timd4, Mertk and Sirpa). The core macrophage signature points to a specialized role in immune surveillance. Macrophages as well as dendritic cells express several opsonic (i.e. antibody and complement) and non-opsonic pattern recognition receptors that recognize a range of related ligands and result in their phagocytosis and endocytosis. Different Fc receptors are involved in uptake and destruction of pathogens as well as the negative regulation of effector functions, whereas various complement receptors such as CR3 mediate macrophage phagocytosis, cell migration and activation. The engulfed microorganisms are subjected to a wide range of reactive oxygen species (ROS), including superoxide anion, hydroxyl radicals, hypochlorous acid, nitric oxide, antimicrobial cationic proteins and peptides, and lysozyme (113).

Non-opsonic pattern recognition receptors include the mannose receptor (CD206 or MR1), the scavenger receptors SR-A, and MARCO, which mediate phagocytosis and endocytosis of a wide range of microorganisms (114), and members of a family of molecules called toll-like receptors (115). These pattern recognition receptors on dendritic cells and macrophages are involved in the recognition of yeast cell wall pathogen associated molecular patterns (PAMPs) such as mannans, lipopolysaccharides on the surface of Gram-negative bacteria, teichoic acids present on Gram positive bacteria, lipoproteins and zymosan, as well as endogenous damage associated molecular patterns (DAMPs) (116).

Macrophages in tissue orchestrate the complex processes involved in tissue development, wound healing, tissue repair, and remodeling. They recognize and engulf dying, senescent and abnormal cells, as well as bacteria and immune complexes. They engage in a dynamic interplay

Text box 1:**Macrophage polarization**

A common example of macrophage plasticity is their existence in two primary activation states: the classical (M1) and the alternative (M2) polarization. Stein et al. described for the first time that macrophages could be alternatively activated via the Th2 cytokine interleukin (IL)-4 to tailor their responses towards fungal infection and allergies (118). The alternate response was phenotypically and functionally distinct from classical priming with the Th1 cytokine interferon (IFN) γ .

Macrophage activation is associated with distinct metabolic phenotypes. Mills et al. identified the differential activation of metabolic pathways in macrophages derived from two mouse strains, leading to the identification of iNOS and arginase 1 as markers for pro-inflammatory (M1) and alternatively activated (M2) macrophages, that are still being used today (119). Classically activated (M1) macrophages, undergo a metabolic shift towards glycolysis, which supports their pro-inflammatory and microbicidal functions. Conversely, alternatively activated (M2) macrophages, rely more on oxidative metabolism, including fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS), to support their tissue repair and immunoregulatory functions.

Mantovani proposed an overarching model of macrophage polarization that encompassed further heterogeneity in polarization responses, whereby M2 macrophages can be further subdivided into different subsets with distinct functions, such as M2a, M2b, and M2c, depending on the activating signals and the microenvironmental context (117, 120). M2a Macrophages are activated by interleukin-4 (IL-4) and interleukin-13 (IL-13), typically produced during type 2 immune responses, and promote tissue repair and remodeling and enhance extracellular matrix deposition and fibrosis. M2b Macrophages are activated by immune complexes in combination with Toll-like receptor (TLR) or IL-1 receptor ligands and they promote resolution of inflammation and tissue repair. M2b macrophages may express a unique set of markers, including CD86 and CD206, and produce interleukin-10 (IL-10) and interleukin-1 receptor antagonist (IL-1Ra). M2c Macrophages are activated by anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF- β), as well as glucocorticoids. Exhibit immunosuppressive and anti-inflammatory properties, participate in tissue remodeling and wound healing, engage in phagocytosis of apoptotic cells (efferocytosis). M2c macrophages often express CD163, a scavenger receptor involved in clearance of hemoglobin-haptoglobin complexes and produce high levels of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF- β). Mosser conceptualized macrophage plasticity as a spectrum of macrophage transcriptional states, where single or combined stimuli drive various transcriptome signatures (121, 122).

Gordon et al. proposed a useful paradigm of macrophage activation that includes 4 stages: differentiation by growth factors such as CSF1 and CSF2, priming or polarization by IFN- γ or IL-4 and IL-13, activation into an effector phenotype (e.g. by TLRs), and finally resolution or deactivation to enable repair functions by anti-inflammatory mediators like IL-10 and TGF- β (123). Colony-stimulating factor 1 (CSF1) and colony-stimulating factor 2 (CSF2), also known as macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) respectively, are two key cytokines that play important roles in the regulation of macrophage maturation and polarization. CSF1 promotes the differentiation and survival of monocytes and macrophages, as well as the development and maintenance of tissue-resident macrophage populations. CSF1 has been associated with the generation of M2-like macrophages, which are typically involved in tissue repair, wound healing, and immunoregulation (124). On the other hand, CSF2, stimulates the production and differentiation of granulocytes and macrophages from bone marrow progenitor cells. GM-CSF has been shown to induce the differentiation of macrophages towards an M1-like phenotype, which is associated with pro-inflammatory functions.

The functional state of macrophages is influenced by individual or combined signals, which leads transcriptional and epigenetic modification in macrophages facilitating the activation of several transcription factors (125). Pro-inflammatory signals, IFN γ , lipopolysaccharide (LPS), granulocyte-macrophage colony-stimulating factor (GM-CSF) and virus-derived molecules, exert responses through transcription factors including signal transducer and activator of transcription 1/2, nuclear factor kappa-light-chain-enhancer of activated B cells (NF κ B), STAT5 and interferon regulatory factor (IRF5), respectively (125, 126). Anti-inflammatory or anti-parasitic infection responses are induced by IL-4, IL-10, glucocorticoids and macrophage colony-stimulating factor (M-CSF) through STAT6, peroxisome proliferator-activated receptors (PPAR γ), jumonji domain-containing protein (JMJD) 3 and IRF4 (125, 126). Pathological conditions generate diverse and dynamic microenvironments in which both M1 and M2 stimulatory factors often co-exist (127). Recent work has identified that macrophages challenged by IFN- γ and IL-4 simultaneously display both M1 and M2 gene transcriptome signatures while each stimulus mutually inhibits its counterpart's activation at transcriptional and epigenomic levels (127).

with stromal and structural cells within each organ by producing growth factors and other signaling molecules underpinning host defense and organ development and function. Macrophages can dynamically adapt their functional characteristics and phenotypes in response to changes in their microenvironment or stimuli, a feature termed *macrophage plasticity* (117) (Textbox 1: Macrophage polarization). Macrophages can transition between different activation states or phenotypes, exhibiting a spectrum of diverse functions that allow them to effectively participate in various physiological processes, including immune responses, tissue repair, and homeostasis maintenance.

5.1.1 Macrophages in the arterial wall: atherosclerosis

Our understanding of myeloid cell ontogeny, tissue specification and activation has benefitted from advancements in fate mapping, single cell biology and parabiosis (when the circulation of two mice of distinct genotype are joined) techniques. For instance, while monocytes, DCs and granulocytes originate by a multipotent stem cell the hematopoietic stem cell (HSC), new evidence was found that tissue macrophages, originally thought to be derived from bone marrow derived HSCs and continually replenished (128), originate from embryonic precursors during fetal development (129-133). We will discuss the fundamental aspects of these models and their application and relevance to atherosclerosis below.

5.1.1.1 Resident vascular macrophages

In the aorta, two macrophage niches are available both at the steady state and during disease development. Resident vascular macrophages are detected in both intimal and adventitial layers in the steady state (134-136) (Figure 2, Figure 5). Lyve1⁺CD206⁺ resident arterial macrophages are typically located in the adventitia and depend on CSF1 (colony-stimulating factor 1 or M-CSF) and CX3CR1 for their survival. Their origin is consistent with successive waves of arterial colonization, entailing yolk sac erythron-myeloid progenitors and fetal liver monocytes during the embryonic period, followed by influx of bone marrow-derived monocytes in the postnatal period. A sharp decline in yolk sac labeling from 60% at birth to 20% in the days following birth indicates a discrete window of replacement of embryonic precursor by hematopoietic stem cells postnatally (134)

Adventitial macrophages have a topographic and functional interaction with smooth muscle cells, contributing to the homeostasis, optimal arterial diameter, and extracellular matrix (ECM) content of the arterial wall (137). Lyve1⁺ resident adventitial macrophages ensure arterial homeostasis under physiological conditions by clearing excessive collagen deposition by smooth muscle cells (SMCs), preventing unfavorable vessel wall remodeling and dilatation (137). Our work showed that resident-like macrophages constitute most of the macrophage pool in the murine atherosclerotic aorta and that their representation decreases during atherogenesis (138, 139). Recent work showed that early exposure to western diet leads to a loss of resident Lyve1⁺ macrophages within the aorta, exacerbating atherogenesis progression and CVD risk in lifespan (140).

Intimal CD11c⁺ myeloid cells been consistently recognized as crucial contributors to atherogenesis. Deletion of these cells via CD11c-DTR (diphtheria toxin receptor) has been shown to reduce the atherogenic burden (136, 141). CD11c⁺ macrophages can be differentiated from intimal dendritic cells using multi-analyte approaches in both human and mouse studies (138,

142). CD11c⁺ aortic intima resident macrophages, referred to as MacAir, are dependent on CSF-1 (colony-stimulating factor 1) and derive from bone-marrow derived progenitors and are seeded at birth (136). CD11c⁺ arterial macrophages originate from the ductus arteriosus and migrate within the aorta, particularly in the inner curvature of the aorta (a predilection site for atherosclerosis) in the immediate post-natal period. These events coincide with systemic circulatory changes. At birth, the closure of the ductus arteriosus, driven by increased oxygen levels, reduced prostaglandins, and rising systemic vascular resistance, redirects blood flow from the fetal shunt to the pulmonary circulation. Simultaneously, pressure in the aorta increases due to the cessation of placental circulation and the increased output from the left ventricle. The CD11c⁺ arterial intimal resident macrophages play a role in preventing thrombosis via the plasminogen receptor (143). In the early stages of atherogenesis, embryonic MacAir cells accumulate lipids and undergo proliferation, contributing to early lesion formation (136).

Parabiosis studies, which involve surgically joining two living organisms to share a common circulatory and hematopoietic system between the paired organisms, have demonstrated that macrophage chimerism in the aorta remains low (approximately 5%). This finding indicates that once the arterial macrophage niche is established postnatally, these cells renew primarily through local proliferation, with only a minimal contribution from circulating monocytes under steady-state conditions (134, 144). Additionally, parabiosis studies have provided key insights into the dynamics of macrophage origin during plaque development. In early atherogenesis, there is a significant wave of monocyte recruitment, as evidenced by similar macrophage chimerism levels in the blood and aorta, supporting previous findings that monocytes contribute to lesion progression (145-148). However, during late atherogenesis, aortic chimerism is low, suggesting that macrophage pools in the aorta are mostly sustained by local proliferation, with relatively limited input from circulating monocytes (144). Macrophage behavior may also be subset- and location- dependent. Further experiments also revealed that under steady-state conditions, resident intimal arterial macrophages maintain their population through a low rate of local proliferation without significant contribution from bone marrow-derived monocytes. As atherosclerosis progresses, intimal resident macrophages are gradually replaced by bone marrow-derived counterparts (136). Thus, macrophage origin in the healthy vessel wall and in atherosclerotic plaques is complex and its importance in vascular biology and atherogenesis require further investigation.

5.1.1.2 Lipid associated macrophages

Traditionally, phagocytosis of lipids has been seen as the principal role of macrophages in atherosclerosis (149). Macrophages present in atherosclerotic plaque contain substantial amounts of cholesterol esters (150) and assume a foamy or bubbly appearance due to a high content of lipid droplet in their cytoplasm, hence the name “foam cells” (Figure 5, Figure 6). Foam cells are the hallmark of atherosclerosis (151).

The initial step in foam cell formation involves the uptake of LDL cholesterol by macrophages in the arterial wall. In 1979, Brown and Goldstein proposed that macrophages express specific receptors, named scavenger receptors (SRs) (151), primarily the LDL receptor (LDLR), as well as scavenger receptor class A (SR-A) and CD36 (152), LDL particles are then degraded into amino acids and free cholesterol within lysosomes (149). Free cholesterol is released from the

lysosomes into the cytosol, whereas excess of cholesterol esters is accumulated in lipid droplets by catalyzing with acyl coenzyme A:cholesterol acyltransferase-1 (ACAT-1) (153).

The LDL receptor (LDLR) enables internalization of LDL via endocytosis, triggering a cascade eventually causing LDL degradation in the lysosomes and downregulation of LDLR expression (154). Individuals with a mutant LDL receptor suffer from familial hypercholesterolemia, elevated LDL particles in their bloodstream and myocardial infarction at a young age (155). The expression of LDLR by macrophages is important for foam cell formation (156).

ApoE^{-/-}*MSR-A* mice show a 60% reduction in atherosclerosis(157). The CD36 and SR-A scavenger receptors enable lipid uptake by macrophages which is important for clearing oxLDL, but unregulated oxLDL uptake creates lipid-loaded foam cells(158). Deleting SR-A in *Ldlr*^{-/-} mice reduces lesion area to a considerable extent (159). However, deleting both SR-A and CD36 in *ApoE*^{-/-} mice has no effect on lesion area or foam cell formation but it achieves a reduction in inflammation, macrophage apoptosis and plaque necrosis (160), suggesting a key role in immune sensing.

As macrophages cannot limit cholesterol uptake through scavenger receptors, they depend on cholesterol and lipid efflux pathways to prevent transforming into foam cells, as demonstrated in *Ldlr*^{-/-} mice deficient in sphingomyelin synthase (161). In *Ldlr*^{-/-} mice, defective ABCA1-mediated cholesterol and lipid efflux causes unlimited lipid accumulation in macrophages (162). IFN- γ affects scavenger receptor expression and hampers cholesterol efflux by macrophages from obese C57BL/6 mice and generally promotes hyperglycemia and fat inflammation(163).

Several transcription factors are involved in foam cell formation. Liver X Receptors (LXRs) are nuclear receptors that play a central role in regulating cholesterol homeostasis. Activation of LXRs promotes the expression of genes involved in cholesterol efflux, such as ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1), which facilitate the removal of excess cholesterol from macrophages. Sterol Regulatory Element-Binding Proteins (SREBPs): SREBPs are transcription factors that control the expression of genes involved in lipid synthesis and uptake. Activation of SREBPs promotes the expression of genes involved in fatty acid and cholesterol biosynthesis, contributing to lipid accumulation in foam cells. Foam cells are not only derived from macrophages, but they have been shown to derive also from smooth muscle cells undergoing transdifferentiation (164).

Lipid droplets (reviewed in (165)) are dynamic organelles found in most cell types, ranging from adipocytes (fat cells) to hepatocytes (liver cells) and macrophages. They serve as key sites for storing and mobilizing neutral lipids, primarily triglycerides (TGs) and cholesterol esters (CEs). Lipid droplets are composed of a hydrophobic core of neutral lipids surrounded by a monolayer of phospholipids, free cholesterol, and associated proteins. The core contains triglycerides, cholesterol esters, and other hydrophobic molecules. Proteins such as perilipins and members of the PAT (perilipin, ADRP, TIP47) protein family coat the surface of LDs, regulating their formation, stability, and interactions with other cellular components. The primary function of LDs is to store excess energy in the form of neutral lipids. They can interact with various organelles such as the endoplasmic reticulum, mitochondria, and peroxisomes to exchange lipids and regulate cellular lipid homeostasis. Autophagy, a cellular process involved in the degradation and recycling of cellular components, plays a role in regulating foam cell formation (166, 167). Dysregulation of autophagy can lead to the accumulation of lipid droplets and exacerbate foam cell formation (168).

Endoplasmic reticulum (ER) stress is emerging as a significant contributor to foam cell biology and atherosclerosis development. The ER is a crucial organelle involved in protein folding, lipid synthesis, and calcium storage. Disruption of ER function leads to ER stress, triggering a cellular response known as the unfolded protein response (UPR) (169). High levels of cholesterol can alter the lipid composition of the ER membrane and impair its integrity and function (170). ER stress activates the UPR, a signaling pathway aimed at restoring ER homeostasis by reducing protein synthesis, enhancing protein folding capacity, and degrading misfolded proteins. The UPR is mediated by three main transmembrane proteins: inositol-requiring enzyme 1 (IRE1), protein kinase RNA-like ER kinase (171), and activating transcription factor 6 (ATF6) (169). Once ER stress is triggered, foam cells undergo apoptotic or necroptotic cell death (170, 172, 173). ER stress can also trigger inflammatory signaling pathways, exacerbating monocyte recruitment and atherosclerosis progression. Foam cells drive necrotic core formation owing to their uptake of intraplaque lipids leading to increased ER stress and cell death (174).

Accumulation of desmosterol in lipid-associated macrophages lead to activation of LXR target genes, inhibition of SREBP target genes, selective reprogramming of fatty acid metabolism, and suppression of inflammatory-response genes, promoting lipid homeostasis (175). Desmocholesterol suppresses inflammasome activation and protects against atherogenesis and athero-inflammation (176). This evidence suggests that lipid-loading pathways are not directly linked to initiation of inflammation and that other signaling events are required to induce inflammation.

OxLDL and other modified forms of LDL have been shown to exert inflammatory effects through several different pattern recognition receptors, including Toll-like receptors (TLR) (171, 177, 178). Increasing evidence supports roles for TLR 2 and 4 in promoting inflammation and atherosclerosis in mouse models and human lesions (179-181). In addition, macrophage uptake of cholesterol crystals has been shown to result in activation of the inflammasome (181). Antioxidant therapies did not achieve the desired clinical efficacy in CVD, indicating that the main driver of atherogenesis is not oxidation.

Nuclear Factor-kappa B (NF- κ B) is a key transcription factor involved in inflammatory signaling. Activation of NF- κ B in response to inflammatory stimuli promotes the expression of pro-inflammatory cytokines and chemokines, which contribute to the recruitment of immune cells and exacerbation of inflammation within the arterial wall. In addition to NF- κ B, other signaling pathways involved in inflammation, such as the mitogen-activated protein kinase (MAPK) pathway and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, also contribute to foam cell formation by promoting the expression of inflammatory mediators and adhesion molecules. NF κ B is involved in macrophage survival (182).

5.1.2.2 Macrophage polarization in atherosclerosis

Macrophages exhibit great plasticity (*see text box*). In murine atherosclerotic lesions, M2 macrophages accumulate initially in early lesions, while during lesion progression M1 macrophages predominate (183). Deletion of Arginase-2 in *Apoe*^{-/-} mice reduces lesion size, macrophage inflammation and necrotic core formation (184). Hypoxia in mice is shown to enhance the expression of M1 macrophage markers while reducing M2 macrophage markers, contributing to necrotic core formation (185). In human atherosclerotic plaques, M1 macrophages are more frequently found in rupture-prone shoulder regions of the plaque, while

M2 macrophages are more common in the adventitia (186). Human symptomatic carotid plaques, which have a greater content of lipid and leukocytes, have increased expression of M1 macrophage markers while femoral plaques, with more fibroconnective tissue, collagen, and calcification, have greater M2 marker expression (187). M2 macrophages have also been observed in stable regions of human plaques (188). Normalizing plasma HDL levels upregulates M2 macrophage markers and downregulates pro-inflammatory markers (189).

Oxidized phospholipids within murine atherosclerotic plaques have been shown to downregulate M1 and M2 gene expression, phagocytic and chemotactic capabilities and induce an Mox macrophage phenotype associated with Nrf2-mediated expression of redox-regulatory genes, such as heme oxygenase-1, thioredoxin reductase 1 and sulfiredoxin (190).

Platelet-derived chemokine CXCL4 has been shown to produce a separate M4 human macrophage phenotype, which is less efficient at phagocytosis, has reduced expression levels of CD163 and HO-1 and is a terminal state in that it not able to transform into other macrophage phenotypes once polarized (191). CXCL4-induced M4 macrophages downregulate scavenger receptor expression, and upregulate cholesterol efflux transporters, in comparison to M-CSF-induced macrophages (191), thus rendering M4 macrophages less able to take up cholesterol and become foam cells. Their presence in atheromatous lesions is enriched in vulnerable plaques (191), where they express MMP7 and S100A8.

Hemoglobin-haptoglobin (Hb:Hp) complexes or Heme – both found in intraplaque hemorrhage – induce hemorrhage-associated or Mhem macrophage phenotypes. Exposure to Hb:Hp or Heme stimulate ATF-1-mediated HO-1 expression, subsequently increasing expression of the Hb:Hp scavenger receptor CD163 and IL-10 while suppressing MHC-II expression by human macrophages (192, 193). This macrophage phenotype is resistant to foam cell formation due to the promotion of LXRA and ABCA1 expression and cholesterol efflux (194). Their role is, however, not wholly protective because CD163⁺ CD206⁺ macrophages in the plaque can promote angiogenesis and vascular permeability and inflammatory cell recruitment (195). They are associated with a vulnerable plaque phenotype (196), suggesting that they can become activated and promote atherogenesis.

5.1.2.3 Macrophage heterogeneity at the single cell level

Three main macrophage populations with different inflammatory properties were identified in human (197-200) and murine single cell studies (201). The first is an inflammatory macrophage population expressing high levels of IL-1 β , a well-recognized immune-target in atherosclerosis, further highlighting its relevance for atherosclerosis progression. The second is a vascular resident-like phenotype that is enriched in genes involved in antigen presentation and endocytosis. Finally, Trem2^{hi} (Triggering Receptor Expressed on Myeloid Cells 2) macrophages, a subset previously identified in obesity as a protective one, highly express genes associated with lipid handling and metabolism and mouse studies have confirmed that these cells might be foamy macrophages, a hallmark of atherosclerosis (202). Trem2^{hi} macrophages express high levels of genes associated with lipid metabolism, cholesterol efflux and oxidative phosphorylation including *Trem2*, *Cd9*, *Lpl*, *Fabp5*, *Plin2*, *Abcg1*, *Spp1* and *Itgax* and do not express inflammatory gene signatures suggesting a homeostatic lipid handling role in atherosclerosis(202) . Recently, two subsets of *Trem2* macrophages have been defined using scRNAseq(203): *Gpnmb*^{hi}*Trem2*^{hi} macrophages displayed the known homeostatic lipid handling signature, while *Slamf9*^{hi}*Trem2*^{hi}




Figure 6. Myeloid cell subsets in atherosclerosis

The immune landscape of the human carotid atherosclerotic plaque has been recently resolved through the use of the single cell biology techniques. Fourteen distinct myeloid populations were identified; a mast cell population (*TPSB2, TPSAB1, MS4A2*), a plasmacytoid dendritic cell population (pDC; *CLEC4C, IRF7, IRF8, JCHAIN, LILRA4*), 4 conventional DCs (cDCs) and 7 monocytes/macrophage populations. The main subsets are further downstream classified as pro (red) or anti (blue) – atherogenic role through analysis of the top differentially expressed genes (DEGs).

All cDCs populations express of HLA-DR genes as well as individual gene signature; cDC2 cells express *CD1C, CLEC10A, FCER1A* while cDC1 cluster is identified by the expression of *CLEC9A, IRF8* and *SNX3*. Mature cDC2s are recognized by high expression of the egress chemokine receptor *CCR7* and *CCR7* specific chemokines (*CCL17, CCL19*, and *CCL22*) as well as maturation genes (*LAMP3, IDO1*) and immunoregulatory genes such as *CD40, CD200, TNFRSF4* (gene coding OX40) and *CD274* (gene coding PDL-1). Finally, a small population of *AXL* and *SIGLEC6* (AS) expressing DC is identified, however, its role in disease is still unknown.

Monocytes/ macrophages in the human carotid plaque segregate into 7 distinct populations. S100A8/IL1B⁺ and S100A8/IL1B⁻ populations have a less differentiated phenotype compared to the rest of the macrophages found in the plaque and are sometimes referred to as monocytes or mono-macs. They share a high expression of calgranulins *S100A8/S1009/S10012*. However, they differ in other genes: Cluster S100A8/IL1B⁻ is characterised by a stress response gene signature including several heat shock protein genes coding for HSP70 (*HSPA1A, HSPA1B, HSP6*), HSP90 (*HSP90AA1*) and HSP40 (*DNAJB1*). The S100A8/IL1B⁺ cluster is characterised by expression of genes in the inflammasome pathway; *IL1B, NLRP3, CASP4*, pro-inflammatory cytokine/chemokines; *TNF, CCL3, CCL4, CCL3L3, CCL4L2, CCL20*, pro-inflammatory transcription factors; *CEBPB* and *NFKB1* and receptors; *TLR2, TREM1*. In line with a highly inflammatory profile, S100A8/IL1B⁺ expresses senescence genes (*CDKN1, PTGER2, PTGS2*) as well as genes involved in cell death, proliferation and survival (*BCL2A1, BTG1, GOS2*). This suggests S100A8/IL1B⁺ as a terminal and a highly pro-inflammatory and pro-atherogenic cluster. The IL10⁺/TNFAIP3⁺ population shares a high *IL1B* expression with S100A8/IL1B⁺, however, in addition to expressing pro-inflammatory genes, IL10⁺/TNFAIP3⁺ has a clear anti-inflammatory signature, exclusively expressing the anti-inflammatory cytokine *IL10*, the NFκB inhibitor *TNFAIP3* and the anti-inflammatory receptor *GPR183*, highlighting the potential role of this subset in rebalancing the immune responses in plaques.

C1Q and HMOX1 clusters are defined by high expression of the complement C1q family (*C1QA*, *C1QB*, *C1QC*), genes common to resident-like macrophages, suggesting an homeostatic role in the atherosclerotic plaque environment. TREM2^{hi} and a PLIN2^{hi}/TREM1^{hi} are 2 distinct lipid-associated macrophages (LAMs) clusters. They share a lipid-associated transcriptional signature including fatty acid-binding proteins (FABP4, FABP5) and lipid scavenger receptors (CD36, MARCO). TREM2^{hi} expresses genes involved in regulating cholesterol metabolism, transport, and efflux (*ANXA2*, *APOC1*, *APOC2*, *APOE*, *CYP27A1* and *NR1H3*-the gene encoding the transcription factor LXRα) as well as genes involved in lysosomal degradation (*LIPA*, *LGMN*, *PSAP*) and a strong antioxidant signature related to metallothionein *MT1G*, *MT1X*, *MT1E*, *MT1F*, a group of antioxidant proteins expressed in response to injury. This gene signature along with a lack of inflammatory genes suggests TREM2^{hi} to be highly competent in lipid uptake, cholesterol metabolism and efflux.

PLIN2^{hi}/TREM1^{hi} macrophages expresses a high level of the perilipin gene *PLIN2*, a *bona fide* lipid storage and foam cells marker, coding for a structural component of lipid droplets. Unlike TREM2^{hi} cluster, PLIN2^{hi}/TREM1^{hi} lacks expression of genes involved in lysosomal degradation and most genes involved in cholesterol efflux suggesting that the lipid uptake is not paralleled by an increase in efflux leading to marked cholesterol storage. PLIN2^{hi}/TREM1^{hi} expresses genes in the inflammatory and inflammasome pathway *TREM1*, *TNF*, *CEBPB*, *OLR1* and *IL1B* as well as genes involved in ER unfolding protein response such as *ATF3*, *CALR*, *ACADVL*, *HSPA5* and *HSP90B1* and genes involved in apoptosis, anti-proliferation and survival such as *GOS2*, *BTG1*, *BCL2A1*, *IER3*, *EGR1*, *BNIP3L* and *MCL1*. Finally, the phenotype of TREM1 foam cells is completed by a high chemokine secretory signature, PLIN2^{hi}/TREM1^{hi} cells selectively express *CCL2* and *CCL7* in the plaque as well as high levels of *CCL20*, *CXCL3*, *CXCL2* and *CXCL8*. This strong and specific chemokine signature suggest that these inflammatory foam cells might propagate the disease by playing a major role in the recruitment of immune cells to the plaque.

macrophages expressed a more inflammatory gene signature (*Tnf*, *Ccl3*, *Ccl4*, *Nfkbiz*) and less lipid handling gene signature when compared to *Gpnmb*^{hi} macrophages.

Recent studies have highlighted the multifaceted role of TREM2 in atherosclerosis. Conditional deletion of TREM2 in CX3CR1-expressing cells revealed a reduction in foam cell formation and survival, accompanied by decreased atherosclerotic lesion size, but with no observable effect on monocyte recruitment (204). In contrast, studies involving global or hematopoietic deletion of TREM2 demonstrated its critical role in promoting efferocytosis (the phagocytic clearance of apoptotic cells) and controlling plaque necrosis, underscoring its contribution to lesion stability (205). Interestingly, therapeutic TREM2 agonism has been shown to reverse atherosclerotic lesion progression and necrotic core formation (205, 206). This suggests that while TREM2-dependent foam cell survival contributes to plaque growth under certain conditions, it also plays a protective role by mitigating the development of the necrotic core, a hallmark of advanced and unstable plaques. These findings point to a dual role for TREM2 in balancing foam cell functions, lesion stability, and progression. Further research is needed to determine whether these distinct effects of TREM2 arise from macrophage heterogeneity within atherosclerotic lesions, such as differences between resident arterial macrophages and recruited monocyte-derived macrophages, or whether they reflect context-dependent mechanisms of TREM2 signaling in foam cells.

A new subset of lipid-associated macrophages that exhibit both a high lipid signature and inflammatory score has been recently identified in human carotid plaques. This subset, termed inflammatory lipid-associated macrophages or iLAMs was referred to as PLIN2^{hi}/TREM1^{hi} due to the highest expression of lipid-droplet associated gene, perilipin (*PLIN2*) and the triggering receptor expressed on myeloid cells 1 (*TREM1*) known to be the inflammatory “antagonist” of TREM2 (198) (Figure 6). The transcriptional signature of this subset is consistent with murine

studies where loss of TREM1 was linked to significant reduction of atherosclerotic lesions, reduction of foam cell formation and recruitment of monocytes (207, 208). Computational and functional experiments demonstrate that PLIN2^{hi}/TREM1^{hi} iLAMs derive from TREM2^{hi} macrophages through loss of lipid handling genes, including cholesterol efflux transporters and acquisition of inflammatory transcriptional signature (e.g. IL1beta, CCL2, NALP3, NFκB) consistent with a pathogenic transition (198).

5.2 Monocytes

Monocytes are mononuclear phagocytes that are produced in the bone marrow and circulate in the bloodstream. They are derived from macrophage-dendritic cell precursors (MDPs) in the bone marrow, which express CD115, c-Kit, CX₃CR1 and Flt3 (209). Monocytes rely on various chemokine receptors and adhesion molecules to traffic from the bone marrow and blood to tissues. There are two main populations of monocytes: classical (mouse-Ly6C^{hi} CCR2^{hi}CX₃CR1^{lo}, human CD14^{hi}CD16⁻) and nonclassical monocytes (mouse-Ly6C^{lo} CCR2^{lo}CX₃CR1^{hi}, human-CD14^{lo}Cd16⁺)(210). CD14 is a co-receptor for TLR-4 enabling lipopolysaccharide detection while CD16 (or FcγRIII) belongs to the Fcγ receptor family that bind to antibodies during immune responses such as antibody-dependent cell-mediated cytotoxicity (ADCC). Ly6C^{high}CCR2^{high}CX₃CR1^{low} monocytes are recruited to inflamed sites, depend on CCR2 to mobilize from the bone marrow (210, 211). Ly-6C^{low}CCR2^{low}CX₃CR1^{high} monocytes – resident or non-classical monocytes - patrol the endothelium to maintain homeostasis, depend on LFA-1 and CX₃CR1 for crawling and extravasation (212). In steady state, patrolling monocytes promote vascular endothelial cell homeostasis; they remove damaged cells and debris from the vasculature and are associated with healthy vascular remodeling (213, 214). Nonclassical monocytes derive from classical monocytes in a Nur77-dependent manner (215, 216). Conversion of classical into non classical monocytes has been demonstrated also in humans (129).

5.2.1 Monocytes in atherosclerosis

Studies in both mice and humans have demonstrated that increased severity of atherosclerosis is associated with an expansion of the blood monocyte pool. Ly6C^{hi} monocytes represent 90% of monocytes accumulating in murine atherosclerotic lesions (146). Hypercholesterolemia increases the proliferation and differentiation of Ly-6C^{hi} monocytes, impairs conversion to resident subsets (which can be reversed by statins) and elevates macrophage foam cell formation (146).

On the other hand, Ly6C^{lo} monocytes, also referred to as patrolling monocytes, preferentially differentiated into disease associated CD11c⁺ myeloid cells (147). In agreement with this finding, a subset of non-classical monocytes was found to be enriched in patients with coronary artery disease using mass cytometry (217). Deficiency of Nur77, the transcription factor involved in Ly6C^{lo} monocyte development, has been shown to increase atherosclerosis and obesity, suggesting an atheroprotective role of patrolling monocytes in line with their homeostatic functions described (214, 218-220). Lyn kinase enhances atherogenesis by impairing the atheroprotective function of Ly6C^{lo} monocytes (220). Depletion of CD11b⁺ cells using a diphtheria toxin system reduces atherosclerotic plaque area and the amount of lipid, macrophages, SMCs, collagen, and necrotic core size, however there is no effect on established plaques (221).

In regression models of atherosclerosis, either by normalizing plasma HDL levels or transplanting the aortic arch from *Apoe*^{-/-} mice into wild-type mice, Ly6C^{hi} monocytes emigrate from regressing plaques, and the expression of M2 macrophage markers is increased in bone marrow-derived macrophages and plaque macrophages (189, 222). Atherosclerotic regression is dependent on the recruitment of monocytes from the blood via CCR2 (223). Loss of arginase 1 and ornithine decarboxylases impairs regression by interfering with MertK dependent efferocytosis (224, 225), suggesting that the establishment of M2 polarization is inherent to atherosclerosis regression and the re-establishment of effective efferocytosis.

The amount of pro-inflammatory CD14⁺CD16⁺ monocytes and serum TNF- α levels is elevated in patients with coronary artery disease (226) and this monocyte subset negatively correlates with fibrous cap thickness (227). Flow cytometry analysis showed CD14⁺⁺CD16⁺ monocytes, particularly those from patients who have suffered a myocardial infarction, upregulate their expression of CD11c in response to VLDL uptake, high fat consumption or elevated circulating triglycerides (following high fructose consumption), and the upregulation is particularly pronounced in patients with large necrotic cores (228). Active and stabilized CD11c increases VLA-4 expression on monocytes and thus enables it to form clusters and bind to endothelial VCAM-1, strengthening the adhesion of recruited monocytes (228).

5.3 Dendritic Cells

Dendritic cells (DCs) are the most capable antigen presenting innate immune cells. DCs come in 3 subsets, i.e., plasmacytoid DCs (pDCs), and 2 conventional DC subsets, cDC1 and cDC2. Plasmacytoid DCs are the main players in viral immunity, and secrete large amounts of interferons, whereas cDCs are responsible for antigen presentation and priming of naïve T cells in the T-cell zones (229). cDC1 cells are involved in cytotoxic immune responses, can cross-present antigens, and are crucial in the response to intracellular pathogens and anti-tumor responses, whereas cDC2 cells have a multitude of functions including responses to extracellular pathogens and directing CD4⁺ T cell responses (230).

5.3.1 Dendritic Cells in Atherosclerosis

Dendritic cells are present in the healthy arterial wall and are predominantly located in the intima in atherosclerosis prone areas (141, 231). When atherosclerosis progresses, the number of arterial DCs increases. DCs are located within the atherosclerotic plaque (232), in the adventitia and PVAT and in arterial tissue lymphoid organs (ATLOs) (233). In atherosclerosis, ApoB100, HSP60, HSP65, and beta2-glycoprotein are considered auto-antigens that are being presented by DCs (234). Following uptake by antigens, DCs mature, produce pro-inflammatory cytokines and naïve T cells become activated, thereby driving atherosclerosis (97). Dendritic cells present atherosclerosis prone areas or atherosclerotic plaques can have a foamy appearance and were shown to be able to take up lipids via scavenger receptors such as SR-A, CD36 and LOX1(235). Lipid laden DCs are very well capable of activating naïve T cells (236). The highest DC content is found in vulnerable plaques. Plaque and adventitial DCs that interact with exhibit a mature phenotype, expressing co-stimulatory molecules like CD86 and CD40 (237, 238).

The healthy intima predominantly contains CD11c⁺CD11b⁺CD103⁻ DCs (141), which are also prominent in atherosclerotic plaques (239). This CD11b⁺ cDC subset can exit atherosclerotic plaques and migrate to draining lymph nodes via CCL19/CCL21 and their receptor CCR7 (240).

CD11c⁺CD11b⁺CD103⁻ DCs in atherosclerotic plaques are inversely correlated with plaque inflammation in humans and mice, suggesting that CD11b⁺ cDCs are protective in atherosclerosis (239).

Elimination of CD11c⁺ DCs in *Apoe*^{-/-} mice decreased lipid content in early atherosclerotic plaques (141). DCs are capable of modulating lipid homeostasis. Absence of CD11c⁺ DCs in *Apoe*^{-/-} mice raises VLDL and LDL cholesterol levels(241). When the lifespan of DCs was prolonged in CD11c-BCL2 transgenic *Apoe*^{-/-} mice, VLDL and LDL cholesterol levels had decreased(242). The underlying mechanism is still unclear, although it gut DCs may affect lipid absorption(243).

CD103⁺ conventional DCs (cDC1), which make up 20-30% of the aortic DC population require fms-like tyrosine kinase 3 (Flt3L) signalling for survival and development (241). Deficiency in Flt3 reduces the representation of CD103⁺ DCs and regulatory T cells and increases the expression of IFN- γ and TNF- α causing the exacerbation of atherosclerosis, suggesting that Flt3-dependent CD103⁺ DCs protect against atherosclerosis (244).

Another DC subset important in atherosclerosis are the CCL17⁺ DCs, which are an alternative CD11b⁺ cDC subset. CCL17⁺ DCs accumulate in the intima and adventitia of atherosclerotic vessels in mice and express CD11c, MHC-II, CD11b, CCR7 and the co-stimulatory molecules CD40, CD80 and CD86. Absence of this CCL17⁺ DC population resulted in a decrease in atherosclerosis, by causing an expansion of Tregs (245).

pDCs are a heterogeneous DC subset, that can be beneficial and detrimental in atherosclerosis (246). pDCs promote atherosclerosis through activation of T_H1 cell responses and secretion of interferon (IFN)- α (247), but can protect against atherosclerosis by inducing a Treg response (248).

Recent single cell RNAseq studies aiming to better phenotype cell subsets present in atherosclerotic plaques showed that there were 4 major DC subsets in murine atherosclerotic plaques: cDC1, cDC2, pDC and mature DCs (201). CyTOF studies showed similar subsets, with clear populations of cDC1 and cDC2 cells, as well as pDCs (138, 249). Studies from human atherosclerotic plaques reveal the presence of up to 5 dendritic cell subsets: cDC1, cDC2, mature cDC2, AS DCs and pDCs (197-199) (Figure 6). The exact function and relevance of these subsets in the pathogenesis of atherosclerosis is still under investigation.

5.4 Neutrophils

Neutrophils constitute the predominant immune cell population in the blood stream, representing approximately 40%–70% of all circulating leukocytes in humans. Elevated levels of circulating neutrophils and neutrophil-derived biomarkers, such as myeloperoxidase (224) and neutrophil gelatinase-associated lipocalin (NGAL), have been associated with adverse outcomes in patients with ACS (250). These biomarkers serve as indicators of ongoing inflammation and neutrophil activation, aiding in risk stratification and prognostication. Despite their abundance in circulation, neutrophils comprise a minor fraction of immune cells within atherosclerotic plaques, where macrophages and T cells predominate.

Recent studies have shed light on the potential significance of targeting neutrophil activation and neutrophil effector mechanisms, including the production of reactive oxygen species (ROS), release of cytotoxic enzymes through degranulation, and formation of neutrophil extracellular traps (NETs). These emerging therapeutic strategies hold promise for ameliorating atherosclerotic burden and enhancing plaque stability, particularly at the preclinical level.

Despite advancements in understanding the molecular machinery underlying neutrophil functions, the upstream signaling pathways and transcriptional regulators governing these processes in neutrophils remain poorly elucidated. Further research is warranted to unravel these complexities and identify novel therapeutic targets for managing atherosclerosis.

Neutrophils are involved in all stages of atherosclerosis (reviewed in (251)). In mice, neutrophil depletion reduces atherogenesis, and increased levels of circulating neutrophils exacerbate plaque formation, suggesting a role in lesion development (252). Neutrophils contribute to atherogenesis by adhering to activated endothelial cells and transmigrating into the arterial intima, where they release pro-inflammatory mediators and reactive oxygen species (ROS). This promotes endothelial dysfunction and facilitates the recruitment of other immune cells, fostering plaque formation and progression (253). Neutrophil Extracellular Traps (NETs), web-like structures based of DNA, histones, and antimicrobial proteins released by activated neutrophils, have been implicated in atherosclerosis (254). NETs promote thrombosis, exacerbate inflammation, and contribute to endothelial dysfunction, macrophage activation and plaque destabilization, thereby enhancing the risk of acute cardiovascular events (255). Neutrophils release NETs that degrade the fibrous cap of atherosclerotic lesions, predisposing them to rupture. NETs contain histone H4, which binds and exert a direct cellular lytic action onto smooth muscle cells resulting in plaque destabilization (256). Moreover, neutrophils can promote platelet activation and aggregation, further exacerbating thrombus formation(257). In addition, NETs induce plaque erosion leading to thrombosis (258). Targeting neutrophil recruitment, activation, or NET formation may represent potential therapeutic strategies for mitigating atherosclerosis progression and reducing cardiovascular events. Recent studies showed that intermittent exposure to high fat diet accelerates atherogenesis via L-1 β -dependent neutrophil progenitor reprogramming (259).

5.5 Mast Cells

Mast cells, traditionally known for their role in allergic reactions and immune responses, have been implicated in the pathophysiology of cardiovascular diseases (CVD). Mast cells are found in connective tissues, mostly submucosal tissues and the dermis and are important for alerting the immune system to local infection. Derived from common myeloid progenitors, they play an important role in allergic reactions by degranulation, releasing proteins such as histamine, which is followed by sustained inflammation (260).

Mast cells accumulate within atherosclerotic plaques as they progress, and their numbers are associated with acute cardiovascular events, indicating their involvement in plaque destabilization. They have been observed in coronary and carotid artery plaques; specifically localized at sites of plaque erosion, hemorrhage or rupture, while the presence of adventitial mast cells correlates with cardiovascular events (261). Within plaques, they release a range of mediators, including proteases such as cathepsin G. These proteases can degrade low-density lipoproteins (LDL) and facilitate their binding to proteoglycans (PGs), thus promoting plaque progression. They secrete serine proteases such as chymase which can activate MMPs promoting plaque instability, and the conversion of angiotensinogen to angiotensin (262) to promote vasoconstriction possibly restricting remodeling of the arterial wall. A deficiency in kit – which depletes mast cells – reduces atherosclerotic disease (263).

Mast cells are involved in regulating vascular permeability. Increased permeability can contribute to intraplaque hemorrhage, vascular leakage, and the recruitment of neutrophils to murine atherosclerotic plaques via the CXCR2/VLA-4 axis (264). They produce chemokines like CXCL1, which recruit inflammatory cells such as CXCR2⁺ neutrophils to the plaque site, exacerbating inflammation within the plaque environment.

The mast cell-derived pro-inflammatory cytokines IL-6 and IFN- γ advance atherogenesis by elevating the production of matrix-degrading proteases(263). Antagonizing CCR3 inhibits perivascular mast cell recruitment, subsequently reduces plaque and necrotic core size, thus stabilizing plaques, and inhibiting mast cell chymase had the same effect (265). Through these mechanisms, mast cells actively contribute to plaque destabilization, erosion, rupture, and thrombosis, all of which are critical events leading to acute cardiovascular syndromes

6. CELLS OF THE ADAPTIVE IMMUNE SYSTEM IN ATHEROSCLEROSIS

The adaptive immune system reacts in a highly specific way. Adaptive immune responses are initiated by the innate immune system and require antigen presentation by antigen presenting cells. Adaptive immunity includes humoral as well as cell-mediated mechanisms, which are executed by B and T lymphocytes respectively. Important features of the adaptive immune response are antigen recognition, co-stimulation, clonal expansion and differentiation of T and B cells into effector, cytotoxic, plasma or memory cells. Therefore, adaptive immune responses are slower than innate responses. Upon exposure to a previously encountered antigen, the appropriate memory cells will generate faster, stronger, and more effective immune responses. The first evidence that the adaptive immune system was crucial in atherosclerosis emerged in the 1980s. T cells, B-cells and other HLA⁺ antigen presenting cells were found to be present in human atherosclerotic plaques (95, 266, 267). In *ApoE*^{-/-} mice, absence of T- and B-cells decreased atherosclerosis when fed a normal chow diet (268), which was also observed in *Id1r*^{-/-} mice on a high cholesterol diet(269). Splenectomized mice developed more atherosclerosis, and transfer of B cells ameliorated atherosclerotic disease (270). Transfer of activated CD4⁺ T cells aggravated atherosclerosis in mice(271). These early studies form the basis of our current knowledge on adaptive immune responses in atherosclerosis.

6.1 T cells

T cells are observed in all stages of atherosclerosis and can progress or regulate inflammation in atherosclerosis (266, 272). Both CD4⁺ and CD8⁺ T cells initiate immune responses after presentation of peptides on major histocompatibility type II (APCs) and type I (all cells) complexes, respectively. Binding of an antigen to a cognate T cell receptor (TCR), together with a co-stimulatory signal, activates T cells and can cause their (clonal) proliferation (229, 273). In patients with CVD, the number of CD4⁺ T cells is increased (197). Mice develop less atherosclerosis when CD4⁺ T cells are being depleted (274), yet MHCII deficiency increased atherosclerosis (275), showing CD4 T cells also contains atheroprotective subsets such as Tregs (276).

Human carotid atherosclerotic plaques contain an increased amount of CD4⁺CD69⁺ T cells compared to that same individual's PBMCs. CD69 becomes rapidly upregulated after TCR-HLA

engagement, indicating an antigen specific T cell response within the atherosclerotic plaque (277). Comparing blood vs carotid plaque scTCR sequencing revealed plaque specific clonal expansion of CD4⁺ T cells, including a small percentage of the Treg population, whereas CD8⁺ T cells only showed little plaque specific clonal expansion (277).

These data suggest that atherosclerosis has an autoimmune component driven by antigen presentation and recognition. The most intensively studied atherosclerosis specific self-antigen is apolipoprotein B, the core protein of LDL. Ex vivo studies showed that plaque CD4⁺ T cells can recognize oxLDL that was processed and presented by APCs (267). More recent work has shown that apoB100 specific CD4⁺ T cells are increased in plasma of patients suffering from ASCVD (278, 279), (280, 281). Antigens are not restricted to apoB100. Other proteins, such as MDA, and PC, beta2 glycoprotein 1, collagen 6A6 (282), and heat shock protein 60, as well as the mitochondrial dehydrogenase ALDH4 (283), have been identified as potential antigens, but whether they cause antigen-induced clonal expansion of T cells needs to be investigated further (234, 284).

CD4⁺ T cells polarize into distinct Th cells or Treg cell subsets, which can either activate or dampen the response of other immune cells, exert pro-or anti-inflammatory effects on tissue resident cells, help B-cells produce IgG antibodies or become cytolytic (285). Each CD4⁺ T cell subset has specific transcriptional programs and patterns of cytokine secretion that can accelerate or attenuate atherosclerosis. These distinct CD4⁺ T cell subsets are Th1, Th2, Th9, Th17, Th22, TFH, CD28⁻ cells, and Treg T cells.

6.1.1 CD4⁺ T cell subsets in atherosclerosis

Th1 cells promote atherosclerosis and is the most prominent Th cell subset found in the atherosclerotic plaque (286-288). *Th1 cells* are driven by the transcription factor Tbet, express CXCR3 and CCR5 and produce IFN γ . In addition to IFN γ , Th1 cells in the plaque also express other pro-atherogenic cytokines including IL2, IL3 and TNF α , which activate macrophages, T cells, VSMCs and ECs and accelerate plaque inflammation (272). Deficiency of Tbet, IFN γ or its receptor protects mice from atherosclerosis (286, 289, 290), whereas administration of IFN γ aggravates atherosclerosis (291). IFN γ was found to inhibit VSMC proliferation (98) and affect macrophage polarization (292).

Th2 cells are involved in the defense against parasites and are pivotal in asthma and allergies, but its role in atherosclerosis is less clear. Their determining transcription factor is GATA3, and they produce IL4. In mouse atherosclerotic plaques, T cells express the Th2 associated cytokines IL4, IL5, IL10 and IL13 (249). However, whether these cells are pro- or anti-atherogenic remains unclear. Patients with more peripheral Th2 cells have lower atherosclerosis burden (293), and IL4 release from activated leukocytes negatively correlates with atherosclerosis (294). However, in a study among 2104 adults from the Multi-Ethnic Study of Atherosclerosis, an increase in circulating Th2 cells was found to be at an increased risk for incident stroke (295).

IL4 can antagonize Th1 responses and diminishes atherosclerosis in mice (296). Other studies show the opposite, i.e. that deficiency of IL4 is atheroprotective (297). Immunization of ApoE^{-/-} mice fed a HCD with and apoB100 peptide increased IL4 expression in T cells but did not show any effect on atherosclerosis (298). Other Th2 associated cytokines were clearly atheroprotective. In humans, plasma IL5 levels correlate with CVD (299, 300). Immunization of *Ldlr*^{-/-} mice with modified LDL is atheroprotective, inducing Th2 skewed response with high production

of IL5 and IL13 (301). IL13 administration increases plaque collagen content and reduces plaque macrophage infiltration (302). IL33 induces the production of Th2 cytokines, reduces atherosclerosis in *Apoe*^{-/-} mice by increasing IL4, IL5 and IL13 levels (303). Absence of IL33 had no effects on atherosclerosis (304, 305).

Th9 cells are poorly characterized. They produce IL9 after stimulation by TGFβ and IL4, and inhibition by IFNγ (305). IL9 levels are increased in patients with CAD, and higher in human atherosclerotic plaques than in the non-atherosclerotic vessel wall (306). IL9 administration in *Apoe*^{-/-} mice exerted pro-atherogenic effects, by inducing VCAM1 expression on endothelial cells, which mediated inflammatory cell infiltration into atherosclerotic lesions (307). Recent work suggests fatty acids such as oleic acid promote differentiation of T cells towards a Th9 phenotype, providing a potential rationale for their increased numbers in CAD patients (308).

Th17 cells are IL17 producing T-cells, that are defined by the transcription factor nuclear receptor RORγt(309). Th17 cells are activated by IL23 (310). In immune cells, and several non-immune cells, IL17 induces the secretion of IL6, gmCSF, and chemokines, all of which are pro-atherogenic (309). IL6 and TGFβ can induce a subtype of Th17 cells that produce both IL10 and IL17 (311, 312). The role of IL17 in atherosclerosis is still under debate (313). IL17A, the most well-known member of the IL17 cytokine family, has been reported to increase (314-316), decrease (317, 318) (319) or not affect (318) atherosclerosis burden. Other studies indicate that IL17 can promote plaque stability by increasing collagen 1 production in VSMCs (320). Both IL17A and its receptor have been reported to affect atherosclerosis dependent on the location within the arterial tree: IL17A- and IL17R- deficient atherosclerotic mice had less atherosclerosis in the aortic arch and aortic roots, but did not affect atherosclerosis in the thoracic aorta (321). Work with antigen (ApoB) specific CD4⁺ T-cells suggests that IL-17 production by these cells increases with disease progression and comes at the expense of regulatory effects of T cells (280).

Also in clinical studies, the role of IL17 in atherosclerotic CVD is still unclear. Although 2 small studies showed that patients with unstable angina or acute MI have higher circulating IL17 levels, compared with patients with stable angina or healthy individuals (322, 323), this could not be confirmed in larger studies(324, 325). In these studies, IL17 levels did not associate with CAD (324), and low IL17 levels were associated with a higher risk of subsequent cardiovascular events in patients with MI (325). IL17 expression in human carotid atherosclerotic plaques was associated with a stable plaque phenotype with a lower macrophage content and a higher VSMC content (319, 326).

Th22 cells are characterized by the production of IL22, and their lack of IL17 and IFNγ (327), and use AHR as AHR as transcription factor. IL22 levels were found increased in patients with symptomatic atherosclerotic disease (328), and patients with acute coronary events have more Th22 cells in their circulation(329, 330). In *Apoe*^{-/-} mice, IL22 stimulates medial VSMC migration, and transforms them into a synthetic phenotype, thereby aggravating atherosclerosis (331). IL22 can repress pro-atherogenic gut microbiota, which reduces atherosclerosis (332).

TFH (follicular helper) cells reside in B cell follicles and, together with B cells, maintain and form germinal centers. There, they interact with germinal center B cells and mediate anti-body isotype switching(333). TFH cells are defined by the transcription factor B-cell lymphoma 6 (BCL6).

TFH cells in atherosclerotic mice exhibit increased autoimmune responses compared to non-atherosclerotic mice (334). Marginal zone B cells inhibit the response of TFH cells, and limit atherosclerosis development and progression (335). TFH cell activity in germinal centers can be

regulated by a subset of CD8⁺ T cells with regulatory function, which was considered defective in *ApoE*^{-/-} mice (336). TFH cells are being maintained using the co-stimulatory ICOS (inducible T-cell co-stimulator)-ICOSL signaling. Absence of ICOS-ICOSL signalling in *ApoE*^{-/-} mice reduces atherosclerosis burden, due to reduced numbers of T_{FH} cells in secondary lymphoid organs (337). Ageing increases the proportion of TFH cells in *ApoE*^{-/-} mice, but not in wild-type mice (336). Interestingly, T_{FH} cells can derive from T_{reg} cells. These 'switched' T_{FH} cells are pro-atherogenic and their depletion reduces atherosclerosis in *ApoE*^{-/-} mice (337).

CD4⁺*CD28*⁻ T cells lack CD28 expression, the main co-stimulatory receptor of naive CD4⁺ T cells. CD28⁻ T cells are only found in humans and non-human primates and are pro-inflammatory and cytotoxic (338). Patients with acute coronary syndrome, but also patients with early atherosclerosis (339) have a higher number of circulating CD28⁻ T cells than healthy individuals (340-342), and CD28⁻ T cells from these patients are resistant to apoptosis (343). ScRNAseq also identified a cluster of CD4⁺CD28⁻ cells in human atherosclerotic plaques, which had a cytotoxic transcriptional profile and contained increased levels of granzyme B in culture (199). Moreover, human unstable atherosclerotic plaques are invaded by clonally expanded T cells, including a large monoclonal population of CD28⁻ T cells (342). Recent work suggests these cytotoxic CD4 T cells may be derived from former regulatory T cells (Treg) which may indicate a self-reactive profile of these cells (344).

6.1.2 Regulatory T cells in atherosclerosis

Regulatory T cells are strong modulators of the immune system. They are essential for maintaining peripheral tolerance, preventing autoimmunity and limiting chronic inflammatory disease (345). Regulatory T cells are defined by the transcription factor FoxP3 and the IL2RA (CD25). Tregs have been shown to play a protective role in atherosclerosis. In *ApoE*^{-/-} and *Ldlr*^{-/-} mouse models, depletion of Tregs increases atherosclerosis (276, 346), whereas treatment with IL-2 complexes, as well as anti-CD3 antibodies increased Treg numbers and reduced atherosclerosis (347)(348-350). The protective effects of Tregs have been attributed to their secretion of TGFβ and IL10, both of which are able to reduce atherosclerosis and/or induce plaque stability in mice (351-353). In patients, low numbers of Tregs are correlated with coronary artery disease (354-356), albeit not in all studies (348), and not with carotid artery disease (348, 356).

Tregs are plastic and can acquire pro-inflammatory features, thereby becoming exTregs. In late-stage experimental atherosclerosis, Tregs start expressing both FoxP3 and T-bet and lose their immune-regulatory phenotype, while still retaining phenotypic similarities with Tregs (288, 357, 358). In a recent study, where Tregs and exTregs from Treg/exTreg lineage tracker (*FoxP3*^{eGFP-Cre-ERT2}*ROSA26*^{GAG-fl-Stop-fl-tdTomato}) *ApoE*^{-/-} mice were submitted to RNAseq, exTregs were found to have a distinct gene signature compared to Tregs, characterized by upregulation of *Tbx21*, *Gzmk*, *Prf1*, *Nkg7*, *ifng* and *ccl4*. Based on this gene signature and Cite-seq data obtained from PBMCs from coronary artery disease patients, human exTregs could be identified as CD3⁺CD4⁺CD16⁺CD56⁺ cells and were found to be distinct from Tregs and NK cells. CD3⁺CD4⁺CD16⁺CD56⁺ cells were found to express inflammatory cytokines, chemokines, chemokine receptors and cytotoxic mediators. Human exTregs lost their suppressive capacities and acquired cytotoxic properties. Interestingly, human exTregs of patients suffering from

coronary artery disease express higher levels of inflammatory and cytotoxic genes than patients without coronary artery disease (344).

The activity of Tregs increases upon binding of their TCR to a cognate antigen. In atherosclerosis, a subpopulation of human and mouse T_{reg} cells was found to react with the ApoB-peptide (278). In early atherosclerosis in *ApoE*^{-/-} mice, apoB-reactive T cells were found to have a Treg-like transcriptome, suggesting that most of the apoB reactive T cells are Tregs. However, throughout atherogenesis, these apoB-reactive Tregs gain mixed Th cell signatures overlapping multiple lineage phenotypes with transcripts of Th1, Th2, Th17 and TFH cells. Transfer of these apoB reactive exTregs failed to protect from atherosclerosis (280). In patients without cardiovascular disease, >60% of ApoB-reactive CD4⁺ T cells were true ApoB-reactive T_{reg} cells (278). In patients with subclinical atherosclerotic disease, the number of true ApoB-reactive T_{reg} cells decreased to 30% and the remaining FoxP3⁺ cells acquired Th1 and Th17 characteristics (278).

6.1.3 CD8⁺ T cells in atherosclerosis

CD8⁺ T cells recognize antigenic peptides that are presented by MHC-I on any nucleated cell. CD8⁺ T cells mature into cytotoxic T cells that can kill virus-infected and abnormal cells, including tumor cells, using cytotoxic pathways. Patients with coronary artery disease have increased levels of cytotoxic CD8⁺ T cells in blood compared with healthy individuals (359, 360) and CD8⁺ T cells are abundant in atherosclerotic plaques in humans and mice (361-363). TCR sequencing of T cells from human atherosclerotic plaques identified a subpopulation of CD8⁺ T cells with an increased frequency, suggesting clonal expansion in the plaque (197, 364). In human coronary atherosclerotic plaques, clonal expansion of CD8⁺ T cells was observed, with TCRs specific for viral epitopes, including influenza and corona virus epitopes (364), which have the potential to cross react with human protein. However, whether this expansion is indeed driven by atherosclerotic plaque antigens remains to be determined, as virus specific CD8⁺ T cells are not phenotypically different from other CD8 T cells in the plaque (365). In another study, circulating CD8⁺ T cells from CAD patients were found to have enrichment of TCR signaling pathways, as well as enrichment of cytotoxic and exhaustion pathways compared to controls without CAD (366). In contrast to CD4⁺ T-cells, antigen specificity of CD8⁺ T-cells in the lesion remains to be determined. In experimental studies, CD8⁺ T cells have been shown to target a wide range of cell types in the plaque affecting smooth muscle cell differentiation (367) and killing endothelial cells and foam cells (368), but also T-cells and dendritic cells. Their wide range of effects has both pro-atherogenic and atheroprotective consequences. CD8⁺ T cell depletion with antibodies reduced atherosclerosis in atheroprone mice (368-370) suggesting that CD8⁺ T cells are pro-atherogenic. Other studies suggest that CD8⁺ T cells can also have an atheroprotective role, for instance by reducing the number of Th1 cells accumulating in the lesion (371) or by eliminating Tfh cells in lymphoid organs (336). Induction of CD8⁺ T cells through immunization may also mediate atheroprotective effects in atherosclerosis. Adoptive transfer of CD8⁺ T cells mediate the atheroprotective effects of immunization with an ApoB-related peptide (p210) in *ApoE*^{-/-} mice (372). Adoptive transfer of CD8⁺ T cells from p210-immunized mice reduced atherosclerosis in *ApoE*^{-/-} mice compared with transfer of CD8⁺ T cells from control mice, primarily through a reduction in dendritic cells (372). Aged atherosclerotic mice exhibit an increase in CD8⁺GranzymeK⁺ T cells (373). Depletion of CD8⁺ T cells attenuated atherosclerosis in aged mice and transfer of aged CD8⁺ T cells significantly enhanced atherosclerosis in recipient mice lacking

CD8⁺ T cells. Within the mouse atherosclerotic plaques, age associated CD8⁺ T cells, including a granzyme K effector memory subset, had accumulated, and clonally expanded. These had a pro-atherogenic transcriptomic signatures of T cell activation, migration, cytotoxicity, and exhaustion, suggesting that aged CD8⁺ T cells, and not young CD8⁺ T cells are detrimental for atherosclerosis (374).

6.1.5 Natural killer T cells in atherosclerosis

Natural killer T (NKT) cells are a unique subset of T cells that recognize lipid antigens presented by the non-classical MHCI molecule CD1d (375). They can be divided into type I or invariant NKT (iNKT) cells, which have few variant TCRs, and type II NKT cells, which have more variable TCRs. Activation of iNKT cells results in the rapid release of T_H1, T_H2 and T_H17 cytokines, depending on the expression of the same transcription factors that define the corresponding T_H cell subtypes: T-bet, GATA3 and ROR γ t, respectively (376). Like CD8⁺ T cells, iNKT cells can also express the cytotoxic proteins perforin and granzyme B (376). Most studies using *ApoE*^{-/-} mice and *Ldlr*^{-/-} mice suggest that iNKT cells are pro-atherogenic (376-384). iNKT cells are thought to promote atherosclerosis by secreting cytokines, which can activate other immune cells present in the atherosclerotic lesion (376-384). These results could not be reproduced in human CVD disease. High levels of iNKT cells were associated with a decreased risk of incident coronary events in patients (385). The role of type II NKT cells in atherosclerosis is unknown.

6.1.6 $\gamma\delta$ T cells in atherosclerosis

$\gamma\delta$ T cells, in contrast to the $\alpha\beta$ T cell, do not recognize specific antigens (386). Increased amounts of $\gamma\delta$ T cells are present in the human and mouse atherosclerotic plaque (387, 388), and produce IL17 and IL23 (388, 389). Hyperlipidemic mice deficient in $\gamma\delta$ T cells mice showed a decrease in early plaque formation (388, 389). Another study failed to see an effect of $\gamma\delta$ T cells in early atherosclerosis (390). In patients with CAD, the number of $\gamma\delta$ T cells, as well as its activation markers had decreased (391). However, in the MESA and Cardiovascular Health Study, the amount of $\gamma\delta$ T cells was not correlated with angina pectoris or myocardial infarction (392). The exact role of this T cell subset in atherosclerosis is unclear.

6.1.7 T-cells in the single cell era

The emergence of single cell analyses has resulted in an increased interest in the role of T cells of atherosclerosis. T cells were found to represent >50% of all immune cells in both mouse and human atherosclerotic plaques and were found to outnumber the plaque macrophages in these analyses. The T cell repertoire, based multi-parameter surface markers, as well as single cell transcriptomes, is very heterogeneous, and has changed the demarcations between our well-defined subsets such as Th1/2/9/17/22, Tregs and cytotoxic T cells.

Single cell RNAseq and CyTOF analysis of atherosclerotic mouse aortas revealed 3-10 different T cell subsets (138, 201, 249, 393), and can generally be subdivided into multiple activating states of CD4⁺ and CD8⁺ T cells, depending on the granularity of the analysis. Next to these subsets, murine plaques contain thymocyte like cells (CD4⁺/CD8⁺ cells) and a Treg cluster (201). Further analysis revealed that peripheral T cell tolerance had deteriorated during atherosclerosis, which was most pronounced within the plaque, as well as the artery tertiary lymphoid organs. Clonal expansion of CD4⁺, CD8⁺ and Tregs could be observed, as well as transcripts associated with T cell exhaustion, Treg-Th17 conversion, and dysfunctional antigen presentation (393). In aged *Ldlr*

$^{-/-}$ mice, whose plaques show more similarities with human plaques, then number of T-cells exceeded that found in young, high cholesterol fed $ldlr^{-/-}$ mice, and show more diversity, including the appearance $GrzK^{+}CD8^{+}$ T-cells and a more prominent representation of exhausted T cells (373).

In human atherosclerotic plaques, the plaque T cell population was even more diverse reporting three (394), four (198), five (199) and thirteen (197) $CD4^{+}$ T cell subsets and two (394), three, four (198, 199) and eight (197) $CD8^{+}$ T cell subsets, depending on the numbers of cells required and analysis methods. In plaques, $CD8^{+}$ T cells are more abundant than $CD4^{+}$ T cells, virtually all T cells are of an effector and/or memory type, and a significant proportion of T cells display signs of exhaustion. Based on transcriptional profiling and clustering, one can define $CD4^{+}$ Tregs, $CD4^{+}$ central memory cells, $CD4^{+}$ effector memory cells, exhausted $CD4^{+}$ T cells, and terminally differentiated $CD45RA$ expressing T cells (Temra) (277). In the $CD8^{+}$ population, one can define effector memory cells, IFN response T cells, cytotoxic effector T cells, Temra, and a T cell population with a 'mucosal associated invariant T cell' signature (198) (Figure 7). These novel data have provided great insights into the heterogeneity of the T cell, characteristics of T cell subsets and their putative functions.




Figure 7. Lymphoid cell subsets in atherosclerosis

Lymphoid cells in the atherosclerosis plaque can be broadly divided into CD4 T-cells, CD8 T-cells, B cells and NK cells, however single cell sequencing has revealed a variety of subsets within these lineages. Apart from regulatory T-cells (T_{regs}), CD4 T cells are not subdivided along the classic T-helper paradigm, but appear to exist in various stages of activation; ranging from a naïve like- central memory CD4 T-cells (T_{CM}) to $CD40L^{+}$ effector memory CD4 T cells (T_{EM}) and ultimately, exhausted CD4 T cells. $CD8^{+}$ T cells consist of highly cytotoxic effector cells (T_{EFF}), which express cytotoxic related genes encoding Granzyme B ($GZMB$), Granulysin ($GNLY$) and perforin ($PRF1$), but also contain terminal differentiation ($GZMK$) or senescence associated subsets (T_{EM} and CD8 IFN response). Mucosal-associated Invariant T-cells (MAIT) and Natural Killer (NK) cells make up minor populations, although 2 distinct NK cell population can be distinguished, with one population bearing markers of cytotoxicity ($FCGR3A^{+}$ NK cells) and a second population expressing chemotaxis related genes ($XCL1^{+}$ NK). Finally, B-cells make up about 10% of the lymphocyte population in the atherosclerotic plaque, but present various stages of B cell maturation, including unswitched IgM^{+} B-cells, class switched (IgG^{+}) memory B cells and antibody producing plasma cells. The enigmatic age-associated B cell is defined by co-expression of genes translating $CD11c$ ($ITGAX$), $CD11b$ ($ITGAM$) and T-bet ($TBX21$).

The first data have come out showing an association of several of these subsets with the occurrence of cerebrovascular disease. Within the CD4⁺ T cell cluster, Fernandez et al. identified 4 transcription-based clusters that showed differential expression between plaques of symptomatic and asymptomatic patients (197). Remarkably, CD4⁺ T cells in plaques from asymptomatic patients were highly enriched for Type I IFN and IFNG transcripts, and the IL1 and IL6 signaling pathway. The CD8⁺ T cells in plaques of asymptomatic patients had a similar activation profile than the CD4⁺ T cells but were also characterized by increase expression of chemotactic and cytotoxicity genes, as well as exhaustion genes (197). In another study, CD4⁺FoxP3⁺ Tregs were found to have acquired Th17 and Th9 features and were, together with CD4⁺NR4A1⁺ and CD8⁺SLC4A10⁺ T cells, associated with cerebrovascular events (395). Additional studies investigating the relevance of these subsets in atherogenesis, their association with clinical features, as well as their drug-targetability are needed.

6.2 B cells

B cells are mostly known for their role in the adaptive immune system through secretion of antibodies, cytokines and their contribution to T cell activation, but also have innate immune cell type functions. As such, B cells play a key role in responses to pathogens but can also mediate chronic autoimmunity. Over the past few decades, we have gained important insights in B cell heterogeneity and function in atherosclerosis. Using preclinical atherosclerosis models and CVD patient material, different B cell subtypes have been identified, with each a distinct role in the progression of atherosclerosis. The surface marker expression profile, location and functionality of B cells show both similarities as well as some diversity between mice and human.

6.2.1 Murine B cell subsets

Murine B cells are generally categorized into B1 and B2 subsets, based on unique characteristics and cell surface markers(396). B1 cells develop in the fetal liver, predominantly inhabit serosal cavities, and undergo self-renewal in the periphery (397). Some B1 cells reside in spleen and bone marrow where they primarily produce IgM antibodies in a T cell-independent (TI) manner (398, 399) (400), serving as the innate arm of adaptive immunity. Murine B1 cells are subdivided into B1a and B1b cells, based on CD5 expression with B1a cells being CD5⁺ and B1b cells CD5⁻ (401, 402), and can be activated by TI-1 antigens (i.e., microbial TLR ligands) and TI-2 antigens (i.e., bacterial antigens that crosslink BCRs). B2 cells are more abundant, and originate in bone marrow, where they develop into immature B cells through Ig heavy and light chain rearrangement (403). Immature B cells then exit the BM and inhabit secondary lymphoid organs (SLOs), where they differentiate into marginal zone (MZ) B cells or follicular (FO) B cells where they complete their maturation (403, 404). The majority of B2 cells are FO B cells that are activated in an antigen-specific T cell dependent manner in the germinal center (GC), where they undergo clonal expansion and somatic hypermutation. This enables them to produce highly antigen-specific antibodies and generate IgG, IgE or IgA antibodies by class switching. GC B cells differentiate into antibody-secreting plasma cells or memory B cells (403). Other B cell subtypes regulate inflammatory reactions through cytokine production. Regulatory B cells (Breg) produce cytokines such as IL10, which suppresses T helper cells, inhibits macrophage antigen presentation and pro-inflammatory cytokine production (405).

6.2.2 B cells and atherosclerosis in mice

Pre-clinical studies revealed that B cells regulate disease progression in a subset-dependent manner (270, 406-411) (Figure 8). Caligiuri et al. showed that splenectomized *ApoE*^{-/-} mice display exacerbated atherosclerosis, a phenotype that could be rescued by reintroducing of B cells (270). Accordingly, Major et al. demonstrated that genetically-induced B cell deficiency in *Ldlr*^{-/-} mice resulted in a loss of anti-oxidized LDL antibodies and a subsequent 30-40% increase in atherosclerotic lesion area (406). These two studies suggested a potential protective role for B cells in atherosclerosis. In line with these findings, it was shown that mice that had deficient IgM secretion had increased atherosclerosis (412-414). B cell depletion studies with an anti-CD20 antibody or B-cell activating factor receptor deletion (*BAFFR*^{-/-}), that mostly affect the B2 cell resulted in decreased atherosclerosis compared to control mice despite comparable serum cholesterol levels (407, 409, 410, 415). Mechanistic studies revealed that B2 cells promoted atherosclerosis via production of pathogenic IgG, activation of T cells, and induction of pro-inflammatory cytokines such as IFN γ , TNF α , IL1 β and chemokines such as MCP-1 (407, 409, 410, 415). Furthermore, murine B2 B cells produce IgG antibodies that bind oxidation specific epitopes (OSE) and stimulate inflammation, at least in part through the Fc- γ receptor (416-418).

Adoptive transfer experiments using different B cell subsets confirmed a subset dependent role of B cells on atherogenesis. B2 cells drive progression of atherosclerosis (418, 419) whereas B1 cells provide protection (419, 420). B1 cells exert their protective function through multiple mechanisms. B1 cells secrete IgM that binds OSE on LDL, preventing lipid uptake and inflammatory cytokine production by macrophages. This reduces the formation of foam cells and inflammation involved in atherosclerosis development. In addition, B1 cell derived IgM facilitates clearance of apoptotic cells by binding to epitopes on their cell surface, hereby limiting inflammation (421). Remarkably, innate response activator (IRA) B cells, derived from B1a cells, are considered pro-atherogenic. IRA B cells are induced by LPS to produce GM-CSF, promoting extramedullary hematopoiesis in the spleen and atherosclerosis (400, 422-424).

Aging induces functional impairment in the B-cell compartment (425, 426). Aging of *Ldlr*^{-/-} mice on standard laboratory diet showed a significant accumulation of age-associated B cells (ABC) which are characterized by expression of CD11c and/or CD11b, in the atherosclerotic aorta (373, 427). Similarly, CD11c expressing B cells were increased in spleen, blood and bone marrow of *ApoE*^{-/-} mice upon aging, concomitant with an increase in aortic plaque size (428). In vitro assays and single cell RNAseq analysis on atherosclerotic plaques from aged *Ldlr*^{-/-} mice demonstrated that ABCs are highly potent antigen-presenting cells and are enriched in genes involved in co-stimulation, inflammation and plasma cell differentiation (373, 427). The presence of ABCs has been associated with several autoimmune diseases, including rheumatoid arthritis (429), multiple sclerosis (430), and systemic lupus erythematosus (431), where they may contribute to disease progression by production of pro-inflammatory cytokines and high levels of autoantibodies. Although the exact contribution of ABCs to atherosclerosis remains to be elucidated, they could potentially drive inflammation and produce atherogenic IgG. Besides ABCs, aged atherosclerotic mice showed an increase in Bregs (373), whose role in atherosclerosis is still not clear. Multiple studies have shown that Bregs can exert a protective role in atherosclerosis via secretion of IL10 (432-435). However, chimeric *Ldlr*^{-/-} mice with a B cell-specific deficiency in IL10 did not display altered atherosclerosis development (408).




Figure 8. Murine B cell subsets. Conventional B2 B cells develop in the bone marrow and reside in follicles or in the marginal zone. B2 cells can differentiate into marginal zone B cells which can rapidly produce antibody, particularly IgM in response to circulating antigens. B2 cells can also become follicular B cells and produce high affinity, class switched, immunoglobulins in a follicular T cell (Tfh) dependent manner. In addition, Tfh cells can contribute to the activation of age-associated B cells (ABCs), characterized by the expression of CD11b, CD11c and the transcription factor T-bet. ABCs are potent antigen-presenting cells and can secrete cytokines and antibodies that may contribute to disease development. B1 B cells develop in the fetal liver and are subdiverted by surface CD5 expression into CD5⁺ B1a cells and CD5⁻ B1b cells. B1a cells are activated by T cell independent type 1 (TI-1) antigen through toll like receptor (TLR) signaling secreting IgM natural antibodies (NAb). B1b cells are additionally activated by T cell independent type 2 (TI-2) antigen through the B cell receptor. Activated B1a cells under inflammatory conditions can become innate response activating (IRA) B cells that secrete GM-CSF. Regulatory B cells (Bregs) can be derived from B2, B1 or possibly a unique B10 lineage. They are defined by IL-10 secretion and immune suppression.

6.2.3 B cells and atherosclerosis in humans

Several B cell subsets are considered to play a major role in human atherosclerosis (Figure 7). Analysis of blood gene expression profiles, single nucleotide polymorphisms (SNP) and Bayesian network analysis constructed from data of 188 coronary heart disease cases and 188 age- and sex-matched controls from the Framingham Heart Study (FHS) identified B cell genes and B cell-centered immune function to predominate in coronary artery disease (436).

Likewise, many studies report an association between coronary artery disease (CAD) and B cell-derived antibodies to OSE on LDL (437-442). Consistent with murine studies demonstrating B1 cell-derived IgM attenuated, and B2-derived IgG promotes atherosclerosis, IgM to OSE was inversely and IgG to OSE was positively associated with coronary stenoses >50% in a cohort of 504 patients (439). Moreover, IgM and IgG autoantibodies and immune complexes could modify risk prediction for CVD (438), predicted incident CVD (ischemic stroke, myocardial infarction, new-onset unstable angina, acute coronary interventions, and vascular death) (440), independently associated with time to incident MACE (441) and were associated with unstable plaque features on intravascular ultrasound IVUS (442).

Likewise, low IgM to native and MDA-modified versions of a specific ApoB100 peptide (p210) were associated with CAD events. However, these studies reported low levels of IgG to p210 and

p45 in CAD events (443, 444). Low levels of IgG to native p210 but not IgM to MDA-modified p210 were inversely associated with severity of CAD and MI risk (445), suggesting a role for different isotypes and/or idiotypes in atherosclerosis. As in murine models, evidence for a protective role for IgM to OSE in human atherosclerosis is more consistent than the evidence for IgG.

Identification of the human B cell that produces antibodies that impact on atherosclerosis has been challenging. While the B cells producing these antibodies in mice have been well described, translation of these murine findings to humans has been challenging (446-449) likely due to differences in surface markers and functional responses (450). Recent advances in single cell analytics, has allowed better characterization of B cell subtypes. An integrated multi-omics single cell atlas of human B cells identified 12 unique circulating human B cell clusters revealing cluster-specific metabolic, biosynthetic and immune signaling activity (451). Multi-omics characterization of B cell subtypes in lymphoid and mucosal tissues revealed spatiotemporal aspects of human memory B cells and marginal zone (MZB) B cells, both of which can transit through germinal centers, acquiring somatic mutations to foster antigen specificity (452-454). Characterization of human B cell subtypes that produce antibodies that modulate atherosclerotic disease is needed to allow the development of B cell-targeted therapeutic strategies.

Although B1 cells have been defined to be the major source of IgM in mice, identification of the human equivalent has been elusive. A putative human B1 cell has been identified by sort-purifying B cell fractions and testing for key murine B1 cell characteristics (spontaneous IgM secretion, efficient T cell stimulations, and tonic intracellular signaling) (455). B cells expressing CD20⁺CD27⁺CD43⁺ fulfilled these criteria. CD20⁺CD27⁺CD43⁺ "B1" cells produced IgM to modified phospholipids linked to atherosclerosis (455, 456).

A higher frequency of CD27⁺CD43⁺ B1-like cells in circulation was associated with fewer secondary cardiovascular events, defined as cardiovascular death, stroke, MI, coronary intervention, and peripheral intervention following carotid endarterectomy (457). While IgM production and reduced can be linked to these CD27⁺CD43⁺ B1-like cells, study of the chemokine receptor CXCR4 demonstrated that the amount of CXCR4 on the surface of these cells provided stronger correlation with atheroprotective IgM antibodies specific for malondialdehyde (MDA)-modified LDL. Moreover, the amount of CXCR4 on CD20⁺CD27⁺CD43⁺ B1-like cells was inversely associated with plaque burden and unstable features as measured by intravascular ultrasound (IVUS)(414). In support of these associative human findings, gain and loss of function studies in mice demonstrated that CXCR4 expression on B1a cells induced migration to bone marrow, enhanced production of IgM to MDA-LDL (414) and loss of CXCR4 on B cells increased atherosclerosis in female mice (458).

B2 cells develop in the bone marrow, move to lymphoid organs and transition into mature naïve B cells in follicular regions, or differentiate to become MZB, memory B cells or antibody producing plasma cells. In germinal centers within secondary lymphoid organs, antigen stimulated B2 cells undergo affinity maturation through somatic hypermutation, and isotype switch to produce highly specific isotype class switched antibodies. In the early antibody response, plasmablasts are rapidly produced but are short lived (459). In humans, increased plasmablasts are associated with atherosclerosis (460). The plasmablasts then further develop into plasma cells, which secrete much higher levels of antibodies, including high-affinity IgG (461). This IgG has been shown to correlate with coronary artery stenosis in some human studies (439, 462, 463).

In addition to IgG antibodies, B2 cells can also class switch to IgE. Evidence linking IgE to human atherosclerosis includes the finding of increased coronary atherosclerosis in patients with hyper IgE syndrome (464, 465), studies showing association of serum IgE levels with coronary artery disease (466, 467). Murine studies have shown that IgE promotes atherosclerosis (468-470). The precise identification of an allergen inducing the IgE response has been more elusive. IgE to the mammalian oligosaccharide galactose- α -1,3-galactose (a-gal) is associated with increased atheroma volume and plaques with unstable characteristics as measured by intravascular ultrasound (IVUS) in a cohort of 118 patients (471). IgE to a-gal is induced by tick bites and can lead to allergy to mammalian products like beef, a syndrome called the a-gal syndrome (AGS). IgE sensitization to a-gal was independently associated with noncalcified plaque burden and obstructive CAD in their cohort of 1056 patients and occurs at higher frequency in patients with STEMI than those with stable or no CAD. Plasma levels of IgE to a-gal are associated with an increased frequency in CCR6+ switched memory B cells both in subjects with increased CAD (472) and those with AGS (473). IgE to common food allergens was found to be associated with cardiovascular mortality in the National Health and Examination Survey (NHANES) and the Multi-Ethnic Study of Atherosclerosis (MESA)(474). These intriguing findings need murine validation for causality but may represent a new tick-induced risk factor for CVD.

B2 cells can also differentiate into memory B and MZB cells. An unbiased approach to identify the atheroprotective IgM-MDA-LDL-producing B cell in humans resulted in the identification of CD27⁺IgM⁺CD24^{hi} cells, that were identified a circulating MZB cells (428). Consistent with these human findings, Nus et.al. had shown murine MZB to be a source of IgM to OSE (335, 475). Unlike mice, B2-derived MZB are a major source of IgM-MDA-LDL antibodies.

ABCs, identified by low cell surface expression of CD21, and high expression of CD11c, CD11b and co-expression of the transcription factor T-bet, are present in the circulation and carotid plaques of CVD patients (373), and subsets of CD11c⁺ B cells showed an association with severe atherosclerosis in humans (428), warranting further research into this B cell subset.

Although cell surface markers for murine Bregs have been identified, markers to identify human Bregs remain unclear (476, 477). Although decreased serum levels of IL10 have long been associated with human cardiovascular disease (478, 479), it is unclear whether IL10 produced Bregs cells is sufficient to attenuate atherosclerosis, although patients with a history of atherosclerotic events had lower levels of IL10⁺ B cells (460).

7. THE IMMUNOLOGICAL SYNAPSE

The innate and adaptive immune system are joint in the immunological synapse (Figure 9). Antigen presenting cells, except for the B-cell, are part of the innate immune system and include dendritic cells and macrophages. APCs express antigenic peptides on their MHCI or MHCII complex, that are recognized by T cell receptors (TCRs) of CD4⁺ and CD8⁺ T cells. Antigens known to play a role in atherosclerosis include ApoB, HSP60, MDA, and PC (234). The MHC-TCR signal is known as signal 1 induces both T cell and APC activation. Following recognition of an antigen by the T cell receptor (TCR) a second signal, 'signal 2' is required to propagate the MHC-TCR response. 'Signal 2' is provided by co-stimulation and boosts (and in some cases dampen) T cell proliferation, activation, and polarization, whereas co-inhibitory molecules counteract these responses(273, 480). A third signal provided by cytokines present in the microenvironment can

influence skewing of naïve T cells towards different T-helper cell subsets. Following successful APC-T cell activation, a plethora of chemokines and cytokines are released to drive or dampen the initiated immune response.

The immunological synapse is a strong regulator of atherosclerosis development and progression. The main players in the synapse, such as MHCII and MHCI, TCR as well as co-stimulatory and coinhibitory molecules are present in both human and murine atherosclerotic plaque tissue, and lymphoid organs (481). In a recent study, Duran et al. found that almost all members of the co-stimulatory and co-inhibitory immune checkpoint family can be detected on few or multiple immune cell subsets that reside within the atherosclerotic plaque (481). Both plaque specific and well as lymphoid organ-based actions of the immunological synapse have proven to play an important role in atherosclerosis (96).




Figure 9. The immunological synapse in atherosclerosis. Antigen-presenting cells (APCs) can mediate T cell activation, proliferation and polarization through three different signals. Signal 1 consists of presentation of atherosclerosis-relevant antigens, including HSP60, ApoB, MDA-LDL, PC, ALDH4A1, on MHC molecules on APCs to the T cell receptor (TCR) on T cells. In addition to antigen recognition, T cells also require co-stimulation for subsequent activation. Such co-stimulatory signals are provided by immune checkpoint proteins, which alternatively may also elicit inhibitory signals that can halt T cell proliferation or induce skewing towards anti-inflammatory immune cells. A third signal is provided by cytokines present in the atherosclerotic microenvironment, which can influence T cell polarization towards for instance IFN γ -secreting Th1 cells. HSP = heat-shock protein, MDA = malondialdehyde, PC=phosphocholine, ALDH= aldehyde dehydrogenase.

7.1 Co-stimulation and co-inhibition in atherosclerosis: immune checkpoints

Immune checkpoints are categorized into 2 major families: the Immunoglobulin Superfamily, which includes both co-stimulatory and coinhibitory immune checkpoint dyads, and the tumor-necrosis factor (TNF)-receptor super family, which primarily exist of co-stimulatory immune checkpoint proteins, though some exhibit co-inhibitory functions (482, 483). The Immunoglobulin Superfamily encompasses CD28-CD80/CD86, CTLA4-CD80/86, PDL1/2-PD1, LAG3, ICOS-ICOSL, BTLA, CD200, CD155, TIM3, and VISTA. The TNF Receptor Superfamily includes

pairs such as CD40L-CD40, OX40-OX40L, CD27-CD70, GITR-GITRL, CD137-CD137L, CD30-CD30L, LT β R-LT α/β , RANK-RANKL, Fn14-TWEAK, and LIGHT-HVEM/LT β R. While each immune checkpoint receptor-ligand pair has a distinct, often cell-type-specific function, a general rule is that co-stimulatory checkpoints enhance inflammation, whereas co-inhibitory checkpoints suppress it. Numerous preclinical studies have demonstrated the involvement of both types of immune checkpoints in various aspects of atherogenesis (481, 484).

7.1.1 Co-stimulation

One of the most investigated co-stimulatory dyads in cardiovascular disease is the *CD40-CD40L* dyad, members of the TNF(R) superfamily. CD40L is primarily expressed on T cells and platelets but is also found on endothelial cells, vascular smooth muscle cells, mast cells, and natural killer cells. CD40 is present on antigen-presenting cells (APCs) such as B cells, dendritic cells, and macrophages, but can also be found on neutrophils, eosinophils, basophils, platelets, endothelial cells, vascular smooth muscle cells, fibroblasts, adipocytes, and epithelial cells. The binding of CD40L to CD40 during T cell-APC interactions drives T cell effector responses, dendritic cell maturation, and B cell antibody production with Ig-isotype switching (485), while in other cell types, this interaction promotes platelet-leukocyte aggregation (486), leukocyte adhesion to the endothelium (487), and macrophage activation (488). In patients, increased levels of soluble CD40L and (soluble) CD40, and/or single nucleotide polymorphisms in the CD40 gene correlate with the presence of CVD, including recurrent myocardial infarction and stroke (489-491). In murine models, Genetic and/or antibody mediated inhibition of CD40L or CD40 effectively reduces atherosclerosis. Plaques were not only smaller, but also rich in collagen and housed a limited number of immune cells, resembling stable, clinically safe, atherosclerotic lesions (487, 492-495). The actions of CD40 and CD40L are cell-divergent, also in atherosclerosis. Selective depletion of CD40L on all T cells significantly reduces plaque load by diminishing (Th)1 responses, resulting in reduced IFN γ levels (496). Besides T cells, CD40L is abundantly expressed on platelets. When platelets are CD40L deficient, no effects on atherosclerosis can be observed (496). However, deficiency of platelet CD40L ameliorates atherothrombosis induced plaque growth (496), and prevents acceleration of atherosclerosis that is induced by thrombin-induced platelet activation (486). Deficiency of CD40 on dendritic cells mirrors T-cell CD40L deficiency, with a reduction in atherosclerosis due to a deficient Th1 response (496). Macrophage CD40-deficiency reduces atherosclerosis and necrotic core formation. CD40-deficient macrophages have anti-inflammatory properties and exhibit enhanced efferocytosis, without affecting Th1 responses (488). Deficiency of macrophage CD40 has no effect on fibrous cap formation (488). Deficiency of endothelial cell CD40 increases atherosclerotic plaque stability (497), and deficiency of adipocyte CD40 decreased atherosclerotic plaques size, but increased the number of lymphoid and myeloid progenitors in the bone marrow, and resulted in an increase in T-cell numbers in the plaques, and increased necrotic core sizes (498). Absence of platelet CD40 reduces atherosclerosis, by affecting platelet induced leukocyte recruitment (499). These data highlight the cell-divergent function of CD40L-CD40 interactions in atherosclerosis. These findings highlight the complex, cell-type-specific roles of CD40L-CD40 signaling in atherogenesis, underscoring its potential as a therapeutic target for modulating plaque composition and disease progression.

Other TNF-(receptor) family members that have been shown to drive atherosclerosis are *GITR-GITRL*, *CD27-CD70*, *CD30-CD30L* and *OX40-OX40L*. GITR is a marker for regulatory T cells, but it exerts different functions. It can enhance Treg's suppressive capacities and facilitate Treg proliferation (500, 501), but it also can enhance effector T cell function (502). Overexpression of T cell GITR, induced by GITRL-overexpressing B cells reduces atherosclerosis by Treg expansion (503). GITR is also expressed by monocytes and macrophages (504-507). Activation of GITR in human and murine macrophage cell lines as well as primary monocytes/macrophages induces release of cytokines (TNF α , IL8, MCP1), and MMP9 (504-506). In atherosclerotic plaques, GITR is expressed on macrophages, T cells, endothelial cells and SMCs. The abundance of GITR expression in the plaque and circulating sGITR levels are associated with plaque vulnerability and the occurrence of cerebrovascular events (508). Global deficiency of GITR in a mouse model of atherosclerosis reduced monocyte recruitment to the arterial wall and prevented macrophage activation and necrotic core formation, thereby reducing atherosclerosis (508). *CD27*, expressed on many immune cell types, has a protective effect on atherosclerosis, due to its role in Treg function (509). The *CD30-CD30L* co-stimulatory pair is involved in activation and proliferation of adaptive immune cells. Blockade of this pathway in *Ldlr*^{-/-} mice reduced atherosclerosis development (510). Interruption of *OX40L*, the ligand of *OX40*, which was found to be present in the CVD risk locus, reduces atherosclerosis and facilitates plaque regression by affecting both T and B cell responses (511, 512). Moreover, scRNAseq data revealed high expression of *OX40* on effector and memory T cells, including Tregs, residing in the atherosclerotic plaque of CVD patients (199). An important co-stimulatory dyad of the immunoglobulin superfamily is *CD28-CD80/CD86*, which is in an intricate balance with the coinhibitory *CTLA4-CD80/86* dyad. *CD80* and *CD86* are expressed on antigen presenting cells, whereas *CD28* and *CTLA4* are restricted to T cells. *CD28-CD80/86* interactions propagate T cell responses and promote survival and memory cell formation of *CD4*⁺ and *CD8*⁺ T cells. *CTLA4* limits T cell activation, and promotes Treg expansion and suppression (513). *CD80/86*-deficient *ApoE*^{-/-} mice show diminished T effector cell responses and a decrease in plaque area (514). Chimeric *CD80/CD86*^{-/-}*LDLr*^{-/-} mice show aggravated atherosclerosis, due to a reduction in regulatory T cell numbers (276). The *CD28/CTLA4-CD80/CD86* system thus has divergent ways to modulate immune responses and determine atherosclerosis progression or reduction. Overexpression of the co-inhibitory *CTLA4* reduced atherosclerotic burden and plaque inflammation, and aneurysm formation in *ApoE*^{-/-} mice, due to a decrease in effector T cells (515, 516). Antibody mediated inhibition of *CTLA4* aggravated atherosclerosis and, with plaques that were enriched in T-cells and had large necrotic cores (517). Expression of *CD80/CD86* in human plaques is correlated with a vulnerable plaque phenotype (518) and a bioinformatic study links *CD86* to immune cell activation in human atherosclerosis (519). Patients suffering from coronary artery disease and those at risk of stroke contain higher expression of *CD80* and *CD86* on monocyte-derived dendritic cells and B cells (520).

7.1.2 Co-inhibition

One of the most powerful co-inhibitory receptors is *PD1*, which binds to *PDL1/2*. Both belong to the immunoglobulin superfamily, and they are important immunotherapeutic targets to induce *CD8*⁺ mediated killing of tumor cells in cancer. *PD1* is expressed on T cells, whereas its ligands, *PD-L1* and *PD-L2* can be found on many cell-types including APCs, endothelial cells and tumor cells (521). *PD1* and its ligands can modulate atherogenesis. Absence of *PD-L1/2* as well as antibody

treatment with PD1 antagonists in atherosclerotic mouse models increases atherosclerosis. The arterial wall contained excessive amounts of CD4⁺ and CD8⁺ T cells into the arterial wall (522, 523). Combination therapy of a PD1 inhibitor, and a CTLA4 inhibitor in *Ldlr*^{-/-} mice, resulted in a vulnerable, pro-inflammatory atherosclerotic plaque phenotype. This phenotype was caused by an excess of effector T-cells that resulted in endothelial activation and increased recruitment of CD8⁺ T-cells within the atherosclerotic lesion (524). *Ldlr*^{-/-} mice that were treated with an agonistic PD1 antibody had less atherosclerosis. PD1 agonism caused a beneficial inflammatory milieu with less IFN γ -producing CD4⁺ effector cells and cytotoxic CD8⁺ T cells, an increase in regulatory IL10⁺ CD4 T-cells and Bregs, supporting the potential of stimulating PD1 as a strategy to reduce atherosclerosis (525). In addition, adoptive transfer of PD-L1 expressing B cells inhibited collar-induced atherosclerosis in *ApoE*^{-/-} mice by inhibition of T follicular helper cell responses (526). PD1 and PD-L1 was reduced on T-cells and dendritic cells in patients with CVD, which was associated with increased T cell activity (527). High levels of PD1 were observed on plaque T-cells, which was associated with T-cell cell exhaustion pathways, occurring after T-cell activation (197). sPD-L1 levels are increased in patients with coronary artery disease (528, 529). CD200-CD200R interactions protect against atherosclerosis. CD200R limits monopoiesis, monocyte recruitment and macrophage activation in experimental atherosclerosis. CD200R is expressed on classical monocytes of ASCVD patients and associates with a lower burden of coronary artery disease and a stable plaque phenotype (530). Like any other co-inhibitory molecules, also TIM-1, TIM-3, TIM4, as well as BTLA can protect against atherosclerosis (435, 531-533). TIM proteins are structurally characterized by an extracellular immunoglobulin V domain and a mucin-like domain, in addition to a transmembrane domain and an intracellular cytoplasmic tail. While TIM-1 and TIM-3 are expressed on B- and/or T cells, TIM-4 is mostly expressed on macrophages and dendritic cells. TIM-1 can interact with TIM-4, while galectin-9 is the binding partner of TIM-3. TIM proteins can also recognize phosphatidylserine (PS) on apoptotic cells, aiding in their clearance. Monoclonal antibody blockade of TIM-1 (clone 3D10), TIM-3 (clone RMT3-23) or TIM-4 (clone 21H12) in *Ldlr*^{-/-} mice significantly enhanced atherosclerosis development and associated inflammation (531, 532). In contrast, treatment of *ApoE*^{-/-} mice with another TIM-1 antibody (RMT1-10) attenuated atherosclerosis via expansion of protective IgM⁺ B1a cells (534). TIM-1 can thus exert both a co-inhibitory and co-stimulatory function, and studies have suggested this may be strongly linked to the ligand density (535) and the extent of TIM-1 engagement by the monoclonal antibodies (536). Mice with a genetic deficiency in TIM-1 signaling (*Tim-1* ^{Δ mucin} mice) show exacerbated atherosclerosis with reduced IL10⁺ Bregs and Th2 cells (532), illustrative of a coinhibitory role for TIM-1 in atherosclerosis. Activation of BTLA reduces early plaque formation and induces a collagen rich phenotype in advanced plaques. The mechanisms of action include a decrease in follicular B-cell and the increase in regulatory T- and B cells upon BTLA activation (537). Coinhibitory protein Tigit was significantly elevated on T cells isolated from *Ldlr*^{-/-} mice fed a Western-type diet, but stimulation of this inhibitory signaling pathway in vivo did not alter atherosclerosis development, despite successful inhibition of T cell proliferation (533). In human carotid plaques, Tigit expressing CD4⁺ T cells are detected, particularly in the Treg compartment (277).

8. INFLAMMATION INDUCED BY NON-IMMUNE CELLS IN ATHEROSCLEROSIS

Over the years, it has become clear that not only immune cells, but also non-immune cells are key in mediating inflammation in the arterial wall, thereby driving atherogenesis. In this review, we will highlight the contribution of 2 non-immune cell-types that play a key role in the 'inflammatory' pathogenesis of atherosclerosis: endothelial cells and vascular smooth muscle cells.

8.1 Endothelial cells in atherosclerosis

Endothelial cells (ECs) form the innermost lining of all blood vessels and fulfill numerous crucial functions in vascular physiology, extending beyond mere separation of blood from the vessel wall. They serve as guardians of vascular equilibrium by managing vascular tone and permeability, facilitating leukocyte adhesion and extravasation, and regulating hemostasis and thrombosis (538). Their response to various stressors, including shear stress, varies depending on their location within the vasculature, impacting their morphology, intracellular signaling, and gene expression, thereby influencing their functionality.

ECs play a pivotal role in regulating vascular reactivity through the secretion of three key vasoactive peptides: nitric oxide, endothelin-1 and prostacyclin (539). Nitric oxide's association with mechanisms underlying hypertension and atherosclerosis has been recognized since the 1980s(540) marking the initial identification of ECs' significant involvement in pathological processes related to vascular tone regulation (541).

The risk of (athero)thrombosis escalates with increased endothelial expression of tissue factor (TF) and the release of von Willebrand factor (vWF). Additionally, endothelial apoptosis contributes to an augmented presence of circulating CD146+ endothelial cells (ECs) in the bloodstream (538). Moreover, endothelial apoptosis and localized endothelial denudation can instigate thrombus formation through plaque erosion, a phenomenon implicated in approximately 20% of acute coronary syndrome cases (542).

Plaques prone to rupture exhibit a distinctive metabolic profile characterized by increased glycolysis, more utilization of amino acids, and reduced fatty acid oxidation (543). Changes in endothelial cell (EC) metabolism are recognized both as consequences of and contributors to endothelial dysfunction in atherosclerosis. Notably, EC activation is mediated through YAP/tafazzin (TAZ) signaling (544, 545). Studies have demonstrated that YAP/TAZ signaling induces glycolysis in ECs, and conversely, heightened glycolytic activity can upregulate the YAP/TAZ pathway (546), potentially leading to a cyclical and sustained pro-inflammatory response in the compromised endothelium (547). In animal models, inhibition of glycolysis has shown promise in mitigating these effects, although further human data is required to validate these findings (548).

8.1.1 Flow and shear stress

EC serve as the interface between blood and vessel walls, sensing shear stress magnitude and patterns through mechanosensory proteins and organelles. They then translate these signals into intracellular changes via mechano-transduction pathways, with alterations occurring at transcriptional, epigenetic, and protein levels, significantly impacting atherosclerosis.

Exposure of endothelial cells to disturbed flow triggers turnover and senescence, elevates oxidative stress (marked by reactive oxygen species, ROS), and compromises barrier function.

Key genes involved in thrombosis, inflammation, and vascular tone regulation are influenced by the flow pattern experienced by endothelial cells (549, 550). Especially Krüppel-like factor (KLF2) KLF2 and -4, highly expressed during laminar flow, are highly responsive to hemodynamic stimuli. They are upregulated in athero-resistant arterial regions and by statin treatment (551), where they maintain an anti-inflammatory program. Disturbed flow lowers KLF2 and -4 expression. Recently, γ proto-cadherins, which are upregulated in the endothelium during ASCVD, were identified as key suppressors of KLF2 and -4, and their genetic deletion protects mice from developing atherosclerosis, and are therefore a potent EC specific target to lower ASCVD (552). While unidirectional, laminar shear stress is considered atheroprotective, pulsatile disturbed shear stress, such as oscillatory flow typically encountered at arterial branches and vessel wall irregularities, fosters chronic inflammation, thereby promoting atherogenesis (553). Shear stress is detected by various mechanosensors, including integrins (e.g., integrin $\alpha 5$ —annexin A2 interaction), CD31/PECAM-1, VE-cadherin, and vascular endothelial growth factor receptor 2 (VEGFR2). The interaction between the mechanosensitive cation channel Piezo1, the purinergic P2Y2 receptor, and Gq/G11-mediated signaling has been identified as mediating inflammatory signaling and atherosclerosis under disturbed flow conditions, but not under laminar shear stress (554). Moreover, plexin D1 (PLXND1) is essential for endothelial cell response to shear stress and regulates the site-specific distribution of atherosclerosis (555). However, disturbed flow also induces anti-inflammatory feedback loops, such as the endothelial adrenomedullin-calcitonin-like receptor (CALCRL) axis, which signals through cAMP, reducing endothelial inflammation and lesion formation (556).

8.1.2 Endothelial cell barrier function

Endothelial cell (EC) barrier integrity relies on tight and adherens junction complexes (557), while transmigration is governed by specific receptor-ligand interactions in conjunction with substrate stiffness and intrinsic endothelial cell stiffness (558). Activation of ECs results in diminished vascular barrier function, heightened paracellular and transcellular transport, and increased deposition of fatty streaks, initially, particularly in regions of disturbed flow.

Endothelial ICAM-1 and VCAM-1 clusters generate cellular protrusions to facilitate leukocyte transmigration. The expression levels of ICAM-1 and VCAM-1 on the cell surface are modulated in response to signals from TNF α or IL-1 β , dictating whether paracellular or transcellular routes are favored for diapedesis (559). During diapedesis, the paracellular space is sealed through RhoA activation and the formation of a contractile actin ring. Pathways leading to heightened endothelial permeability involve targets of HIF1- α and NF- κ B, such as vascular endothelial growth factors, IL-1 β , IL-6, tumor necrosis factor α (TNF α), as well as factors like TGF β and ROS.

The endothelial layer is covered by a dense glycocalyx—a gel-like matrix composed of proteoglycans and extracellular matrix components, crucial for facilitating transendothelial transport, including lipoproteins (560). Degradation of the glycocalyx by plasminogen activator inhibitor (Serpine1) leads to increased endothelial permeability through downregulation of junctional proteins like occludin and claudin-5. Recent insights have unveiled endothelial transcytosis as a mechanism for LDL transportation, an active process mediated by various endothelial receptors, notably scavenger receptors class B type 1 (SR-B1) and activin-like kinase 1 (ALK1), both localized within caveolae, specialized membrane microdomains involved in endocytic processes (561, 562). The absence of caveolin-1, the primary protein constituent of

caveolae, in *Ldlr*^{-/-} mice, diminishes LDL transport across the endothelium and reduces vascular inflammation in early-stage atherosclerosis, irrespective of eNOS activity (563, 564). Although binding of LDL and oxidized LDL (oxLDL) to CD36 and oxLDL receptor 1 (LOX-1) has been observed, none of these receptors influence endothelial LDL transcytosis.

In addition to endothelial transcytosis, studies have revealed endothelial breaches and hemorrhage in the intima of carotid arteries in *Apoe*^{-/-} mice at sites of local flow perturbation. These sites attract leukocytes and foster the formation of fatty streaks (565).

8.1.3 Endothelium – immune system interactions

The involvement of ECs in atherosclerosis encloses their role in inflammation, where they interact with immune cells and respond to LDL and pathogen-associated molecular patterns. ECs directly secrete pro-inflammatory cytokines like IL-1 β , monocyte chemoattractant protein-1 (MCP-1), and IL-8, contributing to atherosclerosis progression (566). EC inflammation promotes leukocyte recruitment by upregulating surface adhesion molecules such as E-selectin, vascular cellular adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1). Activation of NF- κ B, further stimulated by high mobility group box 1 (HMGB1), triggers assembly of the EC inflammasome, leading to further increased interleukin 1 β (IL-1 β) release. ECs expressing these ligands actively facilitate leukocyte transport or favor diapedesis across the endothelial barrier (567). Local immune cell activation perpetuates tissue inflammation, enhancing endothelial permeability and allowing entry of plasma proteins into the interstitial space. Disrupted endothelial homeostasis promotes lipoprotein particle permeation and trapping in the subendothelial space, exacerbating inflammation and plaque progression.

In recent years, the role of extracellular vesicles, varying in size and contents, in mediating vascular cell-cell communication has emerged as a possible modulator of vascular function in atherogenesis(568). These vesicles facilitate intercellular signaling among ECs and between ECs and other immune and non-immune cell types (569). Such communication pathways might hold promise as potential biomarkers or therapeutic targets for future applications.

8.1.4 Endothelial cell plasticity

ECs are renowned for their remarkable plasticity, capable of transitioning between various cell identities, including adopting a mesenchymal phenotype, and then potentially reverting back to an EC state.

Endothelial-to-mesenchymal transition (EndMT) describes the molecular process wherein an endothelial cell undergoes a series of events leading to a shift in phenotype toward a mesenchymal cell, such as a myofibroblast or smooth muscle cell (570). However, there is no universally agreed-upon molecular criteria for defining EndMT. Typically, criteria include reduced expression of endothelial genes/proteins, increased expression of mesenchymal genes/proteins, or ideally, both (571). Examples of endothelial markers include CD31, VE-Cadherin, and endothelial nitric oxide synthase (NOS3), while mesenchymal markers may include alpha-smooth muscle actin (α -SMA), calponin, SM22a, and versican. Additional features, such as upregulation of EndMT-associated transcription factors like TWIST, SMAD3, ZEB2, SNAI1, and SNAI2, are also considered (571). Functionally, EndMT cells display diminished ability to form tubules, inhibit thrombin formation, and uptake LDL cholesterol—characteristics typical of ECs—while exhibiting enhanced mesenchymal cell traits like matrix invasion, migration, contraction, and collagen

production (571-575). However, robust human data confirming the extent and causality of EndMT in adult cardiovascular disease remains scarce.

EndMT is induced by various signaling cascades, including TGF- β , Notch, and Wnt/ β -catenin pathways. Transcriptionally regulated by factors like snail, slug, and twist, EndMT is facilitated by hypoxia, inflammation, and oxidative stress. Signaling through TGF β R1/2 promotes the expression of inflammatory and mesenchymal genes while suppressing conventional EC identity genes, ultimately activating ECs to undergo EndMT and contribute to atherogenic lesion formation. Although TGF β 2 within plaques may aid in maintaining stability by reducing inflammation and matrix degradation (572), targeted inhibition, such as delivering short interfering RNAs specifically to ECs, could potentially induce atherosclerotic plaque regression in mouse models (576). Research into endogenous antagonists of the EndMT program is nascent. Interestingly, FGF signaling shows promise as a potent inhibitor of EndMT and potentially the atherosclerotic process (577, 578).

In addition to inducing endothelial inflammation and EndMT, disturbed flow, termed FIRE (disturbed Flow-Induced Reprogramming of EC)(579), also promotes endothelial-to-immune-cell-like transition (EndIT) during atherogenesis (580, 581). Supporting the EndIT concept, a meta-analysis of 28 microarray datasets from ECs exposed to various stimuli suggests its validity (582), though further confirmation via endothelial cell lineage-tracing studies is warranted (583).

8.1.5 Endothelial heterogeneity

Recent advancements in single-cell RNA-sequencing have unveiled significant heterogeneity among ECs, with its few human studies demonstrating variability across identified clusters (199, 584, 585) (Figure 10). In one of the most recent studies, four distinct clusters were delineated (199): three representing activated endothelium (marked by CD34, PECAM1, and TIE1), which actively exacerbates inflammation in advanced lesions through cell adhesion, neovascularization, and mediating leukocyte extravasation, and one potentially indicating endothelial-to-mesenchymal transition (identified by ACTA2, NOTCH3, and MYH11, typical markers for smooth muscle cells) (199).

The first cluster exhibited unique expression of ACKR1, associated with venous ECs and the vasa vasorum in mice(586) , along with PRCP involved in angiogenesis and regeneration of damaged endothelium. E.1 and E.2 both expressed VCAM1 but were distinguished by differential expression of extracellular matrix genes in E.1 and cell mobility markers such as FGF18 and HEG1 in E.2(586).

In another, even more recent study examining carotid plaques from only three patients, inflammatory ECs (characterized by IL6, ACKR1, HLA-DQA1) were predominant in proximal plaque regions, while distal ECs displayed profiles suggestive of intimal repair (marked by ITLN, DKK2) and extracellular matrix modulation (including FN1)(584). Further investigations involving larger human sample sizes and more comprehensive functional analyses are imperative to deepen our understanding of EC heterogeneity and its implications.




Figure 10. Endothelial cell and VSMC subsets in atherosclerosis

Endothelial cells and VSMC in human atherosclerotic plaques can be categorized into various groups, though no absolute consensus exists. As more studies emerge, newer classifications may arise. These cells undergo phenotypic transitions that are potentially dependent on the stage of the disease and the specific region within the plaque. Their roles range from athero-protective, tentatively mostly anti-atherosclerotic (labeled in blue), to athero-promoting, tentatively mostly pro-atherosclerotic (labeled in red). Some phenotypes may exhibit both functions depending on the context (shaded red and blue), while others remain largely unknown (gray). To simplify this complexity, endothelial cells, all of which express markers such as CD34, PECAM1, and TIE1, can be classified into at least four phenotypes. The ACKR1⁺ phenotype is involved in inflammation, tissue repair, angiogenesis, and vascular integrity maintenance. The BMP4⁺ phenotype is particularly associated with extracellular matrix (ECM)-related mechanisms. The FGF18⁺ phenotype plays a key role in angiogenesis, cell migration, and responses to mechanical stress. The ACTA2⁺ phenotype appears to represent a mesenchymal-like endothelial cell, possibly corresponding to a transitional state, engaging in fibrosis, injury response, and ECM remodeling. This phenotype also exhibits high expression of several genes that are also prominently expressed in VSMC.

VSMCs traditionally perform a contractile function, primarily characterized by ACTA2 expression. However, this expression decreases markedly when VSMC transition into alternative phenotypes in which KLF4 becomes more dominantly expressed. One such phenotype is the synthetic state, in which VSMC adopt a cobblestone morphology, produce ECM, and exhibit reduced expression of contractile proteins. Another phenotype involves VSMC acquiring endothelial-like characteristics, with increased expression of CD31. Some VSMC exhibit markers associated with progenitor cells, such as SCA1 and CD34, developing a mesenchymal-like phenotype. Others take on characteristics of myofibroblast-like cells, which exhibit features between fibroblasts and VSMCs and are highly prolific in

synthesizing collagen type I and fibronectin. In some cases, VSMCs undergo osteogenic and chondrogenic differentiation, expressing markers such as RUNX2 and OPN in osteogenic pathways or SOX9 in chondrogenic pathways, contributing to vascular calcification through mechanisms involving BMP2.

Further illustrating their plasticity, VSMC can also transdifferentiate into foam-cell-like, macrophage-like, and adipocyte-like states. Foam-cell-like VSMCs express CD36, a fatty acid transporter and scavenger receptor of oxidized LDL, playing a role in lipid accumulation. Macrophage-like VSMCs exhibit high levels of CD68, CD11b, galectin-3, and ADGRE1, contributing to immune and inflammatory responses. Adipocyte-like VSMCs express markers initially described in brown adipose tissue, including UCP1, as well as ELOVL3, involved in fatty acid synthesis, and ADIPOQ, which encodes adiponectin. These transitions highlight the remarkable plasticity of both endothelial cells and VSMCs in atherosclerotic plaques, emphasizing their diverse roles in disease progression and their potential as therapeutic targets.

8.2 Vascular smooth muscle cells in atherosclerosis

Under steady-state conditions, arterial smooth muscle cells (SMCs) exhibit a dense, spindle-shaped morphology, tightly packed with microfilaments and featuring characteristic contractile markers such as smooth muscle alpha actin 2 (ACTA2), transgelin (TAGLN), and myosin heavy chain 11 (MYH11). These markers facilitate the exertion of contractile properties crucial for regulating vascular tone and blood pressure. The transcriptional regulation of SMC contractile properties is orchestrated by serum response factor (SRF) and its coactivator myocardin (MYOCD) (587). SRF's binding to MYOCD is essential for the expression of contractile genes, as this interaction enables the specific expression of contractile genes in SMCs.

SMCs are present in the early stages of human pre-atherosclerotic intima and play a crucial role in both the retention of lipoproteins and, later in the formation of the fibrous cap (588). While there are differing viewpoints, prevailing theories propose that intimal SMCs likely originate from a subset of medial SMCs. This occurs through oligoclonal migration from the media to the intima, followed by proliferation within the intima. However, only a fraction of these clones survives, leaving the exact origin of SMCs within human plaques still unclear (589, 590). In general, SMCs are known to migrate into the intima and subsequently proliferate, contributing to the formation of the fibrous cap. The migration of medial SMCs may be preceded by proliferation, and both dividing and non-dividing SMCs can participate in plaque formation (591). However, lineage-tracing studies in various models suggested that SMC migration occurs independently of proliferation. Additionally, evidence indicates that SMC proliferation begins within the media even before migration occurs. Thus far, there is no evidence supporting the notion that intimal SMCs can migrate back to the media. Several studies propose more sources of SMCs within the vessel wall, such as adventitial mesenchymal stem cells (MSCs), pericytes, fibroblasts, or endothelial cells (ECs). (574, 577, 592-594). Some plaque-derived SMCs may originate from ECs through endothelial-to-mesenchymal transition (EndMT), which is induced by factors like transforming growth factor beta signaling, oscillatory shear stress, oxidative stress, and hypoxia (as mentioned in the endothelial cells section).

In advanced atherosclerotic plaques, many SMCs exhibit low proliferative rates, with only a select few clones displaying high proliferation (595). These highly proliferative SMCs are believed to form the fibrous cap and infiltrate the core (596). Apart from reduced proliferation, plaque SMCs demonstrate early senescence, characterized by the up-regulation of cell-cycle arrest markers and shorter telomeres compared to medial SMCs (597). Senescent SMCs contribute to atherosclerosis and plaque instability in mice, promoting calcification by initiating a transition to an osteoblastic phenotype *in vitro* (598). Various forms of SMC death occur within the plaque,

including apoptosis and necrosis such as necroptosis and ferroptosis (599). Apoptosis of medial contractile SMCs or myofibroblast-like SMCs in the intima appears to be detrimental, as it is associated with plaque vulnerability, calcification, and media degeneration (600). However, much remains unknown regarding SMC phenotypes and cell death mechanisms in atherosclerosis.

In the 1950s, Atschul observed through light microscopy that foam cells might originate from smooth muscle cells (601). Building on this, Geer, in the 1960s, noted that "the lipid lay almost exclusively in smooth muscle," and "smooth muscle cells often contained so many vacuoles that they appeared to be in a transitional stage between smooth muscle and foam cells" (602). Ross, in the 1970s, proposed that the accumulation of smooth muscle cells (SMCs) was essential for lipid deposition (603). He argued that "the lipid deposits occur either within smooth muscle cells or outside them in association with connective tissue matrix components, which are secretory products of smooth muscle cells." As SMCs accumulate lipid, they adopt a morphology resembling inefficient foam cells (604). Cholesterol-loaded SMCs exhibit reduced capacities for phagocytosis and efferocytosis compared to bone marrow-derived macrophages (605). These foam cells derived from SMCs also display lower levels of ABCA1, the rate-limiting exporter of excess intracellular cholesterol. This suggests impaired foam cell function and compromised ability to export cholesterol.

Another feature of SMCs is their ability to secrete bioactive molecules, including matrix proteins and pro-inflammatory mediators, which can potentially influence other cells in a paracrine manner. Some of these molecules are encapsulated into vesicles and are shed from the cell surface to facilitate signal transmission between cells. The secretome of phenotypically switched SMCs may contain critical information from the donor cell, and it can even determine the fate of the recipient cell. The identification of specific molecules within this secretome holds promise for clinical applications as potential biomarkers for cardiovascular disease (CVD) in the future. Examples of matrix proteins that could be significant include osteomodulin (606), endotrophin (607), and mimecan (608). Protein groups such as MMP9, S100A8/S100A9, cathepsin D, and galectin-3-binding protein have shown potential to differentiate between symptomatic and asymptomatic carotid plaques, suggesting their utility for risk stratification in cardiovascular diseases (609, 610).

There is a robust bidirectional interaction between SMCs and the extracellular matrix (ECM). The composition of the ECM is influenced by the delicate balance between its production and breakdown. During the early stages of plaque formation, matrix metalloproteinases (MMPs) play a pivotal role in facilitating SMC migration by degrading the surrounding connective tissue. Concurrently, the type and quantity of ECM produced vary depending on the phenotype of the SMCs (611). Particularly, SMCs exhibiting a synthetic phenotype release various inflammatory molecules, leading for instance to cell death in adjacent cells (612). Pro-inflammatory cytokines such as IL-1 β , IL-6, and MCP-1 play significant roles in promoting atherosclerosis by attracting monocytes and inducing cell death. Additionally, these cytokines induce the expression of adhesion molecules and receptors that facilitate monocyte recruitment and regulate inflammatory signaling. While synthetic SMCs are recognized for their role in forming ECM in the fibrous caps, they can also exacerbate inflammation, calcification, cell aging, and plaque instability depending on the local microenvironment and disease stage (613). Specifically, synthetic SMCs release exosomes that may induce calcification when they contain components

such as phosphatidylserine (PS), Annexin A6, and low levels of calcification inhibitors. These exosomes may also promote vascular coagulation by exposing PS and tissue factor on their surface (614). Furthermore, matrix vesicles derived from apoptotic SMCs can be sites for calcification in plaques, while osteochondrocyte-like SMCs secrete calcifying vesicles, contributing to the progression of calcification (615).

Arterial calcification is another mechanism involving SMCs. In calcified arteries, these cells elevate the expression of bone-related transcription factors such as *Msx2*, *Sox9*, and *Runx2*, along with mature chondrogenic markers including collagen X and MMP13 (616). SMCs activate cellular programs aimed at facilitating the deposition of bone matrix within the arterial wall and give rise to the majority of chondrocyte-like precursors (98%) within plaques (617). Deletion of *Runx2* prevents calcification in mouse models by reducing the presence of SMC-derived mature osteochondrogenic-like cells, as well as calcium deposition and mineralization within the deep intima layers (618).

During vascular injury or atherosclerosis, SMC undergo phenotypic switching, initially marked by the downregulation of contractile genes (619). Lineage tracing studies have provided robust evidence indicating that SMC-derived cells constitute a significant proportion (30%–70%) of all plaque cells and over 60% of SMCs in atherosclerotic plaques dedifferentiate to a "pioneer" state, capable of transitioning to several multipotent states (620, 621). Within plaques, SMCs *in vivo* exhibit diverse phenotypes, some of which may have detrimental effects. These cells downregulate contractile markers during atherosclerosis while adopting alternative phenotypes, including macrophage-like, foam cell-like, adipocyte-like, osteochondrogenic-like, myofibroblast-like, and mesenchymal stem cell-like phenotypes, briefly described below (591, 622).

A pivotal molecular factor driving the differentiation of SMCs from a contractile to a dedifferentiated transitional state is the transcription factor Kruppel-like factor 4 (KLF4)(585). KLF4 regulates the transition of SMCs to multiple phenotypes in advanced atherosclerotic lesions. MicroRNAs (miRNAs)(623), epigenetic modifications (e.g., histone acetylations, methylations such as histone modification H3K4me2)(624, 625), and various environmental stimuli (such as integrins, cytokines, and growth factors like Platelet-derived growth factor (PDGF)-BB and TGF-beta) regulate the SMC phenotype(622).

Finally, another intriguing aspect of SMCs is their plasticity, manifested through phenotype switching, which contributes to the extensive heterogeneity of profiles observed(612). Phenotype switching encompasses any phenotypic alteration leading to an alternative non-contractile state in SMCs. Despite the various phenotype switches summarized below, the histone modification H3K4me2 appears to persist and can serve as a possible specific marker for SMCs (626).

A burgeoning body of literature, employing diverse nomenclatures, offers a rich and complex array of information. However, despite some efforts towards consensus, a universal agreement on the classification and categorization of SMC phenotypes remains elusive (107, 627). The discrepancies among reports can be attributed to factors such as the limited number of studies, particularly in humans, variations in arterial beds analyzed, in experimental methodologies, and data analysis approaches.

Nevertheless, the following SMC phenotypes are frequently described, especially in human studies, here presented from those that might contribute mostly to plaque stability to less stability, from a mostly hypothetical perspective (Figure 10).

Contractile SMCs have the capacity to undergo transdifferentiation into fibroblast-like cells or myofibroblast-like SMCs, characterized by an increased expression of fibronectin 1, osteoprotegerin, collagen type 1a1, and various small proteoglycans, along with the upregulation of fibroblast-specific pathways. The transcription factor 21 (TCF21) plays a pivotal role in promoting this phenotypic signature, which is commonly observed in the protective fibrous cap. Interestingly, elevated expression of TCF21 has been associated with a decreased risk of coronary artery disease in humans (628).

Another type of modulated or switched SMCs are the mesenchymal-like SMCs. These cells express the stem cell activating antigen 1 (Sca1) within atherosclerotic plaques and have the capability to differentiate into contractile SMCs (593, 621).

The transition from a contractile to a synthetic phenotype is characterized by the loss of contractile markers such as ACTA2, MYH11, TAGLN, and calponin, coupled with the acquisition of synthetic organelles and increased migratory and proliferative properties (612). While most ACTA2⁺ cells are typically found in the fibrous cap, ACTA2⁻ cells derived from SMCs accumulate within the core, challenging the old notion that the core is predominantly occupied by macrophages (620, 626). The synthetic phenotype serves as a hallmark of vascular repair, driven by the persistent exposure to stimuli inducing phenotypic switching within the plaque. Notably, SMCs retaining the synthetic phenotype may probably still retain the ability to revert back to their contractile phenotype (629).

Intermediate cells derived from SMCs, termed "SEM" cells (stem cell, endothelial cell, monocyte), represent an intermediate state in VSMC phenotypic switching that may lead to various ultimate fates (629). These cells exhibit multipotent characteristics, capable of differentiating into other SMC signatures or reverting to a contractile SMC phenotype. Retinoic acid, known for its anticancer properties, has been identified as a regulator of the transition from SMCs to SEM cells. Dysregulation of retinoic acid signaling has been observed in symptomatic human atherosclerosis. An interesting finding for future potential applications is that the activation of retinoic acid signaling inhibits the transition of SMCs to SEM cells, reduces atherosclerotic burden, and promotes fibrous cap stability.

SMCs may undergo a transformation to an osteochondrogenic phenotype in response to elevated levels of calcium and phosphate (630). Osteochondrogenic SMCs exhibit an upregulation of osteochondrogenic markers such as runt-related transcription factor 2 (RUNX2), SRY-related HMGbox (SOX9), and osteopontin. They deposit a matrix conducive to calcification, including collagen type II and X, and secrete calcifying vesicles (630). Concurrently, they downregulate calcification inhibitors such as vitamin K-dependent matrix Gla-protein and fetuin A. In human coronary arteries, this SMC phenotype is associated with plaque destabilization (585).

The SMC-derived osteochondrogenic population can be manipulated through SMC-specific ablation of specific genes, such as *Ahr* or *Klf4* (585, 631). Notably, SMC-specific ablation of *Ahr* or *Klf4* also alters lesion size, fibrous cap morphology, and the presence of intermediate SMC clusters, suggesting that the regulatory function of these genes in SMC transition go beyond the osteochondrogenic phenotype.

Thioredoxin-interacting protein (TXNIP) is another regulator of the osteochondrogenic SMC switch and appears to be significant in human plaque calcification (632). Microcalcifications (<50 μm) are associated with increased inflammation and are predominantly observed in the fibrous cap of human lesions, making them detrimental to plaque stability. In contrast,

macrocalcifications (>200 μm) tend to accumulate in the deep intima or necrotic core in organized structures and may promote plaque stability (633). Despite their nomenclature, osteochondrogenic SMCs are more susceptible to apoptosis and differ functionally from mature, bone-forming osteoblasts (634).

Contractile SMCs have the capability to transdifferentiate into an endothelial cell (EC)-like phenotype, characterized by the expression of EC markers such as CD31, von Willebrand factor, and VE-cadherin (635). In human SMCs, this conversion into ECs can occur in culture through an intermediate progenitor state induced by stem cell reprogramming factors. Further differentiation into ECs is regulated via Notch signaling pathways (636).

Interestingly, these SMC-derived ECs exhibit full endothelial cell functionality, as evidenced by the expression of CD31, and have been proposed to contribute to intraplaque hemorrhage and neovascularization, phenomena commonly observed in vulnerable plaques (637).

SMCs can also transform into foam cells in humans when exposed to aggregated or oxidized low-density lipoprotein. Intriguingly, it appears that a significant proportion of foam cells may originate from SMCs, at least in mice. The uptake of lipids typically occurs through specialized scavenger receptors such as SR-A and CD36, but alternative pathways such as pinocytosis, phagocytosis and autophagy may also be involved (638-640).

Foam cell-like SMCs exhibit reduced expression of the key cholesterol exporter ABCA1 and lower levels of lysosomal acid lipase, which is the primary enzyme responsible for hydrolyzing lipoprotein-derived and intracellular cholesteryl esters (641). Unlike macrophages, SMCs tend to retain lipoprotein-derived cholesteryl esters in lysosomes rather than storing excess cholesterol in cytosolic droplets, potentially contributing to the reduced likelihood of lesion regression. In addition to their increased lipid uptake, lipid-loaded SMCs in culture can secrete pro-inflammatory mediators and may undergo apoptosis (642).

Furthermore, besides the increased uptake of lipids and potentially impaired efflux or degradation of lipoproteins, SMCs can synthesize fatty acids *de novo* through peroxisome proliferator-activated receptors gamma and the liver X receptor pathway (643). Although they do not fully differentiate into mature adipocytes and their role remains unclear, these adipocyte-like SMCs express high levels of adiponectin and genes associated with lipogenesis in human plaques (644).

Another phenotype transformation induced by lipid accumulation is the transition into macrophage-like SMCs (621, 640). These cells exhibit elevated expression of markers typically associated with macrophages, including LGALS3, CD68, CD11b, and pro-inflammatory cytokines such as CCL2 (640). However, it is important to note that not all lipid-loaded SMCs *in vivo* undergo this macrophage-like transformation, and not all plaque SMCs expressing LGALS3 acquire a macrophage-like phenotype (585, 628). Instead, LGALS3 is detected in over 60% of plaque SMC during a transitional phase towards a non-macrophage state yet characterized by a pro-inflammatory and osteochondrogenic phenotype. These cells may represent some of the earliest inhabitants of the plaque (585). Although the presence of macrophage markers in SMCs suggests an inflammatory response, these cells may not fully function like typical macrophages but are hypothetical quite deleterious for the plaques.

In summary, the current literature on SMCs offers only a partial glimpse into their phenotype, function, interactions, temporal dynamics, and spatial distribution. Recent advancements in spatial transcriptomics and proteomics in atherosclerosis research are contributing additional

pieces to this intricate puzzle (394, 610). However, comprehensive information regarding the true nature of atheroprotective and atheropromoting SMC phenotypes in human arterial territories, as well as within individual plaques, and the mechanisms governing these phenotypes, remains elusive.

Further investigations aimed at delineating the biological trajectory of SMCs, their diverse profiles, spatial distributions, and functional roles, incorporating unbiased various omics approaches alongside functional studies, are imperative. Such efforts are essential to ascertain the potential of SMCs as novel therapeutic targets for advancing the prevention and treatment of atherosclerosis.

9. TARGETING THE IMMUNE SYSTEM IN ATHEROSCLEROSIS

9.1 Targeting inflammation in atherosclerotic CVD: proof of concept trials

9.1.1 Clinical Trials: targeting innate immunity in atherosclerotic CVD

For decades, managing dyslipidemia, hyperglycemia and hypertension has been the primary focus in controlling atherosclerosis. However, despite remarkable advancements in lowering circulating lipoproteins, a residual risk for cardiovascular events persists. This led to exploring novel targets beyond LDL reduction, particularly focusing on modulators of inflammation. Despite efforts with various antioxidants (645-647), losmapimod (a p38 mitogen-activated protein kinase inhibitor) (648), and inclacumab (a P-selectin antagonist) (649), clinical trials have not yielded success.

At the forefront of the inflammatory cascade lie several potential targets, such as the NLRP3 (NOD-like receptor family, pyrin domain-containing protein 3) – IL1 β – IL6 pathway. Drug repurposing from adjacent therapeutic areas also involving inflammation has emerged as an intuitive strategy (Figure 12).

Methotrexate is a first-line anti-inflammatory agent commonly used in rheumatoid arthritis, psoriasis and other forms of inflammatory arthritis. It has also been linked to a decrease in CV events in patients with RA (650). Methotrexate has several mechanisms of actions. It inhibits aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase (ATIC) enzyme, leading to intracellular accumulation of AICAR and increased the release of adenosine release. Methotrexate inhibits activation of nuclear factor- κ B (NF- κ B) by increasing both adenosine release and activation of adenosine receptor A_{2a} and by inhibiting the reduction of BH₂ to BH₄. It also affects T cells (651). It has also been shown to suppress the activation of NF- κ B and NLRP3/Caspase-1 pathways in joint tissue (652). Its efficacy was explored in the Cardiovascular Inflammation Reduction Trial (CIRT), where low doses were administered to patients with stable coronary artery disease (CAD) alongside diabetes mellitus (DM) or metabolic syndrome, or both(653). Contrary to expectations, patients receiving low-dose methotrexate did not experience fewer cardiovascular events, nor exhibit lower levels of IL-1 β , IL-6, or hs-CRP. Instead, they experienced a higher incidence of side effects such as transaminitis, leucopenia, anemia, and infections. This negative trial had no requirements of high residual inflammation among enrolled patients, which underscored the importance of focusing on patients with sufficient inflammatory burden to be worth the benefit of an intervention (653).

This consideration was pivotal in the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) trial (654). In this randomized, double-blind, prospective study, 10,061 patients, at least 30 days post-myocardial infarction, with a hs-CRP level ≥ 2 mg/L (despite optimal guideline-directed medical treatment), received canakinumab—a monoclonal antibody neutralizing IL-1 β —subcutaneously, every 3 months, compared to placebo. Without significantly reducing lipid levels, the 150mg canakinumab dose met the prespecified primary and secondary endpoints, demonstrating a 15% reduction in myocardial infarction, stroke, or cardiovascular death. This effect size was comparable to that achieved with approved PCSK9 inhibitors (655), despite no impact on lipoprotein levels. Canakinumab did reduce the overall CV mortality rate by about 30% in patients that responded with a reduction in hsCRP and IL6 after the first injection. Non-responders were identifiable at the follow-up hsCRP measurement at 3 months (656). However, patients receiving canakinumab experienced an increased incidence of fatal infections, sepsis, and cancer mortality, aligning with theoretical expectations given the role of IL-1 β in host defense mechanisms. CANTOS stands as a landmark trial, illustrating the efficacy of targeting inflammation in atherosclerosis and paving the way for exciting advancements in anti-inflammatory interventions.

Another widely known and cheap agent is colchicine, traditionally used for decades in gout and various other inflammatory conditions. Colchicine operates by inhibiting components of the NLRP3 inflammasome, a mechanism akin to its action in response to the deposition of sodium urate crystals in soft tissue—a phenomenon that bears resemblance to the process observed in atherosclerosis following the deposition of cholesterol crystals in the intima(657). The first outcome trial evaluating colchicine in atherosclerotic cardiovascular disease dates back to 2013 with the Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease (LoDoCo) study (658). This prospective, randomized study involved 532 patients with stable coronary disease, comparing colchicine treatment (0.5 mg/day) to no treatment over a 3-year follow-up period. The composite primary endpoint included acute coronary syndrome, out-of-hospital cardiac arrest or non-cardioembolic ischemic stroke. Despite limitations such as the absence of placebo control and blinding, the small patient cohort, and a short follow-up duration, low-dose colchicine demonstrated efficacy, prompting the subsequent larger LoDoCo2 randomized-controlled, double-blind trial. In LoDoCo2, involving 5522 patients with chronic coronary disease (only 15% of whom were female), daily administration of 0.5 mg colchicine or placebo showcased benefits as early as 6 months into the study, with a composite endpoint comprising cardiovascular death, myocardial infarction, ischemic stroke, or coronary revascularization(659). In a recent study, however, a prespecified subgroup analysis identified a difference in magnitude of treatment effect of colchicine by region (Australia: HR 0.51; 95% CI 0.39-0.67 vs The Netherlands: HR 0.92; 95% CI 0.71-1.20), painting a mixed picture (659, 660).

Colchicine was further investigated in the context of acute coronary syndromes in the COLCOT (Colchicine Cardiovascular Outcomes Trial) trial, which randomized 4745 patients in a double-blind fashion, with only 19% being female, and with a slightly shorter follow-up duration (23 months compared to LoDoCo2's 29 months)(661). Once again, colchicine (0.5 mg daily) exhibited a lower risk of cardiovascular events compared to placebo. Both trials could have benefited from a more comprehensive monitoring of biomarkers to provide insights into mechanistic perspectives. Neither trial demonstrated a reduction in mortality with colchicine; instead, an increased frequency of diarrhea was noted in colchicine-treated patients. Regarding the potential

for elevated infection rates, only COLCOT reported a slight increase in pneumonias (0.9% vs. 0.4%)(661).

Furthermore, an intriguing small-scale prospective, nonrandomized, observational study involving 80 patients with acute coronary syndrome, undergoing coronary computed tomography, compared colchicine 0.5 mg/day with optimal medical therapy alone or in combination with colchicine, with a follow-up period of 1 year. Despite the modest cohort size, the study revealed that low-dose colchicine favorably impacted coronary plaque morphology (662).

The "CLEAR SYNERGY" trial, a recent large-scale clinical study, included 3,528 patients randomized to receive colchicine 0.5 mg and 3,534 assigned to placebo after percutaneous coronary intervention (PCI), with a preference for the Boston Scientific SYNERGY everolimus-eluting platinum chromium stent system. Initially, the dosing of colchicine was weight-based (once daily for patients under 70 kg and twice daily for those 70 kg or above), but it was modified to a once-daily regimen during the trial due to higher discontinuation rates with twice-daily dosing. The study demonstrated no significant difference in major adverse cardiovascular events between the colchicine and placebo groups when added to standard post-MI treatment and PCI. These results differ from earlier studies like COLCOT and LoDoCo2, which showed that colchicine reduced cardiovascular events in similar populations (663). Additional research is needed to explore the reasons for these differing outcomes across trials.

Another alternative target in the inflammatory cascade is interleukin-6 (IL-6), positioned downstream from IL-1 β in the NLRP3 inflammasome pathway. The ASSAIL-MI (ASSessing the effect of Anti-IL-6 treatment in Myocardial Infarction) trial, conducted in a randomized, double-blind, placebo-controlled manner, examined the impact of the interleukin-6 receptor inhibitor tocilizumab on myocardial salvage in acute ST-elevation myocardial infarctions, involving nearly 200 patients. The trial demonstrated an increase in myocardial salvage by magnetic resonance imaging within 3 to 7 days post-treatment (664).

Concurrently, investigations into targeting the IL-6 ligand with monoclonal antibodies like ziltivekimab are underway. Notably, the ZEUS (Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation) randomized trial is of particular interest (NCT05021835). Its objective is to establish the superiority of subcutaneous ziltivekimab (15 mg) once monthly in reducing the risk of cardiovascular events compared to placebo, both in conjunction with standard of care. The trial includes participants with high-sensitivity C-reactive protein levels equal to or greater than 2mg/L, established atherosclerosis, chronic kidney disease (stage 3-4), and systemic inflammation. Commenced in 2021, it aims to enroll 6200 participants and is anticipated to conclude in 2025.

9.1.2 Clinical Trials: targeting adaptive immunity in atherosclerotic CVD

Efforts to modulate the adaptive immune system's response to atherosclerosis and its clinical manifestations are emerging, albeit with considerably less progress compared to autoimmune diseases and cancer (Figure 12).

Observations have revealed that IgM antibodies, known as natural antibodies, recognize epitopes associated to oxidized LDL, prompting numerous strategies aimed at harnessing endogenous antibodies to mitigate atherosclerosis(665). Several groups have pursued strategies involving the

immunization of mice, either actively or passively, using for instance, defined immunogenic epitopes of apolipoprotein B (666-669). Recently, psoriasis patients were randomly assigned to receive a 50-mL infusion of either 1245 mg of orlicumab (n = 52) or placebo (n = 25) for 12 weeks. In the subgroup with elevated coronary inflammation, the CaRi-Heart risk score indicated a potential for an almost 50% relative risk reduction for CVD in response to orlicumab, suggesting that reducing oxLDL-dependent inflammation might be beneficial in patients with psoriasis and possibly the general population (670).

Regarding the adaptive immune system, preclinical evidence suggests the involvement of mature B-cells in the recruitment of inflammatory monocytes to the site of myocardial infarction. Depletion of B-cells through a single injection of CD20 antibody has reduced infarct size and enhanced myocardial contractility (671). Moreover, in patients with myocardial infarction, B-cell activation upon admission was associated with a heightened risk of death and recurrent myocardial infarction over a two-year follow-up period (671). Intriguingly, B-cell depletion using anti-CD20 antibody in murine models has also shown a reduction in the development of atherosclerosis (407, 409).

Monoclonal antibodies like Rituximab, which target human B-cells, have been extensively used in autoimmune disorders, inflammatory conditions, and cancer. Recently, there has been an attempt to repurpose them for cardiovascular diseases. In the prospective, open-label, single-arm, dose-escalation phase 1/2a clinical trial known as RITA-MI (Rituximab in patients with acute ST-elevation myocardial infarction), Rituximab was administered as a single intravenous dose to patients who experienced acute ST-elevation myocardial infarction and underwent successful primary percutaneous coronary intervention within 24 hours of the onset of cardiac chest pain (672). Despite being a small, single-center study involving only 24 patients (mostly white males, lacking a control group) with a follow-up duration of only 6 months, Rituximab was found to be safe (the primary endpoint) and well-tolerated. It effectively depleted 96% of circulating mature B-cells within 30 minutes of infusion initiation, even at low doses (200mg). B-cell repopulation at 6 months was observed to be dose-dependent, while immunoglobulin levels remained unaffected during the follow-up period. These promising findings have led to the initiation of the ongoing RITA-MI2 multinational randomized, double-blind, placebo-controlled clinical trial. Funded by the European Commission, this trial aims to investigate the impact of B-cell depletion with Rituximab (at doses of 200mg, 1000mg, and placebo) on left ventricular systolic function, assessed by cardiac magnetic resonance at 6 months (the primary endpoint). The trial involves 558 patients with acute anterior ST-elevation myocardial infarction. Results regarding cardiac remodeling are anticipated by 2026 (DOI:[10.3030/899991](https://doi.org/10.3030/899991)).

In addition to the modulation of B-cells, ongoing research explores the manipulation of other immune mechanisms. Preclinical models have demonstrated that increasing regulatory T-cells (Tregs, CD4⁺CD25⁺FOXP3⁺) can decrease plaque inflammation, slow progression, and even regress atherosclerosis (276, 673). Low levels of circulating CD4⁺FoxP3⁺ T cells have been associated with an increased risk of acute coronary events during a 15-year follow-up period (356). Moreover, Tregs have shown to promote myocardial wound healing (674), attenuate adverse left ventricular remodeling (675), and improve cardiac function (676). Tregs express the interleukin IL-2 (IL-2) receptor, IL-2Ra, which binds to IL-2 with high affinity, rendering this subset highly sensitive to IL-2 (677). IL-2 appears to be the most crucial cytokine in Tregs development and stability (678).

Inspired by its success in other immune diseases (679-682), subcutaneous low doses of IL-2 have been administered to patients with ischemic heart disease, both in stable coronary disease (trial Part A) and acute coronary syndromes (trial Part B), to assess safety and demonstrate the mechanism of Tregs expansion. This trial, known as LILACS (Low-dose InterLeukin 2 in patients with stable ischaemic heart disease and Acute Coronary Syndromes), utilized Aldesleukin (Proleukin, Novartis), a commercially available recombinantly produced IL-2 licensed for the treatment of metastatic renal cell carcinoma in the UK (683). LILACS not only provided safety data (no related serious adverse events), but also determined the dose required to increase Tregs by 75%, without significantly affecting T effector cells. Single-cell RNA sequencing techniques were employed, allowing for ligand-receptor expression analyses that provided insights into possible mechanisms underlying aldesleukin's Tregs expansion, such as activating co-stimulatory signals through CD28-CD86. Intriguingly, aldesleukin led to dose-dependent decreases in B cells and CD8+ T cells, and was shown to increase the number of Bregs, prompting the need for further investigation (683, 684).

The subsequent IVORY (Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes) trial (685), involved 60 patients with acute coronary syndromes and hsC-reactive protein levels >2mg/L, who were randomized to receive either low-dose IL-2 or placebo for 8 weeks. ¹⁸F-FDG (2-deoxy-2-[Fluorine-18] fluoro-D-glucose) positron emission tomography-computed tomography showed a significant decrease in vascular inflammation in the aorta and carotid arteries, and an increase in circulating Tregs. A trend towards a reduction in major cardiovascular events could be observed after 2.5 years of follow up (<https://doi.org/10.1161/circ.150.suppl.1.4144964>), showing that increasing Tregs is a promising strategy in treating atherosclerotic CVD.

9.2 Future Immunotherapeutics for atherosclerosis: lessons from approved immunotherapies

Over the past 20 years, treatments using monoclonal antibodies specifically targeting the immune system have been developed to treat autoimmune diseases as well as cancer. The cardiovascular impact of these therapies, although infrequently reported, allows us to translate the clinical relevance of the knowledge acquired from experimental studies about the role of these immunotherapeutic targets in atherosclerosis, and explore their potential towards clinical implication (686) (Figure 13).

9.2.1 Lessons from autoimmune diseases

9.2.1.1 Anti-TNF α treatment

Anti-TNF α treatment is standard of care for many autoimmune diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease (687). These auto-immune diseases are associated with an increased risk of CVD(5, 6), which is frequently monitored in clinical trials and databases. Therefore, studying CVD in these patient groups can provide us with valuable information on the potential of anti-TNF α treatment to combat CVD. Rheumatoid arthritis (RA) patients that were treated with anti-TNF α vs other therapies and followed for 2 years, had a lower incidence of cardiovascular events (688). In another study, RA patients that were non- and moderate- responders to anti-TNF α treatment had a >2 times increase in risk of acute coronary syndromes, whereas patients that responded well to anti-TNF α treatment had a risk of acute coronary syndromes comparable to that of the

Targeting inflammation in atherosclerosis					
Trial name	Agent	Target	Patient cohort	Primary end point	Main CVD outcomes
CIRT	Methotrexate	Broad anti-inflammatory effect	4,786 patients with previous MI and DMII or metabolic syndrome	Composite of nonfatal MI, nonfatal stroke, or cardiovascular death	No beneficial effects
Targeting innate immunity in atherosclerosis					
Trial name	Agent	Target	Patient cohort	Primary end point	Main CVD outcomes
CANTOS	Canakinumab	IL1 β	10,061 patients with previous MI and elevated plasma CRP levels	Non-fatal MI, non-fatal stroke or death from cardiovascular causes	The 150-mg dose of canakinumab reduced cardiovascular events compared with placebo, independent of lipid level reductions
COLCOT	Colchicine	Inflammasome	4,745 patients with MI within 30 days before enrolment	Death from cardiovascular causes, resuscitated cardiac arrest, MI, stroke, or hospitalization for angina leading to coronary revascularization	Colchicine decreased the risk of the composite end point compared with placebo
LoDoCo2	Colchicine	Inflammasome	5,522 patients with chronic coronary artery disease	Death from cardiovascular causes, spontaneous MI, ischemic stroke or ischemia-driven coronary revascularization	Colchicine decreased the risk of the composite end point compared with placebo
CLEAR SYNERGY	Colchicine	Inflammasome	7,062 patients after PCI (SYNERGY stent) treatment	Composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization	No beneficial effects
Targeting adaptive immunity in atherosclerosis					
Trial name	Agent	Target	Patient cohort	Primary end point	Main CVD outcomes
IVORY	Low dose IL2	Treg expansion	60 high risk ACS patients	Vascular inflammation (18Fdg-PET/CT)	Reduction of arterial inflammation
Orticumab	Anti-MDA-ApoB100	MDA-LDL	77 psoriasis patients with myocardial inflammation	Coronary inflammation (fat attenuation index)	Reduction of coronary inflammation

Figure 11. Overview of a selection of clinical trials using immunotherapeutics to target the innate or adaptive immune system.

Trials targeting the innate immune system are CIRT (Cardiovascular Inflammation Reduction Trial), CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study), COLCOT (COLchicine Cardiovascular Outcomes Trial), LoDoCo2 (Low Dose Colchicine 2 trial) and the CLEAR SYNERGY TRIAL. Trials targeting the adaptive immune system use orlicumab, and anti-MDA-LDL antibody targeting MDA modified LDL, and IVORY (low dose Interleukin 2 for the reduction of Vascular inflammation in acute coronary syndromes).

general population (689). The *Consortium of Rheumatology Researchers of North America rheumatoid arthritis* registry that followed more than 10,000 patients for 24-months showed a reduction of non-fatal cardiovascular events when RA patients received anti-TNF α treatment compared to other treatments (690). In patients with psoriatic arthritis, anti-TNF α treatment was also shown to reduce plaque burden compared to patients treated with non-selective immunomodulators in a 4-year period (691). Although these studies predict that anti-TNF α therapy is a promising strategy to treat atherosclerotic cardiovascular disease, anti-TNF α therapy in CVD patients had no effect on heart failure (692) or even worsened left ventricular function in heart failure patients (693).

9.2.1.2 CTLA4-Ig treatment

A CTLA4-Ig analogue, called Abatacept has been applied successfully in patients with rheumatoid arthritis, most of them refractive to anti-TNF α therapy. Until now, only limited data are available on the effects of Abatacept on cardiovascular disease in humans. However, most data point towards a beneficial effect on ASCVD outcomes (694-696). Abatacept significantly reduced ASCVD in a study comparing biologics with synthetic disease-modifying antirheumatic drugs (DMARDs) (694) and reduced the incidence of MACE in TNF α non-responders in a 2-year follow-up compared to Rituximab users (695). Similar results were found in a study where rheumatoid arthritis patients using TNF α inhibitors were compared to Abatacept users using Medicare and MarketScan databases. Abatacept was associated with a 20% reduced risk of MACE (696). However, when Abatacept treatment was compared with Tocilizumab in anti-TNF α treatment-resistant rheumatoid arthritis patients, no beneficial effects on ASCVD outcomes were found (697). In experimental settings, Abatacept successfully decreases atherosclerosis in *Ldlr*^{-/-} mice, neointima formation in C57Bl/6J mice (698), and blocks age-related heart failure in mice (699). Well-designed clinical trials testing the effects Abatacept in CVD setting are still being awaited.

9.2.1.3 Anti-IL12/Anti-IL23-p40 treatment

Anti-IL12/IL23p40 therapy showed promising effects on ameliorating psoriatic disease. IL12 is known to be pro-atherogenic (700), and IL23 seems to be anti-atherogenic (332). Treatment with anti-IL12/23p40 antibodies significantly increased the risk of cardiovascular events in patients suffering from psoriasis (701, 702), so does not seem a favorable target to treat CVD.

9.2.1.4 Anti-IL17 treatment

Anti-IL17 antibodies are FDA approved and effective in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The effects on CVD in treated patients are unknown. As described in *section 6*, the effects of IL17 on atherosclerosis in experimental models is still unclear (314-318, 321). Similarly, correlations of plasma IL17 levels and its association with CVD is contradictory. Plasma IL17 levels increase in patients with unstable angina or acute MI compared with patients with stable angina and healthy individuals (322, 323). In other studies IL17 was not associated with CAD, and low IL17 levels (324) were associated with a higher risk of cardiovascular events (325). Anti-IL17 treatment in patients with psoriasis did improve endothelial function, but does not affect cardiovascular biomarkers (703, 704), and is believed to positively affect psoriasis-associated cardiovascular disease (705). Older studies, although underpowered for cardiovascular disease, report that anti-IL17 treatment may increase atherothrombotic events (706).

9.2.2 Lessons from oncology

Co-inhibitory immune checkpoint therapy is associated with an increased risk for cardiovascular events in oncology patients (707). In a systematic review, that included 10,106 patients treated with anti-CTLA4 and/or anti-PD1 antibodies, the incidence of arterial thrombotic events (myocardial infarction or stroke) was 1.1% (708). In another study, involving 2842 cancer patients, the incidence of atherosclerotic cardiovascular events, had increased 4.7-fold in patients that were treated with coinhibitory immune checkpoint inhibitors (709). Anti-PD1 treatment increased the risk for venous and arterial thrombo-embolism, suggesting that PD1 blockage results in a pro-

thrombotic state, although mechanisms are still unknown (710, 711). These studies not only increase awareness to the fact that inhibiting co-inhibitory immune checkpoints can increase the risk for cardiovascular events in cancer patients (712), but also suggest the importance of co-inhibition, and PD1-PDL1 interactions in particular, in keeping atherosclerotic plaque inflammation in control (713). Additional studies detailing the cell-type specific mechanisms of PD-PDL1/2 interactions in atherosclerosis are needed before applying PD(L1/2) based targeted immunotherapeutics in CVD.

9.3 New immunotherapeutic targets: preclinical studies in atherosclerosis with high translational potential

Our understanding of the role of immune cell networks and its mediators in atherosclerosis has increased significantly over the past few decades, as can be read in sections 3 and 4. Based on these data, attractive, new immunotherapeutic targets have been identified. The complexity of the immune system allows the investigation of a myriad of therapeutic targets. The next section will provide a snapshot of current immunotherapeutic targets for atherosclerosis that have a high potential to enter or proceed in the translational pipeline of drug development (Figure 13).

9.3.1 Targeting the innate immune system

9.3.1.1 Bone marrow

Inadequate resolution of low-grade inflammation is integral to all stages of atherosclerosis (96, 106), with macrophages playing key roles in disease initiation, progression, aggravation and acceleration. Swirski, Nahrendorf and others found that atherosclerotic lesions grow through the continuous recruitment of circulating monocytes, and that recruitment is proportional to the severity of the disease (145). In mouse models, they found that hypercholesterolemia triggers progressive monocytosis (146). In the slipstream of these findings, key mechanistic links between accelerated hematopoiesis and lipid metabolism, and the role of extramedullary hematopoiesis in expanding the leukocyte pool have been uncovered (714-716). Besides macrophage expansion through myelopoiesis, local macrophage proliferation as a mechanism that further contributes to lesion growth(144). Most of these insights were acquired in preclinical mouse models of cardiovascular disease, but substantial clinical evidence shows a consistent association between leukocytosis and cardiovascular disease (717).

For the past two decades, stressors that potentially accelerate atherosclerosis progression have been increasingly studied and linked to altered hematopoiesis. Among the different correlations studied, atherothrombotic events themselves, psychosocial stress, sleep and lifestyle factors, and intermitted exposure to high fat diet, have been mechanistically linked to atherosclerosis aggravation in preclinical models and in patients.

In mouse models, macrophage dynamics have been clearly mapped, from monocyte production in the bone marrow, monocyte egress from the spleen (718) and recruitment to the vessel wall to macrophage accumulation in the plaque (146, 716). Importantly, it is becoming increasingly evident, from seminal preclinical work (719) and studies in patients (720), that atherothrombotic events, such as myocardial infarction and stroke, induce monocytosis and aggravate the disease process.

Although our understanding of the immune system's involvement in acute stress-induced cardiovascular events is still in its early stages, its role in the progression of chronic stress-related cardiovascular disease (CVD) is well-established (721-723). Clinical evidence indicates that stress-related disorders, such as post-traumatic stress disorder (PTSD) in combat veterans, significantly elevate the long-term risk of atherosclerosis and related events. Chronic psychosocial stress can increase the risk of myocardial infarction (724-726). A PET imaging study by Tawakol and colleagues showed that increased activity in the amygdala, a brain region central to fear and stress responses, is associated with heightened hematopoietic activity and a greater risk of cardiovascular events (727). Studies in mouse models show that psychosocial stress and atherosclerosis progression are mechanistically linked by hematopoiesis (728-731).

Leukocyte dynamics and dietary habits influence cardiovascular disease risk. For example, fasting leads to systemic suppression of CCL2 production (732) and an increase in CXCR4 expression on circulating monocytes, triggered by elevated corticosterone levels (733). Interestingly, fasting also promoted the re-entry of monocytes from the blood into the bone marrow, increasing their lifespan (734, 735). In a mouse model of atherosclerosis, intermittent fasting decreased the number of circulating Ly6C^{high} monocytes compared to continuous feeding, resulting in smaller aortic lesions. While intermittent fasting has shown clear anti-inflammatory benefits, a recent study in the *Ldlr*^{-/-} mouse model showed that intermittent exposure to a high fat diet causes atherosclerosis acceleration (736). Using bone marrow transplantation and pharmacological interventions, the authors uncovered that myeloid progenitor reprogramming during the first four weeks of high fat diet exposure underlaid the emergency production of neutrophils when re-exposed after an 8-week period of conventional diet (259).

Mediated by chronic, low-grade inflammation, age is among the most critical risk factors for developing atherosclerotic cardiovascular disease. As we age, immune function becomes broadly dysregulated, with innate immune dysfunction increasing systemic inflammation, a process known as inflammaging (737). Accumulating evidence indicates that atherosclerosis accelerates inflammaging. We and others have shown that epigenetic programming of hematopoietic bone marrow stem and progenitor cells (HSPCs)(738) is crucial for immune cell function and drives this premature immune aging process (739).

A landmark immune aging study, published in 2021, shows that transfer of splenocytes from aged mice drives systemic aging, driving senescence of solid organs (740). In human subjects, scoring age based on the frequency of immune cell populations is a much better indicator of immune system function than chronological age and predictive of all-cause mortality in the Framingham Heart Study (741). In line with these observations, the inflammatory age clock correlates with immune senescence, frailty, co-morbidities and cardiovascular aging (741).

As our understanding of the hematopoietic system's central role in atherosclerosis development, leukocyte dynamics, a variety of physical and psychosocial stressors grows, a model in which the bone marrow serves as a central hub that integrating these processes emerges (Figure 12). Continuous research in this space will expand, improve and refine this framework, to aid in designing interventions, which can be focused on lifestyle or diet, but also for developing cardiovascular immunotherapy strategies.

9.3.1.2 Targeting the macrophage

9.3.1.2.1 Macrophage maturation, survival and proliferation

CSF1 is a key cytokine that sustains the differentiation and survival of macrophages. *Csf1op/op* mice have a naturally occurring gene mutation that results in loss of CSF1, and they develop 70% less lesions than control apo E KO mice despite very high cholesterol levels (1300 mg/dL) (742), indicating that maturation and survival of macrophages is a condition *sine qua non* for the establishment of atherosclerotic lesions. Macrophage maturation has been described in detail in an *in situ* immunohistochemical analysis of surface markers expression by macrophages in human aortic lesions at post-mortem (743). Subtyping of macrophages with antibody against CD14 (LPS receptor), anti CD11b, CD36 (scavenger receptor) revealed a distribution pattern. Classical




Figure 12: Innate immune cell dynamics: role of the bone marrow

Atherosclerosis is a lipid-driven inflammatory disease that causes macrophage accumulation in the vessel wall by the recruitment of monocytes from the bone marrow, a process that is regulated by enhanced proliferation of myeloid progenitor cells. With genetics and age being uncontrollable factors, several stressors have been identified that accelerate hematopoiesis through the accumulation of epigenetic modifications in bone marrow progenitors, which in turn reduce hematopoietic diversity and cause a myeloid bias that aggravates the inflammatory process. These stressors include, but are not limited to lifestyle and sleep, lack of exercise, a Western type diet and intermitted exposure to this diet, as well as co-morbidities such as diabetes and obesity. Ultimately, inflammatory atherosclerotic plaque rupture may cause myocardial infarction or stroke, events that themselves cause bone marrow progenitor rewiring, but also indirectly contribute through other stressors, creating a positive feedback loop and an elevated risk of recurrent atherothrombotic events.

atheromatous plaques showed a gradual shift in phenotypic expression towards the center of the lesion. Cells in the superficial layers were positive only for CD14 (a monocyte marker), while deeper localized cells were gradually losing the expression of CD14, to become CD68⁺, CD11b⁺ and CD36⁺ cells, with positivity for phosphatase and oil red O, in part exhibiting the features of

foam cells. This observation showed a gradual change of phenotype of macrophages, which coincides with developmental stages of the atherosclerotic lesions. In successive studies, also HLA-DP+ cells were found in a study of aortic tissue and coronary arterial specimens (743). Lesional macrophages express also ICAM-1, CD11a, and CD11c (744).

Other growth factors also contribute to macrophage survival and activation. CSF2 or GM-CSF is a cytokine that acts as a growth factor for granulocytes (neutrophils, eosinophils, and basophils) and macrophages. GM-CSF promotes the survival and proliferation of CD11c+ myeloid cells in the intima at the site of nascent lesion formation (745). In advanced atherosclerotic lesions GM-CSF-mediated production of interleukin-23 increases apoptosis susceptibility in macrophages by promoting proteasomal degradation of the cell survival protein Bcl-2 (B-cell lymphoma 2) and by increasing oxidative stress (746).

Macrophages from atherosclerotic plaque are able to proliferate (144, 747, 748). Robbins et al showed that macrophage proliferation is important at the steady state to maintain resident vascular macrophage pools but also in advanced atherogenesis (144). Macrophage proliferation in atherogenesis is driven by scavenger receptor Msr1 (144). Moreover, CSF1 could be important in the maturation process from monocytes to macrophages. Targeting mediators of macrophage maturation, survival and proliferation would be beneficial to reduce atherosclerosis progression.

9.3.1.2.2 Macrophage mediated matrix degradation and thrombosis

Lesional macrophages constitutively express matrix degrading proteinases (MMP-1 interstitial collagenase, MMP2 (72 kDa gelatinase), MMP3 stromelysin, and the 92 kDa gelatinase (MMP-9) (749, 750). Macrophages in the plaque express tissue factor (751), another mechanism leading to atherosclerotic disease phases of instability. Cytokines, such as TNF α and IL-1 are key mediators in metalloproteinase upregulation in macrophages (752), such as in tissue factor expression (753).

In rabbits, foam cells downregulate arginase-1, while upregulating MMP-12 and nitric oxide production, particularly near the lipid core (754). MMP-14⁺ foam cells express the M1 marker COX-2 while TIMP3 (an MMP inhibitor which inhibits foam cell invasion) co-localizes with CD206 (755). MMP-14^{high}TIMP3^{low} foam cells – induced by pro-inflammatory cytokines - proliferate and invade tissues more easily but can also undergo apoptosis following challenge by LPS or starvation (755). TIMP3⁺ foam cells surround clusters of TIMP3⁻ foam cells in the plaque's shoulder regions (755). Therefore, MMP upregulation and TIMP downregulation may facilitate collagen degradation in the core of advanced plaques.

Macrophages are an important producer of MMPs in the plaque. NF κ B can activate the expression of MMP-1, -3 and -9 by human macrophages and rabbit foam cells (756). Numerous MMPs have been found in macrophage-rich regions of human plaques, also co-localizing with cleaved collagen, and these MMPs are particularly abundant in inflamed lipid-rich plaques in comparison to fibrous plaques (757). Classical macrophage activation *in vitro* selectively upregulates several MMPs, phospho-JNK and NF κ B, and reduces TIMP3, while alternative macrophage activation upregulates a separate group of MMPs and TIMP3 in human macrophages (758). Targeting matrix degradation is a good therapeutic option to prevent plaque growth and destabilization.

9.3.1.2.3 Macrophage cytokine production

Numerous cytokines that have pivotal roles in the pathogenesis of atherosclerosis are produced by macrophages. Macrophages are very important in immunoregulation as they secrete products such as cytokines and chemokines that influence and modulate the immune response. First, they produce IL-12 and IL-18 that direct naïve T cells towards the T_{H1} subtype and induce cell-mediated immunity (759). IL-12 and IL-18, in turn, induce IFN γ production from T cells that activates macrophages further. This process can be blocked by the T_{H2} products IL-4, IL-10 and IL-13 that inhibit the generation of IL-12 by human monocytes and macrophages.

Macrophages secrete GM-CSF, TNF α and IL-1 that enhance dendritic cell antigen-presenting function by up-regulating the expression of MHC, CD80, CD86, CD40 and other costimulatory molecules. IL-10 produced by macrophages and T_{H2} cells down-regulates dendritic cell antigen-presentation and can block this enhancement of antigen presentation. IL-1 has multiple effects on T cells and especially T_{H0} and T_{H2}. It enhances IL-2 and IFN γ production, induces IL-2 receptors on T cells and augments cytotoxic T lymphocyte activity. TNF α also affects T cells. It augments T cell responsiveness to antigen directly or via stimulation of other cytokines such as IL-6, and it up-regulates the expression of the IL-2R. In combination with IL-2 and IL-6, TNF α can also induce T cell activation in the absence of T cell receptor engagement (760, 761). Chronic exposure, however, of T cells to TNF α , however, has been shown to down-regulate T cell responsiveness and proliferation, suggesting that an autoregulatory mechanism is taking place (762).

TNF- α is primarily produced by macrophages in the plaque and its deletion reduces atherosclerotic disease in *ApoE*^{-/-} mice (763). In humans, TNF α is present in plaques and levels of TNF α in the peripheral blood predict future coronary events in post-MI patients (103, 764).

IL-1 is a pro-inflammatory cytokine that drives inflammation in atherosclerosis (reviewed here (765)). Both isoforms of IL-1, IL-1 α and IL-1 β are involved in atherosclerosis. Recent studies in mice showed that IL-1 α plays a role in the remodeling of arteries during early atherogenesis, whereas IL-1 β is mainly drives vascular inflammation in later stages of atherosclerosis (766). However, IL-1 β showed to have a protective role in mice in advanced atherosclerosis as well, via promotion and maintenance of a smooth muscle cells and collagen in the fibrous cap (767). Additionally, IL-1 α forms a link between the immune system and coagulation through the activation of IL-1 α by thrombin, underscoring its importance of the pathogenesis of CV events (768). In humans, IL-1 is expressed in coronary arteries of patients with CAD and is considered therapeutically tractable (769).

IL-6 is a pro-inflammatory cytokine of innate immunity, that serves as a secondary downstream mediator of cytokines such as IL-1. It is a central stimulus for the acute phase response. IL-6 stimulates the production of CRP, amongst other acute phase reactants, in hepatocytes (770). IL-6 signaling contributes to atherosclerosis and plaque destabilization in mice (771). Human data showed that elevated IL-6 is associated with an increased risk of MI, and genetic studies provided evidence of a causal role for IL-6 receptor signaling in CVD (772-774).

Although anti-IL1 β therapy has been shown to ameliorate atherosclerotic CVD (654), and trials blocking IL6 in ASCVD are ongoing, targeting other macrophage cytokines may have better/additional effects on ASCVD.

9.3.1.2.4 Macrophage efferocytosis

Macrophages are main contributors to the formation of the necrotic core in atherosclerotic plaques by undergoing apoptosis (775). Several pathways contribute to these processes. Free

cholesterol loading of murine peritoneal macrophages activates Fas ligand which subsequently leads to Fas-mediated apoptosis (776). Activation of endoplasmic reticulum (ER) stress pathway through C/EBP-homologous protein (CHOP) triggers macrophage apoptosis (777). Lipoprotein(a), a carrier of oxidized phospholipids triggers apoptosis of ER-stressed macrophages via CD36/TLR2, has been shown to increase the size of the necrotic core in rabbits (778). Deleting type I IFN signaling (779), TLR2 and TLR4 signaling (780), or the scavenger receptors SR-A and CD36 reduce the progression to advanced necrotic lesions.

Development of the necrotic core can also occur due to defective efferocytosis (clearance of apoptotic cells by macrophages) in advanced lesions (781), through downregulation or cleavage of efferocytosis receptors (782, 783), and dysregulation of expression of “eat me” signals (784, 785). MerTK, an efferocytosis receptor expressed by macrophages, has a non-redundant role in efferocytosis, and its loss causes pro-inflammatory immune responses, accelerates atherosclerosis and increases plaque necrosis (783, 786). LRP-1 (LDLR-related protein 1) mediates cell death and impairment of efferocytosis worsening necrotic core formation (787). Blocking CD47 with a neutralising antibody improved efferocytosis and ameliorated atherosclerosis in *ApoE*^{-/-} mice (785) via reintegration of ‘eat me’ signals on macrophages, and was shown to reduce arterial inflammation in patients with ASCVD (788). Drugs targeting CD47 (Hu5F9-G4, TTI-621) are currently being tested in clinical studies as cancer therapies (789, 790).

9.3.1.2.5 Enhancing resident vascular macrophages

Microenvironmental factors have huge importance in tissue-specific macrophage programming. During disease, “stress” pathways will also exert their influence (791). Pattern recognition receptors including toll-like receptor (TLRs) and C-type lectin receptor (CLRs) pathways are well placed to sense the environmental cues in macrophages (792). We and others have shown that TLRs have a role in atherogenesis (reviewed in (793)). CLRs are preferentially expressed by the myeloid lineage and recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) (794). CLRs carry either an immunoreceptor tyrosine-based activation motif or immunoreceptor tyrosine-based inhibition motif (ITIM) in the cytoplasmic domain(795), providing a balance in cellular activation in the immune system. ITAM-bearing CLRs such as CLEC4E and CLEC9A promotes atherogenesis by modulating myeloid functions (796, 797). The role of CLRs with an ITIM, such as CLEC4A2, in atherosclerosis was unknown. We recently revealed the protective role of resident vascular macrophages in atherosclerosis, via a CLR with an ITIM, CLEC4A2 (139). Using single cell technologies and conditional ablation, expression of the C-type lectin receptor CLEC4A2, also known as dendritic cell immunoreceptor 1 (DCIR1), was shown to be a distinguishing feature of vascular resident macrophages endowed with protective properties against atherosclerosis (139). CLEC4A2 is one of the top genes that distinguishes resident macrophages from the activated resident ones at the gene and protein level. Ablation of CLEC4A2⁺ macrophages via a *LysM*^{Cre+}*Clec4a2*^{flox/DTR} mouse strain aggravates lesion formation in response to atherosclerosis. Moreover, CLEC4A2 maintains the vascular resident macrophage pool by licensing monocytes to join the resident pool. CLEC4A2 as an intrinsic regulator of macrophage tissue adaptation by promoting monocyte-to-macrophage differentiation via colony stimulating factor 1 (CSF1) over CSF2 in vascular health and disease.

CLEC4A senses endogenous glycoproteins and HIV1-derived glycoproteins by its carbohydrate recognition domain and signals through its ITIM domain by recruiting tyrosine phosphatases SHP1 and SHP2 (798). Several polymorphisms in the *CLEC4A* gene are strongly associated with susceptibility to rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome (799, 800). Mice deficient in the murine homologue, *Clec4a2*, develop worse collagen-induced arthritis and experimental autoimmune encephalomyelitis (801, 802). We showed that during atherogenesis, CLEC4A2 deficiency results in loss of resident vascular macrophages and their homeostatic properties (139), leading to enhanced lesion formation. CLEC4A2 limits TLR2- and TLR4-dependent pro-inflammatory cytokine production in murine macrophages. Moreover, *Clec4a2*^{-/-} macrophages accumulate higher levels of intracellular lipid when exposed to oxLDL relative to their WT counterpart, due to downregulation of cholesterol efflux gene expression (*Abca1* and *Abcg1*), ultimately leading to dysregulated reverse cholesterol transport (RCT). SHP1 inhibition replicates the CLEC4A2-dependent lipid dysregulation in WT macrophages (139).

9.3.1.3 Targeting monocytes in atherosclerosis

Chemokine/chemokine receptor mediated mechanisms as well as leukocyte adhesion molecules are crucial in recruiting monocytes into the arterial wall. Blocking these systems result in significant reduction of atherosclerosis in murine models (803). LDL receptor deficient mice that carry targeted deletions of the gene for CCL2 or its receptor CCR2 exhibit significantly less atherosclerosis than LDL receptor KO with intact CCL2 signaling (804-806). A deficiency in adhesion molecules such as P-selectin, ICAM-1 and VCAM-1, or blockage of their interactions with their respective ligands and integrins can reduce monocyte recruitment and atherosclerotic lesion size (807, 808). *In vivo* cell tracking studies showed that inflammatory monocytes use chemokine receptors CX3CR1, CCR2 and CCR5 to enter plaques while resident monocytes only use CCR5 (147). Murine knockout studies showed that Ly-6C^{hi} monocytes depend CCR2 for their mobilization from the bone marrow and tissue infiltration, as a deficiency in CCR2 reduces their numbers in the circulation and tissues while maintaining high levels in the bone marrow (148, 809). Treatment with a CCR2-antagonists in CVD patients decreased hsCRP levels (810). A deficiency in CX₃CR1 reduces lesion size and macrophage accumulation leading to morphological features of a stable plaque (811) suggesting Ly-6C^{hi} monocytes may promote plaque instability. Combined deletion of CCL2, CX₃CR1 and CCR5 virtually eliminates atherosclerosis, monocyte accumulation, and halts bone marrow and blood monocytosis (148). Thus, targeting integrin or chemokine signaling is a therapeutic option to reduce monocyte and macrophage accumulation in atherogenesis (803).

When considering targeting monocytes in atherosclerosis, it is crucial to examine changes in the early stages of hematopoiesis of hematopoietic stem and progenitor cells (HSPCs). These progenitor cells differentiate into and renew the myeloid, lymphoid, and erythrocytic lineages in the bone marrow. More recently, attention has broadened to extra-medullary anatomical sites—locations outside of the bone marrow where HSPCs can produce monocytes (731, 812, 813). Monocytes produced within these extra-medullary sites, similar to those derived from the bone marrow, have been shown to infiltrate atherosclerotic lesions and contribute to atherogenesis (146, 716). Conditions such as hypercholesterolemia, stress, inflammation, and other risk factors associated with atherosclerosis can induce emergency hematopoiesis. This includes

extramedullary hematopoiesis, particularly in the spleen, and contributes to disease progression by influencing the differentiation of hematopoietic stem and progenitor cells in the bone marrow towards myeloid lineages. Preclinical murine studies have shown that Ly6Chi splenic monocytes not only contribute to the growth of atheromas but also play a role in plaque instability (716, 718).

Not only classical monocytes are involved in atherogenesis. A recent study identified heterogeneity in nonclassical monocytes in subjects with CAD. An expansion of a Slan⁺CXCR6⁺ nonclassical monocyte subset in CAD subjects was positively correlated with CAD severity. This nonclassical subset can migrate towards CXCL16 and shows an increased efferocytosis capacity, indicating it may play an atheroprotective role (217). Moreover, intermediate monocytes subsets could be distinguished in human PBMC, by the expression of HLA-DR, CXCR3, and CD206. The subset expressing HLA-DR⁺CXCR3⁺CD206⁺ was associated with CAD severity, and it positively correlated with the Gensini Score of CAD severity (814).

9.3.2 Targeting the adaptive immune system

9.3.2.1 Targeting T cells in atherosclerosis

9.3.2.1.1 Vaccination strategies

Immune recognition of antigens in atherosclerosis, especially of (ox)LDL containing peptides results in the generation of autoantibodies and oxLDL-reactive T cells(234). Immunization with ApoB-derived antigens was protective against atherosclerosis via diverse mechanisms including the induction of a humoral antibody response, Treg activation, suppression of CD4⁺ T cells and CD8⁺ T-cell mediated reduction of dendritic cell numbers in the plaque (815). These findings have yet not translated into vaccination strategies in humans. The GLACIER study, conducted in patients with stable atherosclerotic CVD, showed that passive immunization with MLDL1278A, an anti-oxLDL antibody, added to lipid-lowering therapies did not reduce cardio-vascular events or arterial inflammation (816). A caveat of this clinical trial is that in patients with stable atherosclerotic disease, plaque inflammation may be too limited for anti-oxLDL treatment to have an effect. Also, the 3-month follow-up period may be too short to prove effectiveness, or the imaging techniques not sensitive enough to detect changes in atherosclerosis. The strategy of passive immunization, followed in the GLACIER study, bypasses the cellular arm of the immune system and will not lead to protective CD4⁺ and CD8⁺ T cell responses. Finally, the focus on one single antigen (oxLDL) may have been too limited in scope as multiple other antigens have been implicated in the pathogenesis of atherosclerosis.

Recent advancements in this field, have set the first steps to better identify the antigen. In silico prediction models have helped to identify which ApoB peptides can bind to the diverse repertoire of major compatibility complex II variants, resulting in the detection of 30 ApoB peptides that were able to induce a human T cell response in vitro (817). Moreover, several studies using scTCR in atherosclerotic plaques identified clonally expanded CD4⁺ and CD8⁺ T cell in atherosclerotic plaques (277). Resolving the antigen specificity of TCR may reveal new antigen of specify existing ones.

Next to the antigen, the vaccine formulation is critical for the type of immune response that is evoked. Formulations that are specifically designed to induce Treg are particularly appealing and

have been shown to reduce atherosclerosis in preclinical models (818-820). Detailed characteristics of variants of antigenic peptides presented in atherosclerosis, in combination with for a tailored vaccination formulation will enable more precise vaccination strategies.

9.3.2.1.2 Targeting T cell recruitment

T cells, just like myeloid cells, use chemokines and chemokine receptors to traffic towards and into the arterial wall (803). The CXCR6 receptor is expressed on T cells and promotes T cell homing and IFN γ production. Mice lacking CXCR6 show a reduction in atherosclerosis (821). CXCR3 is also expressed on T cells, and mainly interacts with CXCL10, but can also bind CXCL9 and CXCL11. Blocking CXCR3 reduces the number of Th1 cells, thereby reducing atherosclerosis (822), and inhibiting CXCR10 shows similar effects (823). Homo-arginine supplementation decreased CXCR3 on T cells and showed a reduction in atherosclerosis (824). Recently, a non-canonical chemokine receptor pathway was discovered, where CCL17, that binds CXCR4 on Tregs to reduce their suppressive effects, was found to bind CCR8 as well, thereby inducing CCL3 and suppressing Treg functions. Deletion of both CCL3 and CCR8 in T cells increased Treg numbers and led to a reduction in atherosclerosis (825). Although we still do not fully understand the intricate chemokine/chemokine receptor system in atherosclerosis, experimental studies have revealed that these are promising targets.

9.3.2.2 Targeting B cells in atherosclerosis

The advent of single cell analytics and other advanced technologies have allowed unprecedented discovery of B cell subtypes and functions linked to atherosclerosis in humans, providing novel immunotherapeutic targets to counter CVD.

B cell targeted therapies are widely used in a variety of disease states including B cell leukemias, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), and multiple myeloma (MM) to treat patients (826-828). Although B cell-targeted therapies are not currently used for atherosclerosis, the association of B cell subtypes and B cell-derived antibodies in human atherosclerosis coupled with mechanistic studies of subset-specific effects of B cells on atherosclerosis in pre-clinical models, suggests that B cell targeted therapies may impact human atherosclerosis. In the following sections, we review different therapeutic strategies and their potential implications for atherosclerosis.

9.3.2.2.1 B Cell Reduction

Drugs that deplete B cells and plasma cells include rituximab-CD20, ofatumumab-CD20, ocrelizumab-CD20, blinatumumab-CD19, inebilizumab-CD19, inotuzumab-, ozogamicin-CD22, elotuzumab-SLAMF7, daratumumab-CD38, GSK2857916-BCMA, AMG420/BI836909-BCMA (826, 827). Given B cell subset-specific effects on atherosclerosis, the impact of these drugs on atherosclerosis would likely be dependent on which B cell subset is most affected.

CD20-specific monoclonal antibody depletion of B cells in mice preferentially depleted B2 cells, caused a greater reduction in IgG than IgM, resulting in less atherosclerosis (407, 409). The attenuated impact on IgM is likely due to the fact that despite both B1 and B2 cells expressing CD20, the niches where they are predominantly found may not be equally accessible to the delivered antibody. For example, 95-98% of B cells in the bone marrow, blood, spleen, lymph nodes, and gut-associated lymphoid tissues were depleted by anti-CD20 antibody, while only 30-43% of B1 cells and 43-78% of B2 cells were depleted in the peritoneal cavity (the homeostatic

niche for B1 cells) (829). Rheumatoid arthritis (RA) patients that take rituximab demonstrate decreased inflammation, improved endothelial function, and decreased carotid intima-media thickness (cIMT) (828, 830), suggesting that rituximab can be beneficial for CVD. In kidney transplant patients treated with rituximab for desensitization of ABO-incompatible organs, there was a lower cumulative rate of atherosclerotic cardiovascular disease especially if the subjects had diabetes mellitus, pretransplant dialysis or older age (831). Yet, most clinical trials of rituximab for autoimmune diseases do not provide convincing evidence for reduction of major adverse cardiovascular events (832). The RITA-MI study showed that rituximab could be applied safely in CVD patients (672), and follow up studies are eagerly awaited (672).

B cell numbers can also be reduced by agents that target factors that promote B cell survival such as B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL). Binding of these ligands to receptors such as BAFFR and TACI, in conjunction with antigen to the BCR, induces activation of NF- κ B to increase B cell survival. Clinical uses for therapies targeting BAFF/BAFFR and APRIL include treating graft-versus-host disease (GVHD), RA, SLE, and myasthenia gravis (833, 834). Blocking BAFF-BAFFR interaction in mice reduces B2 B cell survival and *Ldlr*^{-/-} mice with BAFFR deficiency had decreased B2 but not B1a B cells and less atherosclerosis (835). Similar findings were reported in BAFFR-deficient *ApoE*^{-/-} mice (410). However, BAFF has been shown to increase anti-oxLDL IgM production and reduce atherosclerosis in hyperlipidemic mice (836) and to have effects on other immune cells such as regulatory T cells (Tregs) which expand in response to BAFFR activation (837). Whether these agents could have a role in reducing atherosclerosis in humans remains to be seen but addressing this may be complex given the myriad effects of the BAFF family members.

9.3.2.2.2 Plasma Cell Depletion

Therapies aimed at depleting plasma cells are frequently applied to treat multiple myeloma (GSK2857916-BCMA, AMG420/BI836909-BCMA, elotuzumab-SLAMF7, daratumumab-CD38) (838), although these therapies have been associated with vascular thrombosis in humans (839). The potential of plasma cell depletion to treat atherosclerosis is debatable. Plasma cell depletion has been shown to reduce atherosclerotic lesion size (840), but to increase plaque instability (841). A similar phenotype was observed in a murine model of deficient antibody production, which had smaller plaques, but showed large necrotic cores (415). These findings raise concern for applying this treatment strategy for atherosclerosis and underscores the importance of evaluating subjects receiving these therapies for untoward cardiovascular effects.

9.3.2.2.3 B Cell Receptor (BCR) Modulation

Several therapies have been developed to modulate BCR activation to treat cancers such as chronic lymphocytic leukemia (842). As BCR activation can result in release of chemokines such as CCL3 and CCL4 that enhance infiltration of monocytes and T cells into local tissues (843), blocking BCR activation with Bruton's tyrosine kinase (BTK) inhibitors, such as Ibrutinib and acalabrutinib, and Epratuzumab, an agonist of CD22, would decrease chemokines (844). Perhaps BCR signaling inhibitors could be atheroprotective due to diminished pro-inflammatory chemokine release, although this is not known.

In summary, B cells are important regulators of diet-induced atherosclerosis in mice, exerting their effects in a subset-dependent manner. Evidence in humans, while largely associative,

supports these findings. Together, they lay a foundation for potential B cell targeted immunotherapy approaches for atherosclerosis. Yet, more work is needed to develop, implement and evaluate the effects of B cell therapies in human atherosclerosis. Attention to utilizing current clinical studies and clinical practice in oncology or rheumatology that employ antibody or small molecules that modulate B cell numbers, function and T cell interactions on subclinical and clinical cardiovascular events could be an important and powerful first step.

9.3.3 Targeting the immunological synapse in atherosclerosis: co-stimulation & co-inhibition

Co-stimulatory and co-inhibitory members of the immune checkpoint family are important regulators of immune responses. Pre-clinical, as well as limited clinical data have proven the potential of co-stimulatory and co-inhibitory immune checkpoint molecules as immunotherapeutic target for atherosclerotic CVD (845).

9.3.3.1 Targeting co-stimulation in atherosclerosis: the CD40-CD40L dyad

Inhibition of CD40 or CD40L results in a reduction of atherosclerosis and atherosclerotic plaque stability. The CD40-CD40L dyad exerts cell divergent functions, that all affect atherosclerosis via different mechanisms as has been described in *section 8*.

CD40's cell divergent functions are also reflected in its signal transduction pathways. CD40 has no intrinsic signaling, but uses adaptor molecules, the TNF Receptor Associated Factors (TRAF), which are involved in signaling of many members of the TNFR family. In B-cells, CD40 signaling is executed by TRAF2 and TRAF3, which often are counteractive, thereby carefully regulating B cell function (846) (847). In endothelial cells, CD40-TRAF1, -3 and -6 interactions seem to hamper inflammation, whereas CD40-TRAF2 and -TRAF5 interactions aggravate inflammation (848). Monocyte and macrophage CD40 favor TRAF6 as main signaling molecule to induce activation (849). In atherosclerosis, blocking CD40-TRAF6 but not CD40-TRAF2/3/5 signaling reduces atherosclerosis burden, which was mostly due to a reduction in monocyte recruitment and macrophage activation (487). Administration of a small molecule inhibitor that was designed to block CD40-TRAF6 signaling (850, 851) reduced atherosclerosis, even when given to mice with established atherosclerosis (852). The CD40-TRAF6 SMI reduced monocyte and macrophage activation, as it lowered canonical NF κ B activation (852). This immunotherapy was safe and selective to macrophage function, as treated *Apoe*^{-/-} mice did not show any immune suppressive side effects: antibody production and Ig isotype switching was still intact, and antigen dependent T cell proliferation was not affected (852). Incorporation of the CD40-TRAF6 inhibitor into HDL nanobiologics, enabling macrophage targeted delivery of the inhibitor stabilized atherosclerotic plaques in *Apoe*^{-/-} mice (853), and was deemed safe in non-human primates (853). Blocking CD40-TRAF6 interactions were also found beneficial to treat obesity- and hypertension-induced vascular inflammation and oxidative stress (854-856), as well as graft vs host disease by modulating trained immunity (857).

CD40L can bind to other receptors than CD40. The interaction between CD40L and Mac-1 plays a significant role in leukocyte recruitment. A peptide that specifically blocks CD40L at its Mac-1 interaction site (cM7) significantly reduces leukocyte recruitment in peritonitis and atherosclerosis (858), and a monoclonal antibody against CD40L's interaction site at Mac1 (anti-

M7) was highly effective in reducing myeloid cell recruitment in a murine model of sterile sepsis (859).

Clinical trials that block CD40 or CD40L with CVD parameters as primary outcomes have not yet been performed. Until now, we have not fully grasped the mechanisms of actions of the CD40L-CD40 dyad in atherogenesis. Our preclinical data have revealed that cell-targeted anti-CD40(L) therapies, therapies targeting CD40-signaling intermediates or therapies targeting non-classical CD40L interactions are preferred to complete blockage of CD40(L) to circumvent immune suppressive side-effects. As many trials are currently running that are testing the clinical effects of blocking CD40L or CD40 in human auto-immune diseases, we hope that cardiovascular readouts of these trials will be assessed and become available. Meanwhile, further development of targeted CD40(L) based immunotherapeutics for ASCVD, including anti-M7 antibodies (859), and CD40-TRAF6 SMIs (852, 853) for 'in human use' are eagerly being awaited.

9.3.3.2 Targeting co-inhibition in atherosclerosis

Inhibitory Immune Checkpoint inhibitors (ICIs) such as nivolumab (anti-PD-1), pembrolizumab (anti-PD-L1/L2), atezolizumab (anti-PD-L1), durvalumab (anti-PD-L1), avelumab (anti-PD-L1), and ipilimumab (anti-CTLA4) (860) are widely used in oncology and mostly act via inhibition of PD1 or PDL1/2. Although very successful in treating cancer, these immunotherapies are associated with cardiotoxicity (i.e., myocarditis, acute myocardial infarction, and vasculitis) and increased atherosclerosis-driven cardiovascular events (707, 861). These studies revealed the importance of the PD1-PDL1/2 axis in atherogenesis. Agonizing PD1/PD-L1 interactions or activating other co-inhibitory molecules, such as CTLA4, Tim3, and Tigit in atherosclerosis would potentially be of interest. However, additional research in both pre-clinical models and in clinical trials using ICIs is sorely needed.




Figure 13: Future immunotherapeutic strategies for the treatment of atherosclerosis. Current immunotherapies in CVD are promising, but need optimization as some induce side effects, and do not decrease overall mortality. Future immunotherapeutics aim to target atherosclerosis-associated immunological and inflammatory pathways in a cell-type specific manner to reduce CVD and overall mortality without causing side-effects.

10. IMMUNOTHERAPIES FOR ATHEROSCLEROTIC CVD: AN OUTLOOK

Immune cell activation and its resulting inflammation play an important role in the pathogenesis of atherosclerosis. We are obtaining more and more insights on the cell-subsets that are involved in atherogenesis and on the intricate networks and mechanisms of immune cell communication that drive plaque progression. The immune system is distributed in its architecture, and it operates through a network of cells, tissues, and organs, collectively defending against pathogens while at the same time maintain homeostasis. This is a lot of moving pieces. To choose the most effective immunotherapy for ASCVD, we need to tackle simultaneously many key components of this decentralized system including: i) the immune cell diversity that allows for specialized functions; ii) the vascular tissue-based immunity tailored to atherosclerosis; iii) the communication networks that coordinate immune responses across different locations in the body. This is more critical now than ever because we witnessed a recent shift in the whole CV *exposome*, with and better management of lipid metabolism and a major epidemic of diabetes and obesity, linked to cardiometabolic inflammation.

The clinical trials so far have highlighted the importance of selecting patients with biomarker evidence of inflammation (653, 656). However, other options for trial design will have a transformative effect on the field. When designing clinical trials to test immunotherapeutics in cardiovascular disease, the current read-out remains the occurrence of a cardiovascular event. This requires large populations, and an extensive trial period, as the percentage of cardiovascular events is rather low. It is therefore of utmost importance to develop novel read outs that can detect (a reduction in) cardiovascular inflammation, such as novel blood biomarkers or CT or PET imaging, or magnetic resonance imaging or ultrasound (110, 862). Finally, biomarkers should be used also to monitor the drug response early. For instance, in a CANTOS sub-study, lack of effect on CRP at 3 months indicated lack of efficacy on outcomes (656). Non-responders can be identified early and numbers needed to treat can be refined, as well as risk of loss of homeostasis. Targeting canakinumab or other immunotherapies to responders might improve clinical effectiveness and cost-effectiveness.

We need to widen our scope of immunotherapeutic targets by sorting the pieces of the cardiovascular immunology puzzle and building a cardiovascular immunology-driven pipeline of therapeutic targets. Numerous pre-clinical studies targeting a myriad of cells, molecules and processes involved in atherogenesis have been shown to reduce atherosclerosis in mouse models, which makes selection of novel therapeutic targets, relevant for human ASCVD difficult. We probably have most pieces of the puzzle, but no framework for their hierarchical spatio-temporal placement and, thus, knowledge on how to target them in the right place, at the right time. There are some pioneering spatial transcriptomics studies ongoing in human atherosclerosis, but much is still unknown.

In the last three decades, the biomedical community has seen the advent and dramatic rise of genomic and functional genomic approaches driven by high throughput sequencing technologies. These have had a dramatic impact on the discovery process including helping generate hypotheses for further downstream mechanistic studies. Along with enabling investigator-initiated studies, these technologies have catalyzed large-scale genomics consortia including those working on the cellular molecular drivers of cardiovascular disease which have helped uncover the critical role the immune system is playing in disease etiology as well as providing valuable data resources. These datasets are increasingly pointing to the importance of the

Immune system in human CVD. In a meta-analysis of genome-wide association studies, the CARDIoGRAMplusC4D consortium assessed 6.7 million common and 2.7 million low-frequency variants (863). Along with confirming known CAD-associated loci, they identified ten new loci which included genes involved in leukocyte migration and anti-inflammatory effects. Another large-scale program, the Trans-Omics for Precision Medicine (TOPMed) works toward elucidating the genetic architecture and biology of heart, lung, blood and sleep disorders and includes a number of CVD-related consortia including Multi-Ethnic Study of Atherosclerosis (MESA) and Cardiovascular Health Study (CHS)(864). TOPMed has generated over 180,000 whole-genome sequences as well as RNA-seq, DNA methylation, protein, and metabolic profiles for thousands to tens of thousands of samples (<https://topmed.nhlbi.nih.gov>). Notably, many of these profiles are derived from human PBMCs. Additionally, the following search of the Gene Expression Omnibus (GEO) database (865) “cardiovascular disease AND immune” yielded 1431 studies which contained some kind of omics data. Many of the datasets generated by these consortia as well as individual investigators contain bulk RNA-seq data which represents an effective average of gene expression levels over cell types. Fortunately, increasingly powerful deconvolution methods are capable of deriving relatively accurate estimates of cell type proportions as well as estimates of average gene expression levels for each cell type (866-868) (869) (870, 871). Along with the results of these and many other studies, the data that they’ve generated and made publicly available together with many powerful tools enable reanalysis that will yield further insights into the role of the immune system in cardiovascular disease.

The recent rise in single cell technologies is enabling the field to obtain a detailed view on immune cell subsets that are present in human atherosclerotic plaque, how they interact with each other, and which pathways they employ to exert their function. Although many more studies, data analyses and validation studies need to be performed, these results will certainly facilitate selection of novel targets that are relevant for human disease. In a recent study, single cell data of PBMCs of patients, suffering from CVD, were used to find a drug combatting inflammation in the LINC database, a drug repurposing database. The drug saracatinib was found to reduce inflammation and successfully reduced atherosclerosis and macrophage activation in pre-clinical models (872). The growing number of single cell studies are revealing the role of the immune system in atherosclerosis at various stages of disease progression. However, a serious limitation of single cell omics approaches is their cost. Machine learning based frameworks are beginning to emerge that are effectively attempting to reduce the cost (873). They leverage existing cohort-based studies where bulk RNA-seq was performed for all patients and single cell RNA-seq was performed for a few. They select the most informative patients for further scRNA-seq and generate representative scRNA-seq for the remaining patients (873). The combination of growing omics assays, available data and powerful analytical frameworks holds great promise for further revealing the critical role that the immune system is playing in cardiovascular disease and identifying immune-based therapeutic targets.

Immunotherapies are not without risks. Targeting the immune system may result in immune suppressive side effects, that are, in a slowly developing disease as atherosclerosis, not acceptable. Recent insights have shown that many pathways in the immune system show cell-divergent effects. Cytokines may be pro-inflammatory for one cell-type, and anti-inflammatory for the other cell type (874), which is also true for other molecules, including costimulatory and co-inhibitory immune checkpoints (845). Therefore, cell-targeted immunotherapeutic

approaches are preferred. Cell targeting can be accomplished using cell-preferential nanoparticles or nanobiologics (875), bi-specific antibodies or targeting unique cell-specific protein-protein interactions. Nucleic acid based immunotherapeutics, in the form of siRNA, antisense oligonucleotides and mRNAs have been proven powerful ways of intervening with the immune system. Recently, a new platform has been developed that enables specific delivery of nucleic acid-based therapeutics to myeloid cells and its progenitors, using apolipoprotein-based nanoparticles (876). This approach was proven successful in a syngeneic tumor model in mice (876), and has great potential for delivering myeloid-cell restricted immunotherapeutics in atherosclerosis.

The atherosclerosis field is entering a new and exciting era, in which we will obtain more detailed insights into the immunological pathways that are so relevant in atherosclerotic cardiovascular disease. Although we will face significant challenges to design and implement (Figure 12) immunotherapeutics to combat atherosclerotic CVD in the next decades, immunotherapies will become part of the standard of care to treat cardiovascular diseases.

ACKNOWLEDGEMENTS

LeDucq Foundation grant (22CVD02): CHECKPOINT ATHERO (all authors are PIs of the CHECKPOINT ATHERO LeDucq international network of excellence).

REFERENCES

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernandez-Sola J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundstrom J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V, and Group G-N-JGBoCDW. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol* 76: 2982-3021, 2020.
2. Mensah GA, Fuster V, Murray CJL, Roth GA, Global Burden of Cardiovascular D, and Risks C. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. *J Am Coll Cardiol* 82: 2350-2473, 2023.
3. Lopez-Bueno R, Nunez-Cortes R, Calatayud J, Salazar-Mendez J, Petermann-Rocha F, Lopez-Gil JF, and Del Pozo Cruz B. Global prevalence of cardiovascular risk factors based on the Life's Essential 8 score: an overview of systematic reviews and meta-analysis. *Cardiovasc Res* 120: 13-33, 2024.
4. Janson C, Potts J, Malinowski A, Agarwal D, Ahmed R, Aquart-Stewart A, Harrabi I, Denguezli M, Devereux G, Erhabor GE, Gislason T, Jogi R, Juvekar SK, Knox-Brown B, Koul P, Mortimer K, Nafees AA, Nielsen R, Mahesh PA, Paraguas SNM, Rotevatn AO, Sooronbaev T, Burney PGJ, Amaral AFS, and Group BCR. Lung function and onset of cardiometabolic diseases in the longitudinal Burden of Obstructive Lung Disease study. *BMJ Open Respir Res* 12: 2025.
5. Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, Mason JC, Rahimi K, McMurray JJV, and Verbakel JY. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. *Lancet* 400: 733-743, 2022.
6. Agca R, Hopman L, Laan KJC, van Halm VP, Peters MJL, Smulders YM, Dekker JM, Nijpels G, Stehouwer CDA, Voskuyl AE, Boers M, Lems WF, and Nurmohamed MT. Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study. *J Rheumatol* 47: 316-324, 2020.
7. Whitney DG, Whitney RT, Prisby RD, and Jepsen KJ. Low-Trauma Fracture Increases 12-Month Incidence of Cardiovascular Disease for Adults With Cerebral Palsy. *J Orthop Res* 38: 803-810, 2020.
8. van Royen FS, Venekamp RP, Bruijning-Verhagen P, and Rutten FH. Acute Respiratory Infections Fuel Cardiovascular Disease. *J Am Coll Cardiol* 84: 2468-2470, 2024.
9. Kristofi R, Bodegard J, Ritsinger V, Thuresson M, Nathanson D, Nystrom T, Norhammar A, and Eriksson JW. Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data. *Cardiovasc Diabetol* 21: 282, 2022.

10. **Grinspoon SK, Zanni MV, Triant VA, Kantor A, Umbleja T, Diggs MR, Chu SM, Fitch KV, Currier JS, Bloomfield GS, Casado JL, de la Pena M, Fantry LE, Gardner E, Aberg JA, Malvestutto CD, Fichtenbaum CJ, Lu MT, Ribaldo HJ, and Douglas PS.** Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE. *Lancet HIV* 2025.
11. **van Zeventer IA, Salzbrunn JB, de Graaf AO, van der Reijden BA, Boezen HM, Vonk JM, van der Harst P, Schuringa JJ, Jansen JH, and Huls G.** Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥ 80 years. *Blood Adv* 5: 2115-2122, 2021.
12. **Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, and Ebert BL.** Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. *N Engl J Med* 377: 111-121, 2017.
13. **Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA, Cooper MA, Andres V, Hirschi KK, Martin KA, and Walsh K.** Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science* 355: 842-847, 2017.
14. **Zuriaga MA, Yu Z, Matesanz N, Truong B, Ramos-Neble BL, Asensio-Lopez MC, Uddin MM, Nakao T, Niroula A, Zorita V, Amoros-Perez M, Moro R, Ebert BL, Honigberg MC, Pascual-Figal D, Natarajan P, and Fuster JJ.** Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. *Eur Heart J* 45: 4601-4615, 2024.
15. **Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, Liu W, Thomas DG, Hajebrahimi MA, Pircher J, Silvestre-Roig C, Kotini AG, Luchsinger LL, Wei Y, Westerterp M, Snoeck HW, Papapetrou EP, Schulz C, Massberg S, Soehnlein O, Ebert B, Levine RL, Reilly MP, Libby P, Wang N, and Tall AR.** The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. *Nature* 592: 296-301, 2021.
16. **Diez-Diez M, Ramos-Neble BL, de la Barrera J, Silla-Castro JC, Quintas A, Vazquez E, Rey-Martin MA, Izzi B, Sanchez-Garcia L, Garcia-Lunar I, Mendieta G, Mass V, Gomez-Lopez N, Espadas C, Gonzalez G, Quesada AJ, Garcia-Alvarez A, Fernandez-Ortiz A, Lara-Pezzi E, Dopazo A, Sanchez-Cabo F, Ibanez B, Andres V, Fuster V, and Fuster JJ.** Unidirectional association of clonal hematopoiesis with atherosclerosis development. *Nat Med* 30: 2857-2866, 2024.
17. **Putala J, and Nieminen T.** Stroke Risk Period After Acute Myocardial Infarction Revised. *J Am Heart Assoc* 7: e011200, 2018.
18. **Brammas A, Jakobsson S, Ulvenstam A, and Moe T.** Mortality after ischemic stroke in patients with acute myocardial infarction: predictors and trends over time in Sweden. *Stroke* 44: 3050-3055, 2013.
19. **Boulanger M, Bejot Y, Rothwell PM, and Touze E.** Long-Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta-Analysis. *J Am Heart Assoc* 7: 2018.

20. **Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Juni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B, and Group ESCSD.** 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44: 3720-3826, 2023.
21. **Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svtil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, and Group ESCSD.** 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 41: 407-477, 2020.
22. **Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, Fowkes FGR, Fowkes FJI, and Rudan I.** Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. *Lancet Glob Health* 8: e721-e729, 2020.
23. **Gulli G, Marquardt L, Rothwell PM, and Markus HS.** Stroke risk after posterior circulation stroke/transient ischemic attack and its relationship to site of vertebrobasilar stenosis: pooled data analysis from prospective studies. *Stroke* 44: 598-604, 2013.
24. **Bamford J.** Clinical examination in diagnosis and subclassification of stroke. *Lancet* 339: 400-402, 1992.
25. **Dorigo W, Pulli R, Nesi M, Alessi Innocenti A, Pratesi G, Inzitari D, and Pratesi C.** Urgent carotid endarterectomy in patients with recent/crescendo transient ischaemic attacks or acute stroke. *Eur J Vasc Endovasc Surg* 41: 351-357, 2011.
26. **Karkos CD, McMahon G, McCarthy MJ, Dennis MJ, Sayers RD, London NJ, and Naylor AR.** The value of urgent carotid surgery for crescendo transient ischemic attacks. *J Vasc Surg* 45: 1148-1154, 2007.
27. **Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, Conte MS, and Murad MH.** The natural history of untreated severe or critical limb ischemia. *J Vasc Surg* 62: 1642-1651 e1643, 2015.
28. **Sigvant B, Lundin F, and Wahlberg E.** The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease. *Eur J Vasc Endovasc Surg* 51: 395-403, 2016.
29. **Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, and Group ESCSD.** 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J* 39: 763-816, 2018.

30. **Pappaccogli M, Robberechts T, Lengele JP, Van der Niepen P, Sarafidis P, Rabbia F, and Persu A.** Endovascular Versus Medical Management of Atherosclerotic Renovascular Disease: Update and Emerging Concepts. *Hypertension* 80: 1150-1161, 2023.
31. **Derkx FH, and Schalekamp MA.** Renal artery stenosis and hypertension. *Lancet* 344: 237-239, 1994.
32. **Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, Burke GL, and Dean RH.** Prevalence of renovascular disease in the elderly: a population-based study. *J Vasc Surg* 36: 443-451, 2002.
33. **Herrmann SM, and Textor SC.** Current Concepts in the Treatment of Renovascular Hypertension. *Am J Hypertens* 31: 139-149, 2018.
34. **Ha C, Magowan S, Accortt NA, Chen J, and Stone CD.** Risk of arterial thrombotic events in inflammatory bowel disease. *Am J Gastroenterol* 104: 1445-1451, 2009.
35. **Reinus JF, Brandt LJ, and Boley SJ.** Ischemic diseases of the bowel. *Gastroenterol Clin North Am* 19: 319-343, 1990.
36. **Roussel A, Castier Y, Nuzzo A, Pellenc Q, Sibert A, Panis Y, Bouhnik Y, and Corcos O.** Revascularization of acute mesenteric ischemia after creation of a dedicated multidisciplinary center. *J Vasc Surg* 62: 1251-1256, 2015.
37. **Atlas Writing G, Esc Atlas of Cardiology is a compendium of cardiovascular statistics compiled by the European Heart Agency adotESoC, Developed in collaboration with the national societies of the European Society of Cardiology member c, Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L, and Vardas P.** European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). *Eur Heart J Qual Care Clin Outcomes* 6: 7-9, 2020.
38. **Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J, and Ziaeian B.** 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 140: e563-e595, 2019.
39. **Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgozoglul L, and Lewis EF.** Atherosclerosis. *Nat Rev Dis Primers* 5: 56, 2019.
40. **Stry HC.** Macrophage foam cells in the coronary artery intima of human infants. *Ann NY Acad Sci* 454: 5-8, 1985.
41. **Stry HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W, Jr., Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, and et al.** A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 85: 391-405, 1992.
42. **Stry HC, Chandler AB, Glagov S, Guyton JR, Insull W, Jr., Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, and Wissler RW.** A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions

of the Council on Arteriosclerosis, American Heart Association. *Circulation* 89: 2462-2478, 1994.

43. **Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., Rosenfeld ME, Schwartz CJ, Wagner WD, and Wissler RW.** A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 92: 1355-1374, 1995.

44. **Gabrovsky AN, O'Neill KD, and Gerszten E.** Paleopathology of cardiovascular diseases in South American mummies. *Int J Cardiol* 223: 101-107, 2016.

45. **Abdelfattah A, Allam AH, Wann S, Thompson RC, Abdel-Maksoud G, Badr I, Amer HA, el-Din Ael H, Finch CE, Miyamoto MI, Sutherland L, Sutherland JD, and Thomas GS.** Atherosclerotic cardiovascular disease in Egyptian women: 1570 BCE-2011 CE. *Int J Cardiol* 167: 570-574, 2013.

46. **Sandison AT.** Degenerative vascular disease in the Egyptian mummy. *Med Hist* 6: 77-81, 1962.

47. **Panzer S, Augat P, Sprenger M, Zesch S, Rosendahl W, Sutherland ML, Thompson RC, Paladin A, Zink AR, Eurac, and Teams HS.** Correlation of atherosclerosis and osteoarthritis in ancient Egypt: A standardized evaluation of 45 whole-body CT examinations. *Int J Paleopathol* 33: 137-145, 2021.

48. **Wurst C, Maixner F, Paladin A, Mussauer A, Valverde G, Narula J, Thompson R, and Zink A.** Genetic Predisposition of Atherosclerotic Cardiovascular Disease in Ancient Human Remains. *Ann Glob Health* 90: 6, 2024.

49. **Virmani R, Kolodgie FD, Burke AP, Farb A, and Schwartz SM.** Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol* 20: 1262-1275, 2000.

50. **Seidel CL.** Cellular heterogeneity of the vascular tunica media. Implications for vessel wall repair. *Arterioscler Thromb Vasc Biol* 17: 1868-1871, 1997.

51. **Stenmark KR, Yeager ME, El Kasmi KC, Nozik-Grayck E, Gerasimovskaya EV, Li M, Riddle SR, and Frid MG.** The adventitia: essential regulator of vascular wall structure and function. *Annu Rev Physiol* 75: 23-47, 2013.

52. **Hara T, and Sata M.** Roles of perivascular adipose tissue in the pathogenesis of atherosclerosis - an update on recent findings. *Front Physiol* 15: 1522471, 2024.

53. **Antoniades C, Tousoulis D, Vavlukis M, Fleming I, Duncker DJ, Eringa E, Manfrini O, Antonopoulos AS, Oikonomou E, Padro T, Trifunovic-Zamaklar D, De Luca G, Guzik T, Cenko E, Djordjevic-Dikic A, and Crea F.** Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. *Eur Heart J* 44: 3827-3844, 2023.

54. **Rokitansky C.** *A Manual of Pathological Anatomy*. Printed for the Sydenham Society, London, 1855.

55. **Virchow R.** *Cellular Pathology as based on upon Physiological and Pathological Histology*. JB Lippincott, 1863.

56. **Mayerl C, Lukasser M, Sedivy R, Niederegger H, Seiler R, and Wick G.** Atherosclerosis research from past to present--on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. *Virchows Arch* 449: 96-103, 2006.

57. **Falk E.** Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. *Circulation* 71: 699-708, 1985.
58. **van der Wal AC, Becker AE, van der Loos CM, and Das PK.** Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation* 89: 36-44, 1994.
59. **Goncalves I, Stenstrom K, Skog G, Mattsson S, Nitulescu M, and Nilsson J.** Short communication: Dating components of human atherosclerotic plaques. *Circ Res* 106: 1174-1177, 2010.
60. **Edsfeldt A, Stenstrom KE, Sun J, Dias N, Skog G, Singh P, Mattsson S, Nilsson J, and Goncalves I.** Human Atherosclerotic Plaque Progression Is Dependent on Apoptosis According to Bomb-Pulse (14)C Dating. *JACC Basic Transl Sci* 6: 734-745, 2021.
61. **Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, and Virmani R.** Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. *Circulation* 93: 1354-1363, 1996.
62. **Faggiotto A, Ross R, and Harker L.** Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. *Arteriosclerosis* 4: 323-340, 1984.
63. **Faggiotto A, and Ross R.** Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. *Arteriosclerosis* 4: 341-356, 1984.
64. **Masuda J, and Ross R.** Atherogenesis during low level hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. *Arteriosclerosis* 10: 178-187, 1990.
65. **Watanabe Y.** Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). *Atherosclerosis* 36: 261-268, 1980.
66. **Fan J, Kitajima S, Watanabe T, Xu J, Zhang J, Liu E, and Chen YE.** Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine. *Pharmacol Ther* 146: 104-119, 2015.
67. **Paigen B, Ishida BY, Verstuyft J, Winters RB, and Albee D.** Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. *Arteriosclerosis* 10: 316-323, 1990.
68. **Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, and Breslow JL.** Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. *Cell* 71: 343-353, 1992.
69. **Nakashima Y, Plump AS, Raines EW, Breslow JL, and Ross R.** ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. *Arterioscler Thromb* 14: 133-140, 1994.
70. **Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, and Schwartz SM.** Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. *Arterioscler Thromb Vasc Biol* 20: 2587-2592, 2000.

71. **Williams H, Johnson JL, Carson KG, and Jackson CL.** Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. *Arterioscler Thromb Vasc Biol* 22: 788-792, 2002.
72. **Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, and Palinski W.** Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. *J Pathol* 195: 257-263, 2001.
73. **Lutgens E, van Suylen RJ, Faber BC, Gijbels MJ, Eurlings PM, Bijmens AP, Cleutjens KB, Heeneman S, and Daemen MJ.** Atherosclerotic plaque rupture: local or systemic process? *Arterioscler Thromb Vasc Biol* 23: 2123-2130, 2003.
74. **Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, and Herz J.** Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. *J Clin Invest* 92: 883-893, 1993.
75. **Roche-Molina M, Sanz-Rosa D, Cruz FM, Garcia-Prieto J, Lopez S, Abia R, Muriana FJ, Fuster V, Ibanez B, and Bernal JA.** Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9. *Arterioscler Thromb Vasc Biol* 35: 50-59, 2015.
76. **Basu D, Hu Y, Huggins LA, Mullick AE, Graham MJ, Wietecha T, Barnhart S, Mogul A, Pfeiffer K, Zirlik A, Fisher EA, Bornfeldt KE, Willecke F, and Goldberg IJ.** Novel Reversible Model of Atherosclerosis and Regression Using Oligonucleotide Regulation of the LDL Receptor. *Circ Res* 122: 560-567, 2018.
77. **Bentzon JF.** Tapping Into the Strengths of Diversity Among Atherosclerotic Pigs. *Arterioscler Thromb Vasc Biol* 39: 2203-2204, 2019.
78. **Reitman JS, Mahley RW, and Fry DL.** Yucatan miniature swine as a model for diet-induced atherosclerosis. *Atherosclerosis* 43: 119-132, 1982.
79. **Hoogendoorn A, den Hoedt S, Hartman EMJ, Krabbendam-Peters I, Te Lintel Hekkert M, van der Zee L, van Gaalen K, Witberg KT, Dorst K, Ligthart JMR, Drouet L, Van der Heiden K, van Lennep JR, van der Steen AFW, Duncker DJ, Mulder MT, and Wentzel JJ.** Variation in Coronary Atherosclerosis Severity Related to a Distinct LDL (Low-Density Lipoprotein) Profile: Findings From a Familial Hypercholesterolemia Pig Model. *Arterioscler Thromb Vasc Biol* 39: 2338-2352, 2019.
80. **Jacobsson L.** Comparison of experimental hypercholesterolemia and atherosclerosis in Gottingen mini-pigs and Swedish domestic swine. *Atherosclerosis* 59: 205-213, 1986.
81. **Al-Mashhadi RH, Sorensen CB, Kragh PM, Christoffersen C, Mortensen MB, Tolbod LP, Thim T, Du Y, Li J, Liu Y, Moldt B, Schmidt M, Vajta G, Larsen T, Purup S, Bolund L, Nielsen LB, Callesen H, Falk E, Mikkelsen JG, and Bentzon JF.** Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. *Sci Transl Med* 5: 166ra161, 2013.
82. **JB D.** Pathogenesis of atherosclerosis. *Lancet* 2: 925-927, 1949.
83. **Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, and Virmani R.** Intraplaque hemorrhage and progression of coronary atheroma. *N Engl J Med* 349: 2316-2325, 2003.
84. **Konstantinov IE, and Jankovic GM.** Alexander I. Ignatowski: a pioneer in the study of atherosclerosis. *Tex Heart Inst J* 40: 246-249, 2013.

85. **Anitschkow ND.** Under die Veränderungen der Kaninchenaorta bei experimenteller cholesterinsteatase. *Beitr Pathol Anat* 56: 379-404, 1913.
86. **Goldstein JL, and Brown MS.** Lipoprotein receptors, cholesterol metabolism, and atherosclerosis. *Arch Pathol* 99: 181-184, 1975.
87. **Brown MS, and Goldstein JL.** Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. *Science* 185: 61-63, 1974.
88. **Brown MS, and Goldstein JL.** Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. *Cell* 6: 307-316, 1975.
89. **Ross R, and Glomset JA.** The pathogenesis of atherosclerosis (first of two parts). *N Engl J Med* 295: 369-377, 1976.
90. **Ross R, and Glomset JA.** The pathogenesis of atherosclerosis (second of two parts). *N Engl J Med* 295: 420-425, 1976.
91. **Ross R.** The pathogenesis of atherosclerosis--an update. *N Engl J Med* 314: 488-500, 1986.
92. **Braunwald E.** Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. *N Engl J Med* 337: 1360-1369, 1997.
93. **Davies MJ.** A macro and micro view of coronary vascular insult in ischemic heart disease. *Circulation* 82: 1138-46, 1990.
94. **Vedeler CA, Nyland H, and Matre R.** In situ characterization of the foam cells in early human atherosclerotic lesions. *Acta Pathol Microbiol Immunol Scand C* 92: 133-137, 1984.
95. **Jonasson L, Holm J, Skalli O, Bondjers G, and Hansson GK.** Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. *Arteriosclerosis* 6: 131-138, 1986.
96. **Engelen SE, Robinson AJB, Zurke YX, and Monaco C.** Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? *Nat Rev Cardiol* 2022.
97. **Legain B, Temmerman L, Biessen EA, and Lutgens E.** Inflammation and immune system interactions in atherosclerosis. *Cell Mol Life Sci* 70: 3847-3869, 2013.
98. **Amento EP, Ehsani N, Palmer H, and Libby P.** Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. *Arterioscler Thromb* 11: 1223-1230, 1991.
99. **Weber C, and Noels H.** Atherosclerosis: current pathogenesis and therapeutic options. *Nat Med* 17: 1410-1422, 2011.
100. **Liuzzo G, Biasucci LM, Rebuffi AG, Gallimore JR, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, and Maseri A.** Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. *Circulation* 94: 2373-2380, 1996.
101. **Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuffi AG, Ciliberto G, and Maseri A.** Elevated levels of interleukin-6 in unstable angina. *Circulation* 94: 874-877, 1996.
102. **Ridker PM, Hennekens CH, Buring JE, and Rifai N.** C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 342: 836-843, 2000.

103. **Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, and Braunwald E.** Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. *Circulation* 101: 2149-2153, 2000.
104. **Mallat Z, and Binder CJ.** The why and how of adaptive immune responses in ischemic cardiovascular disease. *Nat Cardiovasc Res* 1: 431-444, 2022.
105. **Ross R.** Atherosclerosis--an inflammatory disease. *N Engl J Med* 340: 115-126, 1999.
106. **Libby P, Mallat Z, and Weyand C.** Immune and inflammatory mechanisms mediate cardiovascular diseases from head to toe. *Cardiovasc Res* 117: 2503-2505, 2021.
107. **de Winther MPJ, Back M, Evans P, Gomez D, Goncalves I, Jorgensen HF, Koenen RR, Lutgens E, Norata GD, Osto E, Dib L, Simons M, Stellos K, Yla-Herttuala S, Winkels H, Bochaton-Piallat ML, and Monaco C.** Translational opportunities of single-cell biology in atherosclerosis. *Eur Heart J* 44: 1216-1230, 2023.
108. **Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, Prominent R-I, and Investigators S.** Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. *Lancet* 2023.
109. **Dweck MR, Maurovich-Horvat P, Leiner T, Cosyns B, Fayad ZA, Gijzen FJH, Van der Heiden K, Kooi ME, Maehara A, Muller JE, Newby DE, Narula J, Pontone G, Regar E, Serruys PW, van der Steen AFW, Stone PH, Waltenberger JL, Yuan C, Evans PC, Lutgens E, Wentzel JJ, and Back M.** Contemporary rationale for non-invasive imaging of adverse coronary plaque features to identify the vulnerable patient: a Position Paper from the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 21: 1177-1183, 2020.
110. **Antonopoulos AS, Sanna F, Sabharwal N, Thomas S, Oikonomou EK, Herdman L, Margaritis M, Shirodaria C, Kampoli AM, Akoumianakis I, Petrou M, Sayeed R, Krasopoulos G, Psarros C, Ciccone P, Brophy CM, Digby J, Kelion A, Uberoi R, Anthony S, Alexopoulos N, Tousoulis D, Achenbach S, Neubauer S, Channon KM, and Antoniades C.** Detecting human coronary inflammation by imaging perivascular fat. *Sci Transl Med* 9: 2017.
111. **Baeyens N, Bandyopadhyay C, Coon BG, Yun S, and Schwartz MA.** Endothelial fluid shear stress sensing in vascular health and disease. *J Clin Invest* 126: 821-828, 2016.
112. **Gordon S, Pluddemann A, and Martinez Estrada F.** Macrophage heterogeneity in tissues: phenotypic diversity and functions. *Immunol Rev* 262: 36-55, 2014.
113. **Aderem A, and Underhill DM.** Mechanisms of phagocytosis in macrophages. *Annu Rev Immunol* 17: 593-623, 1999.
114. **Pearson AM.** Scavenger receptors in innate immunity. *Curr Opin Immunol* 8: 20-28, 1996.
115. **Medzhitov R, and Janeway C, Jr.** Innate immune recognition: mechanisms and pathways. *Immunol Rev* 173: 89-97, 2000.
116. **Ulevitch RJ, and Tobias PS.** Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. *Annu Rev Immunol* 13: 437-457, 1995.
117. **Biswas SK, and Mantovani A.** Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nat Immunol* 11: 889-896, 2010.

118. **Stein M, Keshav S, Harris N, and Gordon S.** Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. *J Exp Med* 176: 287-292, 1992.
119. **Mills CD, Kincaid K, Alt JM, Heilman MJ, and Hill AM.** M-1/M-2 macrophages and the Th1/Th2 paradigm. *J Immunol* 164: 6166-6173, 2000.
120. **Moore KJ, Sheedy FJ, and Fisher EA.** Macrophages in atherosclerosis: a dynamic balance. *Nat Rev Immunol* 13: 709-721, 2013.
121. **Mosser DM, and Edwards JP.** Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* 8: 958-969, 2008.
122. **Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdts S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, and Wynn TA.** Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 41: 14-20, 2014.
123. **Gordon S, and Martinez FO.** Alternative activation of macrophages: mechanism and functions. *Immunity* 32: 593-604, 2010.
124. **Fleetwood AJ, Lawrence T, Hamilton JA, and Cook AD.** Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. *J Immunol* 178: 5245-5252, 2007.
125. **Lawrence T, and Natoli G.** Transcriptional regulation of macrophage polarization: enabling diversity with identity. *Nat Rev Immunol* 11: 750-761, 2011.
126. **Martinez FO, and Gordon S.** The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep* 6: 13, 2014.
127. **Piccolo V, Curina A, Genua M, Ghisletti S, Simonatto M, Sabo A, Amati B, Ostuni R, and Natoli G.** Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk. *Nat Immunol* 18: 530-540, 2017.
128. **van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, and Langevoort HL.** The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. *Bull World Health Organ* 46: 845-852, 1972.
129. **Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guillemins M, Misharin A, Hume DA, Perlman H, Malissen B, Zelzer E, and Jung S.** Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* 38: 79-91, 2013.
130. **Guillemins M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, Deswarte K, Malissen B, Hammad H, and Lambrecht BN.** Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. *J Exp Med* 210: 1977-1992, 2013.
131. **Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, and Merad M.** Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* 330: 841-845, 2010.
132. **Epelman S, Lavine KJ, and Randolph GJ.** Origin and functions of tissue macrophages. *Immunity* 41: 21-35, 2014.

133. **Bain CC, Bravo-Blas A, Scott CL, Perdiguero EG, Geissmann F, Henri S, Malissen B, Osborne LC, Artis D, and Mowat AM.** Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. *Nat Immunol* 15: 929-937, 2014.
134. **Ensan S, Li A, Besla R, Degousee N, Cosme J, Roufaiel M, Shikatani EA, El-Maklizi M, Williams JW, Robins L, Li C, Lewis B, Yun TJ, Lee JS, Wieghofer P, Khattar R, Farrokhi K, Byrne J, Ouzounian M, Zavitz CC, Levy GA, Bauer CM, Libby P, Husain M, Swirski FK, Cheong C, Prinz M, Hilgendorf I, Randolph GJ, Epelman S, Gramolini AO, Cybulsky MI, Rubin BB, and Robbins CS.** Self-renewing resident arterial macrophages arise from embryonic CX3CR1(+) precursors and circulating monocytes immediately after birth. *Nat Immunol* 17: 159-168, 2016.
135. **Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, and Cybulsky MI.** Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. *J Exp Med* 203: 2073-2083, 2006.
136. **Williams JW, Zaitsev K, Kim KW, Ivanov S, Saunders BT, Schrank PR, Kim K, Elvington A, Kim SH, Tucker CG, Wohltmann M, Fife BT, Epelman S, Artyomov MN, Lavine KJ, Zinselmeier BH, Choi JH, and Randolph GJ.** Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression. *Nat Immunol* 21: 1194-1204, 2020.
137. **Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, Chew SHS, See P, Chakarov S, Wang XN, Lim LH, Johnson LA, Lum J, Fong CY, Bongso A, Biswas A, Goh C, Evrard M, Yeo KP, Basu R, Wang JK, Tan Y, Jain R, Tikoo S, Choong C, Weninger W, Poidinger M, Stanley RE, Collin M, Tan NS, Ng LG, Jackson DG, Ginhoux F, and Angeli V.** Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen. *Immunity* 49: 326-341 e327, 2018.
138. **Cole JE, Park I, Ahern DJ, Kassiteridi C, Danso Abeam D, Goddard ME, Green P, Maffia P, and Monaco C.** Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity. *Cardiovasc Res* 114: 1360-1371, 2018.
139. **Park I, Goddard ME, Cole JE, Zanin N, Lyytikainen LP, Lehtimäki T, Andreakos E, Feldmann M, Udalova I, Drozdov I, and Monaco C.** C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis. *Nat Commun* 13: 215, 2022.
140. **Takaoka M, Zhao X, Lim HY, Magnussen CG, Ang O, Suffee N, Schrank PR, Ong WS, Tsiantoulas D, Sommer F, Mohanta SK, Harrison J, Meng Y, Laurans L, Wu F, Lu Y, Masters L, Newland SA, Denti L, Hong M, Chajadine M, Juonala M, Koskinen JS, Kahonen M, Pahkala K, Rovio SP, Mykkanen J, Thomson R, Kaisho T, Habenicht AJR, Clement M, Tedgui A, Ait-Oufella H, Zhao TX, Nus M, Ruhrberg C, Taleb S, Williams JW, Raitakari OT, Angeli V, and Mallat Z.** Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis. *Nature* 634: 457-465, 2024.
141. **Paulson KE, Zhu SN, Chen M, Nurmohamed S, Jongstra-Bilen J, and Cybulsky MI.** Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. *Circ Res* 106: 383-390, 2010.

142. **Edsfeldt A, Swart M, Singh P, Dib L, Sun J, Cole JE, Park I, Al-Sharif D, Persson A, Nitulescu M, Borges PDN, Kassiteridi C, Goddard ME, Lee R, Volkov P, Orho-Melander M, Maegdefessel L, Nilsson J, Udalova I, Goncalves I, and Monaco C.** Interferon regulatory factor-5-dependent CD11c⁺ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. *Eur Heart J* 43: 1864-1877, 2022.
143. **Hernandez GE, Ma F, Martinez G, Firozabadi NB, Salvador J, Juang LJ, Leung J, Zhao P, Lopez DA, Ardehali R, Beaudin AE, Kastrup CJ, Pellegrini M, Flick MJ, and Iruela-Arispe ML.** Aortic intimal resident macrophages are essential for maintenance of the non-thrombogenic intravascular state. *Nat Cardiovasc Res* 1: 67-84, 2022.
144. **Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, and Swirski FK.** Local proliferation dominates lesional macrophage accumulation in atherosclerosis. *Nat Med* 19: 1166-1172, 2013.
145. **Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, and Weissleder R.** Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. *Proc Natl Acad Sci U S A* 103: 10340-10345, 2006.
146. **Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, and Pittet MJ.** Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. *J Clin Invest* 117: 195-205, 2007.
147. **Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, and Randolph GJ.** Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. *J Clin Invest* 117: 185-194, 2007.
148. **Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, and Mallat Z.** Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. *Circulation* 117: 1649-1657, 2008.
149. **Brown MS, and Goldstein JL.** Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. *Annu Rev Biochem* 52: 223-261, 1983.
150. **Rosenfeld ME, Khoo JC, Miller E, Parthasarathy S, Palinski W, and Witztum JL.** Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. *J Clin Invest* 87: 90-99, 1991.
151. **Hegy L, Skepper JN, Cary NR, and Mitchinson MJ.** Foam cell apoptosis and the development of the lipid core of human atherosclerosis. *J Pathol* 180: 423-429, 1996.
152. **Steinberg D, Parthasarathy S, Carew TE, Khoo JC, and Witztum JL.** Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. *N Engl J Med* 320: 915-924, 1989.
153. **Sakashita N, Miyazaki A, Chang CC, Chang TY, Kiyota E, Satoh M, Komohara Y, Morganelli PM, Horiuchi S, and Takeya M.** Acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) is induced in monocyte-derived macrophages: in vivo and in vitro studies. *Lab Invest* 83: 1569-1581, 2003.

154. **Brown MS, and Goldstein JL.** Receptor-mediated endocytosis: insights from the lipoprotein receptor system. *Proc Natl Acad Sci U S A* 76: 3330-3337, 1979.
155. **Goldstein JL, and Brown MS.** The LDL receptor. *Arterioscler Thromb Vasc Biol* 29: 431-438, 2009.
156. **Linton MF, Babaev VR, Gleaves LA, and Fazio S.** A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation. *J Biol Chem* 274: 19204-19210, 1999.
157. **Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T, and et al.** A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. *Nature* 386: 292-296, 1997.
158. **Greaves DR, and Gordon S.** The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. *J Lipid Res* 50 Suppl: S282-286, 2009.
159. **Babaev VR, Gleaves LA, Carter KJ, Suzuki H, Kodama T, Fazio S, and Linton MF.** Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. *Arterioscler Thromb Vasc Biol* 20: 2593-2599, 2000.
160. **Manning-Tobin JJ, Moore KJ, Seimon TA, Bell SA, Sharuk M, Alvarez-Leite JJ, de Winther MP, Tabas I, and Freeman MW.** Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. *Arterioscler Thromb Vasc Biol* 29: 19-26, 2009.
161. **Liu J, Huan C, Chakraborty M, Zhang H, Lu D, Kuo MS, Cao G, and Jiang XC.** Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. *Circ Res* 105: 295-303, 2009.
162. **Out R, Hoekstra M, Habets K, Meurs I, de Waard V, Hildebrand RB, Wang Y, Chimini G, Kuiper J, Van Berkel TJ, and Van Eck M.** Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. *Arterioscler Thromb Vasc Biol* 28: 258-264, 2008.
163. **Rocha VZ, Folco EJ, Sukhova G, Shimizu K, Gotsman I, Vernon AH, and Libby P.** Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. *Circ Res* 103: 467-476, 2008.
164. **Wang Y, Dubland JA, Allahverdian S, Asonye E, Sahin B, Jaw JE, Sin DD, Seidman MA, Leeper NJ, and Francis GA.** Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (Apolipoprotein E)-Deficient Mouse Atherosclerosis. *Arterioscler Thromb Vasc Biol* 39: 876-887, 2019.
165. **Zadoorian A, Du X, and Yang H.** Lipid droplet biogenesis and functions in health and disease. *Nat Rev Endocrinol* 19: 443-459, 2023.
166. **Ouimet M, Franklin V, Mak E, Liao X, Tabas I, and Marcel YL.** Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. *Cell Metab* 13: 655-667, 2011.
167. **Zhang X, Evans TD, Jeong SJ, and Razani B.** Classical and alternative roles for autophagy in lipid metabolism. *Curr Opin Lipidol* 29: 203-211, 2018.

168. **Michiels CF, Kurdi A, Timmermans JP, De Meyer GRY, and Martinet W.** Spermidine reduces lipid accumulation and necrotic core formation in atherosclerotic plaques via induction of autophagy. *Atherosclerosis* 251: 319-327, 2016.
169. **Hetz C.** The unfolded protein response: controlling cell fate decisions under ER stress and beyond. *Nat Rev Mol Cell Biol* 13: 89-102, 2012.
170. **Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, and Schaffer JE.** Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. *J Lipid Res* 47: 2726-2737, 2006.
171. **Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Backhed F, Miller YI, Horkko S, Corr M, Witztum JL, and Binder CJ.** Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. *J Clin Invest* 119: 1335-1349, 2009.
172. **Yao S, Tian H, Miao C, Zhang DW, Zhao L, Li Y, Yang N, Jiao P, Sang H, Guo S, Wang Y, and Qin S.** D4F alleviates macrophage-derived foam cell apoptosis by inhibiting CD36 expression and ER stress-CHOP pathway. *J Lipid Res* 56: 836-847, 2015.
173. **Wu H, Chen Z, Chen JZ, Pei LG, Xie J, Wei ZH, Kang LN, Wang L, and Xu B.** High Mobility Group B-1 (HMGB-1) Promotes Apoptosis of Macrophage-Derived Foam Cells by Inducing Endoplasmic Reticulum Stress. *Cell Physiol Biochem* 48: 1019-1029, 2018.
174. **Tabas I.** Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. *Antioxid Redox Signal* 11: 2333-2339, 2009.
175. **Spann NJ, Garmire LX, McDonald JG, Myers DS, Milne SB, Shibata N, Reichart D, Fox JN, Shaked I, Heudobler D, Raetz CR, Wang EW, Kelly SL, Sullards MC, Murphy RC, Merrill AH, Jr., Brown HA, Dennis EA, Li AC, Ley K, Tsimikas S, Fahy E, Subramaniam S, Quehenberger O, Russell DW, and Glass CK.** Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. *Cell* 151: 138-152, 2012.
176. **Zhang X, McDonald JG, Aryal B, Canfran-Duque A, Goldberg EL, Araldi E, Ding W, Fan Y, Thompson BM, Singh AK, Li Q, Tellides G, Ordovas-Montanes J, Garcia Milian R, Dixit VD, Ikonen E, Suarez Y, and Fernandez-Hernando C.** Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis. *Proc Natl Acad Sci U S A* 118: e2107682118, 2021.
177. **Choi JS, Kang SW, Li J, Kim JL, Bae JY, Kim DS, Shin SY, Jun JG, Wang MH, and Kang YH.** Blockade of oxidized LDL-triggered endothelial apoptosis by quercetin and rutin through differential signaling pathways involving JAK2. *J Agric Food Chem* 57: 2079-2086, 2009.
178. **Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, and Arditi M.** Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. *Circulation* 104: 3103-3108, 2001.
179. **Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, and Arditi M.** Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. *Proc Natl Acad Sci U S A* 101: 10679-10684, 2004.

180. **Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, and Feldmann M.** Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. *Circulation* 120: 2462-2469, 2009.
181. **Mullick AE, Soldau K, Kiosses WB, Bell TA, 3rd, Tobias PS, and Curtiss LK.** Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. *J Exp Med* 205: 373-383, 2008.
182. **Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ, Clausen BE, Forster I, Kockx MM, Rajewsky K, Kraal G, Hofker MH, and de Winther MP.** Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. *J Clin Invest* 112: 1176-1185, 2003.
183. **Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, and Caligiuri G.** Macrophage plasticity in experimental atherosclerosis. *PLoS One* 5: e8852, 2010.
184. **Ming XF, Rajapakse AG, Yepuri G, Xiong Y, Carvas JM, Ruffieux J, Scerri I, Wu Z, Popp K, Li J, Sartori C, Scherrer U, Kwak BR, Montani JP, and Yang Z.** Arginase II Promotes Macrophage Inflammatory Responses Through Mitochondrial Reactive Oxygen Species, Contributing to Insulin Resistance and Atherogenesis. *J Am Heart Assoc* 1: e000992, 2012.
185. **Marsch E, Theelen TL, Demandt JA, Jeurissen M, van Gink M, Verjans R, Janssen A, Cleutjens JP, Meex SJ, Donners MM, Haenen GR, Schalkwijk CG, Dubois LJ, Lambin P, Mallat Z, Gijbels MJ, Heemskerk JW, Fisher EA, Biessen EA, Janssen BJ, Daemen MJ, and Sluimer JC.** Reversal of hypoxia in murine atherosclerosis prevents necrotic core expansion by enhancing efferocytosis. *Arterioscler Thromb Vasc Biol* 34: 2545-2553, 2014.
186. **Stoger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, Daemen MJ, Lutgens E, and de Winther MP.** Distribution of macrophage polarization markers in human atherosclerosis. *Atherosclerosis* 225: 461-468, 2012.
187. **Shaikh S, Brittenden J, Lahiri R, Brown PA, Thies F, and Wilson HM.** Macrophage subtypes in symptomatic carotid artery and femoral artery plaques. *Eur J Vasc Endovasc Surg* 44: 491-497, 2012.
188. **Chinetti-Gbaguidi G, Baron M, Bouhrel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, and Staels B.** Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. *Circ Res* 108: 985-995, 2011.
189. **Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, Rayner K, Moore K, Garabedian M, and Fisher EA.** HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. *Proc Natl Acad Sci U S A* 108: 7166-7171, 2011.
190. **Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, Elliott MR, Gruber F, Han J, Chen W, Kensler T, Ravichandran KS, Isakson BE, Wamhoff BR, and Leitinger N.** Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. *Circ Res* 107: 737-746, 2010.
191. **Gleissner CA, Shaked I, Little KM, and Ley K.** CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. *J Immunol* 184: 4810-4818, 2010.

192. **Boyle JJ, Johns M, Kampfer T, Nguyen AT, Game L, Schaer DJ, Mason JC, and Haskard DO.** Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection. *Circ Res* 110: 20-33, 2012.
193. **Schaer CA, Schoedon G, Imhof A, Kurrer MO, and Schaer DJ.** Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. *Circ Res* 99: 943-950, 2006.
194. **Finn AV, and Narula J.** Intraplaque hemorrhage: most dangerous is the wound that bleedeth inwardly. *JACC Cardiovasc Imaging* 5: 856-858, 2012.
195. **Guo L, Akahori H, Harari E, Smith SL, Polavarapu R, Karmali V, Otsuka F, Gannon RL, Braumann RE, Dickinson MH, Gupta A, Jenkins AL, Lipinski MJ, Kim J, Chhour P, de Vries PS, Jinnouchi H, Kutys R, Mori H, Kutyna MD, Torii S, Sakamoto A, Choi CU, Cheng Q, Grove ML, Sawan MA, Zhang Y, Cao Y, Kolodgie FD, Cormode DP, Arking DE, Boerwinkle E, Morrison AC, Erdmann J, Sotoodehnia N, Virmani R, and Finn AV.** CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis. *J Clin Invest* 128: 1106-1124, 2018.
196. **Bengtsson E, Hultman K, Edsfeldt A, Persson A, Nitulescu M, Nilsson J, Goncalves I, and Bjorkbacka H.** CD163+ macrophages are associated with a vulnerable plaque phenotype in human carotid plaques. *Sci Rep* 10: 14362, 2020.
197. **Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, Khan NS, Wong CK, Shamailova R, Hill CA, Wang Z, Remark R, Li JR, Pina C, Faries C, Awad AJ, Moss N, Bjorkegren JLM, Kim-Schulze S, Gnjjatic S, Ma'ayan A, Mocco J, Faries P, Merad M, and Giannarelli C.** Single-cell immune landscape of human atherosclerotic plaques. *Nat Med* 25: 1576-1588, 2019.
198. **Dib L, Koneva LA, Edsfeldt A, Zurke YX, Sun J, Nitulescu M, Attar M, Lutgens E, Schmidt S, Lindholm MW, Choudhury RP, Cassimjee I, Lee R, Handa A, Goncalves I, Sansom SN, and Monaco C.** Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis increasing the risk of cerebrovascular complications. *Nat Cardiovasc Res* 2: 656-672, 2023.
199. **Depuydt MAC, Prange KHM, Slenders L, Ord T, Elbersen D, Boltjes A, de Jager SCA, Asselbergs FW, de Borst GJ, Aavik E, Lonnberg T, Lutgens E, Glass CK, den Ruijter HM, Kaikkonen MU, Bot I, Slutter B, van der Laan SW, Yla-Herttuala S, Mokry M, Kuiper J, de Winther MPJ, and Pasterkamp G.** Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics. *Circ Res* 127: 1437-1455, 2020.
200. **Mosquera JV, Auguste G, Wong D, Turner AW, Hodonsky CJ, Alvarez-Yela AC, Song Y, Cheng Q, Lino Cardenas CL, Theofilatos K, Bos M, Kavousi M, Peyser PA, Mayr M, Kovacic JC, Bjorkegren JLM, Malhotra R, Stukenberg PT, Finn AV, van der Laan SW, Zang C, Sheffield NC, and Miller CL.** Integrative single-cell meta-analysis reveals disease-relevant vascular cell states and markers in human atherosclerosis. *Cell Rep* 42: 113380, 2023.
201. **Zernecke A, Winkels H, Cochain C, Williams JW, Wolf D, Soehnlein O, Robbins CS, Monaco C, Park I, McNamara CA, Binder CJ, Cybulsky MI, Scipione CA, Hedrick CC, Galkina EV, Kyaw T, Ghosheh Y, Dinh HQ, and Ley K.** Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas. *Circ Res* 127: 402-426, 2020.

202. **Kim K, Shim D, Lee JS, Zaitsev K, Williams JW, Kim KW, Jang MY, Seok Jang H, Yun TJ, Lee SH, Yoon WK, Prat A, Seidah NG, Choi J, Lee SP, Yoon SH, Nam JW, Seong JK, Oh GT, Randolph GJ, Artyomov MN, Cheong C, and Choi JH.** Transcriptome Analysis Reveals Nonfoamy Rather Than Foamy Plaque Macrophages Are Proinflammatory in Atherosclerotic Murine Models. *Circ Res* 123: 1127-1142, 2018.
203. **Zernecke A, Erhard F, Weinberger T, Schulz C, Ley K, Saliba AE, and Cochain C.** Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis. *Cardiovasc Res* 119: 1676-1689, 2023.
204. **Patterson MT, Firulyova MM, Xu Y, Hillman H, Bishop C, Zhu A, Hickok GH, Schrank PR, Ronayne CE, Caillot Z, Fredrickson G, Kennedy AE, Acharya N, Neels JG, Chinetti G, Revelo X, Stromnes IM, Ivanov S, Bold TD, Zaitsev K, and Williams JW.** Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis. *Nat Cardiovasc Res* 2: 1015-1031, 2023.
205. **Piollet M, Porsch F, Rizzo G, Kapser F, Schulz DJJ, Kiss MG, Schlepckow K, Morenas-Rodriguez E, Sen MO, Gropper J, Bandi SR, Schafer S, Krammer T, Leipold AM, Hoke M, Ozsvar-Kozma M, Benes H, Schillinger M, Minar E, Roesch M, Goderle L, Hladik A, Knapp S, Colonna M, Martini R, Saliba AE, Haass C, Zernecke A, Binder CJ, and Cochain C.** TREM2 protects from atherosclerosis by limiting necrotic core formation. *Nat Cardiovasc Res* 3: 269-282, 2024.
206. **Patterson MT, Xu Y, Hillman H, Osinski V, Schrank PR, Kennedy AE, Barrow F, Zhu A, Tollison S, Shekhar S, Stromnes IM, Tassi I, Wu D, Revelo XS, Binstadt BA, and Williams JW.** Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report. *Arterioscler Thromb Vasc Biol* 44: 1646-1657, 2024.
207. **Joffre J, Potteaux S, Zeboudj L, Loyer X, Boufenzler A, Laurans L, Esposito B, Vandestienne M, de Jager SC, Henique C, Zlatanova I, Taleb S, Bruneval P, Tedgui A, Mallat Z, Gibot S, and Ait-Oufella H.** Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis. *J Am Coll Cardiol* 68: 2776-2793, 2016.
208. **Zysset D, Weber B, Rihs S, Brasseit J, Freigang S, Riether C, Banz Y, Cerwenka A, Simillion C, Marques-Vidal P, Ochsenbein AF, Saurer L, and Mueller C.** TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. *Nat Commun* 7: 13151, 2016.
209. **Auffray C, Fogg DK, Narni-Mancinelli E, Senechal B, Trouillet C, Saederup N, Leemput J, Bigot K, Campisi L, Abitbol M, Molina T, Charo I, Hume DA, Cumano A, Lauvau G, and Geissmann F.** CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. *J Exp Med* 206: 595-606, 2009.
210. **Geissmann F, Jung S, and Littman DR.** Blood monocytes consist of two principal subsets with distinct migratory properties. *Immunity* 19: 71-82, 2003.
211. **Gautier EL, Jakubzick C, and Randolph GJ.** Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. *Arterioscler Thromb Vasc Biol* 29: 1412-1418, 2009.

212. **Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, Sarnacki S, Cumano A, Lauvau G, and Geissmann F.** Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. *Science* 317: 666-670, 2007.
213. **Thomas G, Tacke R, Hedrick CC, and Hanna RN.** Nonclassical patrolling monocyte function in the vasculature. *Arterioscler Thromb Vasc Biol* 35: 1306-1316, 2015.
214. **Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, Vizcay-Barrena G, Hedrick CC, Cook HT, Diebold S, and Geissmann F.** Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. *Cell* 153: 362-375, 2013.
215. **Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, and Leenen PJ.** Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. *J Immunol* 172: 4410-4417, 2004.
216. **Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, Geissmann F, and Hedrick CC.** The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. *Nat Immunol* 12: 778-785, 2011.
217. **Hamers AAJ, Dinh HQ, Thomas GD, Marcovecchio P, Blatchley A, Nakao CS, Kim C, McSkimming C, Taylor AM, Nguyen AT, McNamara CA, and Hedrick CC.** Human Monocyte Heterogeneity as Revealed by High-Dimensional Mass Cytometry. *Arterioscler Thromb Vasc Biol* 39: 25-36, 2019.
218. **Hu YW, Zhang P, Yang JY, Huang JL, Ma X, Li SF, Zhao JY, Hu YR, Wang YC, Gao JJ, Sha YH, Zheng L, and Wang Q.** Nur77 decreases atherosclerosis progression in apoE(-/-) mice fed a high-fat/high-cholesterol diet. *PLoS One* 9: e87313, 2014.
219. **Hamers AA, Vos M, Rassam F, Marinkovic G, Kurakula K, van Gorp PJ, de Winther MP, Gijbels MJ, de Waard V, and de Vries CJ.** Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis. *Circ Res* 110: 428-438, 2012.
220. **Quintar A, McArdle S, Wolf D, Marki A, Ehinger E, Vassallo M, Miller J, Mikulski Z, Ley K, and Buscher K.** Endothelial Protective Monocyte Patrolling in Large Arteries Intensified by Western Diet and Atherosclerosis. *Circ Res* 120: 1789-1799, 2017.
221. **Stoneman V, Braganza D, Figg N, Mercer J, Lang R, Goddard M, and Bennett M.** Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. *Circ Res* 100: 884-893, 2007.
222. **Feig JE, Vengrenyuk Y, Reiser V, Wu C, Statnikov A, Aliferis CF, Garabedian MJ, Fisher EA, and Puig O.** Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. *PLoS One* 7: e39790, 2012.
223. **Rahman K, Vengrenyuk Y, Ramsey SA, Vila NR, Girgis NM, Liu J, Gusarova V, Gromada J, Weinstock A, Moore KJ, Loke P, and Fisher EA.** Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression. *J Clin Invest* 127: 2904-2915, 2017.
224. **Yurdagul A, Jr., Kong N, Gerlach BD, Wang X, Ampomah P, Kuriakose G, Tao W, Shi J, and Tabas I.** ODC (Ornithine Decarboxylase)-Dependent Putrescine Synthesis Maintains MerTK (MER Tyrosine-Protein Kinase) Expression to Drive Resolution. *Arterioscler Thromb Vasc Biol* 41: e144-e159, 2021.

225. **Yurdagul A, Jr., Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, Kolluru GK, Rymond CC, Gerlach BD, Zheng Z, Kuriakose G, Kevil CG, Koomen JM, Cleveland JL, Muoio DM, and Tabas I.** Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury. *Cell Metab* 31: 518-533 e510, 2020.
226. **Schlitt A, Heine GH, Blankenberg S, Espinola-Klein C, Dopheide JF, Bickel C, Lackner KJ, Iz M, Meyer J, Darius H, and Rupprecht HJ.** CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. *Thromb Haemost* 92: 419-424, 2004.
227. **Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Takeshita T, and Akasaka T.** Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. *Atherosclerosis* 212: 628-635, 2010.
228. **Foster GA, Gower RM, Stanhope KL, Havel PJ, Simon SI, and Armstrong EJ.** On-chip phenotypic analysis of inflammatory monocytes in atherogenesis and myocardial infarction. *Proc Natl Acad Sci U S A* 110: 13944-13949, 2013.
229. **Steinman RM.** Decisions about dendritic cells: past, present, and future. *Annu Rev Immunol* 30: 1-22, 2012.
230. **Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, and Reis e Sousa C.** Dendritic Cells Revisited. *Annu Rev Immunol* 39: 131-166, 2021.
231. **Busch M, Westhofen TC, Koch M, Lutz MB, and Zernecke A.** Dendritic cell subset distributions in the aorta in healthy and atherosclerotic mice. *PLoS One* 9: e88452, 2014.
232. **Niessner A, and Weyand CM.** Dendritic cells in atherosclerotic disease. *Clin Immunol* 134: 25-32, 2010.
233. **Hu D, Mohanta SK, Yin C, Peng L, Ma Z, Srikakulapu P, Grassia G, MacRitchie N, Dever G, Gordon P, Burton FL, Ialenti A, Sabir SR, McInnes IB, Brewer JM, Garside P, Weber C, Lehmann T, Teupser D, Habenicht L, Beer M, Grabner R, Maffia P, Weih F, and Habenicht AJ.** Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin beta Receptors. *Immunity* 42: 1100-1115, 2015.
234. **Deroissart J, Binder CJ, and Porsch F.** Role of Antibodies and Their Specificities in Atherosclerotic Cardiovascular Disease. *Arterioscler Thromb Vasc Biol* 44: 2154-2168, 2024.
235. **Nickel T, Schmauss D, Hanssen H, Sicic Z, Krebs B, Jankl S, Summo C, Fraunberger P, Walli AK, Pfeiler S, and Weis M.** oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. *Atherosclerosis* 205: 442-450, 2009.
236. **Packard RR, Maganto-Garcia E, Gotsman I, Tabas I, Libby P, and Lichtman AH.** CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. *Circ Res* 103: 965-973, 2008.
237. **Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, Raaz D, Anger T, Amann K, Probst T, Ludwig J, Daniel WG, and Garlich CD.** Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. *Atherosclerosis* 176: 101-110, 2004.

238. **Dietel B, Cicha I, Voskens CJ, Verhoeven E, Achenbach S, and Garlichs CD.** Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. *Atherosclerosis* 230: 92-99, 2013.
239. **Rombouts M, Ammi R, Van Brussel I, Roth L, De Winter BY, Vercauteren SR, Hendriks JM, Lauwers P, Van Schil PE, De Meyer GR, Franssen E, Cools N, and Schrijvers DM.** Linking CD11b (+) Dendritic Cells and Natural Killer T Cells to Plaque Inflammation in Atherosclerosis. *Mediators Inflamm* 2016: 6467375, 2016.
240. **Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, and Randolph GJ.** Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. *Proc Natl Acad Sci U S A* 101: 11779-11784, 2004.
241. **Alberts-Grill N, Denning TL, Rezvan A, and Jo H.** The role of the vascular dendritic cell network in atherosclerosis. *Am J Physiol Cell Physiol* 305: C1-21, 2013.
242. **Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, Ginhoux F, Miller ER, Witztum JL, Chapman MJ, and Lesnik P.** Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. *Circulation* 119: 2367-2375, 2009.
243. **Marvin J, Rhoads JP, and Major AS.** FcγRIIb on CD11c(+) cells modulates serum cholesterol and triglyceride levels and differentially affects atherosclerosis in male and female Ldlr(-/-) mice. *Atherosclerosis* 285: 108-119, 2019.
244. **Choi JH, Cheong C, Dandamudi DB, Park CG, Rodriguez A, Mehandru S, Velinzon K, Jung IH, Yoo JY, Oh GT, and Steinman RM.** Flt3 signaling-dependent dendritic cells protect against atherosclerosis. *Immunity* 35: 819-831, 2011.
245. **Weber C, Meiler S, Doring Y, Koch M, Drechsler M, Megens RT, Rowinska Z, Bidzhekov K, Fecher C, Ribechini E, van Zandvoort MA, Binder CJ, Jelinek I, Hristov M, Boon L, Jung S, Korn T, Lutz MB, Forster I, Zenke M, Hieronymus T, Junt T, and Zernecke A.** CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. *J Clin Invest* 121: 2898-2910, 2011.
246. **Chistiakov DA, Orekhov AN, Sobenin IA, and Bobryshev YV.** Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation. *Front Physiol* 5: 279, 2014.
247. **Doring Y, Manthey HD, Drechsler M, Lievens D, Megens RT, Soehnlein O, Busch M, Manca M, Koenen RR, Pelisek J, Daemen MJ, Lutgens E, Zenke M, Binder CJ, Weber C, and Zernecke A.** Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. *Circulation* 125: 1673-1683, 2012.
248. **Daissormont IT, Christ A, Temmerman L, Sampedro Millares S, Seijkens T, Manca M, Rousch M, Poggi M, Boon L, van der Loos C, Daemen M, Lutgens E, Halvorsen B, Aukrust P, Janssen E, and Biessen EA.** Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. *Circ Res* 109: 1387-1395, 2011.
249. **Winkels H, Ehinger E, Vassallo M, Buscher K, Dinh HQ, Kobiyama K, Hamers AAJ, Cochain C, Vafadarnejad E, Saliba AE, Zernecke A, Pramod AB, Ghosh AK, Anto Michel N, Hoppe N, Hilgendorf I, Zirlik A, Hedrick CC, Ley K, and Wolf D.** Atlas of the Immune Cell Repertoire in Mouse Atherosclerosis Defined by Single-Cell RNA-Sequencing and Mass Cytometry. *Circ Res* 122: 1675-1688, 2018.

250. **Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, and Maseri A.** Widespread coronary inflammation in unstable angina. *N Engl J Med* 347: 5-12, 2002.
251. **Silvestre-Roig C, Braster Q, Ortega-Gomez A, and Soehnlein O.** Neutrophils as regulators of cardiovascular inflammation. *Nat Rev Cardiol* 17: 327-340, 2020.
252. **Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober A, Sperandio M, Soehnlein O, Bornemann J, Tacke F, Biessen EA, and Weber C.** Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. *Circ Res* 102: 209-217, 2008.
253. **Wang L, Ai Z, Khoiratty T, Zec K, Eames HL, van Grinsven E, Hudak A, Morris S, Ahern D, Monaco C, Eruslanov EB, Luqmani R, and Udalova IA.** ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies. *JCI Insight* 5: 2020.
254. **Warnatsch A, Ioannou M, Wang Q, and Papayannopoulos V.** Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. *Science* 349: 316-320, 2015.
255. **Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr., Wroblewski SK, Wakefield TW, Hartwig JH, and Wagner DD.** Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci U S A* 107: 15880-15885, 2010.
256. **Silvestre-Roig C, Braster Q, Wichapong K, Lee EY, Teulon JM, Berrebeh N, Winter J, Adrover JM, Santos GS, Froese A, Lemnitzer P, Ortega-Gomez A, Chevre R, Marschner J, Schumski A, Winter C, Perez-Olivares L, Pan C, Paulin N, Schoufour T, Hartwig H, Gonzalez-Ramos S, Kamp F, Megens RTA, Mowen KA, Gunzer M, Maegdefessel L, Hackeng T, Lutgens E, Daemen M, von Blume J, Anders HJ, Nikolaev VO, Pellequer JL, Weber C, Hidalgo A, Nicolaes GAF, Wong GCL, and Soehnlein O.** Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. *Nature* 569: 236-240, 2019.
257. **Puhr-Westerheide D, Schink SJ, Fabritius M, Mittmann L, Hessenauer MET, Pircher J, Zuchtriegel G, Uhl B, Holzer M, Massberg S, Krombach F, and Reichel CA.** Neutrophils promote venular thrombosis by shaping the rheological environment for platelet aggregation. *Scientific Reports* 9: 15932, 2019.
258. **Ionita MG, van den Borne P, Catanzariti LM, Moll FL, de Vries JP, Pasterkamp G, Vink A, and de Kleijn DP.** High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. *Arterioscler Thromb Vasc Biol* 30: 1842-1848, 2010.
259. **Lavillegrand JR, Al-Rifai R, Thietart S, Guyon T, Vandestienne M, Cohen R, Duval V, Zhong X, Yen D, Ozturk M, Negishi Y, Konkell J, Pinteaux E, Lenoir O, Vilar J, Laurans L, Esposito B, Bredon M, Sokol H, Diedisheim M, Saliba AE, Zernecke A, Cochain C, Haub J, Tedgui A, Speck NA, Taleb S, Mhlanga MM, Schlitzer A, Riksen NP, and Ait-Oufella H.** Alternating high-fat diet enhances atherosclerosis by neutrophil reprogramming. *Nature* 634: 447-456, 2024.
260. **Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang SK, Bieber J, and Chi DS.** The human mast cell: functions in physiology and disease. *Front Biosci* 6: D1109-1127, 2001.
261. **Constantinides P.** Mast Cells and Susceptibility to Experimental Atherosclerosis. *Science* 117: 505-506, 1953.

262. **Caughey GH.** Mast cell tryptases and chymases in inflammation and host defense. *Immunol Rev* 217: 141-154, 2007.
263. **Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St Clair J, and Shi GP.** Mast cells promote atherosclerosis by releasing proinflammatory cytokines. *Nat Med* 13: 719-724, 2007.
264. **Bot I, de Jager SC, Zerneck A, Lindstedt KA, van Berkel TJ, Weber C, and Biessen EA.** Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. *Circulation* 115: 2516-2525, 2007.
265. **Bot I, Bot M, van Heiningen SH, van Santbrink PJ, Lankhuizen IM, Hartman P, Gruener S, Hilpert H, van Berkel TJ, Fingerle J, and Biessen EA.** Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE^{-/-} mice. *Cardiovasc Res* 89: 244-252, 2011.
266. **Hansson GK, Holm J, and Jonasson L.** Detection of activated T lymphocytes in the human atherosclerotic plaque. *Am J Pathol* 135: 169-175, 1989.
267. **Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, and Hansson GK.** T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. *Proc Natl Acad Sci U S A* 92: 3893-3897, 1995.
268. **Dansky HM, Charlton SA, Harper MM, and Smith JD.** T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. *Proc Natl Acad Sci U S A* 94: 4642-4646, 1997.
269. **Song L, Leung C, and Schindler C.** Lymphocytes are important in early atherosclerosis. *J Clin Invest* 108: 251-259, 2001.
270. **Caligiuri G, Nicoletti A, Poirier B, and Hansson GK.** Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. *J Clin Invest* 109: 745-753, 2002.
271. **Zhou X, Robertson AK, Hjerpe C, and Hansson GK.** Adoptive transfer of CD4⁺ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. *Arterioscler Thromb Vasc Biol* 26: 864-870, 2006.
272. **Saigusa R, Winkels H, and Ley K.** T cell subsets and functions in atherosclerosis. *Nat Rev Cardiol* 17: 387-401, 2020.
273. **Croft M.** The role of TNF superfamily members in T-cell function and diseases. *Nat Rev Immunol* 9: 271-285, 2009.
274. **Zhou X, Robertson AK, Rudling M, Parini P, and Hansson GK.** Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. *Circ Res* 96: 427-434, 2005.
275. **Wigren M, Rattik S, Yao Mattisson I, Tomas L, Gronberg C, Soderberg I, Alm R, Sundius L, Ljungcrantz I, Bjorkbacka H, Fredrikson GN, and Nilsson J.** Lack of Ability to Present Antigens on Major Histocompatibility Complex Class II Molecules Aggravates Atherosclerosis in ApoE^(-/-) Mice. *Circulation* 139: 2554-2566, 2019.
276. **Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, and Mallat Z.** Natural regulatory T cells control the development of atherosclerosis in mice. *Nat Med* 12: 178-180, 2006.

277. **Depuydt MAC, Schaftenaar FH, Prange KHM, Boltjes A, Hemme E, Delfos L, de Mol J, de Jong MJM, Bernabé Kleijn MNA, Peeters JAHM, Goncalves L, Wezel A, Smeets HJ, de Borst GJ, Foks AC, Pasterkamp G, de Winther MPJ, Kuiper J, Bot I, and Slütter B.** Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells. *Nature Cardiovascular Research* 2: 112-125, 2023.
278. **Kimura T, Kobiyama K, Winkels H, Tse K, Miller J, Vassallo M, Wolf D, Ryden C, Orecchioni M, Dileepan T, Jenkins MK, James EA, Kwok WW, Hanna DB, Kaplan RC, Strickler HD, Durkin HG, Kassaye SG, Karim R, Tien PC, Landay AL, Gange SJ, Sidney J, Sette A, and Ley K.** Regulatory CD4(+) T Cells Recognize Major Histocompatibility Complex Class II Molecule-Restricted Peptide Epitopes of Apolipoprotein B. *Circulation* 138: 1130-1143, 2018.
279. **Tse K, Gonen A, Sidney J, Ouyang H, Witztum JL, Sette A, Tse H, and Ley K.** Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100. *Front Immunol* 4: 493, 2013.
280. **Wolf D, Gerhardt T, Winkels H, Michel NA, Pramod AB, Ghosheh Y, Brunel S, Buscher K, Miller J, McArdle S, Baas L, Kobiyama K, Vassallo M, Ehinger E, Dileepan T, Ali A, Schell M, Mikulski Z, Sidler D, Kimura T, Sheng X, Horstmann H, Hansen S, Mitre LS, Stachon P, Hilgendorf I, Gaddis DE, Hedrick C, Benedict CA, Peters B, Zirlik A, Sette A, and Ley K.** Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B100-Reactive CD4(+) T-Regulatory Cells. *Circulation* 142: 1279-1293, 2020.
281. **Roy P, Sidney J, Lindestam Arlehamn CS, Phillips E, Mallal S, Armstrong Suthahar SS, Billitti M, Rubiro P, Marrama D, Drago F, Vallejo J, Suryawanshi V, Orecchioni M, Makings J, Kim PJ, McNamara CA, Peters B, Sette A, and Ley K.** Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B. *Circ Res* 131: 258-276, 2022.
282. **Tang D, Liu Y, Duan R, Lin R, Li Z, Liu X, Huang J, and Zhao M.** COL6A6 Peptide Vaccine Alleviates Atherosclerosis through Inducing Immune Response and Regulating Lipid Metabolism in Apoe(-/-) Mice. *Cells* 13: 2024.
283. **Lorenzo C, Delgado P, Busse CE, Sanz-Bravo A, Martos-Folgado I, Bonzon-Kulichenko E, Ferrarini A, Gonzalez-Valdes IB, Mur SM, Roldan-Montero R, Martinez-Lopez D, Martin-Ventura JL, Vazquez J, Wardemann H, and Ramiro AR.** ALDH4A1 is an atherosclerosis auto-antigen targeted by protective antibodies. *Nature* 589: 287-292, 2021.
284. **Raposo-Gutiérrez I, Rodríguez-Ronchel A, and Ramiro AR.** Atherosclerosis antigens as targets for immunotherapy. *Nature Cardiovascular Research* 2: 1129-1147, 2023.
285. **Zhu J, and Paul WE.** CD4 T cells: fates, functions, and faults. *Blood* 112: 1557-1569, 2008.
286. **Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, and Lichtman AH.** T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. *Proc Natl Acad Sci U S A* 102: 1596-1601, 2005.
287. **Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, and Hansson GK.** Cytokine expression in advanced human atherosclerotic plaques: dominance

- of pro-inflammatory (Th1) and macrophage-stimulating cytokines. *Atherosclerosis* 145: 33-43, 1999.
288. **Li J, McArdle S, Gholami A, Kimura T, Wolf D, Gerhardt T, Miller J, Weber C, and Ley K.** CCR5+T-bet+FoxP3+ Effector CD4 T Cells Drive Atherosclerosis. *Circ Res* 118: 1540-1552, 2016.
289. **Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, and Lichtman AH.** Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. *Arterioscler Thromb Vasc Biol* 23: 454-460, 2003.
290. **Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, and Schindler C.** IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. *J Clin Invest* 99: 2752-2761, 1997.
291. **Whitman SC, Ravisankar P, Elam H, and Daugherty A.** Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. *Am J Pathol* 157: 1819-1824, 2000.
292. **Kuznetsova T, Prange KHM, Glass CK, and de Winther MPJ.** Transcriptional and epigenetic regulation of macrophages in atherosclerosis. *Nat Rev Cardiol* 17: 216-228, 2020.
293. **Tracy RP, Doyle MF, Olson NC, Huber SA, Jenny NS, Sallam R, Psaty BM, and Kronmal RA.** T-helper type 1 bias in healthy people is associated with cytomegalovirus serology and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. *J Am Heart Assoc* 2: e000117, 2013.
294. **Engelbertsen D, Andersson L, Ljungcrantz I, Wigren M, Hedblad B, Nilsson J, and Bjorkbacka H.** T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. *Arterioscler Thromb Vasc Biol* 33: 637-644, 2013.
295. **Feinstein MJ, Buzkova P, Olson NC, Doyle MF, Sitlani CM, Fohner AE, Huber SA, Floyd J, Sinha A, Thorp EB, Landay A, Freiberg MS, Longstreth WT, Jr., Tracy RP, Psaty BM, and Delaney JA.** Monocyte subsets, T cell activation profiles, and stroke in men and women: The Multi-Ethnic Study of Atherosclerosis and Cardiovascular Health Study. *Atherosclerosis* 351: 18-25, 2022.
296. **Davenport P, and Tipping PG.** The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. *Am J Pathol* 163: 1117-1125, 2003.
297. **King VL, Szilvassy SJ, and Daugherty A.** Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. *Arterioscler Thromb Vasc Biol* 22: 456-461, 2002.
298. **Engelbertsen D, Rattik S, Knutsson A, Bjorkbacka H, Bengtsson E, and Nilsson J.** Induction of T helper 2 responses against human apolipoprotein B100 does not affect atherosclerosis in ApoE-/- mice. *Cardiovasc Res* 103: 304-312, 2014.
299. **Sampi M, Ukkola O, Paivansalo M, Kesaniemi YA, Binder CJ, and Horkko S.** Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. *J Am Coll Cardiol* 52: 1370-1378, 2008.
300. **Silveira A, McLeod O, Strawbridge RJ, Gertow K, Sennblad B, Baldassarre D, Veglia F, Deleskog A, Persson J, Leander K, Gigante B, Kauhanen J, Rauramaa R, Smit AJ, Mannarino E, Giral P, Gustafsson S, Soderberg S, Ohrvik J, Humphries SE, Tremoli E,**

- de Faire U, and Hamsten A.** Plasma IL-5 concentration and subclinical carotid atherosclerosis. *Atherosclerosis* 239: 125-130, 2015.
301. **Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M, and Witztum JL.** IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. *J Clin Invest* 114: 427-437, 2004.
302. **Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, Wagner O, Stangl H, Soehnlein O, and Binder CJ.** Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. *EMBO Mol Med* 4: 1072-1086, 2012.
303. **Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, and Liew FY.** IL-33 reduces the development of atherosclerosis. *J Exp Med* 205: 339-346, 2008.
304. **Martin P, Palmer G, Rodriguez E, Woldt E, Mean I, James RW, Smith DE, Kwak BR, and Gabay C.** Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling. *Immun Inflamm Dis* 3: 239-246, 2015.
305. **Kaplan MH.** Th9 cells: differentiation and disease. *Immunol Rev* 252: 104-115, 2013.
306. **Gregersen I, Skjelland M, Holm S, Holven KB, Krogh-Sorensen K, Russell D, Askevold ET, Dahl CP, Orn S, Gullestad L, Mollnes TE, Ueland T, Aukrust P, and Halvorsen B.** Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis. *PLoS One* 8: e72769, 2013.
307. **Zhang W, Tang T, Nie D, Wen S, Jia C, Zhu Z, Xia N, Nie S, Zhou S, Jiao J, Dong W, Lv B, Xu T, Sun B, Lu Y, Li Y, Cheng L, Liao Y, and Cheng X.** IL-9 aggravates the development of atherosclerosis in ApoE^{-/-} mice. *Cardiovasc Res* 106: 453-464, 2015.
308. **Reilly NA, Sonnet F, Dekkers KF, Kwekkeboom JC, Sinke L, Hilt S, Suleiman HM, Hoeksema MA, Mei H, van Zwet EW, Everts B, Ioan-Facsinay A, Jukema JW, and Heijmans BT.** Oleic acid triggers metabolic rewiring of T cells poising them for T helper 9 differentiation. *iScience* 27: 109496, 2024.
309. **McGeachy MJ, Cua DJ, and Gaffen SL.** The IL-17 Family of Cytokines in Health and Disease. *Immunity* 50: 892-906, 2019.
310. **Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, Garefalaki A, Potocnik AJ, and Stockinger B.** Fate mapping of IL-17-producing T cells in inflammatory responses. *Nat Immunol* 12: 255-263, 2011.
311. **McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, and Cua DJ.** TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. *Nat Immunol* 8: 1390-1397, 2007.
312. **Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, Wu C, Kleinewietfeld M, Kunder S, Hafler DA, Sobel RA, Regev A, and Kuchroo VK.** Induction and molecular signature of pathogenic TH17 cells. *Nat Immunol* 13: 991-999, 2012.
313. **Taleb S, Tedgui A, and Mallat Z.** IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. *Arterioscler Thromb Vasc Biol* 35: 258-264, 2015.
314. **Usui F, Kimura H, Ohshiro T, Tatsumi K, Kawashima A, Nishiyama A, Iwakura Y, Ishibashi S, and Takahashi M.** Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. *Biochem Biophys Res Commun* 420: 72-77, 2012.

315. **Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, and Galkina E.** Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. *Circulation* 121: 1746-1755, 2010.
316. **Erbel C, Chen L, Bea F, Wangler S, Celik S, Lasitschka F, Wang Y, Bockler D, Katus HA, and Dengler TJ.** Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. *J Immunol* 183: 8167-8175, 2009.
317. **Danzaki K, Matsui Y, Ikesue M, Ohta D, Ito K, Kanayama M, Kurotaki D, Morimoto J, Iwakura Y, Yagita H, Tsutsui H, and Uede T.** Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 32: 273-280, 2012.
318. **Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, Iwakura Y, Blinder Y, Rahman A, Quyyumi AA, and Harrison DG.** Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. *Arterioscler Thromb Vasc Biol* 31: 1565-1572, 2011.
319. **Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, Yoshimura A, Tedgui A, and Mallat Z.** Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. *J Exp Med* 206: 2067-2077, 2009.
320. **Brauner S, Jiang X, Thorlacius GE, Lundberg AM, Ostberg T, Yan ZQ, Kuchroo VK, Hansson GK, and Wahren-Herlenius M.** Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content. *Cardiovasc Res* 114: 158-167, 2018.
321. **Butcher MJ, Gjurich BN, Phillips T, and Galkina EV.** The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. *Circ Res* 110: 675-687, 2012.
322. **Hashmi S, and Zeng QT.** Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. *Coron Artery Dis* 17: 699-706, 2006.
323. **Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT, Yao R, Chen Y, and Liao YH.** The Th17/Treg imbalance in patients with acute coronary syndrome. *Clin Immunol* 127: 89-97, 2008.
324. **Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, and Tellides G.** Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. *Circulation* 119: 1424-1432, 2009.
325. **Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, Montely JM, Dubourg O, Tedgui A, Kotti S, and Mallat Z.** Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. *Eur Heart J* 34: 570-577, 2013.
326. **Gistera A, Robertson AK, Andersson J, Ketelhuth DF, Ovchinnikova O, Nilsson SK, Lundberg AM, Li MO, Flavell RA, and Hansson GK.** Transforming growth factor-beta signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. *Sci Transl Med* 5: 196ra100, 2013.

327. **Azizi G, Yazdani R, and Mirshafiey A.** Th22 cells in autoimmunity: a review of current knowledge. *Eur Ann Allergy Clin Immunol* 47: 108-117, 2015.
328. **Xia Q, Xiang X, Patel S, Puranik R, Xie Q, and Bao S.** Characterisation of IL-22 and interferon-gamma-inducible chemokines in human carotid plaque. *Int J Cardiol* 154: 187-189, 2012.
329. **Lin YZ, Wu BW, Lu ZD, Huang Y, Shi Y, Liu H, Liu L, Zeng QT, Wang X, and Ji QW.** Circulating Th22 and Th9 levels in patients with acute coronary syndrome. *Mediators Inflamm* 2013: 635672, 2013.
330. **Zhang L, Wang T, Wang XQ, Du RZ, Zhang KN, Liu XG, Ma DX, Yu S, Su GH, Li ZH, Guan YQ, and Du NL.** Elevated frequencies of circulating Th22 cell in addition to Th17 cell and Th17/Th1 cell in patients with acute coronary syndrome. *PLoS One* 8: e71466, 2013.
331. **Rattik S, Hultman K, Rauch U, Soderberg I, Sundius L, Ljungcrantz I, Hultgardh- Nilsson A, Wigren M, Bjorkbacka H, Fredrikson GN, and Nilsson J.** IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice. *Atherosclerosis* 242: 506-514, 2015.
332. **Fatkhullina AR, Peshkova IO, Dzutsev A, Aghayev T, McCulloch JA, Thovarai V, Badger JH, Vats R, Sundd P, Tang HY, Kossenkov AV, Hazen SL, Trinchieri G, Grivennikov SI, and Koltsova EK.** An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. *Immunity* 49: 943-957 e949, 2018.
333. **Crotty S.** T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. *Immunity* 50: 1132-1148, 2019.
334. **Ryu H, Lim H, Choi G, Park YJ, Cho M, Na H, Ahn CW, Kim YC, Kim WU, Lee SH, and Chung Y.** Atherogenic dyslipidemia promotes autoimmune follicular helper T cell responses via IL-27. *Nat Immunol* 19: 583-593, 2018.
335. **Nus M, Sage AP, Lu Y, Masters L, Lam BYH, Newland S, Weller S, Tsiantoulas D, Raffort J, Marcus D, Finigan A, Kitt L, Figg N, Schirmbeck R, Kneilling M, Yeo GSH, Binder CJ, de la Pompa JL, and Mallat Z.** Marginal zone B cells control the response of follicular helper T cells to a high-cholesterol diet. *Nat Med* 23: 601-610, 2017.
336. **Clement M, Guedj K, Andreato F, Morvan M, Bey L, Khallou-Laschet J, Gaston AT, Delbosc S, Alsac JM, Bruneval P, Deschildre C, Le Borgne M, Castier Y, Kim HJ, Cantor H, Michel JB, Caligiuri G, and Nicoletti A.** Control of the T follicular helper-germinal center B-cell axis by CD8(+) regulatory T cells limits atherosclerosis and tertiary lymphoid organ development. *Circulation* 131: 560-570, 2015.
337. **Gaddis DE, Padgett LE, Wu R, McSkimming C, Romines V, Taylor AM, McNamara CA, Kronenberg M, Crotty S, Thomas MJ, Sorci-Thomas MG, and Hedrick CC.** Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. *Nat Commun* 9: 1095, 2018.
338. **Weng NP, Akbar AN, and Goronzy J.** CD28(-) T cells: their role in the age-associated decline of immune function. *Trends Immunol* 30: 306-312, 2009.
339. **Pratama MZ, Wahono CS, Aslam ABN, Chilmi S, Sari VP, Abdurrohman A, Sulistiyowati I, Aditya A, Johono MF, and Robert.** T-cell senescence was correlated with early atherosclerosis in patients with systemic lupus erythematosus. *Int J Rheum Dis* 27: e15339, 2024.

340. **Dumitriu IE, Baruah P, Finlayson CJ, Loftus IM, Antunes RF, Lim P, Bunce N, and Kaski JC.** High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. *Circ Res* 110: 857-869, 2012.
341. **Teo FH, de Oliveira RT, Mamoni RL, Ferreira MC, Nadruz W, Jr., Coelho OR, Fernandes Jde L, and Blotta MH.** Characterization of CD4+CD28null T cells in patients with coronary artery disease and individuals with risk factors for atherosclerosis. *Cell Immunol* 281: 11-19, 2013.
342. **Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, and Weyand CM.** Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. *Circulation* 101: 2883-2888, 2000.
343. **Kovalcsik E, Antunes RF, Baruah P, Kaski JC, and Dumitriu IE.** Proteasome-mediated reduction in proapoptotic molecule Bim renders CD4(+)CD28null T cells resistant to apoptosis in acute coronary syndrome. *Circulation* 131: 709-720, 2015.
344. **Freuchet A, Roy P, Armstrong SS, Ollaeimotlagh M, Kumar S, Orecchioni M, Ali AJ, Khan A, Makings J, Lyu Q, Winkels H, Wang E, Durant C, Ghosheh Y, Gulati R, Nettersheim F, and Ley K.** Identification of human exT(reg) cells as CD16(+)/CD56(+) cytotoxic CD4(+) T cells. *Nat Immunol* 24: 1748-1761, 2023.
345. **Vignali DA, Collison LW, and Workman CJ.** How regulatory T cells work. *Nat Rev Immunol* 8: 523-532, 2008.
346. **Klingenberg R, Gerdes N, Badeau RM, Gistera A, Strodthoff D, Ketelhuth DF, Lundberg AM, Rudling M, Nilsson SK, Olivecrona G, Zoller S, Lohmann C, Luscher TF, Jauhainen M, Sparwasser T, and Hansson GK.** Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. *J Clin Invest* 123: 1323-1334, 2013.
347. **Foks AC, Frodermann V, ter Borg M, Habets KL, Bot I, Zhao Y, van Eck M, van Berkel TJ, Kuiper J, and van Puijvelde GH.** Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. *Atherosclerosis* 218: 53-60, 2011.
348. **Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, Marenzi G, Panciroli C, Tumminello G, Anzuini A, Palloshi A, Grigore L, Garlaschelli K, Tramontana S, Tavano D, Airoldi F, Manfredi AA, Catapano AL, and Norata GD.** Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. *Arterioscler Thromb Vasc Biol* 30: 1832-1841, 2010.
349. **Dinh TN, Kyaw TS, Kanellakis P, To K, Tipping P, Toh BH, Bobik A, and Agrotis A.** Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. *Circulation* 126: 1256-1266, 2012.
350. **Kita T, Yamashita T, Sasaki N, Kasahara K, Sasaki Y, Yodoi K, Takeda M, Nakajima K, and Hirata K.** Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice. *Cardiovasc Res* 102: 107-117, 2014.
351. **Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliensky VE, and Daemen MJ.** Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. *Arterioscler Thromb Vasc Biol* 22: 975-982, 2002.

352. **Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, and Hansson GK.** Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. *J Clin Invest* 112: 1342-1350, 2003.
353. **Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, and Nicoletti A.** Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. *Mol Med* 9: 10-17, 2003.
354. **Mor A, Luboshits G, Planer D, Keren G, and George J.** Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. *Eur Heart J* 27: 2530-2537, 2006.
355. **George J, Schwartzberg S, Medvedovsky D, Jonas M, Charach G, Afek A, and Shamiss A.** Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. *Atherosclerosis* 222: 519-523, 2012.
356. **Wigren M, Bjorkbacka H, Andersson L, Ljungcrantz I, Fredrikson GN, Persson M, Bryngelsson C, Hedblad B, and Nilsson J.** Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. *Arterioscler Thromb Vasc Biol* 32: 2000-2004, 2012.
357. **Butcher MJ, Filipowicz AR, Waseem TC, McGary CM, Crow KJ, Magilnick N, Boldin M, Lundberg PS, and Galkina EV.** Atherosclerosis-Driven Treg Plasticity Results in Formation of a Dysfunctional Subset of Plastic IFNgamma+ Th1/Tregs. *Circ Res* 119: 1190-1203, 2016.
358. **Maganto-Garcia E, Tarrio ML, Grabie N, Bu DX, and Lichtman AH.** Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. *Circulation* 124: 185-195, 2011.
359. **Hwang Y, Yu HT, Kim DH, Jang J, Kim HY, Kang I, Kim HC, Park S, and Lee WW.** Expansion of CD8(+) T cells lacking the IL-6 receptor alpha chain in patients with coronary artery diseases (CAD). *Atherosclerosis* 249: 44-51, 2016.
360. **Bergstrom I, Backteman K, Lundberg A, Ernerudh J, and Jonasson L.** Persistent accumulation of interferon-gamma-producing CD8+CD56+ T cells in blood from patients with coronary artery disease. *Atherosclerosis* 224: 515-520, 2012.
361. **van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, and Becker AE.** Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. *Lab Invest* 61: 166-170, 1989.
362. **Kolbus D, Ramos OH, Berg KE, Persson J, Wigren M, Bjorkbacka H, Fredrikson GN, and Nilsson J.** CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe(-/-) mice. *BMC Immunol* 11: 58, 2010.
363. **Gewaltig J, Kummer M, Koella C, Cathomas G, and Biedermann BC.** Requirements for CD8 T-cell migration into the human arterial wall. *Hum Pathol* 39: 1756-1762, 2008.
364. **Chowdhury RR, D'Addabbo J, Huang X, Veizades S, Sasagawa K, Louis DM, Cheng P, Sokol J, Jensen A, Tso A, Shankar V, Wendel BS, Bakerman I, Liang G, Koyano T, Fong R, Nau AN, Ahmad H, Gopakumar J, Wirka R, Lee AS, Boyd J, Woo YJ, Quertermous T, Gulati GS, Jaiswal S, Chien YH, Chan CKF, Davis MM, and Nguyen PK.** Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self. *Circ Res* 130: 1510-1530, 2022.

365. **de Jong MJM, Schaftenaar FH, Depuydt MAC, Lozano Vigario F, Janssen GMC, Peeters J, Goncalves L, Wezel A, Smeets HJ, Kuiper J, Bot I, van Veelen P, and Slutter B.** Virus-Associated CD8(+) T-Cells Are Not Activated Through Antigen-Mediated Interaction Inside Atherosclerotic Lesions. *Arterioscler Thromb Vasc Biol* 44: 1302-1314, 2024.
366. **Iqneibi S, Saigusa R, Khan A, Oliaeimotlagh M, Armstrong Suthahar SS, Kumar S, Alimadadi A, Durant CP, Ghosheh Y, McNamara CA, Hedrick CC, and Ley K.** Single cell transcriptomics reveals recent CD8T cell receptor signaling in patients with coronary artery disease. *Front Immunol* 14: 1239148, 2023.
367. **Schafer S, Gogiraju R, Rosch M, Kerstan Y, Beck L, Garbisch J, Saliba AE, Gistera A, Hermanns HM, Boon L, Kastenmuller W, Schafer K, Cochain C, and Zerneck A.** CD8(+) T Cells Drive Plaque Smooth Muscle Cell Dedifferentiation in Experimental Atherosclerosis. *Arterioscler Thromb Vasc Biol* 44: 1852-1872, 2024.
368. **Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, Li P, Tipping P, Bobik A, and Toh BH.** Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. *Circulation* 127: 1028-1039, 2013.
369. **Cochain C, Koch M, Chaudhari SM, Busch M, Pelisek J, Boon L, and Zerneck A.** CD8+ T Cells Regulate Monopoiesis and Circulating Ly6C-high Monocyte Levels in Atherosclerosis in Mice. *Circ Res* 117: 244-253, 2015.
370. **Seijkens TTP, Poels K, Meiler S, van Tiel CM, Kusters PJH, Reiche M, Atzler D, Winkels H, Tjwa M, Poelman H, Slutter B, Kuiper J, Gijbels M, Kuivenhoven JA, Matic LP, Paulsson-Berne G, Hedin U, Hansson GK, Nicolaes GAF, Daemen M, Weber C, Gerdes N, de Winther MPJ, and Lutgens E.** Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death. *Eur Heart J* 40: 372-382, 2019.
371. **van Duijn J, Kritikou E, Benne N, van der Heijden T, van Puijvelde GH, Kroner MJ, Schaftenaar FH, Foks AC, Wezel A, Smeets H, Yagita H, Bot I, Jiskoot W, Kuiper J, and Slutter B.** CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses. *Cardiovasc Res* 115: 729-738, 2019.
372. **Chyu KY, Zhao X, Dimayuga PC, Zhou J, Li X, Yano J, Lio WM, Chan LF, Kirzner J, Trinidad P, Cercek B, and Shah PK.** CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide. *PLoS One* 7: e30780, 2012.
373. **Smit V, de Mol J, Schaftenaar FH, Depuydt MAC, Postel RJ, Smeets D, Verheijen FWM, Bogers L, van Duijn J, Verwilligen RAF, Grievink HW, Bernabe Kleijn MNA, van Ingen E, de Jong MJM, Goncalves L, Peeters J, Smeets HJ, Wezel A, Polansky JK, de Winther MPJ, Binder CJ, Tsiantoulas D, Bot I, Kuiper J, and Foks AC.** Single-cell profiling reveals age-associated immunity in atherosclerosis. *Cardiovasc Res* 119: 2508-2521, 2023.
374. **Tyrrell DJ, Wragg KM, Chen J, Wang H, Song J, Blin MG, Bolding C, Vardaman D, 3rd, Giles K, Tidwell H, Ali MA, Janappareddi A, Wood SC, and Goldstein DR.** Clonally expanded memory CD8(+) T cells accumulate in atherosclerotic plaques and are pro-atherogenic in aged mice. *Nat Aging* 3: 1576-1590, 2023.
375. **Getz GS, and Reardon CA.** Natural killer T cells in atherosclerosis. *Nat Rev Cardiol* 14: 304-314, 2017.

376. **Bondarenko S, Catapano AL, and Norata GD.** The CD1d-natural killer T cell axis in atherosclerosis. *J Innate Immun* 6: 3-12, 2014.
377. **Rogers L, Burchat S, Gage J, Hasu M, Thabet M, Willcox L, Ramsamy TA, and Whitman SC.** Deficiency of invariant V alpha 14 natural killer T cells decreases atherosclerosis in LDL receptor null mice. *Cardiovasc Res* 78: 167-174, 2008.
378. **VanderLaan PA, Reardon CA, Sagiv Y, Blachowicz L, Lukens J, Nissenbaum M, Wang CR, and Getz GS.** Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. *Am J Pathol* 170: 1100-1107, 2007.
379. **Aslanian AM, Chapman HA, and Charo IF.** Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. *Arterioscler Thromb Vasc Biol* 25: 628-632, 2005.
380. **Li Y, To K, Kanellakis P, Hosseini H, Deswaerte V, Tipping P, Smyth MJ, Toh BH, Bobik A, and Kyaw T.** CD4+ natural killer T cells potently augment aortic root atherosclerosis by perforin- and granzyme B-dependent cytotoxicity. *Circ Res* 116: 245-254, 2015.
381. **van Puijvelde GH, van Wanrooij EJ, Hauer AD, de Vos P, van Berkel TJ, and Kuiper J.** Effect of natural killer T cell activation on the initiation of atherosclerosis. *Thromb Haemost* 102: 223-230, 2009.
382. **Major AS, Wilson MT, McCaleb JL, Ru Su Y, Stanic AK, Joyce S, Van Kaer L, Fazio S, and Linton MF.** Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 24: 2351-2357, 2004.
383. **Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, and Berne GP.** CD1d-dependent activation of NKT cells aggravates atherosclerosis. *J Exp Med* 199: 417-422, 2004.
384. **Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, Watano K, Mishima T, Iwabuchi C, Tanaka S, Bezbradica JS, Nakayama T, Taniguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer L, and Onoe K.** Natural killer T cells accelerate atherogenesis in mice. *Blood* 104: 2051-2059, 2004.
385. **Tomas L, Katra P, Badn W, Andersson L, Nilsson J, Schiopu A, Engelbertsen D, Goncalves I, Bengtsson E, and Bjorkbacka H.** Invariant natural killer T cells and incidence of first-time coronary events: a nested case-control study. *Eur Heart J Open* 3: oead094, 2023.
386. **Nielsen MM, Witherden DA, and Havran WL.** gammadelta T cells in homeostasis and host defence of epithelial barrier tissues. *Nat Rev Immunol* 17: 733-745, 2017.
387. **Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, and Wick G.** Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. *Am J Pathol* 142: 1927-1937, 1993.
388. **Vu DM, Tai A, Tatro JB, Karas RH, Huber BT, and Beasley D.** gammadeltaT cells are prevalent in the proximal aorta and drive nascent atherosclerotic lesion progression and neutrophilia in hypercholesterolemic mice. *PLoS One* 9: e109416, 2014.
389. **Gil-Pulido J, Amezaga N, Jorgacevic I, Manthey HD, Rosch M, Brand T, Cidlinsky P, Schafer S, Beilhack A, Saliba AE, Lorenz K, Boon L, Prinz I, Waisman A, Korn T, Cochain C, and Zerneck A.** Interleukin-23 receptor expressing gammadelta T cells locally

promote early atherosclerotic lesion formation and plaque necrosis in mice. *Cardiovasc Res* 118: 2932-2945, 2022.

390. **Cheng HY, Wu R, and Hedrick CC.** Gammadelta (gammadelta) T lymphocytes do not impact the development of early atherosclerosis. *Atherosclerosis* 234: 265-269, 2014.

391. **Li Y, Jiang S, Li J, Yin M, Yan F, Chen Y, Chen Y, Wu T, Cheng M, He Y, Liang H, Yu H, Qiao Q, Guo Z, Xu Y, Zhang Y, Xiang Z, and Yin Z.** Phenotypic Changes of Peripheral gammadelta T Cell and Its Subsets in Patients With Coronary Artery Disease. *Front Immunol* 13: 900334, 2022.

392. **Olson NC, Sitalani CM, Doyle MF, Huber SA, Landay AL, Tracy RP, Psaty BM, and Delaney JA.** Innate and adaptive immune cell subsets as risk factors for coronary heart disease in two population-based cohorts. *Atherosclerosis* 300: 47-53, 2020.

393. **Wang Z, Zhang X, Lu S, Zhang C, Ma Z, Su R, Li Y, Sun T, Li Y, Hong M, Deng X, Monjezi MR, Hristov M, Steffens S, Santovito D, Dornmair K, Ley K, Weber C, Mohanta SK, Habenicht AJR, and Yin C.** Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis. *Nat Cardiovasc Res* 2: 290-306, 2023.

394. **Bashore AC, Yan H, Xue C, Zhu LY, Kim E, Mawson T, Coronel J, Chung A, Sachs N, Ho S, Ross LS, Kissner M, Passegue E, Bauer RC, Maegdefessel L, Li M, and Reilly MP.** High-Dimensional Single-Cell Multimodal Landscape of Human Carotid Atherosclerosis. *Arterioscler Thromb Vasc Biol* 2024.

395. **Tan J, Liang Y, Yang Z, He Q, Tong J, Deng Y, Guo W, Liang K, Tang J, Shi W, and Yu B.** Single-Cell Transcriptomics Reveals Crucial Cell Subsets and Functional Heterogeneity Associated With Carotid Atherosclerosis and Cerebrovascular Events. *Arterioscler Thromb Vasc Biol* 43: 2312-2332, 2023.

396. **Cooper MD.** The early history of B cells. *Nat Rev Immunol* 15: 191-197, 2015.

397. **Kantor AB, and Herzenberg LA.** Origin of murine B cell lineages. *Annu Rev Immunol* 11: 501-538, 1993.

398. **Alugupalli KR, and Gerstein RM.** Divide and conquer: division of labor by B-1 B cells. *Immunity* 23: 1-2, 2005.

399. **Baumgarth N.** B-1 Cell Heterogeneity and the Regulation of Natural and Antigen-Induced IgM Production. *Front Immunol* 7: 324, 2016.

400. **Upadhye A, Sturek JM, and McNamara CA.** 2019 Russell Ross Memorial Lecture in Vascular Biology: B Lymphocyte-Mediated Protective Immunity in Atherosclerosis. *Arterioscler Thromb Vasc Biol* 40: 309-322, 2020.

401. **Hardy RR.** B-1 B cell development. *J Immunol* 177: 2749-2754, 2006.

402. **Berland R, and Wortis HH.** Origins and functions of B-1 cells with notes on the role of CD5. *Annu Rev Immunol* 20: 253-300, 2002.

403. **Ghosn EE, Yamamoto R, Hamanaka S, Yang Y, Herzenberg LA, Nakauchi H, and Herzenberg LA.** Distinct B-cell lineage commitment distinguishes adult bone marrow hematopoietic stem cells. *Proc Natl Acad Sci U S A* 109: 5394-5398, 2012.

404. **Ghosn EE, Sadate-Ngatchou P, Yang Y, Herzenberg LA, and Herzenberg LA.** Distinct progenitors for B-1 and B-2 cells are present in adult mouse spleen. *Proc Natl Acad Sci U S A* 108: 2879-2884, 2011.

405. **Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, and Tedder TF.** A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. *Immunity* 28: 639-650, 2008.
406. **Major AS, Fazio S, and Linton MF.** B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. *Arterioscler Thromb Vasc Biol* 22: 1892-1898, 2002.
407. **Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van Vre E, Esposito B, Vilar J, Sirvent J, Van Snick J, Tedgui A, Tedder TF, and Mallat Z.** B cell depletion reduces the development of atherosclerosis in mice. *J Exp Med* 207: 1579-1587, 2010.
408. **Sage AP, Nus M, Baker LL, Finigan AJ, Masters LM, and Mallat Z.** Regulatory B cell-specific interleukin-10 is dispensable for atherosclerosis development in mice. *Arterioscler Thromb Vasc Biol* 35: 1770-1773, 2015.
409. **Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, Kehry M, Dunn R, Agrotis A, Tipping P, Bobik A, and Toh BH.** Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. *J Immunol* 185: 4410-4419, 2010.
410. **Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, Tipping P, Bobik A, and Toh BH.** Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. *PLoS One* 7: e29371, 2012.
411. **Doran AC, Lipinski MJ, Oldham SN, Garmey JC, Campbell KA, Skafien MD, Cutchins A, Lee DJ, Glover DK, Kelly KA, Galkina EV, Ley K, Witztum JL, Tsimikas S, Bender TP, and McNamara CA.** B-cell aortic homing and atheroprotection depend on Id3. *Circ Res* 110: e1-12, 2012.
412. **Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, and Haskard DO.** Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. *Circulation* 120: 417-426, 2009.
413. **Cherepanova OA, Srikakulapu P, Greene ES, Chaklader M, Haskins RM, McCanna ME, Bandyopadhyay S, Ban B, Leitinger N, McNamara CA, and Owens GK.** Novel Autoimmune IgM Antibody Attenuates Atherosclerosis in IgM Deficient Low-Fat Diet-Fed, but Not Western Diet-Fed Apoe(-/-) Mice. *Arterioscler Thromb Vasc Biol* 40: 206-219, 2020.
414. **Upadhye A, Srikakulapu P, Gonen A, Hendriks S, Perry HM, Nguyen A, McSkimming C, Marshall MA, Garmey JC, Taylor AM, Bender TP, Tsimikas S, Holodick NE, Rothstein TL, Witztum JL, and McNamara CA.** Diversification and CXCR4-Dependent Establishment of the Bone Marrow B-1a Cell Pool Governs Atheroprotective IgM Production Linked to Human Coronary Atherosclerosis. *Circ Res* 125: e55-e70, 2019.
415. **Sage AP, Nus M, Bagchi Chakraborty J, Tsiantoulas D, Newland SA, Finigan AJ, Masters L, Binder CJ, and Mallat Z.** X-Box Binding Protein-1 Dependent Plasma Cell Responses Limit the Development of Atherosclerosis. *Circ Res* 121: 270-281, 2017.
416. **Oksjoki R, Kovanen PT, Lindstedt KA, Jansson B, and Pentikainen MO.** OxLDL-IgG immune complexes induce survival of human monocytes. *Arterioscler Thromb Vasc Biol* 26: 576-583, 2006.

417. **Saad AF, Virella G, Chassereau C, Boackle RJ, and Lopes-Virella MF.** OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. *J Lipid Res* 47: 1975-1983, 2006.
418. **Nagarajan S.** Anti-OxLDL IgG blocks OxLDL interaction with CD36, but promotes FcγR, CD32A-dependent inflammatory cell adhesion. *Immunol Lett* 108: 52-61, 2007.
419. **Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, Bobik A, and Toh BH.** B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. *Circ Res* 109: 830-840, 2011.
420. **Rosenfeld SM, Perry HM, Gonen A, Prohaska TA, Srikakulapu P, Grewal S, Das D, McSkimming C, Taylor AM, Tsimikas S, Bender TP, Witztum JL, and McNamara CA.** B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. *Circ Res* 117: e28-39, 2015.
421. **Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, and Witztum JL.** Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. *Circ Res* 108: 235-248, 2011.
422. **Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, Tiglao E, Figueiredo JL, Iwamoto Y, Theurl I, Gorbатов R, Waring MT, Chicoine AT, Mouded M, Pittet MJ, Nahrendorf M, Weissleder R, and Swirski FK.** Innate response activator B cells protect against microbial sepsis. *Science* 335: 597-601, 2012.
423. **Sage AP, Tsiantoulas D, Binder CJ, and Mallat Z.** The role of B cells in atherosclerosis. *Nat Rev Cardiol* 16: 180-196, 2019.
424. **Srikakulapu P, and McNamara CA.** B cells and atherosclerosis. *Am J Physiol Heart Circ Physiol* 312: H1060-H1067, 2017.
425. **de Mol J, Kuiper J, Tsiantoulas D, and Foks AC.** The Dynamics of B Cell Aging in Health and Disease. *Front Immunol* 12: 733566, 2021.
426. **Snijckers RPM, and Foks AC.** Adaptive immunity and atherosclerosis: aging at its crossroads. *Front Immunol* 15: 1350471, 2024.
427. **Smit V, de Mol J, Kleijn M, Depuydt MAC, de Winther MPJ, Bot I, Kuiper J, and Foks AC.** Sexual dimorphism in atherosclerotic plaques of aged Ldlr(-/-) mice. *Immun Ageing* 21: 27, 2024.
428. **Pattarabanjird T, Srikakulapu P, Ransegnola B, Marshall MA, Ghosheh Y, Gulati R, Durant C, Drago F, Taylor AM, Ley K, and McNamara CA.** Single-cell profiling of CD11c+ B cells in atherosclerosis. *Front Immunol* 14: 1296668, 2023.
429. **Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, and Marrack P.** Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity. *Blood* 118: 1305-1315, 2011.
430. **Couloume L, Ferrant J, Le Gallou S, Mandon M, Jean R, Bescher N, Zephir H, Edan G, Thouvenot E, Ruet A, Debouverie M, Tarte K, Ame P, Roussel M, and Michel L.** Mass Cytometry Identifies Expansion of T-bet(+) B Cells and CD206(+) Monocytes in Early Multiple Sclerosis. *Front Immunol* 12: 653577, 2021.
431. **Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, Tomar D, Woodruff MC, Simon Z, Bugrovsky R, Blalock EL, Scharer CD, Tipton CM, Wei C, Lim SS,**

- Petri M, Niewold TB, Anolik JH, Gibson G, Lee FE, Boss JM, Lund FE, and Sanz I.** Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. *Immunity* 49: 725-739 e726, 2018.
432. **Strom AC, Cross AJ, Cole JE, Blair PA, Leib C, Goddard ME, Rosser EC, Park I, Hultgardh Nilsson A, Nilsson J, Mauri C, and Monaco C.** B regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10. *Thromb Haemost* 114: 835-847, 2015.
433. **Gjurich BN, Taghavi-Moghadam PL, Ley K, and Galkina EV.** L-selectin deficiency decreases aortic B1a and Breg subsets and promotes atherosclerosis. *Thromb Haemost* 112: 803-811, 2014.
434. **Douna H, Amersfoort J, Schaftenaar FH, Kroon S, van Puijvelde GHM, Kuiper J, and Foks AC.** Bidirectional effects of IL-10(+) regulatory B cells in Ldlr(-/-) mice. *Atherosclerosis* 280: 118-125, 2019.
435. **Douna H, Smit V, van Puijvelde GHM, Kiss MG, Binder CJ, Bot L, Kuchroo VK, Lichtman AH, Kuiper J, and Foks AC.** Tim-1 mucin domain-mutant mice display exacerbated atherosclerosis. *Atherosclerosis* 352: 1-9, 2022.
436. **Huan T, Zhang B, Wang Z, Joehanes R, Zhu J, Johnson AD, Ying S, Munson PJ, Raghavachari N, Wang R, Liu P, Courchesne P, Hwang SJ, Assimes TL, McPherson R, Samani NJ, Schunkert H, Coronary AGwR, Meta-analysis Consortium ICfBPG, Meng Q, Suver C, O'Donnell CJ, Derry J, Yang X, and Levy D.** A systems biology framework identifies molecular underpinnings of coronary heart disease. *Arterioscler Thromb Vasc Biol* 33: 1427-1434, 2013.
437. **Fraleay AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S, and Investigators MS.** Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. *J Am Coll Cardiol* 53: 2186-2196, 2009.
438. **Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, and Tsimikas S.** Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. *J Lipid Res* 52: 1829-1836, 2011.
439. **Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, and Berger PB.** Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. *J Lipid Res* 48: 425-433, 2007.
440. **Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, Mayr A, Witztum JL, and Kiechl S.** Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. *J Am Coll Cardiol* 60: 2218-2229, 2012.
441. **Prasad A, Clopton P, Ayers C, Khera A, de Lemos JA, Witztum JL, and Tsimikas S.** Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity,

Subclinical Atherosclerosis, and Cardiovascular Events. *Arterioscler Thromb Vasc Biol* 37: 1213-1221, 2017.

442. **van den Berg VJ, Haskard DO, Fedorowski A, Hartley A, Kardys I, Caga-Anan M, Akkerhuis KM, Oemrawsingh RM, van Geuns RJ, de Jaegere P, van Mieghem N, Regar E, Ligthart JMR, Umans V, Serruys PW, Melander O, Boersma E, and Khamis RY.** IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). *EBioMedicine* 36: 63-72, 2018.

443. **Asciutto G, Dias NV, Edsfeldt A, Alm R, Fredrikson GN, Goncalves I, and Nilsson J.** Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy. *Atherosclerosis* 239: 289-294, 2015.

444. **Bjorkbacka H, Alm R, Persson M, Hedblad B, Nilsson J, and Fredrikson GN.** Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events. *Arterioscler Thromb Vasc Biol* 36: 765-771, 2016.

445. **Sjogren P, Fredrikson GN, Samnegard A, Ericsson CG, Ohrvik J, Fisher RM, Nilsson J, and Hamsten A.** High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. *Eur Heart J* 29: 2218-2226, 2008.

446. **Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF, Inflamm, and Host Response to Injury Large Scale Collab. Res P.** A network-based analysis of systemic inflammation in humans. *Nature* 437: 1032-1037, 2005.

447. **Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden DL, Hennessy L, Moore EE, Minei JP, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Brownstein BH, Mason PH, Baker HV, Finnerty CC, Jeschke MG, Lopez MC, Klein MB, Gamelli RL, Gibran NS, Arnoldo B, Xu W, Zhang Y, Calvano SE, McDonald-Smith GP, Schoenfeld DA, Storey JD, Cobb JP, Warren HS, Moldawer LL, Herndon DN, Lowry SF, Maier RV, Davis RW, Tompkins RG, Inflammation, and Host Response to Injury Large-Scale Collaborative Research P.** A genomic storm in critically injured humans. *J Exp Med* 208: 2581-2590, 2011.

448. **Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D, Inflammation, and the Host Response to Injury I.** Acute inflammatory response to endotoxin in mice and humans. *Clin Diagn Lab Immunol* 12: 60-67, 2005.

449. **Brownstein BH, Logvinenko T, Lederer JA, Cobb JP, Hubbard WJ, Chaudry IH, Remick DG, Baker HV, Xiao W, and Mannick JA.** Commonality and differences in leukocyte gene expression patterns among three models of inflammation and injury. *Physiol Genomics* 24: 298-309, 2006.

450. **Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon**

- DN, Davis RW, Xiao W, Tompkins RG, Inflammation, and Host Response to Injury LSCRP.** Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A* 110: 3507-3512, 2013.
451. **Glass DR, Tsai AG, Oliveria JP, Hartmann FJ, Kimmey SC, Calderon AA, Borges L, Glass MC, Wagar LE, Davis MM, and Bendall SC.** An Integrated Multi-omic Single-Cell Atlas of Human B Cell Identity. *Immunity* 53: 217-232 e215, 2020.
452. **Zhao Y, Uduman M, Siu JHY, Tull TJ, Sanderson JD, Wu YB, Zhou JQ, Petrov N, Ellis R, Todd K, Chavele KM, Guesdon W, Vossenkamper A, Jassem W, D'Cruz DP, Fear DJ, John S, Scheel-Toellner D, Hopkins C, Moreno E, Woodman NL, Ciccarelli F, Heck S, Kleinstein SH, Bemark M, and Spencer J.** Spatiotemporal segregation of human marginal zone and memory B cell populations in lymphoid tissue. *Nat Commun* 9: 3857, 2018.
453. **Spencer J, Siu JHY, and Montorsi L.** Human intestinal lymphoid tissue in time and space. *Mucosal Immunol* 12: 296-298, 2019.
454. **Tull TJ, Pitcher MJ, Guesdon W, Siu JHY, Lebrero-Fernandez C, Zhao Y, Petrov N, Heck S, Ellis R, Dhimi P, Kadolsky UD, Kleeman M, Kamra Y, Fear DJ, John S, Jassem W, Groves RW, Sanderson JD, Robson MG, D'Cruz DP, Bemark M, and Spencer J.** Human marginal zone B cell development from early T2 progenitors. *J Exp Med* 218: 2021.
455. **Griffin DO, Holodick NE, and Rothstein TL.** Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. *J Exp Med* 208: 67-80, 2011.
456. **Engelbertsen D, Vallejo J, Quach TD, Fredrikson GN, Alm R, Hedblad B, Bjorkbacka H, Rothstein TL, Nilsson J, and Bengtsson E.** Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects. *J Immunol* 195: 3020-3025, 2015.
457. **Meeuwssen JAL, van Duijvenvoorde A, Gohar A, Kozma MO, van de Weg SM, Gijssberts CM, Haitjema S, Bjorkbacka H, Fredrikson GN, de Borst GJ, den Ruijter HM, Pasterkamp G, Binder CJ, Hofer IE, and de Jager SCA.** High Levels of (Un)Switched Memory B Cells Are Associated With Better Outcome in Patients With Advanced Atherosclerotic Disease. *J Am Heart Assoc* 6: 2017.
458. **Doring Y, Jansen Y, Cimen I, Aslani M, Gencer S, Peters LJJ, Duchene J, Weber C, and van der Vorst EPC.** B-Cell-Specific CXCR4 Protects Against Atherosclerosis Development and Increases Plasma IgM Levels. *Circ Res* 126: 787-788, 2020.
459. **Nutt SL, Hodgkin PD, Tarlinton DM, and Corcoran LM.** The generation of antibody-secreting plasma cells. *Nat Rev Immunol* 15: 160-171, 2015.
460. **Rincon-Arevalo H, Quintero JC, Fortich F, Rojas M, Vasquez G, Castano D, and Yassin LM.** Low frequency of IL-10(+) B cells in patients with atherosclerosis is related with inflammatory condition. *Heliyon* 6: e03441, 2020.
461. **Ye J, Bromage ES, and Kaattari SL.** The strength of B cell interaction with antigen determines the degree of IgM polymerization. *J Immunol* 184: 844-850, 2010.
462. **Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, and Witztum JL.** Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. *Arterioscler Thromb* 14: 32-40, 1994.

463. **Tsimikas S, Palinski W, and Witztum JL.** Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. *Arterioscler Thromb Vasc Biol* 21: 95-100, 2001.
464. **Freeman AF, Avila EM, Shaw PA, Davis J, Hsu AP, Welch P, Matta JR, Hadigan C, Pettigrew RI, Holland SM, and Gharib AM.** Coronary artery abnormalities in Hyper-IgE syndrome. *J Clin Immunol* 31: 338-345, 2011.
465. **Abd-Elmoniem KZ, Ramos N, Yazdani SK, Ghanem AM, Holland SM, Freeman AF, and Gharib AM.** Coronary atherosclerosis and dilation in hyper IgE syndrome patients: Depiction by magnetic resonance vessel wall imaging and pathological correlation. *Atherosclerosis* 258: 20-25, 2017.
466. **Guo X, Yuan S, Liu Y, Zeng Y, Xie H, Liu Z, Zhang S, Fang Q, Wang J, and Shen Z.** Serum IgE levels are associated with coronary artery disease severity. *Atherosclerosis* 251: 355-360, 2016.
467. **Lambert K, Tse R, Tettamanti C, Scarpelli MP, Rousseau G, Bonsignore A, and Palmiere C.** Postmortem IgE determination in coronary artery disease. *J Forensic Leg Med* 62: 1-6, 2019.
468. **Tsiantoulas D, Bot I, Ozsvar-Kozma M, Goderle L, Perkmann T, Hartvigsen K, Conrad DH, Kuiper J, Mallat Z, and Binder CJ.** Increased Plasma IgE Accelerate Atherosclerosis in Secreted IgM Deficiency. *Circ Res* 120: 78-84, 2017.
469. **Wang J, Cheng X, Xiang MX, Alanne-Kinnunen M, Wang JA, Chen H, He A, Sun X, Lin Y, Tang TT, Tu X, Sjoberg S, Sukhova GK, Liao YH, Conrad DH, Yu L, Kawakami T, Kovanen PT, Libby P, and Shi GP.** IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe^{-/-} mice. *J Clin Invest* 121: 3564-3577, 2011.
470. **Zhang X, Li J, Luo S, Wang M, Huang Q, Deng Z, de Febbo C, Daoui A, Liew PX, Sukhova GK, Metso J, Jauhainen M, Shi GP, and Guo J.** IgE Contributes to Atherosclerosis and Obesity by Affecting Macrophage Polarization, Macrophage Protein Network, and Foam Cell Formation. *Arterioscler Thromb Vasc Biol* 40: 597-610, 2020.
471. **Wilson JM, Nguyen AT, Schuyler AJ, Commins SP, Taylor AM, Platts-Mills TAE, and McNamara CA.** IgE to the Mammalian Oligosaccharide Galactose-alpha-1,3-Galactose Is Associated With Increased Atheroma Volume and Plaques With Unstable Characteristics-Brief Report. *Arterioscler Thromb Vasc Biol* 38: 1665-1669, 2018.
472. **Pattarabanjird T, Li C, and McNamara C.** B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications. *JACC Basic Transl Sci* 6: 546-563, 2021.
473. **Cox KM, Commins SP, Capaldo BJ, Workman LJ, Platts-Mills TAE, Amir ED, Lannigan JA, Schuyler AJ, and Erickson LD.** An integrated framework using high-dimensional mass cytometry and fluorescent flow cytometry identifies discrete B cell subsets in patients with red meat allergy. *Clin Exp Allergy* 49: 615-625, 2019.
474. **Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, and Wilson JM.** IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. *J Allergy Clin Immunol* 153: 471-478 e473, 2024.
475. **Nus M, Basatemur G, Galan M, Cros-Brunso L, Zhao TX, Masters L, Harrison J, Figg N, Tsiantoulas D, Geissmann F, Binder CJ, Sage AP, and Mallat Z.** NR4A1 Deletion in

Marginal Zone B Cells Exacerbates Atherosclerosis in Mice-Brief Report. *Arterioscler Thromb Vasc Biol* 40: 2598-2604, 2020.

476. **Mauri C, and Bosma A.** Immune regulatory function of B cells. *Annu Rev Immunol* 30: 221-241, 2012.

477. **Mauri C, and Menon M.** Human regulatory B cells in health and disease: therapeutic potential. *J Clin Invest* 127: 772-779, 2017.

478. **Smith DA, Irving SD, Sheldon J, Cole D, and Kaski JC.** Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. *Circulation* 104: 746-749, 2001.

479. **Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM, and Investigators CS.** Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. *Circulation* 107: 2109-2114, 2003.

480. **ElTanbouly MA, and Noelle RJ.** Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey. *Nat Rev Immunol* 21: 257-267, 2021.

481. **Barcia Duran JG, Das D, Gildea M, Amadori L, Gourvest M, Kaur R, Eberhardt N, Smyrnis P, Cilhoroz B, Sajja S, Rahman K, Fernandez DM, Faries P, Narula N, Vanguri R, Goldberg IJ, Fisher EA, Berger JS, Moore KJ, and Giannarelli C.** Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors. *Nat Cardiovasc Res* 3: 1482-1502, 2024.

482. **Chen L, and Flies DB.** Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol* 13: 227-242, 2013.

483. **Nitz K, Herrmann J, Lerman A, and Lutgens E.** Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis. *JACC: Basic to Translational Science* 0.

484. **Kusters PJH, Lutgens E, and Seijkens TTP.** Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. *Cardiovasc Res* 114: 368-377, 2018.

485. **Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, and Noelle RJ.** Molecular mechanism and function of CD40/CD40L engagement in the immune system. *Immunol Rev* 229: 152-172, 2009.

486. **Lievens D, Zerneck A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, Wijnands E, Goossens P, van Kruchten R, Thevissen L, Boon L, Flavell RA, Noelle RJ, Gerdes N, Biessen EA, Daemen MJ, Heemskerk JW, Weber C, and Lutgens E.** Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. *Blood* 116: 4317-4327, 2010.

487. **Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zerneck A, Seijkens T, Engel D, Cleutjens J, Keller AM, Naik SH, Boon L, Oufella HA, Mallat Z, Ahonen CL, Noelle RJ, de Winther MP, Daemen MJ, Biessen EA, and Weber C.** Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. *J Exp Med* 207: 391-404, 2010.

488. **Bosmans LA, van Tiel CM, Aarts S, Willemsen L, Baardman J, van Os BW, Toom MD, Beckers L, Ahern DJ, Levels JHM, Jongejan A, Moerland PD, Verberk SGS, den Bossche JV, de Winther M, Weber C, Atzler D, Monaco C, Gerdes N, Shami A, and Lutgens E.** Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state. *Cardiovasc Res* 119: 1146-1160, 2023.

489. **Shami A, Edsfeldt A, Bengtsson E, Nilsson J, Shore AC, Natali A, Khan F, Lutgens E, and Goncalves I.** Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype. *J Stroke* 23: 367-376, 2021.
490. **Schonbeck U, Varo N, Libby P, Buring J, and Ridker PM.** Soluble CD40L and cardiovascular risk in women. *Circulation* 104: 2266-2268, 2001.
491. **Sultan CS, Weitnauer M, Turinsky M, Kessler T, Brune M, Gleissner CA, Leuschner F, Wagner AH, and Hecker M.** Functional association of a CD40 gene single-nucleotide polymorphism with the pathogenesis of coronary heart disease. *Cardiovasc Res* 116: 1214-1225, 2020.
492. **Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, and Flavell RA.** Requirement for CD154 in the progression of atherosclerosis. *Nat Med* 5: 1313-1316, 1999.
493. **Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, and Daemen MJ.** Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. *Proc Natl Acad Sci U S A* 97: 7464-7469, 2000.
494. **Schonbeck U, Sukhova GK, Shimizu K, Mach F, and Libby P.** Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. *Proc Natl Acad Sci U S A* 97: 7458-7463, 2000.
495. **Mach F, Schonbeck U, Sukhova GK, Atkinson E, and Libby P.** Reduction of atherosclerosis in mice by inhibition of CD40 signalling. *Nature* 394: 200-203, 1998.
496. **Lacy M, Burger C, Shami A, Ahmadsei M, Winkels H, Nitz K, van Tiel CM, Seijkens TTP, Kusters PJH, Karshovka E, Prange KHM, Wu Y, Brouns SLN, Unterlugauer S, Kuijpers MJE, Reiche ME, Steffens S, Edsfeldt A, Megens RTA, Heemskerk JWM, Goncalves I, Weber C, Gerdes N, Atzler D, and Lutgens E.** Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. *Nat Commun* 12: 3754, 2021.
497. **Gissler MC, Scherrer P, Anto-Michel N, Pennig J, Hoppe N, Funer L, Hardtner C, Stachon P, Li X, Mitre LS, Marchini T, Madl J, Wadle C, Hilgendorf I, von Zur Muhlen C, Bode C, Weber C, Lutgens E, Wolf D, Gerdes N, Zirlik A, and Willecke F.** Deficiency of Endothelial CD40 Induces a Stable Plaque Phenotype and Limits Inflammatory Cell Recruitment to Atherosclerotic Lesions in Mice. *Thromb Haemost* 121: 1530-1540, 2021.
498. **Reiche ME, Poels K, Bosmans LA, Vos WG, Van Tiel CM, Gijbels MJJ, Aarts S, Den Toom M, Beckers L, Weber C, Atzler D, Rensen PCN, Kooijman S, and Lutgens E.** Adipocytes control haematopoiesis and inflammation through CD40 signaling. *Haematologica* 2022.
499. **Gerdes N, Seijkens T, Lievens D, Kuijpers MJ, Winkels H, Projahn D, Hartwig H, Beckers L, Megens RT, Boon L, Noelle RJ, Soehnlein O, Heemskerk JW, Weber C, and Lutgens E.** Platelet CD40 Exacerbates Atherosclerosis by Transcellular Activation of Endothelial Cells and Leukocytes. *Arterioscler Thromb Vasc Biol* 36: 482-490, 2016.
500. **Tian J, Zhang B, Rui K, and Wang S.** The Role of GITR/GITRL Interaction in Autoimmune Diseases. *Front Immunol* 11: 588682, 2020.
501. **Shimizu J, Yamazaki S, Takahashi T, Ishida Y, and Sakaguchi S.** Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. *Nat Immunol* 3: 135-142, 2002.

502. **Bosmans LA, Shami A, Atzler D, Weber C, Goncalves I, and Lutgens E.** Glucocorticoid induced TNF receptor family-related protein (GITR) - A novel driver of atherosclerosis. *Vascul Pharmacol* 139: 106884, 2021.
503. **Meiler S, Smeets E, Winkels H, Shami A, Pascutti MF, Nolte MA, Beckers L, Weber C, Gerdes N, and Lutgens E.** Constitutive GITR Activation Reduces Atherosclerosis by Promoting Regulatory CD4+ T-Cell Responses-Brief Report. *Arterioscler Thromb Vasc Biol* 36: 1748-1752, 2016.
504. **Bae E, Kim WJ, Kang YM, Suk K, Koh EM, Cha HS, Ahn KS, Huh TL, and Lee WH.** Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis. *Clin Exp Immunol* 148: 410-418, 2007.
505. **Kim WJ, Bae EM, Kang YJ, Bae HU, Hong SH, Lee JY, Park JE, Kwon BS, Suk K, and Lee WH.** Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. *Immunology* 119: 421-429, 2006.
506. **Shin HH, Kwon BS, and Choi HS.** Recombinant glucocorticoid induced tumour necrosis factor receptor (rGITR) induced COX-2 activity in murine macrophage Raw 264.7 cells. *Cytokine* 19: 187-192, 2002.
507. **Nocentini G, and Riccardi C.** GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. *Eur J Immunol* 35: 1016-1022, 2005.
508. **Shami A, Atzler D, Bosmans LA, Winkels H, Meiler S, Lacy M, van Tiel C, Ta Megens R, Nitz K, Baardman J, Kusters P, Seijkens T, Buerger C, Janjic A, Riccardi C, Edsfeldt A, Monaco C, Daemen M, de Winther MPJ, Nilsson J, Weber C, Gerdes N, Goncalves I, and Lutgens E.** Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. *Eur Heart J* 41: 2938-2948, 2020.
509. **Winkels H, Meiler S, Lievens D, Engel D, Spitz C, Burger C, Beckers L, Dandl A, Reim S, Ahmadsei M, Hartwig H, Holdt LM, Hristov M, Megens RTA, Schmitt MM, Biessen EA, Borst J, Faussner A, Weber C, Lutgens E, and Gerdes N.** CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice. *Eur Heart J* 38: 3590-3599, 2017.
510. **Foks AC, Bot I, Frodermann V, de Jager SC, Ter Borg M, van Santbrink PJ, Yagita H, Kuiper J, and van Puijvelde GH.** Interference of the CD30-CD30L pathway reduces atherosclerosis development. *Arterioscler Thromb Vasc Biol* 32: 2862-2868, 2012.
511. **van Wanrooij EJ, van Puijvelde GH, de Vos P, Yagita H, van Berkel TJ, and Kuiper J.** Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. *Arterioscler Thromb Vasc Biol* 27: 204-210, 2007.
512. **Foks AC, van Puijvelde GH, Bot I, ter Borg MN, Habets KL, Johnson JL, Yagita H, van Berkel TJ, and Kuiper J.** Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis. *J Immunol* 191: 4573-4580, 2013.
513. **Brzostek J, Gascoigne NR, and Rybakin V.** Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition. *Front Immunol* 7: 24, 2016.

514. **Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, and Lichtman AH.** B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. *Circulation* 109: 2009-2015, 2004.
515. **Matsumoto T, Sasaki N, Yamashita T, Emoto T, Kasahara K, Mizoguchi T, Hayashi T, Yodoi K, Kitano N, Saito T, Yamaguchi T, and Hirata K.** Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice. *Arterioscler Thromb Vasc Biol* 36: 1141-1151, 2016.
516. **Amin HZ, Sasaki N, Yamashita T, Mizoguchi T, Hayashi T, Emoto T, Matsumoto T, Yoshida N, Tabata T, Horibe S, Kawauchi S, Rikitake Y, and Hirata KI.** CTLA-4 Protects against Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice. *Sci Rep* 9: 8065, 2019.
517. **Poels K, van Leent MMT, Reiche ME, Kusters PJH, Huveneers S, de Winther MPJ, Mulder WJM, Lutgens E, and Seijkens TTP.** Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice. *Cells* 9: 2020.
518. **de Boer OJ, Hirsch F, van der Wal AC, van der Loos CM, Das PK, and Becker AE.** Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. *Atherosclerosis* 133: 227-234, 1997.
519. **Zhao B, Wang D, Liu Y, Zhang X, Wan Z, Wang J, Su T, Duan L, Wang Y, Zhang Y, and Zhao Y.** Six-Gene Signature Associated with Immune Cells in the Progression of Atherosclerosis Discovered by Comprehensive Bioinformatics Analyses. *Cardiovasc Ther* 2020: 1230513, 2020.
520. **Dopheide JF, Sester U, Schlitt A, Horstick G, Rupprecht HJ, Munzel T, and Blankenberg S.** Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. *Coron Artery Dis* 18: 523-531, 2007.
521. **Bardhan K, Anagnostou T, and Boussiotis VA.** The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. *Front Immunol* 7: 550, 2016.
522. **Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, and Lichtman AH.** Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. *J Clin Invest* 117: 2974-2982, 2007.
523. **Bu DX, Tarrío M, Maganto-García E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, and Lichtman AH.** Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. *Arterioscler Thromb Vasc Biol* 31: 1100-1107, 2011.
524. **Poels K, van Leent MMT, Boutros C, Tissot H, Roy S, Meerwaldt AE, Toner YCA, Reiche ME, Kusters PJH, Malinova T, Huveneers S, Kaufman AE, Mani V, Fayad ZA, de Winther MPJ, Marabelle A, Mulder WJM, Robert C, Seijkens TTP, and Lutgens E.** Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. *JACC CardioOncol* 2: 599-610, 2020.
525. **Grievink HW, Smit V, Verwilligen RAF, Bernabe Kleijn MNA, Smeets D, Binder CJ, Yagita H, Moerland M, Kuiper J, Bot I, and Foks AC.** Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice. *Front Cardiovasc Med* 8: 740531, 2021.

526. **Douna H, de Mol J, Amersfoort J, Schaftenaar FH, Kiss MG, Suur BE, Kroner MJ, Binder CJ, Bot I, Van Puijvelde GHM, Kuiper J, and Foks AC.** IFN γ -stimulated B cells inhibit T follicular helper cells and protect against atherosclerosis. *Front Cardiovasc Med* 9: 781436, 2022.
527. **Lee J, Zhuang Y, Wei X, Shang F, Wang J, Zhang Y, Liu X, Yang Y, Liu L, and Zheng Q.** Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. *J Mol Cell Cardiol* 46: 169-176, 2009.
528. **Li S, Yi L, Wei X, Zhang J, Wang X, Jiang C, Yan Z, Song L, Yang B, Wei P, Gao X, Wang J, Zhang H, and Zhang J.** Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. *Front Cardiovasc Med* 9: 971414, 2022.
529. **Fujisue K, Yamamoto E, Sueta D, Takae M, Nishihara T, Komorita T, Usuku H, Yamanaga K, Ito M, Hoshiyama T, Kanazawa H, Takashio S, Arima Y, Araki S, Soejima H, Kaikita K, Matsushita K, and Tsujita K.** Increased soluble programmed cell death-ligand 1 is associated with acute coronary syndrome. *Int J Cardiol* 349: 1-6, 2022.
530. **Kassiteridi C, Cole JE, Griseri T, Falck-Hansen M, Goddard ME, Seneviratne AN, Green PA, Park I, Shami AG, Pattarabanjird T, Upadhye A, Taylor AM, Handa A, Channon KM, Lutgens E, McNamara CA, Williams RO, and Monaco C.** CD200 limits monopoiesis and monocyte recruitment in atherosclerosis. *Circ Res* 129: 280-295, 2021.
531. **Foks AC, Engelbertsen D, Kuperwaser F, Alberts-Grill N, Gonen A, Witztum JL, Lederer J, Jarolim P, DeKruyff RH, Freeman GJ, and Lichtman AH.** Blockade of Tim-1 and Tim-4 enhances atherosclerosis in low-density lipoprotein receptor-deficient mice. *Arterioscler Thromb Vasc Biol* 36: 456-465, 2016.
532. **Foks AC, Ran IA, Wasserman L, Frodermann V, Ter Borg MN, de Jager SC, van Santbrink PJ, Yagita H, Akiba H, Bot I, Kuiper J, and van Puijvelde GH.** T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. *Arterioscler Thromb Vasc Biol* 33: 2558-2565, 2013.
533. **Foks AC, Ran IA, Frodermann V, Bot I, van Santbrink PJ, Kuiper J, and van Puijvelde GH.** Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development. *PLoS One* 8: e83134, 2013.
534. **Hosseini H, Yi L, Kanellakis P, Cao A, Tay C, Peter K, Bobik A, Toh BH, and Kyaw T.** Anti-TIM-1 monoclonal antibody (RMT1-10) attenuates atherosclerosis by expanding IgM-producing B1a cells. *J Am Heart Assoc* 7: 2018.
535. **Meyers JH, Chakravarti S, Schlesinger D, Illes Z, Waldner H, Umetsu SE, Kenny J, Zheng XX, Umetsu DT, DeKruyff RH, Strom TB, and Kuchroo VK.** TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. *Nat Immunol* 6: 455-464, 2005.
536. **Xiao S, Najafian N, Reddy J, Albin M, Zhu C, Jensen E, Imitola J, Korn T, Anderson AC, Zhang Z, Gutierrez C, Moll T, Sobel RA, Umetsu DT, Yagita H, Akiba H, Strom T, Sayegh MH, DeKruyff RH, Khoury SJ, and Kuchroo VK.** Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. *J Exp Med* 204: 1691-1702, 2007.
537. **Douna H, Amersfoort J, Schaftenaar FH, Kroner MJ, Kiss MG, Slutter B, Depuydt MAC, Bernabe Kleijn MNA, Wezel A, Smeets HJ, Yagita H, Binder CJ, Bot I, van Puijvelde**

- GHM, Kuiper J, and Foks AC.** B- and T-lymphocyte attenuator stimulation protects against atherosclerosis by regulating follicular B cells. *Cardiovasc Res* 116: 295-305, 2020.
538. **Mussbacher M, Schossleitner K, Kral-Pointner JB, Salzmann M, Schrammel A, and Schmid JA.** More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis. *Curr Atheroscler Rep* 24: 483-492, 2022.
539. **Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, and Schiffrin EL.** Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. *Circulation* 110: 2233-2240, 2004.
540. **Furchgott RF, and Zawadzki JV.** The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 288: 373-376, 1980.
541. **Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, and Fishman MC.** Hypertension in mice lacking the gene for endothelial nitric oxide synthase. *Nature* 377: 239-242, 1995.
542. **Partida RA, Libby P, Crea F, and Jang IK.** Plaque erosion: a new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes. *Eur Heart J* 39: 2070-2076, 2018.
543. **Tomas L, Edsfeldt A, Mollet IG, Perisic Matic L, Prehn C, Adamski J, Paulsson-Berne G, Hedin U, Nilsson J, Bengtsson E, Goncalves I, and Bjorkbacka H.** Altered metabolism distinguishes high-risk from stable carotid atherosclerotic plaques. *Eur Heart J* 39: 2301-2310, 2018.
544. **Wang KC, Yeh YT, Nguyen P, Limqueco E, Lopez J, Thorossian S, Guan KL, Li YJ, and Chien S.** Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis. *Proc Natl Acad Sci U S A* 113: 11525-11530, 2016.
545. **Wang L, Luo JY, Li B, Tian XY, Chen LJ, Huang Y, Liu J, Deng D, Lau CW, Wan S, Ai D, Mak KK, Tong KK, Kwan KM, Wang N, Chiu JJ, Zhu Y, and Huang Y.** Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. *Nature* 540: 579-582, 2016.
546. **Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G, Bicciato S, and Dupont S.** Aerobic glycolysis tunes YAP/TAZ transcriptional activity. *EMBO J* 34: 1349-1370, 2015.
547. **Theodorou K, and Boon RA.** Endothelial Cell Metabolism in Atherosclerosis. *Front Cell Dev Biol* 6: 82, 2018.
548. **Poels K, Schnitzler JG, Waissi F, Levels JHM, Stroes ESG, Daemen M, Lutgens E, Pennekamp AM, De Kleijn DPV, Seijkens TTP, and Kroon J.** Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. *Front Cell Dev Biol* 8: 581641, 2020.
549. **Pepin ME, and Gupta RM.** The Role of Endothelial Cells in Atherosclerosis: Insights from Genetic Association Studies. *Am J Pathol* 194: 499-509, 2024.
550. **Souilhol C, Serbanovic-Canic J, Fragiadaki M, Chico TJ, Ridger V, Roddie H, and Evans PC.** Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes. *Nat Rev Cardiol* 17: 52-63, 2020.
551. **Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, Kratz JR, Lin Z, Jain MK, Gimbrone MA, Jr., and Garcia-Cardena G.** Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. *J Clin Invest* 116: 49-58, 2006.

552. **Joshi D, Coon BG, Chakraborty R, Deng H, Yang Z, Babar MU, Fernandez-Tussy P, Meredith E, Attanasio J, Joshi N, Traylor JG, Jr., Orr AW, Fernandez-Hernando C, Libreros S, and Schwartz MA.** Endothelial gamma-protocadherins inhibit KLF2 and KLF4 to promote atherosclerosis. *Nat Cardiovasc Res* 3: 1035-1048, 2024.
553. **Zhang C, Zhou T, Chen Z, Yan M, Li B, Lv H, Wang C, Xiang S, Shi L, Zhu Y, and Ai D.** Coupling of Integrin alpha5 to Annexin A2 by Flow Drives Endothelial Activation. *Circ Res* 127: 1074-1090, 2020.
554. **Albarran-Juarez J, Iring A, Wang S, Joseph S, Grimm M, Strilic B, Wettschureck N, Althoff TF, and Offermanns S.** Piezo1 and G(q)/G(11) promote endothelial inflammation depending on flow pattern and integrin activation. *J Exp Med* 215: 2655-2672, 2018.
555. **Mehta V, Pang KL, Rozbesky D, Nather K, Keen A, Lachowski D, Kong Y, Karia D, Ameismeier M, Huang J, Fang Y, Del Rio Hernandez A, Reader JS, Jones EY, and Tzima E.** The guidance receptor plexin D1 is a mechanosensor in endothelial cells. *Nature* 578: 290-295, 2020.
556. **Nakayama A, Albarran-Juarez J, Liang G, Roquid KA, Iring A, Tonack S, Chen M, Muller OJ, Weinstein LS, and Offermanns S.** Disturbed flow-induced Gs-mediated signaling protects against endothelial inflammation and atherosclerosis. *JCI Insight* 5: 2020.
557. **Claesson-Welsh L, Dejana E, and McDonald DM.** Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies. *Trends Mol Med* 27: 314-331, 2021.
558. **Huveneers S, Daemen MJ, and Hordijk PL.** Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. *Circ Res* 116: 895-908, 2015.
559. **Heemskerk N, Schimmel L, Oort C, van Rijssel J, Yin T, Ma B, van Unen J, Pitter B, Huveneers S, Goedhart J, Wu Y, Montanez E, Woodfin A, and van Buul JD.** F-actin-rich contractile endothelial pores prevent vascular leakage during leukocyte diapedesis through local RhoA signalling. *Nat Commun* 7: 10493, 2016.
560. **Michiels C.** Endothelial cell functions. *J Cell Physiol* 196: 430-443, 2003.
561. **Jang E, Robert J, Rohrer L, von Eckardstein A, and Lee WL.** Transendothelial transport of lipoproteins. *Atherosclerosis* 315: 111-125, 2020.
562. **Huang L, Chambliss KL, Gao X, Yuhanna IS, Behling-Kelly E, Bergaya S, Ahmed M, Michaely P, Luby-Phelps K, Darehshouri A, Xu L, Fisher EA, Ge WP, Mineo C, and Shaul PW.** SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis. *Nature* 569: 565-569, 2019.
563. **Wang DX, Pan YQ, Liu B, and Dai L.** Cav-1 promotes atherosclerosis by activating JNK-associated signaling. *Biochem Biophys Res Commun* 503: 513-520, 2018.
564. **Ramirez CM, Zhang X, Bandyopadhyay C, Rotllan N, Sugiyama MG, Aryal B, Liu X, He S, Kraehling JR, Ulrich V, Lin CS, Velazquez H, Lasuncion MA, Li G, Suarez Y, Tellides G, Swirski FK, Lee WL, Schwartz MA, Sessa WC, and Fernandez-Hernando C.** Caveolin-1 Regulates Atherogenesis by Attenuating Low-Density Lipoprotein Transcytosis and Vascular Inflammation Independently of Endothelial Nitric Oxide Synthase Activation. *Circulation* 140: 225-239, 2019.
565. **Franck G, Even G, Gautier A, Salinas M, Loste A, Procopio E, Gaston AT, Morvan M, Dupont S, Deschildre C, Berissi S, Laschet J, Nataf P, Nicoletti A, Michel JB, and**

- Caligiuri G.** Haemodynamic stress-induced breaches of the arterial intima trigger inflammation and drive atherogenesis. *Eur Heart J* 40: 928-937, 2019.
566. **Berman JW, and Calderon TM.** The role of endothelial cell adhesion molecules in the development of atherosclerosis. *Cardiovasc Pathol* 1: 17-28, 1992.
567. **Lum H, and Malik AB.** Mechanisms of increased endothelial permeability. *Can J Physiol Pharmacol* 74: 787-800, 1996.
568. **Charla E, Mercer J, Maffia P, and Nicklin SA.** Extracellular vesicle signalling in atherosclerosis. *Cell Signal* 75: 109751, 2020.
569. **Peng M, Liu X, and Xu G.** Extracellular Vesicles as Messengers in Atherosclerosis. *J Cardiovasc Transl Res* 13: 121-130, 2020.
570. **Schwartz MA, Vestweber D, and Simons M.** A unifying concept in vascular health and disease. *Science* 360: 270-271, 2018.
571. **Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, and Baker AH.** Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol* 73: 190-209, 2019.
572. **Moonen JR, Lee ES, Schmidt M, Maleszewska M, Koerts JA, Brouwer LA, van Kooten TG, van Luyn MJ, Zeebregts CJ, Krenning G, and Harmsen MC.** Endothelial-to-mesenchymal transition contributes to fibro-proliferative vascular disease and is modulated by fluid shear stress. *Cardiovasc Res* 108: 377-386, 2015.
573. **Correia AC, Moonen JR, Brinker MG, and Krenning G.** FGF2 inhibits endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-beta signaling. *J Cell Sci* 129: 569-579, 2016.
574. **Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, d'Escamard V, Li JR, Hadri L, Fujitani K, Moreno PR, Benard L, Rimmel P, Cohain A, Mecham B, Randolph GJ, Nabel EG, Hajjar R, Fuster V, Boehm M, and Kovacic JC.** Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. *Nat Commun* 7: 11853, 2016.
575. **Moonen JR, Krenning G, Brinker MG, Koerts JA, van Luyn MJ, and Harmsen MC.** Endothelial progenitor cells give rise to pro-angiogenic smooth muscle-like progeny. *Cardiovasc Res* 86: 506-515, 2010.
576. **Chen PY, Qin L, Li G, Wang Z, Dahlman JE, Malagon-Lopez J, Gujja S, Cilfone NA, Kauffman KJ, Sun L, Sun H, Zhang X, Aryal B, Canfran-Duque A, Liu R, Kusters P, Sehgal A, Jiao Y, Anderson DG, Gulcher J, Fernandez-Hernando C, Lutgens E, Schwartz MA, Pober JS, Chittenden TW, Tellides G, and Simons M.** Endothelial TGF-beta signalling drives vascular inflammation and atherosclerosis. *Nat Metab* 1: 912-926, 2019.
577. **Chen PY, Qin L, Baeyens N, Li G, Afolabi T, Budatha M, Tellides G, Schwartz MA, and Simons M.** Endothelial-to-mesenchymal transition drives atherosclerosis progression. *J Clin Invest* 125: 4514-4528, 2015.
578. **Chen PY, Qin L, Tellides G, and Simons M.** Fibroblast growth factor receptor 1 is a key inhibitor of TGFbeta signaling in the endothelium. *Sci Signal* 7: ra90, 2014.
579. **Tamargo IA, Baek KI, Kim Y, Park C, and Jo H.** Flow-induced reprogramming of endothelial cells in atherosclerosis. *Nat Rev Cardiol* 20: 738-753, 2023.

580. **Andueza A, Kumar S, Kim J, Kang DW, Mumme HL, Perez JI, Villa-Roel N, and Jo H.** Endothelial Reprogramming by Disturbed Flow Revealed by Single-Cell RNA and Chromatin Accessibility Study. *Cell Rep* 33: 108491, 2020.
581. **Souilhol C, Harmsen MC, Evans PC, and Krenning G.** Endothelial-mesenchymal transition in atherosclerosis. *Cardiovasc Res* 114: 565-577, 2018.
582. **Shao Y, Saredy J, Xu K, Sun Y, Saaoud F, Drummer Ct, Lu Y, Luo JJ, Lopez-Pastrana J, Choi ET, Jiang X, Wang H, and Yang X.** Endothelial Immunity Trained by Coronavirus Infections, DAMP Stimulations and Regulated by Anti-Oxidant NRF2 May Contribute to Inflammations, Myelopoiesis, COVID-19 Cytokine Storms and Thromboembolism. *Front Immunol* 12: 653110, 2021.
583. **Plein A, Fantin A, Denti L, Pollard JW, and Ruhrberg C.** Erythro-myeloid progenitors contribute endothelial cells to blood vessels. *Nature* 562: 223-228, 2018.
584. **Alsaigh T, Evans D, Frankel D, and Torkamani A.** Decoding the transcriptome of calcified atherosclerotic plaque at single-cell resolution. *Commun Biol* 5: 1084, 2022.
585. **Alencar GF, Owsiany KM, Karnewar S, Sukhavasi K, Mocchi G, Nguyen AT, Williams CM, Shamsuzzaman S, Mokry M, Henderson CA, Haskins R, Baylis RA, Finn AV, McNamara CA, Zunder ER, Venkata V, Pasterkamp G, Bjorkegren J, Bekiranov S, and Owens GK.** Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis. *Circulation* 142: 2045-2059, 2020.
586. **Kalucka J, de Rooij L, Goveia J, Rohlenova K, Dumas SJ, Meta E, Conchinha NV, Taverna F, Teuwen LA, Veys K, Garcia-Caballero M, Khan S, Geldhof V, Sokol L, Chen R, Treps L, Borri M, de Zeeuw P, Dubois C, Karakach TK, Falkenberg KD, Parys M, Yin X, Vinckier S, Du Y, Fenton RA, Schoonjans L, Dewerchin M, Eelen G, Thienpont B, Lin L, Bolund L, Li X, Luo Y, and Carmeliet P.** Single-Cell Transcriptome Atlas of Murine Endothelial Cells. *Cell* 180: 764-779 e720, 2020.
587. **Yoshida T, Sinha S, Dandre F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, and Owens GK.** Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. *Circ Res* 92: 856-864, 2003.
588. **Francis GA.** The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis. *Curr Atheroscler Rep* 25: 741-749, 2023.
589. **Gomez D, and Owens GK.** Reconciling Smooth Muscle Cell Oligoclonality and Proliferative Capacity in Experimental Atherosclerosis. *Circ Res* 119: 1262-1264, 2016.
590. **Dobnikar L, Taylor AL, Chappell J, Oldach P, Harman JL, Oerton E, Dzierzak E, Bennett MR, Spivakov M, and Jorgensen HF.** Disease-relevant transcriptional signatures identified in individual smooth muscle cells from healthy mouse vessels. *Nat Commun* 9: 4567, 2018.
591. **Chappell J, Harman JL, Narasimhan VM, Yu H, Foote K, Simons BD, Bennett MR, and Jorgensen HF.** Extensive Proliferation of a Subset of Differentiated, yet Plastic, Medial Vascular Smooth Muscle Cells Contributes to Neointimal Formation in Mouse Injury and Atherosclerosis Models. *Circ Res* 119: 1313-1323, 2016.
592. **Tigges U, Komatsu M, and Stallcup WB.** Adventitial pericyte progenitor/mesenchymal stem cells participate in the restenotic response to arterial injury. *J Vasc Res* 50: 134-144, 2013.

593. **Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, and Xu Q.** Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. *J Clin Invest* 113: 1258-1265, 2004.
594. **Coen M, Gabbiani G, and Bochaton-Piallat ML.** Myofibroblast-mediated adventitial remodeling: an underestimated player in arterial pathology. *Arterioscler Thromb Vasc Biol* 31: 2391-2396, 2011.
595. **Bennett MR, Macdonald K, Chan SW, Boyle JJ, and Weissberg PL.** Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. *Circ Res* 82: 704-712, 1998.
596. **Misra A, Feng Z, Chandran RR, Kabir I, Rotllan N, Aryal B, Sheikh AQ, Ding L, Qin L, Fernandez-Hernando C, Tellides G, and Greif DM.** Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells. *Nat Commun* 9: 2073, 2018.
597. **Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, Goddard M, and Bennett M.** Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. *Circ Res* 99: 156-164, 2006.
598. **Han L, Zhang Y, Zhang M, Guo L, Wang J, Zeng F, Xu D, Yin Z, Xu Y, Wang D, and Zhou H.** Interleukin-1beta-Induced Senescence Promotes Osteoblastic Transition of Vascular Smooth Muscle Cells. *Kidney Blood Press Res* 45: 314-330, 2020.
599. **Coornaert I, Hofmans S, Devisscher L, Augustyns K, Van Der Veken P, De Meyer GRY, and Martinet W.** Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis. *Expert Opin Drug Discov* 13: 477-488, 2018.
600. **Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, and Bennett MR.** Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. *Circ Res* 102: 1529-1538, 2008.
601. **R A.** *Selected studies on arteriosclerosis.* Springfield, IL: Charles C Thomas, 1950.
602. **Geer JC, Mc GH, Jr., and Strong JP.** The fine structure of human atherosclerotic lesions. *Am J Pathol* 38: 263-287, 1961.
603. **Ross R, and Glomset JA.** Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. *Science* 180: 1332-1339, 1973.
604. **Rong JX, Shapiro M, Trogan E, and Fisher EA.** Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. *Proc Natl Acad Sci U S A* 100: 13531-13536, 2003.
605. **Vengrenyuk Y, Nishi H, Long X, Ouimet M, Savji N, Martinez FO, Cassella CP, Moore KJ, Ramsey SA, Miano JM, and Fisher EA.** Cholesterol loading reprograms the microRNA-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. *Arterioscler Thromb Vasc Biol* 35: 535-546, 2015.
606. **Goncalves I, Oduor L, Matthes F, Rakem N, Meryn J, Skenteris NT, Aspberg A, Orho-Melander M, Nilsson J, Matic L, Edsfeldt A, Sun J, and Bengtsson E.** Osteomodulin Gene Expression Is Associated With Plaque Calcification, Stability, and Fewer Cardiovascular Events in the CPIP Cohort. *Stroke* 53: e79-e84, 2022.

607. **Holm Nielsen S, Edsfeldt A, Tengryd C, Gustafsson H, Shore AC, Natali A, Khan F, Genovese F, Bengtsson E, Karsdal M, Leeming DJ, Nilsson J, and Goncalves I.** The novel collagen matrikine, endotrophin, is associated with mortality and cardiovascular events in patients with atherosclerosis. *J Intern Med* 290: 179-189, 2021.
608. **Tengryd C, Nielsen SH, Cavalera M, Bengtsson E, Genovese F, Karsdal M, Duner P, Orho-Melander M, Nilsson J, Edsfeldt A, and Goncalves I.** The proteoglycan mimecan is associated with carotid plaque vulnerability and increased risk of future cardiovascular death. *Atherosclerosis* 313: 88-95, 2020.
609. **Langley SR, Willeit K, Didangelos A, Matic LP, Skroblin P, Barallobre-Barreiro J, Lengquist M, Rungger G, Kapustin A, Kedenko L, Molenaar C, Lu R, Barwari T, Suna G, Yin X, Iglseder B, Paulweber B, Willeit P, Shalhoub J, Pasterkamp G, Davies AH, Monaco C, Hedin U, Shanahan CM, Willeit J, Kiechl S, and Mayr M.** Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques. *J Clin Invest* 127: 1546-1560, 2017.
610. **Sun J, Singh P, Shami A, Kluza E, Pan M, Djordjevic D, Michaelsen NB, Kennback C, van der Wel NN, Orho-Melander M, Nilsson J, Formentini I, Conde-Knape K, Lutgens E, Edsfeldt A, and Goncalves I.** Spatial Transcriptional Mapping Reveals Site-Specific Pathways Underlying Human Atherosclerotic Plaque Rupture. *J Am Coll Cardiol* 81: 2213-2227, 2023.
611. **Johnson JL.** Metalloproteinases in atherosclerosis. *Eur J Pharmacol* 816: 93-106, 2017.
612. **Allahverdian S, Chaabane C, Boukais K, Francis GA, and Bochaton-Piallat ML.** Smooth muscle cell fate and plasticity in atherosclerosis. *Cardiovasc Res* 114: 540-550, 2018.
613. **Orr AW, Hastings NE, Blackman BR, and Wamhoff BR.** Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. *J Vasc Res* 47: 168-180, 2010.
614. **Kapustin AN, Chatrou ML, Drozdov I, Zheng Y, Davidson SM, Soong D, Furmanik M, Sanchis P, De Rosales RT, Alvarez-Hernandez D, Shroff R, Yin X, Muller K, Skepper JN, Mayr M, Reutelingsperger CP, Chester A, Bertazzo S, Schurgers LJ, and Shanahan CM.** Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. *Circ Res* 116: 1312-1323, 2015.
615. **Schurgers LJ, Akbulut AC, Kaczor DM, Halder M, Koenen RR, and Kramann R.** Initiation and Propagation of Vascular Calcification Is Regulated by a Concert of Platelet- and Smooth Muscle Cell-Derived Extracellular Vesicles. *Front Cardiovasc Med* 5: 36, 2018.
616. **Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, Frutkin A, Dichek D, and Giachelli CM.** Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. *Circ Res* 104: 733-741, 2009.
617. **Naik V, Leaf EM, Hu JH, Yang HY, Nguyen NB, Giachelli CM, and Speer MY.** Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study. *Cardiovasc Res* 94: 545-554, 2012.
618. **Lin ME, Chen TM, Wallingford MC, Nguyen NB, Yamada S, Sawangmake C, Zhang J, Speer MY, and Giachelli CM.** Runx2 deletion in smooth muscle cells inhibits vascular

osteochondrogenesis and calcification but not atherosclerotic lesion formation. *Cardiovasc Res* 112: 606-616, 2016.

619. **Nakashima Y, Wight TN, and Sueishi K.** Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. *Cardiovasc Res* 79: 14-23, 2008.

620. **Jacobsen K, Lund MB, Shim J, Gunnarsen S, Fuchtbauer EM, Kjolby M, Carramolino L, and Bentzon JF.** Diverse cellular architecture of atherosclerotic plaque derives from clonal expansion of a few medial SMCs. *JCI Insight* 2: 2017.

621. **Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ, and Owens GK.** KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. *Nat Med* 21: 628-637, 2015.

622. **Grootaert MOJ, and Bennett MR.** Vascular smooth muscle cells in atherosclerosis: time for a re-assessment. *Cardiovasc Res* 117: 2326-2339, 2021.

623. **Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, and Srivastava D.** miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. *Nature* 460: 705-710, 2009.

624. **Cao D, Wang Z, Zhang CL, Oh J, Xing W, Li S, Richardson JA, Wang DZ, and Olson EN.** Modulation of smooth muscle gene expression by association of histone acetyltransferases and deacetylases with myocardin. *Mol Cell Biol* 25: 364-376, 2005.

625. **Natarajan R.** Drugs targeting epigenetic histone acetylation in vascular smooth muscle cells for restenosis and atherosclerosis. *Arterioscler Thromb Vasc Biol* 31: 725-727, 2011.

626. **Gomez D, Shankman LS, Nguyen AT, and Owens GK.** Detection of histone modifications at specific gene loci in single cells in histological sections. *Nat Methods* 10: 171-177, 2013.

627. **Espinosa-Diez C, Mandi V, Du M, Liu M, and Gomez D.** Smooth muscle cells in atherosclerosis: clones but not carbon copies. *JVS Vasc Sci* 2: 136-148, 2021.

628. **Wirka RC, Wagh D, Paik DT, Pjanic M, Nguyen T, Miller CL, Kundu R, Nagao M, Collier J, Koyano TK, Fong R, Woo YJ, Liu B, Montgomery SB, Wu JC, Zhu K, Chang R, Alamprese M, Tallquist MD, Kim JB, and Quertermous T.** Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. *Nat Med* 25: 1280-1289, 2019.

629. **Pan H, Xue C, Auerbach BJ, Fan J, Bashore AC, Cui J, Yang DY, Trignano SB, Liu W, Shi J, Ihuegbu CO, Bush EC, Worley J, Vlahos L, Laise P, Solomon RA, Connolly ES, Califano A, Sims PA, Zhang H, Li M, and Reilly MP.** Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human. *Circulation* 142: 2060-2075, 2020.

630. **Durham AL, Speer MY, Scatena M, Giachelli CM, and Shanahan CM.** Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. *Cardiovasc Res* 114: 590-600, 2018.

631. **Kim JB, Zhao Q, Nguyen T, Pjanic M, Cheng P, Wirka R, Travisano S, Nagao M, Kundu R, and Quertermous T.** Environment-Sensing Aryl Hydrocarbon Receptor Inhibits

the Chondrogenic Fate of Modulated Smooth Muscle Cells in Atherosclerotic Lesions. *Circulation* 142: 575-590, 2020.

632. **Woo SH, Kyung D, Lee SH, Park KS, Kim M, Kim K, Kwon HJ, Won YS, Choi I, Park YJ, Go DM, Oh JS, Yoon WK, Paik SS, Kim JH, Kim YH, Choi JH, and Kim DY.** TXNIP Suppresses the Osteochondrogenic Switch of Vascular Smooth Muscle Cells in Atherosclerosis. *Circ Res* 132: 52-71, 2023.

633. **Reutelingsperger C, and Schurgers L.** Coronary Artery Calcification: A Janus-Faced Biomarker? *JACC Cardiovasc Imaging* 11: 1324-1326, 2018.

634. **Patel JJ, Bourne LE, Davies BK, Arnett TR, MacRae VE, Wheeler-Jones CP, and Orriss IR.** Differing calcification processes in cultured vascular smooth muscle cells and osteoblasts. *Exp Cell Res* 380: 100-113, 2019.

635. **Wang H, Yan S, Chai H, Riha GM, Li M, Yao Q, and Chen C.** Shear stress induces endothelial transdifferentiation from mouse smooth muscle cells. *Biochem Biophys Res Commun* 346: 860-865, 2006.

636. **Hong X, Margariti A, Le Bras A, Jacquet L, Kong W, Hu Y, and Xu Q.** Transdifferentiated Human Vascular Smooth Muscle Cells are a New Potential Cell Source for Endothelial Regeneration. *Sci Rep* 7: 5590, 2017.

637. **Michel JB, Virmani R, Arbustini E, and Pasterkamp G.** Intraplaque haemorrhages as the trigger of plaque vulnerability. *Eur Heart J* 32: 1977-1985, 1985a, 1985b, 1985c, 2011.

638. **Mietus-Snyder M, Gowri MS, and Pitas RE.** Class A scavenger receptor up-regulation in smooth muscle cells by oxidized low density lipoprotein. Enhancement by calcium flux and concurrent cyclooxygenase-2 up-regulation. *J Biol Chem* 275: 17661-17670, 2000.

639. **Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Costales P, and Badimon L.** Cholesteryl esters of aggregated LDL are internalized by selective uptake in human vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 26: 117-123, 2006.

640. **Allahverdian S, Chehroudi AC, McManus BM, Abraham T, and Francis GA.** Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. *Circulation* 129: 1551-1559, 2014.

641. **Maguire EM, Pearce SWA, and Xiao Q.** Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease. *Vascul Pharmacol* 112: 54-71, 2019.

642. **Klouche M, Rose-John S, Schmiedt W, and Bhakdi S.** Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. *Circulation* 101: 1799-1805, 2000.

643. **Davies JD, Carpenter KL, Challis IR, Figg NL, McNair R, Proudfoot D, Weissberg PL, and Shanahan CM.** Adipocytic differentiation and liver x receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells. *J Biol Chem* 280: 3911-3919, 2005.

644. **Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, and Touyz RM.** Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. *Hypertension* 58: 479-488, 2011.

645. **Investigators S, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R,**

Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, Lopez-Sendon J, Manolis AJ, Mohler ER, 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, and Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med* 370: 1702-1711, 2014.

646. **Bjelakovic G, Nikolova D, and Gluud C.** Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? *PLoS One* 8: e74558, 2013.

647. **Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA, and Aggressive Reduction of Inflammation Stops Events Trial I.** Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. *Lancet* 371: 1761-1768, 2008.

648. **O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA, and Investigators L-T.** Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. *JAMA* 315: 1591-1599, 2016.

649. **Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Gregoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, and L'Allier PL.** Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. *J Am Coll Cardiol* 61: 2048-2055, 2013.

650. **Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ, and Edwards CJ.** The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. *Rheumatology (Oxford)* 49: 295-307, 2010.

651. **Cronstein BN, and Aune TM.** Methotrexate and its mechanisms of action in inflammatory arthritis. *Nat Rev Rheumatol* 16: 145-154, 2020.

652. **Pang Z, Wang G, Ran N, Lin H, Wang Z, Guan X, Yuan Y, Fang K, Liu J, and Wang F.** Inhibitory Effect of Methotrexate on Rheumatoid Arthritis Inflammation and Comprehensive Metabolomics Analysis Using Ultra-Performance Liquid Chromatography-Quadrupole Time of Flight-Mass Spectrometry (UPLC-Q/TOF-MS). *Int J Mol Sci* 19: 2018.

653. **Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ, and Investigators C.** Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. *N Engl J Med* 380: 752-762, 2019.

654. **Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D,**

Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, and Group CT. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* 377: 1119-1131, 2017.

655. **Hassan M.** FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors. *Glob Cardiol Sci Pract* 2017: 13, 2017.

656. **Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, and Group CT.** Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* 391: 319-328, 2018.

657. **Dalbeth N, Merriman TR, and Stamp LK.** Gout. *Lancet* 388: 2039-2052, 2016.

658. **Nidorf SM, Eikelboom JW, Budgeon CA, and Thompson PL.** Low-dose colchicine for secondary prevention of cardiovascular disease. *J Am Coll Cardiol* 61: 404-410, 2013.

659. **Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL, and LoDoCo2 Trial I.** Colchicine in Patients with Chronic Coronary Disease. *N Engl J Med* 383: 1838-1847, 2020.

660. **Budgeon CA, Nidorf S, Mosterd A, Fiolet A, Eikelboom J, O'Halloran S, Joyce D, Schut A, Tijssen J, Cornel JH, Murray K, and Thompson P.** Exploration of the regional effects of colchicine in the LoDoCo2 trial. *Am Heart J* 278: 186-194, 2024.

661. **Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, and Roubille F.** Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med* 381: 2497-2505, 2019.

662. **Vaidya K, Arnott C, Martinez GJ, Ng B, McCormack S, Sullivan DR, Celermajer DS, and Patel S.** Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. *JACC Cardiovasc Imaging* 11: 305-316, 2018.

663. **Jolly SS, d'Entremont MA, Lee SF, Mian R, Tyrwhitt J, Kedev S, Montalescot G, Cornel JH, Stankovic G, Moreno R, Storey RF, Henry TD, Mehta SR, Bossard M, Kala P, Layland J, Zafirovska B, Devereaux PJ, Eikelboom J, Cairns JA, Shah B, Sheth T, Sharma SK, Tarhuni W, Conen D, Tawadros S, Lavi S, Yusuf S, and Investigators C.** Colchicine in Acute Myocardial Infarction. *N Engl J Med* 2024.

664. **Broch K, Anstensrud AK, Woxholt S, Sharma K, Tollefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damas JK, Berg ES, Bjorkelund E, Bendz C, Hopp E, Kleveland O, Stensaeth KH, Opdahl A, Klow NE, Seljeflot I, Andersen GO, Wiseth R, Aukrust P, and Gullestad L.** Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol* 77: 1845-1855, 2021.

665. **Tsiantoulas D, Diehl CJ, Witztum JL, and Binder CJ.** B cells and humoral immunity in atherosclerosis. *Circ Res* 114: 1743-1756, 2014.

666. **Goncalves I, Gronholdt ML, Soderberg I, Ares MP, Nordestgaard BG, Bentzon JF, Fredrikson GN, and Nilsson J.** Humoral immune response against defined oxidized low-

- density lipoprotein antigens reflects structure and disease activity of carotid plaques. *Arterioscler Thromb Vasc Biol* 25: 1250-1255, 2005.
667. **Nilsson J, and Shah PK.** Promoting athero-protective immunity by vaccination with low density lipoprotein-derived antigens. *Atherosclerosis* 335: 89-97, 2021.
668. **Gistera A, Hermansson A, Strodthoff D, Klement ML, Hedin U, Fredrikson GN, Nilsson J, Hansson GK, and Ketelhuth DF.** Vaccination against T-cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis. *J Intern Med* 281: 383-397, 2017.
669. **Fredrikson GN, Andersson L, Soderberg I, Dimayuga P, Chyu KY, Shah PK, and Nilsson J.** Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. *Autoimmunity* 38: 171-179, 2005.
670. **Farina CJ, Davidson MH, Shah PK, Stark C, Lu W, Shirodaria C, Wright T, Antoniades CA, Nilsson J, and Mehta NN.** Inhibition of oxidized low-density lipoprotein with orlicumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. *Cardiovasc Res* 120: 678-680, 2024.
671. **Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guerin C, Vilar J, Caligiuri G, Tsiantoulas D, Laurans L, Dumeau E, Kotti S, Bruneval P, Charo IF, Binder CJ, Danchin N, Tedgui A, Tedder TF, Silvestre JS, and Mallat Z.** B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. *Nat Med* 19: 1273-1280, 2013.
672. **Zhao TX, Aetesam-Ur-Rahman M, Sage AP, Victor S, Kurian R, Fielding S, Ait-Oufella H, Chiu YD, Binder CJ, McKie M, Hoole SP, and Mallat Z.** Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study. *Cardiovasc Res* 118: 872-882, 2022.
673. **Sharma M, Schlegel MP, Afonso MS, Brown EJ, Rahman K, Weinstock A, Sansbury BE, Corr EM, van Solingen C, Koelwyn GJ, Shanley LC, Beckett L, Peled D, Lafaille JJ, Spite M, Loke P, Fisher EA, and Moore KJ.** Regulatory T Cells License Macrophage Pro-Resolving Functions During Atherosclerosis Regression. *Circ Res* 127: 335-353, 2020.
674. **Dobaczewski M, Xia Y, Bujak M, Gonzalez-Quesada C, and Frangogiannis NG.** CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. *Am J Pathol* 176: 2177-2187, 2010.
675. **Yu X, Newland SA, Zhao TX, Lu Y, Sage AS, Sun Y, Sriranjana RS, Ma MKL, Lam BYH, Nus M, Harrison JE, Bond SJ, Cheng X, Silvestre JS, Rudd JHF, Cheriyan J, and Mallat Z.** Innate Lymphoid Cells Promote Recovery of Ventricular Function After Myocardial Infarction. *J Am Coll Cardiol* 78: 1127-1142, 2021.
676. **Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G, Kerkau T, and Frantz S.** Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. *Circulation* 125: 1652-1663, 2012.
677. **Klatzmann D, and Abbas AK.** The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. *Nat Rev Immunol* 15: 283-294, 2015.

678. **Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, and Farrar MA.** IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. *J Immunol* 181: 3285-3290, 2008.
679. **Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, and Ritz J.** Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. *Sci Transl Med* 5: 179ra143, 2013.
680. **He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Zhang X, Su Y, Guo J, Shen N, Morand EF, Yu D, and Li Z.** Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. *Nat Med* 22: 991-993, 2016.
681. **Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, and Soiffer RJ.** Interleukin-2 and regulatory T cells in graft-versus-host disease. *N Engl J Med* 365: 2055-2066, 2011.
682. **Rosenzweig M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, C RI, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Dagueneil-Nguyen A, Doppler V, Mariau J, Vicaut E, and Klatzmann D.** Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. *Ann Rheum Dis* 78: 209-217, 2019.
683. **Zhao TX, Kostapanos M, Griffiths C, Arbon EL, Hubsch A, Kaloyirou F, Helmy J, Hoole SP, Rudd JHF, Wood G, Burling K, Bond S, Cheriyan J, and Mallat Z.** Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial. *BMJ Open* 8: e022452, 2018.
684. **Inaba A, Tuong ZK, Zhao TX, Stewart AP, Mathews R, Truman L, Sriranjana R, Kennet J, Saeb-Parsy K, Wicker L, Waldron-Lynch F, Cheriyan J, Todd JA, Mallat Z, and Clatworthy MR.** Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells. *Nat Commun* 14: 2071, 2023.
685. **Sriranjana R, Zhao TX, Tarkin J, Hubsch A, Helmy J, Vamvaka E, Jalaludeen N, Bond S, Hoole SP, Knott P, Buckenham S, Warnes V, Bird N, Cheow H, Templin H, Cacciottolo P, Rudd JHF, Mallat Z, and Cheriyan J.** Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial. *BMJ Open* 12: e062602, 2022.
686. **Lutgens E, Joffre J, van Os B, and Ait-Oufella H.** Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies. *Atherosclerosis* 335: 98-109, 2021.
687. **Udalova I, Monaco C, Nanchahal J, and Feldmann M.** Anti-TNF Therapy. *Microbiol Spectr* 4: 2016.
688. **Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, and Geborek P.** Treatment with tumor necrosis factor blockers is associated with a lower

incidence of first cardiovascular events in patients with rheumatoid arthritis. *J Rheumatol* 32: 1213-1218, 2005.

689. **Ljung L, Rantapaa-Dahlqvist S, Jacobsson LT, and Askling J.** Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. *Ann Rheum Dis* 75: 2087-2094, 2016.

690. **Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH, and Investigators C.** Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. *Ann Rheum Dis* 70: 576-582, 2011.

691. **Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G, and Ca Rsg.** Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs. *Arterioscler Thromb Vasc Biol* 31: 705-712, 2011.

692. **Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, and Fleming T.** Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 109: 1594-1602, 2004.

693. **Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, and Anti TNFTACHFI.** Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 107: 3133-3140, 2003.

694. **Ozen G, Pedro S, and Michaud K.** The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. *J Rheumatol* 48: 648-655, 2021.

695. **Hsieh MJ, Lee CH, Tsai ML, Kao CF, Lan WC, Huang YT, Tseng WY, Wen MS, and Chang SH.** Biologic Agents Reduce Cardiovascular Events in Rheumatoid Arthritis Not Responsive to Tumour Necrosis Factor Inhibitors: A National Cohort Study. *Can J Cardiol* 36: 1739-1746, 2020.

696. **Kang EH, Jin Y, Brill G, Lewey J, Patorno E, Desai RJ, and Kim SC.** Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. *J Am Heart Assoc* 7: 2018.

697. **Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, and Schneeweiss S.** No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. *Semin Arthritis Rheum* 48: 399-405, 2018.

698. **Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, Redeker A, Kuiper J, Toes RE, Arens R, Jukema JW, and Quax PH.** T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. *Int J Cardiol* 168: 1965-1974, 2013.

699. **Martini E, Cremonesi M, Panico C, Carullo P, Bonfiglio CA, Serio S, Jachetti E, Colombo MP, Condorelli G, and Kallikourdis M.** T Cell Costimulation Blockade Blunts Age-Related Heart Failure. *Circ Res* 127: 1115-1117, 2020.
700. **Lee TS, Yen HC, Pan CC, and Chau LY.** The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. *Arterioscler Thromb Vasc Biol* 19: 734-742, 1999.
701. **Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, and Valdes JM.** A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. *J Invest Dermatol* 132: 304-314, 2012.
702. **Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, Li S, Hsu MC, and Griffiths CE.** Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. *Br J Dermatol* 164: 862-872, 2011.
703. **Garcia-Martinez P, Collado-Diaz V, Mateu-Puchades A, Villarroya-Vicente C, Rovira-Llopis S, Blas-Garcia A, Alvarez A, Esplugues JV, and Andujar I.** Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis. *J Invest Dermatol* 140: 2294-2298 e2296, 2020.
704. **von Stebut E, Boehncke WH, Ghoreschi K, Gori T, Kaya Z, Thaci D, and Schaffler A.** IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. *Front Immunol* 10: 3096, 2019.
705. **Makavos G, Ikonomidis I, Andreadou I, Varoudi M, Kapniari I, Loukeri E, Theodoropoulos K, Pavlidis G, Triantafyllidi H, Thymis J, Parissis J, Tsoumani M, Rafouli-Stergiou P, Katsimbri P, and Papadavid E.** Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis. *Can J Cardiol* 36: 100-111, 2020.
706. **Sieper J, Braun J, Dougados M, and Baeten D.** Axial spondyloarthritis. *Nat Rev Dis Primers* 1: 15013, 2015.
707. **Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, Ciardiello F, Pane F, Au L, Emmerich M, Plummer C, Gulati G, Ramalingam S, Cardinale D, Brezden-Masley C, Iakobishvili Z, Thavendiranathan P, Santoro C, Bergler-Klein J, Keramida K, de Boer RA, Maack C, Lutgens E, Rassaf T, Fradley MG, Moslehi J, Yang EH, De Keulenaer G, Ameri P, Bax J, Neilan TG, Herrmann J, Mbakwem AC, Mirabel M, Skouri H, Hirsch E, Cohen-Solal A, Sverdlov AL, van der Meer P, Asteggiano R, Barac A, Ky B, Lenihan D, Dent S, Seferovic P, Coats AJS, Metra M, Rosano G, Suter T, Lopez-Fernandez T, and Lyon AR.** Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. *Eur J Heart Fail* 26: 2055-2076, 2024.
708. **Solinas C, Saba L, Sganzerla P, and Petrelli F.** Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. *Thromb Res* 196: 444-453, 2020.
709. **Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, and Neilan TG.** Association Between

Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. *Circulation* 142: 2299-2311, 2020.

710. **Roopkumar J, Swaidani S, Kim AS, Thapa B, Gervaso L, Hobbs BP, Wei W, Alban TJ, Funchain P, Kundu S, Sangwan N, Rayman P, Pavicic PG, Jr., Diaz-Montero CM, Barnard J, McCrae KR, and Khorana AA.** Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. *Med* 2: 423-434, 2021.

711. **Sheng IY, Gupta S, Reddy CA, Angelini D, Funchain P, Sussman TA, Sleiman J, Ornstein MC, McCrae K, and Khorana AA.** Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors. *Target Oncol* 17: 563-569, 2022.

712. **Josan K, and Neilan TG.** Immune checkpoint inhibitors: acute and chronic cardiovascular complications. *Nat Rev Cardiol* 20: 73-74, 2023.

713. **Poels K, Neppelenbroek SIM, Kersten MJ, Antoni ML, Lutgens E, and Seijkens TTP.** Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. *J Immunother Cancer* 9: 2021.

714. **Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL, Wang M, Sanson M, Abramowicz S, Welch C, Boehm AE, Kuivenhoven JA, Yvan-Charvet L, and Tall AR.** ApoE regulates hematopoietic stem cell proliferation, monocytois, and monocyte accumulation in atherosclerotic lesions in mice. *J Clin Invest* 121: 4138-4149, 2011.

715. **Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, and Tall AR.** ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. *Science* 328: 1689-1693, 2010.

716. **Robbins CS, Chudnovskiy A, Rauch PJ, Figueiredo JL, Iwamoto Y, Gorbатов R, Etzrodt M, Weber GF, Ueno T, van Rooijen N, Mulligan-Kehoe MJ, Libby P, Nahrendorf M, Pittet MJ, Weissleder R, and Swirski FK.** Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. *Circulation* 125: 364-374, 2012.

717. **Hilgendorf I, and Swirski FK.** Making a difference: monocyte heterogeneity in cardiovascular disease. *Curr Atheroscler Rep* 14: 450-459, 2012.

718. **Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, and Pittet MJ.** Identification of splenic reservoir monocytes and their deployment to inflammatory sites. *Science* 325: 612-616, 2009.

719. **Dutta P, Courties G, Wei Y, Leuschner F, Gorbатов R, Robbins CS, Iwamoto Y, Thompson B, Carlson AL, Heidt T, Majmudar MD, Lasitschka F, Etzrodt M, Waterman P, Waring MT, Chicoine AT, van der Laan AM, Niessen HW, Piek JJ, Rubin BB, Butany J, Stone JR, Katus HA, Murphy SA, Morrow DA, Sabatine MS, Vinegoni C, Moskowitz MA, Pittet MJ, Libby P, Lin CP, Swirski FK, Weissleder R, and Nahrendorf M.** Myocardial infarction accelerates atherosclerosis. *Nature* 487: 325-329, 2012.

720. **Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, Fayad ZA, Lehrer-Graiwer J, Korsgren M, Figueroa AL, Fredrickson J, Rubin B, Hoffmann U, Truong QA, Min JK, Baruch A, Nasir K, Nahrendorf M, and Tawakol A.** Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. *JACC Cardiovasc Imaging* 8: 121-130, 2015.

721. **Osborne MT, Shin LM, Mehta NN, Pitman RK, Fayad ZA, and Tawakol A.** Disentangling the Links Between Psychosocial Stress and Cardiovascular Disease. *Circ Cardiovasc Imaging* 13: e010931, 2020.
722. **Step toe A, and Kivimaki M.** Stress and cardiovascular disease: an update on current knowledge. *Annu Rev Public Health* 34: 337-354, 2013.
723. **Nahrendorf M, and Swirski FK.** Lifestyle effects on hematopoiesis and atherosclerosis. *Circ Res* 116: 884-894, 2015.
724. **Ahmadi N, Hajsadeghi F, Mirshkarlo HB, Budoff M, Yehuda R, and Ebrahimi R.** Post-traumatic stress disorder, coronary atherosclerosis, and mortality. *Am J Cardiol* 108: 29-33, 2011.
725. **Burg MM, Brandt C, Buta E, Schwartz J, Bathulapalli H, Dziura J, Edmondson DE, and Haskell S.** Risk for Incident Hypertension Associated With Posttraumatic Stress Disorder in Military Veterans and the Effect of Posttraumatic Stress Disorder Treatment. *Psychosom Med* 79: 181-188, 2017.
726. **Brudey C, Park J, Wiaderkiewicz J, Kobayashi I, Mellman TA, and Marvar PJ.** Autonomic and inflammatory consequences of posttraumatic stress disorder and the link to cardiovascular disease. *Am J Physiol Regul Integr Comp Physiol* 309: R315-321, 2015.
727. **Tawakol A, Ishai A, Takx RA, Figueroa AL, Ali A, Kaiser Y, Truong QA, Solomon CJ, Calcagno C, Mani V, Tang CY, Mulder WJ, Murrrough JW, Hoffmann U, Nahrendorf M, Shin LM, Fayad ZA, and Pitman RK.** Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. *Lancet* 389: 834-845, 2017.
728. **Heidt T, Sager HB, Courties G, Dutta P, Iwamoto Y, Zaltsman A, von Zur Muhlen C, Bode C, Fricchione GL, Denninger J, Lin CP, Vinegoni C, Libby P, Swirski FK, Weissleder R, and Nahrendorf M.** Chronic variable stress activates hematopoietic stem cells. *Nat Med* 20: 754-758, 2014.
729. **Barrett TJ, Corr EM, van Solingen C, Schlamp F, Brown EJ, Koelwyn GJ, Lee AH, Shanley LC, Spruill TM, Bozal F, de Jong A, Newman AAC, Drenkova K, Silvestro M, Ramkhelawon B, Reynolds HR, Hochman JS, Nahrendorf M, Swirski FK, Fisher EA, Berger JS, and Moore KJ.** Chronic stress primes innate immune responses in mice and humans. *Cell Rep* 36: 109595, 2021.
730. **Poller WC, Downey J, Mooslechner AA, Khan N, Li L, Chan CT, McAlpine CS, Xu C, Kahles F, He S, Janssen H, Mindur JE, Singh S, Kiss MG, Alonso-Herranz L, Iwamoto Y, Kohler RH, Wong LP, Chetal K, Russo SJ, Sadreyev RI, Weissleder R, Nahrendorf M, Frenette PS, Divangahi M, and Swirski FK.** Brain motor and fear circuits regulate leukocytes during acute stress. *Nature* 607: 578-584, 2022.
731. **Schloss MJ, Swirski FK, and Nahrendorf M.** Modifiable Cardiovascular Risk, Hematopoiesis, and Innate Immunity. *Circ Res* 126: 1242-1259, 2020.
732. **Jordan S, Tung N, Casanova-Acebes M, Chang C, Cantoni C, Zhang D, Wirtz TH, Naik S, Rose SA, Broucker CN, Gainullina A, Hornburg D, Horng S, Maier BB, Cravedi P, LeRoith D, Gonzalez FJ, Meissner F, Ochando J, Rahman A, Chipuk JE, Artyomov MN, Frenette PS, Piccio L, Berres ML, Gallagher EJ, and Merad M.** Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool. *Cell* 178: 1102-1114 e1117, 2019.
733. **Janssen H, Kahles F, Liu D, Downey J, Koekkoek LL, Roudko V, D'Souza D, McAlpine CS, Halle L, Poller WC, Chan CT, He S, Mindur JE, Kiss MG, Singh S, Anzai A,**

- Iwamoto Y, Kohler RH, Chetal K, Sadreyev RI, Weissleder R, Kim-Schulze S, Merad M, Nahrendorf M, and Swirski FK. Monocytes re-enter the bone marrow during fasting and alter the host response to infection. *Immunity* 56: 783-796 e787, 2023.
734. Collins N, Han SJ, Enamorado M, Link VM, Huang B, Moseman EA, Kishton RJ, Shannon JP, Dixit D, Schwab SR, Hickman HD, Restifo NP, McGavern DB, Schwartzberg PL, and Belkaid Y. The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction. *Cell* 178: 1088-1101 e1015, 2019.
735. Nagai M, Noguchi R, Takahashi D, Morikawa T, Koshida K, Komiyama S, Ishihara N, Yamada T, Kawamura YI, Muroi K, Hattori K, Kobayashi N, Fujimura Y, Hirota M, Matsumoto R, Aoki R, Tamura-Nakano M, Sugiyama M, Katakai T, Sato S, Takubo K, Dohi T, and Hase K. Fasting-Refeeding Impacts Immune Cell Dynamics and Mucosal Immune Responses. *Cell* 178: 1072-1087 e1014, 2019.
736. Chen Y, Su J, Yan Y, Zhao Q, Ma J, Zhu M, He X, Zhang B, Xu H, Yang X, Duan Y, and Han J. Intermittent Fasting Inhibits High-Fat Diet-Induced Atherosclerosis by Ameliorating Hypercholesterolemia and Reducing Monocyte Chemoattraction. *Front Pharmacol* 12: 719750, 2021.
737. Hearps AC, Martin GE, Angelovich TA, Cheng WJ, Maisa A, Landay AL, Jaworowski A, and Crowe SM. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. *Aging Cell* 11: 867-875, 2012.
738. Ponnappan S, and Ponnappan U. Aging and immune function: molecular mechanisms to interventions. *Antioxid Redox Signal* 14: 1551-1585, 2011.
739. Ahuja SK, Manoharan MS, Lee GC, McKinnon LR, Meunier JA, Steri M, Harper N, Fiorillo E, Smith AM, Restrepo MI, Branum AP, Bottomley MJ, Orru V, Jimenez F, Carrillo A, Pandranki L, Winter CA, Winter LA, Gaitan AA, Moreira AG, Walter EA, Silvestri G, King CL, Zheng YT, Zheng HY, Kimani J, Blake Ball T, Plummer FA, Fowke KR, Harden PN, Wood KJ, Ferris MT, Lund JM, Heise MT, Garrett N, Canady KR, Abdool Karim SS, Little SJ, Gianella S, Smith DM, Letendre S, Richman DD, Cucca F, Trinh H, Sanchez-Reilly S, Hecht JM, Cadena Zuluaga JA, Anzueto A, Pugh JA, South Texas Veterans Health Care System C-t, Agan BK, Root-Bernstein R, Clark RA, Okulicz JF, and He W. Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection. *Nat Commun* 14: 3286, 2023.
740. Yousefzadeh MJ, Flores RR, Zhu Y, Schmiechen ZC, Brooks RW, Trussoni CE, Cui Y, Angelini L, Lee KA, McGowan SJ, Burrack AL, Wang D, Dong Q, Lu A, Sano T, O'Kelly RD, McGuckian CA, Kato JI, Bank MP, Wade EA, Pillai SPS, Klug J, Ladiges WC, Burd CE, Lewis SE, LaRusso NF, Vo NV, Wang Y, Kelley EE, Huard J, Stromnes IM, Robbins PD, and Niedernhofer LJ. An aged immune system drives senescence and ageing of solid organs. *Nature* 594: 100-105, 2021.
741. Sayed N, Huang Y, Nguyen K, Krejciowa-Rajaniemi Z, Grawe AP, Gao T, Tibshirani R, Hastie T, Alpert A, Cui L, Kuznetsova T, Rosenberg-Hasson Y, Ostan R, Monti D, Lehallier B, Shen-Orr SS, Maecker HT, Dekker CL, Wyss-Coray T, Franceschi C, Jojic V, Haddad F, Montoya JG, Wu JC, Davis MM, and Furman D. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. *Nat Aging* 1: 598-615, 2021.

742. **Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, and Miyata M.** Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. *Proc Natl Acad Sci U S A* 92: 8264-8268, 1995.
743. **van der Wal AC, Das PK, Tigges AJ, and Becker AE.** Macrophage differentiation in atherosclerosis. An in situ immunohistochemical analysis in humans. *Am J Pathol* 141: 161-168, 1992.
744. **Xu QB, Oberhuber G, Gruschwitz M, and Wick G.** Immunology of atherosclerosis: cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. *Clin Immunol Immunopathol* 56: 344-359, 1990.
745. **Zhu SN, Chen M, Jongstra-Bilen J, and Cybulsky MI.** GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. *J Exp Med* 206: 2141-2149, 2009.
746. **Subramanian M, Thorp E, and Tabas I.** Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. *Circ Res* 116: e13-24, 2015.
747. **Lutgens E, Daemen M, Kockx M, Doevendans P, Hofker M, Havekes L, Wellens H, and de Muinck ED.** Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage. *Circulation* 99: 276-283, 1999.
748. **Lutgens E, de Muinck ED, Kitslaar PJ, Tordoir JH, Wellens HJ, and Daemen MJ.** Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. *Cardiovasc Res* 41: 473-479, 1999.
749. **Galis ZS, Sukhova GK, Lark MW, and Libby P.** Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. *J Clin Invest* 94: 2493-2503, 1994.
750. **Galis ZS, Sukhova GK, Kranzhofer R, Clark S, and Libby P.** Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. *Proc Natl Acad Sci U S A* 92: 402-406, 1995.
751. **Wilcox JN, Smith KM, Schwartz SM, and Gordon D.** Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. *Proc Natl Acad Sci U S A* 86: 2839-2843, 1989.
752. **Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, and Libby P.** Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. *Ann N Y Acad Sci* 748: 501-507, 1995.
753. **Edgington TS, Mackman N, Fan ST, and Ruf W.** Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. *Nouv Rev Fr Hematol (1978)* 34 Suppl: S15-27, 1992.
754. **Thomas AC, Sala-Newby GB, Ismail Y, Johnson JL, Pasterkamp G, and Newby AC.** Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-I as a differential regulator of nitric oxide production. *Arterioscler Thromb Vasc Biol* 27: 571-577, 2007.
755. **Johnson JL, Sala-Newby GB, Ismail Y, Aguilera CM, and Newby AC.** Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. *Arterioscler Thromb Vasc Biol* 28: 1647-1653, 2008.

756. **Chase AJ, Bond M, Crook MF, and Newby AC.** Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. *Arterioscler Thromb Vasc Biol* 22: 765-771, 2002.
757. **Newby AC.** Metalloproteinases and vulnerable atherosclerotic plaques. *Trends Cardiovasc Med* 17: 253-258, 2007.
758. **Huang WC, Sala-Newby GB, Susana A, Johnson JL, and Newby AC.** Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-kappaB. *PLoS One* 7: e42507, 2012.
759. **Fearon DT, and Locksley RM.** The instructive role of innate immunity in the acquired immune response. *Science* 272: 50-53, 1996.
760. **Sebbag M, Parry SL, Brennan FM, and Feldmann M.** Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. *Eur J Immunol* 27: 624-632, 1997.
761. **Unutmaz D, Pileri P, and Abrignani S.** Antigen-independent activation of naive and memory resting T cells by a cytokine combination. *J Exp Med* 180: 1159-1164, 1994.
762. **Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, and Feldmann M.** Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. *J Clin Invest* 94: 749-760, 1994.
763. **Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, and Jovinge S.** Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. *Arterioscler Thromb Vasc Biol* 24: 2137-2142, 2004.
764. **Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, and Forrester JS.** Detection and localization of tumor necrosis factor in human atheroma. *Am J Cardiol* 65: 297-302, 1990.
765. **Grebe A, Hoss F, and Latz E.** NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. *Circ Res* 122: 1722-1740, 2018.
766. **Vromman A, Ruvkun V, Shvartz E, Wojtkiewicz G, Santos Masson G, Tesmenitsky Y, Folco E, Gram H, Nahrendorf M, Swirski FK, Sukhova GK, and Libby P.** Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis. *Eur Heart J* 40: 2482-2491, 2019.
767. **Gomez D, Baylis RA, Durgin BG, Newman AAC, Alencar GF, Mahan S, St Hilaire C, Muller W, Waisman A, Francis SE, Pinteaux E, Randolph GJ, Gram H, and Owens GK.** Interleukin-1beta has atheroprotective effects in advanced atherosclerotic lesions of mice. *Nat Med* 24: 1418-1429, 2018.
768. **Burzynski LC, Humphry M, Pyriou K, Wiggins KA, Chan JNE, Figg N, Kitt LL, Summers C, Tatham KC, Martin PB, Bennett MR, and Clarke MCH.** The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1alpha by Thrombin. *Immunity* 50: 1033-1042 e1036, 2019.
769. **Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, and Holt CM.** Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. *Arterioscler Thromb Vasc Biol* 16: 1000-1006, 1996.

770. **Ridker PM.** Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. *Circ Res* 124: 437-450, 2019.
771. **Zhang K, Huang XZ, Li XN, Feng M, Li L, Cai XJ, Zhang C, Liu XL, Zhang MX, Zhang Y, Wang XL, and Zhang M.** Interleukin 6 destabilizes atherosclerotic plaques by downregulating prolyl-4-hydroxylase alpha1 via a mitogen-activated protein kinase and c-Jun pathway. *Arch Biochem Biophys* 528: 127-133, 2012.
772. **Ridker PM, Rifai N, Stampfer MJ, and Hennekens CH.** Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation* 101: 1767-1772, 2000.
773. **Collaboration IRGCERF, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjaerg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Witteman JC, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundstrom J, Wassertheil-Smoller S, Mellstrom D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith G, de Bakker PI, O'Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten A, Ljunggren O, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Holm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, and Danesh J.** Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet* 379: 1205-1213, 2012.
774. **Interleukin-6 Receptor Mendelian Randomisation Analysis C, Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, Mooijaart SP, Ireland HA, Leusink M, Langenberg C, Li KW, Palmén J, Howard P, Cooper JA, Drenos F, Hardy J, Nalls MA, Li YR, Lowe G, Stewart M, Bielinski SJ, Peto J, Timpson NJ, Gallacher J, Dunlop M, Houlston R, Tomlinson I, Tzoulaki I, Luan J, Boer JM, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Ferrucci L, Bandenelli S, Tanaka T, Meschia JF, Singleton A, Navis G, Mateo Leach I, Bakker SJ, Gansevoort RT, Ford I, Epstein SE, Burnett MS, Devaney JM, Jukema JW, Westendorp RG, Jan de Borst G, van der Graaf Y, de Jong PA, Mailand-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Stephens JW, Eaton CB, Robinson JG, Manson JE, Fowkes FG, Frayling TM, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Redline S, Lange LA, Kumari M, Wareham NJ, Verschuren WM, Benjamin EJ, Whittaker JC, Hamsten A, Dudbridge F, Delaney JA, Wong A, Kuh D, Hardy R, Castillo BA, Connolly JJ, van der Harst P, Brunner EJ, Marmot MG, Wassel CL, Humphries SE, Talmud PJ, Kivimaki M, Asselbergs FW, Voevodova M, Bobak M, Pikhart H, Wilson JG, Hakonarson H, Reiner AP, Keating BJ, Sattar N, Hingorani AD, and Casas JP.** The interleukin-6 receptor as a target for

prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* 379: 1214-1224, 2012.

775. **Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, and Martinet W.** Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. *Arterioscler Thromb Vasc Biol* 25: 1256-1261, 2005.

776. **Yao PM, and Tabas I.** Free cholesterol loading of macrophages induces apoptosis involving the fas pathway. *J Biol Chem* 275: 23807-23813, 2000.

777. **Thorp E, Li G, Seimon TA, Kuriakose G, Ron D, and Tabas I.** Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe^{-/-} and Ldlr^{-/-} mice lacking CHOP. *Cell Metab* 9: 474-481, 2009.

778. **Sun H, Unoki H, Wang X, Liang J, Ichikawa T, Arai Y, Shiomi M, Marcovina SM, Watanabe T, and Fan J.** Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). *J Biol Chem* 277: 47486-47492, 2002.

779. **Goossens P, Gijbels MJ, Zerneck A, Eijgelaar W, Vergouwe MN, van der Made I, Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Kalinke U, Weber C, Lutgens E, and de Winther MP.** Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. *Cell Metab* 12: 142-153, 2010.

780. **Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, and Tabas I.** Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. *Cell Metab* 12: 467-482, 2010.

781. **Tabas I.** Macrophage death and defective inflammation resolution in atherosclerosis. *Nat Rev Immunol* 10: 36-46, 2010.

782. **Cai B, Thorp EB, Doran AC, Sansbury BE, Daemen MJ, Dorweiler B, Spite M, Fredman G, and Tabas I.** MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. *J Clin Invest* 127: 564-568, 2017.

783. **Thorp E, Cui D, Schrijvers DM, Kuriakose G, and Tabas I.** MERTK receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe^{-/-} mice. *Arterioscler Thromb Vasc Biol* 28: 1421-1428, 2008.

784. **Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancero H, Raaz U, Perisic L, Hedin U, Schadt E, Maegdefessel L, Quertermous T, and Leeper NJ.** Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. *J Clin Invest* 124: 1083-1097, 2014.

785. **Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusic AJ, Miller CL, Drenzo D, Nanda V, Ye J, Connolly AJ, Schadt EE, Quertermous T, Betancur P, Maegdefessel L, Matic LP, Hedin U, Weissman IL, and Leeper NJ.** CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. *Nature* 536: 86-90, 2016.

786. **Ait-Oufella H, Poursmail V, Simon T, Blanc-Brude O, Kinugawa K, Merval R, Offenstadt G, Leseche G, Cohen PL, Tedgui A, and Mallat Z.** Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. *Arterioscler Thromb Vasc Biol* 28: 1429-1431, 2008.

787. **Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, Linton MF, and Fazio S.** Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. *Arterioscler Thromb Vasc Biol* 30: 787-795, 2010.
788. **Jarr KU, Nakamoto R, Doan BH, Kojima Y, Weissman IL, Advani RH, Iagaru A, and Leeper NJ.** Effect of CD47 Blockade on Vascular Inflammation. *N Engl J Med* 384: 382-383, 2021.
789. **Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, and Smith SM.** CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. *N Engl J Med* 379: 1711-1721, 2018.
790. **Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, Minden MD, Villa D, Percival MM, Advani AS, Foran JM, Horwitz SM, Mei MG, Zain J, Savage KJ, Querfeld C, Akilov OE, Johnson LDS, Catalano T, Petrova PS, Uger RA, Sievers EL, Milea A, Roberge K, Shou Y, and O'Connor OA.** Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. *Clin Cancer Res* 27: 2190-2199, 2021.
791. **Bleriot C, Chakarov S, and Ginhoux F.** Determinants of Resident Tissue Macrophage Identity and Function. *Immunity* 52: 957-970, 2020.
792. **Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, and Schultze JL.** Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity* 40: 274-288, 2014.
793. **Cole JE, Kassiteridi C, and Monaco C.** Toll-like receptors in atherosclerosis: a 'Pandora's box' of advances and controversies. *Trends Pharmacol Sci* 34: 629-636, 2013.
794. **Hoving JC, Wilson GJ, and Brown GD.** Signalling C-type lectin receptors, microbial recognition and immunity. *Cell Microbiol* 16: 185-194, 2014.
795. **Billadeau DD, and Leibson PJ.** ITAMs versus ITIMs: striking a balance during cell regulation. *J Clin Invest* 109: 161-168, 2002.
796. **Clement M, Basatemur G, Masters L, Baker L, Bruneval P, Iwawaki T, Kneilling M, Yamasaki S, Goodall J, and Mallat Z.** Necrotic Cell Sensor Clec4e Promotes a Proatherogenic Macrophage Phenotype Through Activation of the Unfolded Protein Response. *Circulation* 134: 1039-1051, 2016.
797. **Haddad Y, Lahoute C, Clement M, Laurans L, Metghalchi S, Zeboudj L, Giraud A, Loyer X, Vandestienne M, Wain-Hobson J, Esposito B, Potteaux S, Ait-Oufella H, Tedgui A, Mallat Z, and Taleb S.** The Dendritic Cell Receptor DNGR-1 Promotes the Development of Atherosclerosis in Mice. *Circ Res* 121: 234-243, 2017.
798. **Kanazawa N, Okazaki T, Nishimura H, Tashiro K, Inaba K, and Miyachi Y.** DCIR acts as an inhibitory receptor depending on its immunoreceptor tyrosine-based inhibitory motif. *J Invest Dermatol* 118: 261-266, 2002.
799. **Lorentzen JC, Flornes L, Eklow C, Backdahl L, Ribbhammar U, Guo JP, Smolnikova M, Dissen E, Seddighzadeh M, Brookes AJ, Alfredsson L, Klareskog L,**

- Padyukov L, and Fossum S.** Association of arthritis with a gene complex encoding C-type lectin-like receptors. *Arthritis Rheum* 56: 2620-2632, 2007.
800. **Liu M, Wu X, Liu X, He J, Su Y, Guo J, and Li Z.** Contribution of dendritic cell immunoreceptor (DCIR) polymorphisms in susceptibility of systemic lupus erythematosus and primary Sjogren's syndrome. *Hum Immunol* 76: 808-811, 2015.
801. **Fujikado N, Saijo S, Yonezawa T, Shimamori K, Ishii A, Sugai S, Kotaki H, Sudo K, Nose M, and Iwakura Y.** Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. *Nat Med* 14: 176-180, 2008.
802. **Seno A, Maruhashi T, Kaifu T, Yabe R, Fujikado N, Ma G, Ikarashi T, Kakuta S, and Iwakura Y.** Exacerbation of experimental autoimmune encephalomyelitis in mice deficient for DCIR, an inhibitory C-type lectin receptor. *Exp Anim* 64: 109-119, 2015.
803. **Doring Y, van der Vorst EPC, and Weber C.** Targeting immune cell recruitment in atherosclerosis. *Nat Rev Cardiol* 21: 824-840, 2024.
804. **Boring L, Gosling J, Cleary M, and Charo IF.** Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. *Nature* 394: 894-897, 1998.
805. **Dawson TC, Kuziel WA, Osahar TA, and Maeda N.** Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. *Atherosclerosis* 143: 205-211, 1999.
806. **Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, and Rollins BJ.** Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. *Mol Cell* 2: 275-281, 1998.
807. **Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, and Beaudet AL.** Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. *Arterioscler Thromb Vasc Biol* 17: 1517-1520, 1997.
808. **Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, and Milstone DS.** A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. *J Clin Invest* 107: 1255-1262, 2001.
809. **Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, Mack M, and Charo IF.** Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. *J Clin Invest* 117: 902-909, 2007.
810. **Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M, and Group MLNS.** Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. *Am J Cardiol* 107: 906-911, 2011.
811. **Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, and Mallat Z.** Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. *Circulation* 107: 1009-1016, 2003.
812. **Leuschner F, Rauch PJ, Ueno T, Gorbатов R, Marinelli B, Lee WW, Dutta P, Wei Y, Robbins C, Iwamoto Y, Sena B, Chudnovskiy A, Panizzi P, Keliher E, Higgins JM, Libby P, Moskowitz MA, Pittet MJ, Swirski FK, Weissleder R, and Nahrendorf M.** Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. *J Exp Med* 209: 123-137, 2012.

813. **Abdali A, and Marinkovic G.** Assessment of medullary and extramedullary myelopoiesis in cardiovascular diseases. *Pharmacol Res* 169: 105663, 2021.
814. **Chatterjee N, Komaravolu RK, Durant CP, Wu R, McSkimming C, Drago F, Kumar S, Valentin-Guillama G, Miller YI, McNamara CA, Ley K, Taylor A, Alimadadi A, and Hedrick CC.** Single Cell High Dimensional Analysis of Human Peripheral Blood Mononuclear Cells Reveals Unique Intermediate Monocyte Subsets Associated with Sex Differences in Coronary Artery Disease. *Int J Mol Sci* 25: 2024.
815. **Nilsson J, and Hansson GK.** Vaccination Strategies and Immune Modulation of Atherosclerosis. *Circ Res* 126: 1281-1296, 2020.
816. **Lehrer-Graiwer J, Singh P, Abdelbaky A, Vucic E, Korsgren M, Baruch A, Fredrickson J, van Bruggen N, Tang MT, Frendeus B, Rudd JHF, Hsieh F, Ballantyne CM, Ghoshhajra B, Rosenson RS, Koren M, Roth EM, Duprez DA, Fayad ZA, and Tawakol AA.** FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. *JACC Cardiovasc Imaging* 8: 493-494, 2015.
817. **Marchini T, Malchow S, Caceres L, El Rabih AAH, Hansen S, Mwinyella T, Spiga L, Piepenburg S, Horstmann H, Olawale T, Li X, Mitre LS, Gissler MC, Bugger H, Zirlik A, Heidt T, Hilgendorf I, Stachon P, von Zur Muehlen C, Bode C, and Wolf D.** Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease. *Front Cardiovasc Med* 9: 826729, 2022.
818. **Benne N, van Duijn J, Lozano Vigario F, Lebox RJT, van Veelen P, Kuiper J, Jiskoot W, and Slutter B.** Anionic 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) liposomes induce antigen-specific regulatory T cells and prevent atherosclerosis in mice. *J Control Release* 291: 135-146, 2018.
819. **Yi X, Wang Y, Jia Z, Hiller S, Nakamura J, Luft JC, Tian S, and DeSimone JM.** Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis. *J Biomed Nanotechnol* 16: 467-480, 2020.
820. **Kobiyama K, Vassallo M, Mitzi J, Winkels H, Pei H, Kimura T, Miller J, Wolf D, and Ley K.** A clinically applicable adjuvant for an atherosclerosis vaccine in mice. *Eur J Immunol* 48: 1580-1587, 2018.
821. **Galkina E, Harry BL, Ludwig A, Liehn EA, Sanders JM, Bruce A, Weber C, and Ley K.** CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. *Circulation* 116: 1801-1811, 2007.
822. **van Wanrooij EJ, de Jager SC, van Es T, de Vos P, Birch HL, Owen DA, Watson RJ, Biessen EA, Chapman GA, van Berkel TJ, and Kuiper J.** CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. *Arterioscler Thromb Vasc Biol* 28: 251-257, 2008.
823. **Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, and Gerszten RE.** Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. *Circulation* 113: 2301-2312, 2006.

824. **Nitz K, Lacy M, Bianchini M, Wichapong K, Kucukgoze IA, Bonfiglio CA, Migheli R, Wu Y, Burger C, Li Y, Forne I, Ammar C, Janjic A, Mohanta S, Duchene J, Heemskerk JWM, Megens RTA, Schwedhelm E, Huveneers S, Lygate CA, Santovito D, Zimmer R, Imhof A, Weber C, Lutgens E, and Atzler D.** The Amino Acid Homoarginine Inhibits Atherogenesis by Modulating T-Cell Function. *Circ Res* 131: 701-712, 2022.
825. **Doring Y, van der Vorst EPC, Yan Y, Neideck C, Blanchet X, Jansen Y, Kemmerich M, Bayasgalan S, Peters LJJ, Hristov M, Bidzhekov K, Yin C, Zhang X, Leberzammer J, Li Y, Park I, Kral M, Nitz K, Parma L, Gencer S, Habenicht A, Faussner A, Teupser D, Monaco C, Holdt L, Megens RTA, Atzler D, Santovito D, von Hundelshausen P, and Weber C.** Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis. *Nat Cardiovasc Res* 3: 221-242, 2024.
826. **Hofmann K, Clauder AK, and Manz RA.** Targeting B Cells and Plasma Cells in Autoimmune Diseases. *Front Immunol* 9: 835, 2018.
827. **Ramos-Casals M, Sanz I, Bosch X, Stone JH, and Khamashta MA.** B-cell-depleting therapy in systemic lupus erythematosus. *Am J Med* 125: 327-336, 2012.
828. **Novikova DS, Popkova TV, Lukina GV, Luchikhina EL, Karateev DE, Volkov AV, Novikov AA, Aleksandrova EN, and Nasonov EL.** The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis. *J Korean Med Sci* 31: 202-207, 2016.
829. **Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, and Tedder TF.** The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. *J Immunol* 174: 4389-4399, 2005.
830. **Kerekes G, Soltesz P, Der H, Veres K, Szabo Z, Vegvari A, Szegedi G, Shoenfeld Y, and Szekanecz Z.** Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. *Clin Rheumatol* 28: 705-710, 2009.
831. **Kim DG, Lee J, Seo WJ, Lee JG, Kim BS, Kim MS, Kim SI, Kim YS, and Huh KH.** Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study. *Sci Rep* 9: 16475, 2019.
832. **Morris-Rosenfeld S, Lipinski MJ, and McNamara CA.** Understanding the role of B cells in atherosclerosis: potential clinical implications. *Expert Rev Clin Immunol* 10: 77-89, 2014.
833. **Huda R.** New Approaches to Targeting B Cells for Myasthenia Gravis Therapy. *Front Immunol* 11: 240, 2020.
834. **Lee YH, and Song GG.** Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials. *Lupus* 27: 112-119, 2018.
835. **Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, Murphy D, Loinard C, Binder CJ, and Mallat Z.** BAFF receptor deficiency reduces the development of atherosclerosis in mice--brief report. *Arterioscler Thromb Vasc Biol* 32: 1573-1576, 2012.
836. **Jackson SW, Scharping NE, Jacobs HM, Wang S, Chait A, and Rawlings DJ.** Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation. *J Immunol* 197: 4529-4534, 2016.

837. **Walters S, Webster KE, Sutherland A, Gardam S, Groom J, Liuwantara D, Marino E, Thaxton J, Weinberg A, Mackay F, Brink R, Sprent J, and Grey ST.** Increased CD4⁺Foxp3⁺ T cells in BAFF-transgenic mice suppress T cell effector responses. *J Immunol* 182: 793-801, 2009.
838. **Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD, Jr., Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, and Cohen AD.** Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. *Lancet Oncol* 19: 1641-1653, 2018.
839. **Plummer C, Driessen C, Szabo Z, and Mateos MV.** Management of cardiovascular risk in patients with multiple myeloma. *Blood Cancer J* 9: 26, 2019.
840. **Tay C, Liu YH, Kanellakis P, Kallies A, Li Y, Cao A, Hosseini H, Tipping P, Toh BH, Bobik A, and Kyaw T.** Follicular B Cells Promote Atherosclerosis via T Cell-Mediated Differentiation Into Plasma Cells and Secreting Pathogenic Immunoglobulin G. *Arterioscler Thromb Vasc Biol* 38: e71-e84, 2018.
841. **Centa M, Jin H, Hofste L, Hellberg S, Busch A, Baumgartner R, Verzaal NJ, Lind Enoksson S, Perisic Matic L, Boddul SV, Atzler D, Li DY, Sun C, Hansson GK, Ketelhuth DFJ, Hedin U, Wermeling F, Lutgens E, Binder CJ, Maegdesfessel L, and Malin SG.** Germinal Center-Derived Antibodies Promote Atherosclerosis Plaque Size and Stability. *Circulation* 139: 2466-2482, 2019.
842. **Woyach JA, Johnson AJ, and Byrd JC.** The B-cell receptor signaling pathway as a therapeutic target in CLL. *Blood* 120: 1175-1184, 2012.
843. **Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemester FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, and Burger JA.** CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. *Br J Haematol* 171: 726-735, 2015.
844. **Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, Farooqui M, and Wiestner A.** Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. *Blood* 123: 3286-3295, 2014.
845. **Nitz K, Herrmann J, Lerman A, and Lutgens E.** Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis: Therapeutic Targets in Atherosclerosis? *JACC Basic Transl Sci* 9: 827-843, 2024.
846. **Woolaver RA, Wang X, Dollin Y, Xie P, Wang JH, and Chen Z.** TRAF2 Deficiency in B Cells Impairs CD40-Induced Isotype Switching That Can Be Rescued by Restoring NF-kappaB1 Activation. *J Immunol* 201: 3421-3430, 2018.
847. **Bishop GA, Stunz LL, and Hostager BS.** TRAF3 as a Multifaceted Regulator of B Lymphocyte Survival and Activation. *Front Immunol* 9: 2161, 2018.
848. **Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, Jagielska J, Ernst S, Aikawa M, Nakano H, Tsitsikov E, and Schonbeck U.** TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. *Arterioscler Thromb Vasc Biol* 27: 1101-1107, 2007.

849. **Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl LM, and Suttles J.** TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. *J Immunol* 174: 1081-1090, 2005.
850. **Zarzycka B, Seijkens T, Nabuurs SB, Ritschel T, Grommes J, Soehnlein O, Schrijver R, van Tiel CM, Hackeng TM, Weber C, Giehler F, Kieser A, Lutgens E, Vriend G, and Nicolaes GA.** Discovery of small molecule CD40-TRAF6 inhibitors. *J Chem Inf Model* 55: 294-307, 2015.
851. **Seijkens T, Kusters P, Chatzigeorgiou A, Chavakis T, and Lutgens E.** Immune cell crosstalk in obesity: a key role for costimulation? *Diabetes* 63: 3982-3991, 2014.
852. **Seijkens TTP, van Tiel CM, Kusters PJH, Atzler D, Soehnlein O, Zarzycka B, Aarts S, Lameijer M, Gijbels MJ, Beckers L, den Toom M, Slutter B, Kuiper J, Duchene J, Aslani M, Megens RTA, van 't Veer C, Kooij G, Schrijver R, Hoeksema MA, Boon L, Fay F, Tang J, Baxter S, Jongejan A, Moerland PD, Vriend G, Bleijlevens B, Fisher EA, Duivenvoorden R, Gerdes N, de Winther MPJ, Nicolaes GA, Mulder WJM, Weber C, and Lutgens E.** Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. *J Am Coll Cardiol* 71: 527-542, 2018.
853. **Lameijer M, Binderup T, van Leent MMT, Senders ML, Fay F, Malkus J, Sanchez-Gaytan BL, Teunissen AJP, Karakatsanis N, Robson P, Zhou X, Ye Y, Wojtkiewicz G, Tang J, Seijkens TTP, Kroon J, Stroes ESG, Kjaer A, Ochando J, Reiner T, Perez-Medina C, Calcagno C, Fisher EA, Zhang B, Temel RE, Swirski FK, Nahrendorf M, Fayad ZA, Lutgens E, Mulder WJM, and Duivenvoorden R.** Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. *Nat Biomed Eng* 2: 279-292, 2018.
854. **Steven S, Dib M, Hausding M, Kashani F, Oelze M, Kroller-Schon S, Hanf A, Daub S, Roohani S, Gramlich Y, Lutgens E, Schulz E, Becker C, Lackner KJ, Kleinert H, Knosalla C, Niesler B, Wild PS, Munzel T, and Daiber A.** CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice. *Cardiovasc Res* 114: 312-323, 2018.
855. **Strohm L, Daiber A, Ubbens H, Krishnankutty R, Oelze M, Kuntic M, Hahad O, Klein V, Hoefler IE, von Kriegsheim A, Kleinert H, Atzler D, Lurz P, Weber C, Wild PS, Munzel T, Knosalla C, Lutgens E, and Daub S.** Role of inflammatory signaling pathways involving the CD40-CD40L-TRAF cascade in diabetes and hypertension-insights from animal and human studies. *Basic Res Cardiol* 119: 1-18, 2024.
856. **Strohm L, Ubbens H, Mihalikova D, Czarnowski A, Stamm P, Molitor M, Finger S, Oelze M, Atzler D, Wenzel P, Lurz P, Munzel T, Weber C, Lutgens E, Daiber A, and Daub S.** CD40-TRAF6 inhibition suppresses cardiovascular inflammation, oxidative stress and functional complications in a mouse model of arterial hypertension. *Redox Biol* 80: 103520, 2025.
857. **Jacobs MME, Maas RJF, Jonkman I, Negishi Y, Tielemans Zamora W, Yanginlar C, van Heck J, Matzaraki V, Martens JHA, Baltissen M, Vermeulen M, Morla-Folch J, Ranzenigo A, Wang W, Umali M, Ochando J, van der Vlag J, Hilbrands LB, Joosten LAB, Netea MG, Mulder WJM, van Leent MMT, Mhlanga MM, Teunissen AJP, Rother N, and Duivenvoorden R.** Trained immunity is regulated by T cell-induced CD40-TRAF6 signaling. *Cell Rep* 43: 114664, 2024.

858. **Wolf D, Hohmann JD, Wiedemann A, Bledzka K, Blankenbach H, Marchini T, Gutte K, Zeschky K, Bassler N, Hoppe N, Rodriguez AO, Herr N, Hilgendorf I, Stachon P, Willecke F, Duerschmied D, von zur Muhlen C, Soloviev DA, Zhang L, Bode C, Plow EF, Libby P, Peter K, and Zirlík A.** Binding of CD40L to Mac-1's I-domain involves the EQLKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice. *Circ Res* 109: 1269-1279, 2011.
859. **Wolf D, Anto-Michel N, Blankenbach H, Wiedemann A, Buscher K, Hohmann JD, Lim B, Bauml M, Marki A, Mauler M, Duerschmied D, Fan Z, Winkels H, Sidler D, Diehl P, Zajonc DM, Hilgendorf I, Stachon P, Marchini T, Willecke F, Schell M, Sommer B, von Zur Muhlen C, Reinohl J, Gerhardt T, Plow EF, Yakubenko V, Libby P, Bode C, Ley K, Peter K, and Zirlík A.** A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. *Nat Commun* 9: 525, 2018.
860. **Mahoney KM, Rennert PD, and Freeman GJ.** Combination cancer immunotherapy and new immunomodulatory targets. *Nat Rev Drug Discov* 14: 561-584, 2015.
861. **Lutgens E, and Seijkens TTP.** Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease. *J Immunother Cancer* 8: 2020.
862. **Maier A, Teunissen AJP, Nauta SA, Lutgens E, Fayad ZA, and van Leent MMT.** Uncovering atherosclerotic cardiovascular disease by PET imaging. *Nat Rev Cardiol* 2024.
863. **Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, Webb TR, Zeng L, Dehghan A, Alver M, Armasu SM, Auro K, Bjorndal A, Chasman DI, Chen S, Ford I, Franceschini N, Gieger C, Grace C, Gustafsson S, Huang J, Hwang SJ, Kim YK, Kleber ME, Lau KW, Lu X, Lu Y, Lyttikainen LP, Mihailov E, Morrison AC, Pervjakova N, Qu L, Rose LM, Salfati E, Saxena R, Scholz M, Smith AV, Tikkanen E, Uitterlinden A, Yang X, Zhang W, Zhao W, de Andrade M, de Vries PS, van Zuydam NR, Anand SS, Bertram L, Beutner F, Dedoussis G, Frossard P, Gauguier D, Goodall AH, Gottesman O, Haber M, Han BG, Huang J, Jalilzadeh S, Kessler T, König IR, Lannfelt L, Lieb W, Lind L, Lindgren CM, Lokki ML, Magnusson PK, Mallick NH, Mehra N, Meitinger T, Memon FU, Morris AP, Nieminen MS, Pedersen NL, Peters A, Rallidis LS, Rasheed A, Samuel M, Shah SH, Sinisalo J, Stirrups KE, Trompet S, Wang L, Zaman KS, Ardic D, Boerwinkle E, Borecki IB, Bottinger EP, Buring JE, Chambers JC, Collins R, Cupples LA, Danesh J, Demuth I, Elosua R, Epstein SE, Esko T, Feitosa MF, Franco OH, Franzosi MG, Granger CB, Gu D, Gudnason V, Hall AS, Hamsten A, Harris TB, Hazen SL, Hengstenberg C, Hofman A, Ingelsson E, Iribarren C, Jukema JW, Karhunen PJ, Kim BJ, Kooner JS, Kullo IJ, Lehtimäki T, Loos RJF, Melander O, Metspalu A, März W, Palmer CN, Perola M, Quertermous T, Rader DJ, Ridker PM, Ripatti S, Roberts R, Salomaa V, Sanghera DK, Schwartz SM, Seedorf U, Stewart AF, Stott DJ, Thiery J, Zalloua PA, O'Donnell CJ, Reilly MP, Assimes TL, Thompson JR, Erdmann J, Clarke R, Watkins H, Kathiresan S, McPherson R, Deloukas P, Schunkert H, Samani NJ, and Farrall M.** A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet* 47: 1121-1130, 2015.
864. **Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, Taliun SAG, Corvelo A, Gogarten SM, Kang HM, Pitsillides AN, LeFaive J, Lee SB, Tian X, Browning BL, Das S, Emde AK, Clarke WE, Loesch DP, Shetty AC, Blackwell TW, Smith AV, Wong Q,**

Liu X, Conomos MP, Bobo DM, Aguet F, Albert C, Alonso A, Ardlie KG, Arking DE, Aslibekyan S, Auer PL, Barnard J, Barr RG, Barwick L, Becker LC, Beer RL, Benjamin EJ, Bielak LF, Blangero J, Boehnke M, Bowden DW, Brody JA, Burchard EG, Cade BE, Casella JF, Chalazan B, Chasman DI, Chen YI, Cho MH, Choi SH, Chung MK, Clish CB, Correa A, Curran JE, Custer B, Darbar D, Daya M, de Andrade M, DeMeo DL, Dutcher SK, Ellinor PT, Emery LS, Eng C, Fatkin D, Fingerlin T, Forer L, Fornage M, Franceschini N, Fuchsberger C, Fullerton SM, Germer S, Gladwin MT, Gottlieb DJ, Guo X, Hall ME, He J, Heard-Costa NL, Heckbert SR, Irvin MR, Johnsen JM, Johnson AD, Kaplan R, Kardia SLR, Kelly T, Kelly S, Kenny EE, Kiel DP, Klemmer R, Konkle BA, Kooperberg C, Kottgen A, Lange LA, Lasky-Su J, Levy D, Lin X, Lin KH, Liu C, Loos RJF, Garman L, Gerszten R, Lubitz SA, Lunetta KL, Mak ACY, Manichaikul A, Manning AK, Mathias RA, McManus DD, McGarvey ST, Meigs JB, Meyers DA, Mikulla JL, Minear MA, Mitchell BD, Mohanty S, Montasser ME, Montgomery C, Morrison AC, Murabito JM, Natale A, Natarajan P, Nelson SC, North KE, O'Connell JR, Palmer ND, Pankratz N, Peloso GM, Peyser PA, Pleiness J, Post WS, Psaty BM, Rao DC, Redline S, Reiner AP, Roden D, Rotter JI, Ruczinski I, Sarnowski C, Schoenherr S, Schwartz DA, Seo JS, Seshadri S, Sheehan VA, Sheu WH, Shoemaker MB, Smith NL, Smith JA, Sotoodehnia N, Stilp AM, Tang W, Taylor KD, Telen M, Thornton TA, Tracy RP, Van Den Berg DJ, Vasani RS, Viaud-Martinez KA, Vrieze S, Weeks DE, Weir BS, Weiss ST, Weng LC, Willer CJ, Zhang Y, Zhao X, Arnett DK, Ashley-Koch AE, Barnes KC, Boerwinkle E, Gabriel S, Gibbs R, Rice KM, Rich SS, Silverman EK, Qasba P, Gan W, Consortium NT-OfPM, Papanicolaou GJ, Nickerson DA, Browning SR, Zody MC, Zollner S, Wilson JG, Cupples LA, Laurie CC, Jaquish CE, Hernandez RD, O'Connor TD, and Abecasis GR. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* 590: 290-299, 2021.

865. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, and Soboleva A. NCBI GEO: archive for functional genomics data sets—update. *Nucleic Acids Res* 41: D991-995, 2013.

866. Khatri R, Machart P, and Bonn S. DISSECT: deep semi-supervised consistency regularization for accurate cell type fraction and gene expression estimation. *Genome Biol* 25: 112, 2024.

867. Chen Y, Wang Y, Chen Y, Cheng Y, Wei Y, Li Y, Wang J, Wei Y, Chan TF, and Li Y. Deep autoencoder for interpretable tissue-adaptive deconvolution and cell-type-specific gene analysis. *Nat Commun* 13: 6735, 2022.


868. Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, and Alizadeh AA. Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nat Biotechnol* 37: 773-782, 2019.

869. Wang X, Park J, Susztak K, Zhang NR, and Li M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. *Nat Commun* 10: 380, 2019.

870. Chu T, Wang Z, Pe'er D, and Danko CG. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. *Nature Cancer* 3: 505-517, 2022.

871. **Menden K, Marouf M, Oller S, Dalmia A, Magruder DS, Kloiber K, Heutink P, and Bonn S.** Deep learning-based cell composition analysis from tissue expression profiles. *Sci Adv* 6: eaba2619, 2020.
872. **Amadori L, Calcagno C, Fernandez DM, Koplev S, Fernandez N, Kaur R, Mury P, Khan NS, Sajja S, Shamailova R, Cyr Y, Jeon M, Hill CA, Chong PS, Naidu S, Sakurai K, Ghotbi AA, Soler R, Eberhardt N, Rahman A, Faries P, Moore KJ, Fayad ZA, Ma'ayan A, and Giannarelli C.** Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis. *Nat Cardiovasc Res* 2: 550-571, 2023.
873. **Wang J, Fonseca GJ, and Ding J.** scSemiProfiler: Advancing large-scale single-cell studies through semi-profiling with deep generative models and active learning. *Nat Commun* 15: 5989, 2024.
874. **Cui A, Huang T, Li S, Ma A, Perez JL, Sander C, Keskin DB, Wu CJ, Fraenkel E, and Hacohen N.** Dictionary of immune responses to cytokines at single-cell resolution. *Nature* 625: 377-384, 2024.
875. **van Leent MMT, Meerwaldt AE, Berchouchi A, Toner YC, Burnett ME, Klein ED, Verschuur AVD, Nauta SA, Munitz J, Prevot G, van Leeuwen EM, Ordikhani F, Mourits VP, Calcagno C, Robson PM, Soultanidis G, Reiner T, Joosten RRM, Friedrich H, Madsen JC, Kluza E, van der Meel R, Joosten LAB, Netea MG, Ochando J, Fayad ZA, Perez-Medina C, Mulder WJM, and Teunissen AJP.** A modular approach toward producing nanotherapeutics targeting the innate immune system. *Sci Adv* 7: 2021.
876. **Hofstraat SRJ, Anbergen T, Zwolsman R, Deckers J, van Elsas Y, Trines MM, Versteeg I, Hoorn D, Ros GWB, Bartelet BM, Hendrikx MMA, Darwish YB, Kleuskens T, Borges F, Maas RJF, Verhalle LM, Tielemans W, Vader P, de Jong OG, Tabaglio T, Wee DKB, Teunissen AJP, Brechbuhl E, Janssen HM, Fransen PM, de Dreu A, Schrijver DP, Priem B, Toner YC, Beldman TJ, Netea MG, Mulder WJM, Kluza E, and van der Meel R.** Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. *Nat Nanotechnol* 2025.

Epidemiology (CVD mortality rates per 100,000)



Risk factors



Non-modifiable

- Age
- Sex
- Genetic predisposition (i.e., dyslipidemia, AID)



Environmental

- Air pollution
- Particle exposure
- Extreme temperatures



Metabolic

- Increased LDL/TG/Lp(a)
- High BMI
- Diabetes
- Reduced kidney function



Behavioral


- Smoking/alcohol
- Unhealthy diet
- Lack of physical exercise
- Psychosocial stress
- Mood disorders
- Sleep disruption





Inflammation

- CID
- AID
- CHIP
- Infections

Clinical manifestations









1 Intimal thickening

The accumulation of SMCs and lipids in the proteoglycan-rich intima.




2 Intimal xanthoma

The accumulation of lipid-laden macrophages and other immune cells (i.e. T cells).




3 Pathological intimal thickening

An atherosclerotic plaque with lipid-laden macrophages and other immune cells, extracellular lipid pools and a (small) fibrous cap.




4 Fibrous cap atheroma

An atherosclerotic plaque with lipid-laden macrophages and other immune cells, a necrotic core with cholesterol crystals and/or calcifications and a fibrous cap. If the fibrous cap is <math><65 \mu\text{m}</math>, it is called a thin fibrous cap atheroma (coronary artery).



5 Plaque rupture

An atherosclerotic plaque with a fissure. The thrombus is in direct contact with the inner plaque components.




6 Plaque erosion

An atherosclerotic plaque with a thrombus, but no fissure. The endothelial cells are absent, damaged or dysfunctional at the site of the thrombus. This can occur at any plaque stage.


Legend											
	Endothelial cell		Proteoglycan		T cell		Neutrophil		Calcification		Thrombus
	SMC		B cell		Macrophage		Lipid		Cholesterol crystal		Collagen

1 1850
Von Rokitsansky: the encrustation model




Arterial injury causes the generation of mural thrombi. These thrombi undergo organization, with SMCs and fibrous tissue growing into them, resulting in "vascular lesions".

2 1856
Virchow: the infiltration model




Low grade injury to the arterial wall results in inflammatory cell infiltration, causing an increased passage and accumulation of "plasma constituents" in the intima.

3 1913 - 1980
Anitschkow, Brown and Goldstein: the lipid model




Lipids infiltrate into the arterial intima, where they become engulfed by macrophages. "Overeating" causes these foam cells to die, resulting in lipid deposits and cholesterol crystal formation: the atheroma.

4 1976 - 1986
Ross: the response to injury model




Endothelial injury, induced by shear stress and reactive oxygen species (ROS) is the initiating event in atherosclerosis. As a "response to injury", VSMCs migrate into the intima, proliferate, produce extra-cellular matrix. Lipids accumulate and attract macrophages.

5 1990s - now
Atherosclerosis: a lipid-driven immune disease











Modified lipids cause leukocyte recruitment into the arterial intima. Immune cells become activated and/or lipid laden, and produce chemokines and cytokines. Migration and proliferation of SMCs and ECM formation results in a fibrous cap that overlies a core of lipids, calcium and necrotic tissue. Inflammation contributes to plaque rupture. The presence of immune cells is not restricted to the atherosclerotic plaque itself. Whereas the media is an immune-privileged site, immune cells in the adventitia and perivascular adipose tissue are an important source of vascular inflammation.







	Endothelial cell		Proteoglycan		T cell		Neutrophil		Calcification		Thrombus
	SMC		B cell		Macrophage		Lipid		Cholesterol crystal		Collagen
	Inflammatory cell		Dendritic cell		ROS		Adipocyte		Vasa vasorum		







Monocytes / Macrophages

S100A8/ILB ⁻	S100A8/ILB ⁺	IL10 ⁺ / TNFAIP3 ⁺	IFN resp.	HMOX1	C1Q	TREM2 ^{hi}	TREM1 ^{hi} / PLIN2 ^{hi}
							
<i>DNAJB1, HSPA1A, HSPA1B, HSP90AA1</i>	<i>TLR2, CASP4, CDKN1, PTGER2, PTGS2, MCL1</i>	<i>IL10, GPR183</i>	<i>IFIT1, IFIT3, IFI6, MX1, CXCL10</i>	<i>HMOX1, FTL, SLC40A1, ATOX1, BLVRB</i>	<i>VSIG4, MRC1, MSR1, F13A1, IFG1R, HLA_DR, HLA_DRB1, CD74, CD14, FCGR3A, FCGR1A</i>	<i>NR1H3, CYP27A1, LIPA, LPL, SPP1, MT1G, MT1X, MT1F</i>	<i>TREM1, PLIN2, OLR1, IL1B, CCL2, CCL7, CCL20, TLR2</i>
<i>S100A8, S100A9, S100A12, VCAN, LYZ, PLAC8, CSF3R</i>				<i>C1QA, C1QB, C1QC, SELENOP, FOLR2</i>			
	<i>IL1B, NLRP3, SOCS3</i>				<i>CD63, CD9, GPNMB, TREM2</i>		
						<i>CD36, FABP5, FABP4, MARCO, LGALS3</i>	




Dendritic cells

cDC1	cDC2	Mature cDC2	AS DC	pDC	Mast cells
					
<i>CLEC9A- IRF8- SNX3-XCR1</i>	<i>CD1C, CLEC10A, FCER1A, IL1R2</i>	<i>CCR7, CCL7, CCL19, CCL22, LAMP3, CD40, CD200, TNFRSF4, IDO1</i>	<i>AXL, SIGLEC6, PP1R14A, SOX4, TCF4</i>	<i>CLEC4C, LILRA4, IRF7, IRF8</i>	<i>TPSB2, TPSAB1, MS4A2</i>
<i>CD74, HLA_DRA, HLA_DRB1, HLA_DRB5, HLA_DPA1</i>					




CD4 T cells

CD4 T _{regs}	CD4 T _{CM}	CD4 T _{EM}	CD4 exhausted
			
FOXP3, CTLA4, TNFRSF4, TNFRSF18, TIGIT, IL2RA	SELL, LEF1, CCR7	CD40LG, IL7R, LTB	CXCL13, NR3C1, IL21, CD200, PDCD1
CD3D-TRAC-CD4-LTB			


NK cells

XCL1+ NK	FCGR3A+ NK	Proliferating lymphocytes
		
XCL1, XCL2, CD160, KLRC1, KLRB1	FCGR3A, PRF1, GZMB, GZMH, GZMA, SPON2, GNLY	MKI67, STMN1, TOP2A, NKG7, TRAC, CD3D
NKG7, KLRF1, KLRD1		





CD8 T cells


CD8 T _{EM}	CD8 IFN resp.	Cytotoxic CD8 T _{EFF}
		
GZMK, IFNG, CCL5, KLRG1	IFIT1, IFIT3, ISG15, MX1	GZMH, GZMB, GNLY, PRF1, FCGR3A, CX3CR1
TRAC, CD3D, CD8A, CD8B		


CD8+ other

MAIT

CD8A, KLRB1, ZBTB16, RORA, SLC4A10





B cells and plasma cells

IgM+ B cell	Age-associated B cell	Class-switched memory B cell	Plasma cell
			
CXCR4, IGHM	ITGAX, ITGAM, TBX21	CD27, IGHG2	IGKC, MZB1, JCHAIN
	CD19	IGHG1, IGHG3	
	CD79A		














Endothelial cells


ACKR1 ⁺	BMP4 ⁺ ECM	FGF18 ⁺ migratory	ACTA2 ⁺ EndMT
			
ACKR1, DNASE1L3, ITGA6, APLNR, VWA1, RASA4, COL15A1, CEMIP2	PLAT, BMP4, EFEMP1, IGFBP3, EDN1, THBS1, MGP, OMD, CTGF, CP, CXCL2	DKK2, FGF18, CPAMD8, ELN, HEG1, CDH23, FBLN2, CLDN5, ITLN1, PTGDS	NOTCH3, MYH11, RGS5, C11orf96, MFAP4, LTBP1, TAGLN, MYL9, ACTA2, APOE
CD34, PECAM1, TIE1			
PRCP, VCAM1			

Smooth muscle cells

Contractile	Synthetic	Mesenchymal-like	Endothelial cell-like
			
TAGLN, MYH11, MYOCD, SMTN, CNN1	VIM, COL1A2, NOTCH3, MYH10	SCA1, CD34, CD44, C3	CD31
KLF4			
ACTA2			

Myofibroblast-like	Osteochondrogenic	Foam cell-like	Macrophage-like	Adipocyte-like
				
TNFRSF11B, FN1, BGN, DCN, COL1A1	SOX9, MSX2, RUNX2, KLF14, OPN, BMP2	CD36	LGALS3, ITGAM, ADGRE1	UCP1, ELOVL3, ADIPOQ
KLF4				
CD68				

Targeting inflammation in atherosclerosis					
Trial name	Agent	Target	Patient cohort	Primary end point	Main CVD outcomes
CIRT	Methotrexate	Broad anti-inflammatory effect	4,786 patients with previous MI and DMII or metabolic syndrome	Composite of nonfatal MI, nonfatal stroke, or cardiovascular death	No beneficial effects
Targeting innate immunity in atherosclerosis					
Trial name	Agent	Target	Patient cohort	Primary end point	Main CVD outcomes
CANTOS	Canakinumab	IL1 β	10,061 patients with previous MI and elevated plasma CRP levels	Non-fatal MI, non-fatal stroke or death from cardiovascular causes	The 150-mg dose of canakinumab reduced cardiovascular events compared with placebo, independent of lipid level reductions
COLCOT	Colchicine	Inflammasome	4,745 patients with MI within 30 days before enrolment	Death from cardiovascular causes, resuscitated cardiac arrest, MI, stroke, or hospitalization for angina leading to coronary revascularization	Colchicine decreased the risk of the composite end point compared with placebo
LoDoCo2	Colchicine	Inflammasome	5,522 patients with chronic coronary artery disease	Death from cardiovascular causes, spontaneous MI, ischemic stroke or ischemia-driven coronary revascularization	Colchicine decreased the risk of the composite end point compared with placebo
CLEAR SYNERGY	Colchicine	Inflammasome	7,062 patients after PCI (SYNERGY stent) treatment	Composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization	No beneficial effects
Targeting adaptive immunity in atherosclerosis					
Trial name	Agent	Target	Patient cohort	Primary end point	Main CVD outcomes
IVORY	Low dose IL2	Treg expansion	60 high risk ACS patients	Vascular inflammation (18Fdg-PET/CT)	Reduction of arterial inflammation
Orticumab	Anti-MDA-ApoB100	MDA-LDL	77 psoriasis patients with myocardial inflammation	Coronary inflammation (fat attenuation index)	Reduction of coronary inflammation



Future immunotherapies



Monocytes / macrophages

- bone-marrow – tissue axis
- recruitment
- migration, proliferation
- activation
- trained immunity
- efferocytosis (CD47)
- resident cell homeostasis




T cells

- increase Tregs (low dose IL2)
- maintain Treg function
- vaccination against atherosclerosis antigens (apoB100)
- block co-stimulation
- enhance co-inhibition



B cells

- depletion (anti-CD20)
- plasma cell reduction
- block BCR signaling
- block co-stimulation
- enhance co-inhibition






Immune checkpoints

- block co-stimulation (CD40, TRAF6, CD86)
- enhance co-inhibition (PD1, TIM3, Tigit, CTLA4)
- target co-stimulatory/co-inhibitory proteins on specific (non)-immune cells




Cytokines / Chemokines


- IL1 β
- IL6
- CCL2
- IL17
- CCL17
- CCR5




Atherosclerosis is an inflammatory disease




Evidence of the role of the immune system in atherosclerosis



Clinical



Future immunotherapies



Cell-type specific targeting of atherosclerosis-associated immunological pathways

